e424b7
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of
|
|
|
|
|
Maximum Aggregate
|
|
|
|
Registration
|
|
Title of Each Class of Securities Offered
|
|
|
Offering Price
|
|
|
|
Fee (1)(2)
|
|
Common Equity Units, $75.00 stated value
|
|
|
$
|
3,315,200,000
|
|
|
|
$
|
384,894.72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Calculated in accordance with Rule 457(r) under the
Securities Act of 1933 as amended (the Securities
Act).
|
|
(2)
|
A registration fee of $384,894.72 has been paid with respect to
this offering.
|
Filed
pursuant to Rule 424(b)(7)
Registration No. 333-170876
(To Prospectus dated November 30, 2010)
40,000,000 Common Equity
Units
This is an offering of Common Equity Units of MetLife, Inc. by
ALICO Holdings LLC, the selling securityholder (the
Selling Securityholder), and a subsidiary of
American International Group, Inc. (AIG).
Each Common Equity Unit initially consists of:
|
|
|
|
|
three stock purchase contracts (each a Stock Purchase
Contract and together, the Stock Purchase
Contracts) under which each holder must purchase, and
MetLife, Inc. must sell, on each of the three stock purchase
dates (each a Stock Purchase Date), a
variable number of shares of MetLife, Inc.s common stock,
par value $0.01 per share (the Common Stock),
in each case for an aggregate purchase price of $25.00;
|
|
|
|
prior to the First Stock Purchase Date (as defined in this
prospectus supplement), a 1/40, or 2.50%, undivided beneficial
ownership interest in a Series C Senior Debenture due 2023
of MetLife, Inc. (the Series C
Debentures) having a principal amount of $1,000;
|
prior to the Second Stock Purchase Date (as defined
in this prospectus supplement), a 1/40, or 2.50%, undivided
beneficial ownership interest in a Series D Senior
Debenture due 2024 of MetLife, Inc. (the Series D
Debentures) having a principal amount of
$1,000; and
a 1/40, or 2.50%, undivided beneficial ownership
interest in a Series E Senior Debenture due 2045 of
MetLife, Inc. (the Series E Debentures,
and collectively with the Series C Debentures and the
Series D Debentures, the Debentures)
having a principal amount of $1,000.
The Stock Purchase Contracts that will be settled on the First
Stock Purchase Date, the Second Stock Purchase Date and the
Third Stock Purchase Date (as defined in this prospectus
supplement) are referred to as the Series C Stock
Purchase Contracts, the Series D Stock
Purchase Contracts and the Series E
Stock Purchase Contracts, respectively.
The amount of Common Stock you will purchase and receive on the
First Stock Purchase Date, the Second Stock Purchase Date and
the Third Stock Purchase Date will depend on the volume-weighted
average price per share of the Common Stock (the
VWAP) for each of the 20 consecutive Trading
Days (as defined in this prospectus supplement) ending on, and
including, the third Trading Day immediately preceding
October 10, 2012, September 11, 2013 and
October 8, 2014, respectively.
Each Stock Purchase Contract has a stated amount of $25.00. Each
Common Equity Unit has a stated amount of (i) $75.00 from,
and including, the issue date of the Common Equity Units, to,
but excluding, the First Stock Purchase Date; (ii) $50.00
from, and including, the First Stock Purchase Date to, but
excluding, the Second Stock Purchase Date; and (iii) $25.00
from, and including, the Second Stock Purchase Date to, but
excluding, the Third Stock Purchase Date.
Your ownership interest in the Debentures initially will be
pledged to secure your obligation to purchase the Common Stock
on each Stock Purchase Date under the Stock Purchase Contracts.
Subject to certain conditions and restrictions described below,
as well as the payment of applicable fees and expenses, you may
separate the Debentures from the Stock Purchase Contracts by
substituting zero coupon Treasury Securities (as defined in this
prospectus supplement) for the Debentures.
MetLife, Inc. will make quarterly Contract Payments (as defined
in this prospectus supplement) to you on your Stock Purchase
Contracts at the annual rate of 3.436% on the stated amount of
$25.00 per Series C Stock Purchase Contract until the First
Stock Purchase Date, at the annual rate of 3.077% on the stated
amount of $25.00 per Series D Stock Purchase Contract until
the Second Stock Purchase Date and at the annual rate of 2.537%
on the stated amount of $25.00 per Series E Stock Purchase
Contract until the Third Stock Purchase Date. MetLife, Inc. may
defer any of these Contract Payments as described in this
prospectus supplement. MetLife, Inc. will make payments
(Contract Payments) on each Stock Purchase
Contract, payable quarterly in arrears on each March 15, June
15, September 15 and December 15 of each year (each such date, a
Contract Payment Date). However, the
Contract Payment that is scheduled to be made on March 15, 2011
will be paid to the Selling Securityholder as holder of record
on March 1, 2011.
MetLife, Inc. will make interest payments on the principal
amount of the Series C Debentures, the Series D
Debentures and the Series E Debentures at an initial rate
per annum equal to 1.564%, 1.923% and 2.463%, respectively.
Interest on the Debentures will be payable quarterly in arrears
on March 15, June 15, September 15 and December 15 of
each year. However, the interest payment that is scheduled to be
made on March 15, 2011 will be paid to the Selling
Securityholder as holder of record on March 1, 2011.
The Remarketing Agent (as defined in this prospectus supplement)
appointed by MetLife, Inc. will attempt to remarket the
Debentures on or before the applicable Stock Purchase Dates as
more fully described in this prospectus supplement
(Remarketings). Following a successful
Remarketing, the interest rate on the relevant series of
Debentures may be reset.
The Common Stock is listed on the New York Stock Exchange under
the symbol MET. The last reported sale price of the
Common Stock on March 2, 2011 was $43.41 per share. The
Normal Common Equity Units (as defined in this prospectus
supplement) have been approved for listing on the New York Stock
Exchange under the symbol MLU, subject to official
notice. MetLife, Inc. expects trading of the Normal Common
Equity Units on the New York Stock Exchange to begin on
March 7, 2011. It is a condition to the closing of the
offering of the Common Equity Units that the Coordination
Agreement is in full force and effect.
Concurrently with this offering, by means of a separate
prospectus supplement, MetLife, Inc. is offering
68,570,000 shares of its Common Stock (the MetLife
Concurrent Offering) and the Selling Securityholder is
offering 78,239,712 shares of MetLife, Inc.s Common
Stock (the ALICO Holdings Concurrent Offering
and, together with the MetLife Concurrent Offering, the
Concurrent Offerings). MetLife, Inc. intends
to use all its net proceeds from the MetLife Concurrent Offering
to repurchase and cancel the Series B Contingent
Convertible Junior Participating Non-Cumulative Perpetual
Preferred Stock (the Series B Preferred
Stock) that it issued to the Selling Securityholder on
November 1, 2010 in connection with the Acquisition (as
defined in this prospectus supplement). This offering of Common
Equity Units is not conditioned on the completion of either of
the Concurrent Offerings. There can be no assurance that the
Concurrent Offerings will be completed. It is a condition to the
closing of the MetLife Concurrent Offering that all of the
closing conditions of the Repurchase (as defined below) (except
the condition that the MetLife Concurrent Offering has been
consummated) under the Coordination Agreement (as defined below)
will need to be satisfied or waived.
See Risk Factors beginning on
page S-23
of this prospectus supplement to read about important factors
you should consider before buying any Common Equity Units.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Common
|
|
|
|
|
|
|
Equity Unit
|
|
|
Total
|
|
|
Public offering price
|
|
$
|
82.8800
|
|
|
$
|
3,315,200,000.00
|
|
Underwriting discounts and commissions
|
|
$
|
0.4144
|
|
|
$
|
16,576,000.00
|
|
Proceeds, before expenses, to the Selling Securityholder
|
|
$
|
82.4656
|
|
|
$
|
3,298,624,000.00
|
|
Contract Payments on the Stock Purchase Contracts and interest
payments attributable to the applicable ownership interests in
the Debentures will accrue from, and including, March 15,
2011.
The underwriters expect to deliver the Common Equity Units
against payment in New York, New York on March 8, 2011.
|
|
Goldman,
Sachs & Co. |
Citi |
|
|
|
Credit
Suisse |
BofA
Merrill Lynch |
Barclays Capital |
|
|
|
Deutsche
Bank Securities |
J.P.
Morgan |
Morgan Stanley |
|
|
UBS
Investment Bank |
Wells Fargo Securities |
Prospectus Supplement dated March 3, 2011.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
Prospectus Supplement
|
|
|
|
S-3
|
|
|
|
|
S-3
|
|
|
|
|
S-5
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-23
|
|
|
|
|
S-66
|
|
|
|
|
S-69
|
|
|
|
|
S-76
|
|
|
|
|
S-77
|
|
|
|
|
S-78
|
|
|
|
|
S-79
|
|
|
|
|
S-81
|
|
|
|
|
S-82
|
|
|
|
|
S-84
|
|
|
|
|
S-88
|
|
|
|
|
S-104
|
|
|
|
|
S-108
|
|
|
|
|
S-114
|
|
|
|
|
S-116
|
|
|
|
|
S-123
|
|
|
|
|
S-126
|
|
|
|
|
S-132
|
|
|
|
|
S-132
|
|
Prospectus
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
28
|
|
|
|
|
30
|
|
|
|
|
32
|
|
|
|
|
32
|
|
You should rely only on the information contained or
incorporated by reference in this prospectus supplement and the
accompanying prospectus. Neither we nor the underwriters have
authorized anyone to provide you with additional or different
information. If anyone provided you with additional or different
information, you should not rely on it. Neither we nor the
underwriters are making an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You
should assume that the information contained in this prospectus
supplement, the accompanying prospectus and the documents
incorporated by reference, is accurate only as of their
respective dates. MetLifes business, financial condition,
results of operations and prospects may have changed since those
dates.
S-2
The Common Equity Units are offered for sale in those
jurisdictions in the United States, Europe, Asia and elsewhere
where it is lawful to make such offers. The distribution of this
prospectus supplement and the accompanying prospectus and the
offering or sale of the Common Equity Units in some
jurisdictions may be restricted by law. Persons into whose
possession this prospectus supplement and the accompanying
prospectus come are required by us, the Selling Securityholder
and the underwriters to inform themselves about and to observe
any applicable restrictions. This prospectus supplement and the
accompanying prospectus may not be used for or in connection
with an offer or solicitation by any person in any jurisdiction
in which that offer or solicitation is not authorized or to any
person to whom it is unlawful to make that offer or
solicitation. See Underwriting in this
prospectus supplement.
ABOUT
THIS PROSPECTUS SUPPLEMENT
You should read this prospectus supplement along with the
accompanying prospectus carefully before investing in the Common
Equity Units. This prospectus supplement and the accompanying
prospectus contain the terms of this offering of Common Equity
Units. This prospectus supplement may add, update or change
information in the accompanying prospectus. In addition, the
information incorporated by reference in the accompanying
prospectus may have added, updated or changed information in the
accompanying prospectus. If information in this prospectus
supplement is inconsistent with any information in the
accompanying prospectus (or any information incorporated therein
by reference), this prospectus supplement will apply and will
supersede such information.
It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying
prospectus in making your investment decision. You should also
read and consider the additional information under the caption
Where You Can Find More Information in this
prospectus supplement and the accompanying prospectus.
Unless otherwise stated or the context otherwise requires,
references in this prospectus supplement and the accompanying
prospectus to MetLife, we,
our, or us refer to
MetLife, Inc., together with its direct and indirect
subsidiaries, while references to MetLife,
Inc. refer only to the holding company on an
unconsolidated basis.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the Securities and Exchange Commission (the
SEC). These reports, proxy statements and
other information can be read and copied at the SECs
public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s Common
Stock is listed and trading on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York 10005.
The SEC allows incorporation by reference into this
prospectus supplement and the accompanying prospectus of
information that MetLife, Inc. files with the SEC. This permits
MetLife, Inc. to disclose important information to you by
referencing these filed documents. Any information referenced
this way is considered part of this prospectus supplement and
accompanying prospectus, and any information filed with the SEC
subsequent to the date of this prospectus supplement will
automatically be deemed to update and supersede this
information. Information furnished under Item 2.02 and
Item 7.01 of MetLife, Inc.s Current Reports on
Form 8-K
is not
S-3
incorporated by reference in this prospectus supplement and
accompanying prospectus. MetLife, Inc. incorporates by reference
the following documents which have been filed with the SEC:
|
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2010 and Amendment
No. 1 on
Form 10-K/A,
filed on March 1, 2011 (as so amended, the 2010
Form 10-K); and
|
|
|
|
Current Reports on
Form 8-K
filed on August 2, 2010, November 30, 2010,
March 1, 2011 and March 2, 2011.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the Exchange
Act), until MetLife, Inc. files a post-effective
amendment which indicates the termination of the offering of
Common Equity Units made by this prospectus supplement and
accompanying prospectus. Any reports filed by MetLife, Inc. with
the SEC after the date of this prospectus supplement and before
the date that the offering of Common Equity Units by means of
this prospectus supplement and accompanying prospectus is
terminated will automatically update and, where applicable,
supersede any information contained or incorporated by reference
in this prospectus supplement and accompanying prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents that are
incorporated by reference into this prospectus supplement and
accompanying prospectus, other than exhibits to those documents,
unless those exhibits are specifically incorporated by reference
into those documents. Requests should be directed to Investor
Relations, MetLife, Inc., 1095 Avenue of the Americas, New York,
New York 10036, by electronic mail (metir@metlife.com), or by
telephone
(212-578-2211).
You may also obtain the documents incorporated by reference into
this document as of the date hereof at MetLifes website,
www.metlife.com. All other information contained on
MetLifes website is not a part of this document.
S-4
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and the accompanying prospectus may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. These statements can be identified by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining the actual future results of MetLife,
Inc., its subsidiaries and affiliates. These statements are
based on current expectations and the current economic
environment. They involve a number of risks and uncertainties
that are difficult to predict. These statements are not
guarantees of future performance. Actual results could differ
materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the SEC. These factors include:
(1) difficult conditions in the global capital markets;
(2) increased volatility and disruption of the capital and
credit markets, which may affect our ability to seek financing
or access our credit facilities; (3) uncertainty about the
effectiveness of the United States (U.S.)
governments programs to stabilize the financial system,
the imposition of fees relating thereto, or the promulgation of
additional regulations; (4) impact of comprehensive
financial services regulation reform on us; (5) exposure to
financial and capital market risk; (6) changes in general
economic conditions, including the performance of financial
markets and interest rates, which may affect our ability to
raise capital, generate fee income and market-related revenue
and finance statutory reserve requirements and may require us to
pledge collateral or make payments related to declines in value
of specified assets; (7) potential liquidity and other
risks resulting from our participation in a securities lending
program and other transactions; (8) investment losses and
defaults, and changes to investment valuations;
(9) impairments of goodwill and realized losses or market
value impairments to illiquid assets; (10) defaults on our
mortgage loans; (11) the impairment of other financial
institutions that could adversely affect our investments or
business; (12) our ability to address unforeseen
liabilities, asset impairments, loss of key contractual
relationships, or rating actions arising from acquisitions or
dispositions, including our acquisition of American Life
Insurance Company (American Life), a
subsidiary of the Selling Securityholder, and Delaware American
Life Insurance Company (DelAm, together with
American Life, collectively ALICO) (the
Acquisition) and to successfully integrate
and manage the growth of acquired businesses with minimal
disruption; (13) uncertainty with respect to the outcome of
the closing agreement entered into between American Life and the
United States Internal Revenue Service (IRS)
in connection with the Acquisition; (14) uncertainty with
respect to any incremental tax benefits resulting from the
planned elections for ALICO and certain of its subsidiaries
under Section 338 of the U.S. Internal Revenue Code of
1986, as amended (the Section 338
Elections); (15) the dilutive impact of the
settlement of the stock purchase contracts forming part of the
Common Equity Units and the issuance of Common Stock upon
conversion of any Series B Preferred Stock not repurchased
and cancelled by MetLife, Inc.; (16) downward pressure on
MetLife, Inc.s stock price as a result of the Selling
Securityholders ability to sell its equity securities;
(17) the conditional payment obligation of up to
approximately $300 million to the Selling Securityholder,
to the extent any of the Series B Preferred Stock is not
repurchased and cancelled by MetLife, Inc. and the conversion of
the Series B Preferred Stock is not approved;
(18) economic, political, currency and other risks relating
to our international operations, including with respect to
fluctuations of exchange rates; (19) MetLife, Inc.s
primary reliance, as a holding company, on dividends from its
subsidiaries to meet debt payment obligations and the applicable
regulatory restrictions on the ability of the subsidiaries to
pay such dividends; (20) downgrades in our claims paying
ability, financial strength or credit ratings;
(21) ineffectiveness of risk management policies and
procedures; (22) availability and effectiveness of
reinsurance or indemnification arrangements, as well as default
or failure of counterparties to perform; (23) discrepancies
between actual claims experience and assumptions used in setting
prices for our products and establishing the liabilities for our
obligations for future policy benefits and claims;
(24) catastrophe losses; (25) heightened competition,
including with respect to pricing, entry of new competitors,
consolidation of
S-5
distributors, the development of new products by new and
existing competitors, distribution of amounts available under
U.S. government programs, and for personnel;
(26) unanticipated changes in industry trends;
(27) changes in accounting standards, practices
and/or
policies; (28) changes in assumptions related to deferred
policy acquisition costs, deferred sales inducements, value of
business acquired or goodwill; (29) increased expenses
relating to pension and postretirement benefit plans, as well as
health care and other employee benefits; (30) exposure to
losses related to variable annuity guarantee benefits, including
from significant and sustained downturns or extreme volatility
in equity markets, reduced interest rates, unanticipated
policyholder behavior, mortality or longevity, and the
adjustment for nonperformance risk; (31) deterioration in
the experience of the closed block established in
connection with the reorganization of Metropolitan Life
Insurance Company (MLIC); (32) adverse
results or other consequences from litigation, arbitration or
regulatory investigations; (33) inability to protect our
intellectual property rights or claims of infringement of the
intellectual property rights of others, (34) discrepancies
between actual experience and assumptions used in establishing
liabilities related to other contingencies or obligations;
(35) regulatory, legislative or tax changes relating to our
insurance, banking, international, or other operations that may
affect the cost of, or demand for, our products or services,
impair our ability to attract and retain talented and
experienced management and other employees, or increase the cost
or administrative burdens of providing benefits to employees;
(36) the effects of business disruption or economic
contraction due to terrorism, other hostilities, or natural
catastrophes, including any related impact on our disaster
recovery systems and management continuity planning which could
impair our ability to conduct business effectively;
(37) the effectiveness of our programs and practices in
avoiding giving our associates incentives to take excessive
risks; and (38) other risks and uncertainties described
from time to time in MetLife, Inc.s filings with the SEC.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
S-6
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus
supplement and the accompanying prospectus, please remember that
they are incorporated to provide you with information regarding
their terms and are not intended to provide any other factual or
disclosure information about MetLife, Inc., its subsidiaries or
the other parties to the agreements. The agreements contain
representations and warranties by each of the parties to the
applicable agreement. These representations and warranties have
been made solely for the benefit of the other parties to the
applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties to the agreement if those statements prove to be
inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time.
S-7
SUMMARY
This summary contains basic information about us and this
offering. Because it is a summary, it does not contain all of
the information that you should consider before investing in the
Common Equity Units. You should read this entire prospectus
supplement carefully, including the sections entitled Risk
Factors, our financial statements and the notes thereto
incorporated by reference into this prospectus supplement, and
the accompanying prospectus, before making an investment
decision.
MetLife
MetLife, Inc. is a leading provider of insurance, employee
benefits and financial services with operations throughout the
United States and the regions of Latin America, Asia Pacific,
Europe and the Middle East. Through subsidiaries and affiliates,
MetLife, Inc. reaches more than 90 million customers around
the world and MetLife is the largest life insurer in the
U.S. (based on life insurance in-force), and holds leading
market positions in the U.S., Japan, Latin America, Asia
Pacific, Europe and the Middle East. The MetLife companies offer
life insurance, annuities, auto and home insurance, retail
banking and other financial services to individuals, as well as
group insurance and retirement & savings products and
services to corporations and other institutions.
MetLife is one of the largest insurance and financial services
companies in the United States. MetLife believes that its
franchises and brand names uniquely position it to be the
preeminent provider of protection and savings and investment
products in the United States. In addition, its international
operations are focused on markets where the demand for insurance
and savings and investment products is expected to grow rapidly
in the future.
Over the past several years, we have grown our core businesses,
as well as successfully executed on our growth strategy. This
has included completing a number of transactions that have
resulted in the acquisition and, in some cases, divestiture of
certain businesses while also further strengthening our balance
sheet to position MetLife for continued growth. On
November 1, 2010 (the Acquisition Date),
MetLife, Inc. completed the acquisition (the
Acquisition) of American Life Insurance
Company (American Life), from the Selling
Securityholder, a subsidiary of AIG, and Delaware American Life
Insurance Company (DelAm and, together with
American Life, ALICO) from AIG for a total
purchase price of $16.4 billion, subject to adjustment,
including $7.2 billion of cash, 78,239,712 shares of
MetLife, Inc.s Common Stock, 6,857,000 shares of the
Series B Preferred Stock (convertible into
68,570,000 shares of MetLife, Inc.s Common Stock
(subject to anti-dilution adjustments) upon a favorable vote of
MetLife, Inc.s common shareholders) and 40,000,000 Common
Equity Units with an aggregate stated value of
$3.0 billion. The business acquired in the Acquisition
provides consumers and businesses with products and services,
life insurance, accident and health insurance, retirement and
wealth management solutions. This transaction delivers on our
global growth strategies, adding significant scale and reach to
MetLifes international footprint, furthering our
diversification in geographic mix and product offerings, as well
as increasing our distribution strength.
MetLife is organized into five operating segments: Insurance
Products, Retirement Products, Corporate Benefit Funding,
Auto & Home (collectively,
U.S. Business) and International. The
assets and liabilities of ALICO as of November 30, 2010 and
the operating results of ALICO from the Acquisition Date through
November 30, 2010 are included in the International
segment. For reporting periods beginning in 2011, our
non-U.S. Business
results will be presented within two separate segments: Japan
and Other International Region. MetLifes management
continues to evaluate its segment performance and allocated
resources and may adjust such measurements in the future to
better reflect segment profitability.
|
|
|
|
|
Insurance Products. The Insurance
Products segment offers a broad range of protection products and
services aimed at serving the financial needs of MetLifes
customers throughout their lives. These products are sold to
individuals and corporations, as well as other institutions and
their respective employees. MetLife has built a leading position
in the U.S. group insurance market through long-standing
relationships with many of the largest corporate employers in
the United States, and is one of the largest issuers of
individual life insurance products in the United States.
|
|
|
|
Retirement Products. The Retirement
products segment includes a variety of variable and fixed
annuities that are primarily sold to individuals and employees
of corporations and other institutions.
|
S-8
|
|
|
|
|
Corporate Benefit Funding. The
Corporate Benefit Funding segment includes an array of annuity
and investment products, including guaranteed interest products
and other stable value products, income annuities, and separate
account contracts for the investment management of defined
benefit and defined contribution plan assets. This segment also
includes certain products to fund postretirement benefits and
company, bank or trust owned life insurance used to finance
non-qualified benefit programs for executives.
|
|
|
|
Auto & Home. The
Auto & Home segment includes personal lines property
and casualty insurance offered directly to employees at their
employers worksite, as well as to individuals through a
variety of retail distribution channels, including independent
agents, property and casualty specialists, direct response
marketing and the individual distribution sales group.
|
|
|
|
International. International provides
life insurance, accident and health insurance, credit insurance,
annuities, endowment and retirement & savings products
to both individuals and groups. MetLife focuses on markets
primarily within Japan, Latin America, Asia Pacific, Europe and
the Middle East. MetLife operates in international markets
through subsidiaries and affiliates. MetLifes
International segment is the fastest-growing of MetLifes
businesses, and we believe it will be one of the largest future
growth areas.
|
Banking, Corporate & Other contains the excess capital
not allocated to the segments, which is invested to optimize
investment spread and to fund company initiatives, various
start-up
entities and run-off entities. Banking, Corporate &
Other also includes interest expense related to the majority of
MetLifes outstanding debt and expenses associated with
certain legal proceedings, as well as the financial results of
MetLife Bank, National Association (MetLife
Bank), which offers a variety of residential mortgage
and deposit products, including forward and reverse residential
mortgage loans and consumer deposits. The elimination of
transactions from activity between U.S. Business,
International and Banking, Corporate & Other occurs
within Banking, Corporate & Other.
Accounting
Treatment of Repurchase
In connection with the repurchase of the Series B Preferred
Stock, in the first quarter of 2011 MetLife will recognize a
reduction in net income available to common shareholders of
approximately $145 million (approximately $0.14 per common
share), representing a return to the Selling Securityholder
calculated as the excess of the repurchase price over the
carrying value of the Series B Preferred Stock. This return
to the Selling Securityholder will have no effect on
MetLifes operating earnings, operating earnings available
to common shareholders, operating earnings per common share or
operating earnings available to common shareholders per common
share.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188
and its telephone number is
(212) 578-2211.
S-9
The
Offering
What are
the Common Equity Units?
The common equity units (each, a Common Equity
Unit) were issued in connection with the Acquisition
by MetLife, Inc. to the Selling Securityholder pursuant to the
Stock Purchase Contract Agreement, dated November 1, 2010
(the Stock Purchase Contract Agreement),
between MetLife, Inc. and Deutsche Bank Trust Company
Americas, as stock purchase contract agent (the Stock
Purchase Contract Agent). The Common Equity Units may
be either normal Common Equity Units (each, a Normal
Common Equity Unit) or stripped Common Equity Units
(each, a Stripped Common Equity Unit). Unless
indicated otherwise, the term Common Equity
Units will include both Normal Common Equity Units and
Stripped Common Equity Units. The Common Equity Units initially
consist of 40,000,000 Normal Common Equity Units, all of which
are being offered by the Selling Securityholder in this
offering. Each Common Equity Unit has a stated amount of
(i) $75.00 up to, but excluding, the First Stock Purchase
Date, (ii) $50.00 from, and including, the First Stock
Purchase Date to, but excluding, the Second Stock Purchase Date,
and (iii) $25.00 from, and including, the Second Stock
Purchase Date to, but excluding, the Third Stock Purchase Date.
What are
the Normal Common Equity Units?
Each Normal Common Equity Unit initially consists of the
following:
(a) three Stock Purchase Contracts, as described below:
(1) Under the Series C Stock Purchase Contract, you
will agree to purchase from MetLife, Inc., and MetLife, Inc.
will agree to sell to you, on a specified date (the
First Stock Purchase Date), for $25.00 in
cash, a variable number of shares of Common Stock equal to the
settlement rate described under Description of the Stock
Purchase Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. See
Description of the Stock Purchase Contracts
Adjustments to the Fixed Settlement Rate. The First Stock
Purchase Date is expected to occur on October 10, 2012 (the
Initial Scheduled First Stock Purchase Date)
but can be deferred for up to two three-month periods in the
event of a failed Remarketing.
(2) Under the Series D Stock Purchase Contract, you
will agree to purchase from MetLife, Inc., and MetLife, Inc.
will agree to sell to you, on a specified date (the
Second Stock Purchase Date), for $25.00 in
cash, a variable number of shares of Common Stock equal to the
settlement rate described under Description of the Stock
Purchase Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. The Second
Stock Purchase Date will be on the later of (x) the date
that is six calendar months after the First Stock Purchase Date
and (y) September 11, 2013 (such date in this clause
(y), the Initial Scheduled Second Stock Purchase
Date). However, the Second Stock Purchase Date can be
deferred for up to two three-month periods in the event of a
failed Remarketing.
(3) Under the Series E Stock Purchase Contract, you
will agree to purchase from MetLife, Inc., and MetLife, Inc.
will agree to sell to you, on a specified date (the
Third Stock Purchase Date), for $25.00 in
cash, a variable number of shares of Common Stock equal to the
settlement rate described under Description of the Stock
Purchase Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. The Third
Stock Purchase Date will be on the later of (x) the date
that is six calendar months after the Second Stock Purchase Date
and (y) October 8, 2014 (such date in this clause (y),
the Initial Scheduled Third Stock Purchase
Date). However, the Third Stock Purchase Date can be
deferred for up to two three-month periods in the event of a
failed Remarketing.
(4) MetLife, Inc. will make quarterly payments on each
Stock Purchase Contract as described under Description of
the Stock Purchase Contracts Contract Payments.
(b) prior to the First Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series C Senior Debenture due 2023 of MetLife, Inc. (the
Series C Debentures) having a principal
amount of $1,000;
S-10
(c) prior to the Second Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series D Senior Debenture due 2024 of MetLife, Inc. (the
Series D Debentures) having a principal
amount of $1,000; and
(d) a 1/40, or 2.50%, undivided beneficial ownership
interest in a Series E Senior Debenture due 2045 of
MetLife, Inc. (the Series E Debenture,
and, collectively with the Series C Debentures and the
Series D Debentures, the Debentures)
having a principal amount of $1,000.
As long as a Common Equity Unit is in the form of a Normal
Common Equity Unit, your applicable ownership interest in the
Debentures forming a part of the Normal Common Equity Unit will
be pledged to MetLife, Inc. through Deutsche Bank
Trust Company Americas, acting as the collateral agent (the
Collateral Agent), to secure your obligation
to purchase Common Stock under your Stock Purchase Contracts, as
provided for in the Pledge Agreement.
What are
the Stock Purchase Contracts?
The Stock Purchase Contracts underlying a Common Equity Unit
will obligate you to purchase, and us to sell, for $25.00, on
each of the First Stock Purchase Date, the Second Stock Purchase
Date and the Third Stock Purchase Date, a variable number of
shares of the Common Stock per Common Equity Unit equal to the
applicable Settlement Rate. Each Settlement Rate will be
calculated based on the VWAP during a specified period preceding
the applicable Initial Scheduled Stock Purchase Date, as
described below.
What are
the Debentures?
The Debentures are senior debt securities, as described in the
accompanying prospectus, divided into three series. MetLife,
Inc. issued the Debentures under the Indenture, dated as of
November 9, 2001 (the Indenture),
between MetLife, Inc. and The Bank of New York Mellon
Trust Company, N.A. (as successor in interest to
J.P. Morgan Trust Company, National Association (as
successor in interest to Bank One Trust Company, N.A.)), as
trustee (the Trustee), as supplemented by the
Twentieth Supplemental Indenture, with respect to the
Series C Debentures, the Twenty-First Supplemental
Indenture, with respect to the Series D Debentures and the
Twenty-Second Supplemental Indenture, with respect to the
Series E Debentures. The Series C Debentures, the
Series D Debentures and the Series E Debentures were
each issued with an initial aggregate principal amount of
$1,000,000,000. There is no limit on the aggregate principal
amount of each series of the Debentures that MetLife, Inc. may
issue. The Series C Debentures and the Series E
Debentures were issued only in principal amounts equal to an
integral multiple of $2,000 and, following a bifurcation of
either such series, as described below under Description
of the Debentures Bifurcation, Component
Debentures (as defined in this prospectus supplement) of either
such series will be denominated only in principal amounts equal
to an integral multiple of $1,000. The Series D Debentures
were issued only in principal amounts equal to an integral
multiple of $1,000.
None of the Debentures will be entitled to any sinking fund.
Each series of Debentures and each Supplemental Indenture and
the Indenture are governed by, and construed in accordance with,
the laws of the State of New York.
When are
interest payments on the Debentures made and at what
rate?
Interest payments will be made on the principal amount of the
Series C Debentures, the Series D Debentures and the
Series E Debentures at an initial rate per annum equal to
1.564%, 1.923% and 2.463%, respectively. Interest on the
Debentures will be payable quarterly in arrears on
March 15, June 15, September 15 and December 15 of
each year, (each such date, an Interest Payment
Date). Interest that is due on any Debentures on any
March 15, June 15, September 15, or December 15
will be paid to the person who is the holder of such Debentures
as of the close of business on the immediately preceding
March 1, June 1, September 1 or December 1,
respectively (whether or not such date is a Business Day). The
interest payment that is scheduled to be made on March 15,
2011 will be paid to the Selling Securityholder as holder of
record on March 1, 2011. If you purchase Common Equity
Units pursuant to this offering, interest payments attributable
to your ownership interests in the Debentures will accrue
S-11
from, and including, March 15, 2011. Interest rates in the
Debentures may be reset at different rates in connection with a
remarketing, as described below.
What is
the bifurcation of the Debentures?
On the Interest Payment Date occurring on or immediately
preceding the Initial Scheduled First Stock Purchase Date (such
Interest Payment Date, the Series C Debenture
Bifurcation Date), the Series C Debentures will
automatically convert, without any act of any holder, into units
(each, a Series C Debenture Unit)
consisting of two tranches, with each $2,000 principal amount of
Series C Debentures thereafter consisting of $1,000
principal amount of a first tranche debenture (the
First Series C Tranche Debentures)
and $1,000 principal amount of a second tranche debenture (the
Second Series C Tranche Debentures,
and, together with the First Series C
Tranche Debentures, the Series C Component
Debentures). On the Interest Payment Date occurring on
or immediately preceding the Initial Third Stock Purchase Date
(as defined in this prospectus supplement) (such Interest
Payment Date, the Series E Debenture Bifurcation
Date, and, together with the Series C Debenture
Bifurcation Date, the Bifurcation Dates), the
Series E Debentures will automatically convert, without any
act of any holder, into units (each, a Series E
Debenture Unit, and, together with the Series C
Debenture Units, the Debenture Units)
consisting of two tranches, with each $2,000 principal amount of
Series E Debentures thereafter consisting of $1,000
principal amount of a first tranche debenture (the
First Series E Tranche Debentures)
and $1,000 principal amount of a second tranche debenture (the
Second Series E Tranche Debentures,
and, together with the First Series E
Tranche Debentures, the Series E Component
Debentures). The Series C Component Debentures
and the Series E Component Debentures are collectively
referred to as Component Debentures. For
purposes hereof, the term Debentures includes
Component Debentures after the applicable
Bifurcation Date.
Initial Third Stock Purchase Date means the
later of (1) the date that is six calendar months after the
Second Stock Purchase Date; and (2) the Initial Scheduled
Third Stock Purchase Date.
The terms of each Component Debenture for the Series C
Debentures and the Series E Debentures will be identical to
the terms of the applicable predecessor Debentures, with the
following exceptions:
|
|
|
|
|
In connection with a successful Remarketing, the interest rate
of each tranche of Component Debentures need not, but may, be
equal to each other.
|
|
|
|
Each tranche has different stated maturity dates, as described
under Description of the Debentures
Maturity.
|
|
|
|
The holder of a Debenture Unit that consists of Component
Debentures will be deemed to be the holder of such Component
Debentures.
|
|
|
|
No Component Debenture will be separated from the Debenture Unit
of which such Component Debenture forms a part, except pursuant
to a redemption or Remarketing (as defined below), and a
Component Debenture can be separated from the Debenture Unit of
which such Component Debenture forms part only in integral
multiples of $1,000 in principal amount of such Component
Debenture.
|
What is
the maturity of the Debentures?
As described above, on the Series C Bifurcation Date, the
Series C Debentures will automatically bifurcate into two
tranches, the First Series C Tranche Debentures and
the Second Series C Tranche Debentures. The First
Series C Tranche Debentures will mature on
June 15, 2018, unless there is a successful Remarketing or
a Final Failed Remarketing (as defined below), in which case the
First Series C Tranche Debentures will mature on the
date that is the 21st Interest Payment Date immediately
following the First Stock Purchase Date. The Second
Series C Tranche Debentures will mature on
June 15, 2023, unless there is a successful Remarketing or
a Final Failed Remarketing in which case the Second
Series C Tranche Debentures will mature on the date
that is the 41st Interest Payment Date immediately
following the First Stock Purchase Date.
The Series D Debentures will mature on the date that is the
41st Interest Payment Date immediately following the Second
Stock Purchase Date.
S-12
As described above, on the Series E Bifurcation Date, the
Series E Debentures will automatically bifurcate into two
tranches, the First Series E Tranche Debentures and
the Second Series E Tranche Debentures. The First
Series E Tranche Debentures will mature on
June 15, 2018, unless there is a successful Remarketing or
a Final Failed Remarketing, in which case the First
Series E Tranche Debentures will mature on the date
that is the 13th Interest Payment Date immediately
following the Third Stock Purchase Date. The Second
Series E Tranche Debentures will mature on
June 15, 2045, unless there is a successful Remarketing or
a Final Failed Remarketing, in which case the Second
Series E Tranche Debentures will mature on the date
that is the 121st Interest Payment Date immediately
following the Third Stock Purchase Date.
What are
Stripped Common Equity Units and how can I create Stripped
Common Equity Units from Normal Common Equity Units?
You may consider it beneficial either to hold the Debentures
directly or to realize proceeds from their sale. These
investment choices are facilitated by creating Stripped Common
Equity Units. You will have the right (but not during the period
that begins at 5:00 p.m., New York City time, on the tenth
Business Day immediately preceding any scheduled Stock Purchase
Date and ends at 5:00 p.m., New York City time, on such
scheduled Stock Purchase Date), in accordance with the
procedures described below, to create Stripped Common Equity
Units by substituting (i) for the Series C Debentures,
zero coupon Series C Treasury Securities, (ii) for the
Series D Debentures, zero coupon Series D Treasury
Securities, and (iii) for the Series E Debentures,
zero coupon Series E Treasury Securities (each such zero
coupon treasury security, a Treasury
Security), that mature on the respective dates set
forth in the table below, in a total principal amount at
maturity equal to the aggregate principal amount of such
Debentures for which substitution is being made. You may make
this substitution only in integral multiples of 80 Normal Common
Equity Units. Each of these substitutions will create Stripped
Common Equity Units, and the ownership interest in the
Debentures will be released to you and be separately tradeable
from the Stripped Common Equity Units.
If you choose to create Stripped Common Equity Units, you must
substitute Treasury Securities for each series of Debentures
then underlying the Normal Common Equity Units that are being
made into Stripped Common Equity Units. The Treasury Securities
substituted for the Debentures of each series must be purchased
in the open market at your expense unless otherwise owned by
you. If you elect to substitute Treasury Securities for your
Debentures, thereby creating Stripped Common Equity Units, you
will be responsible for any fees or expenses payable in
connection with the substitution.
The following table sets forth the CUSIP numbers of the Treasury
Securities maturing on the dates indicated.
|
|
|
|
|
|
|
Treasury Security
|
|
Maturity Date
|
|
CUSIP No.
|
|
Series C Treasury Securities
|
|
September 30, 2012
|
|
|
912833Y61
|
|
Series D Treasury Securities
|
|
August 31, 2013
|
|
|
912834AF5
|
|
Series E Treasury Securities
|
|
September 30, 2014
|
|
|
912834BE7
|
|
If any of the Treasury Securities underlying Stripped Common
Equity Units mature prior to the applicable Stock Purchase Date,
the proceeds from such maturity will be invested at the sole
discretion of MetLife, Inc. and the applicable Treasury
Securities will, subject to limited exceptions, be deemed to
have matured on the applicable Stock Purchase Date.
Each Stripped Common Equity Unit consists of the following:
(a) prior to the First Stock Purchase Date, one
Series C Stock Purchase Contract;
(b) prior to the Second Stock Purchase Date, one
Series D Stock Purchase Contract;
(c) one Series E Stock Purchase Contract;
(b) prior to the First Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series C Treasury Security having a principal amount at
maturity of $1,000;
(c) prior to the Second Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series D Treasury Security having a principal amount at
maturity of $1,000; and
S-13
(d) a 1/40, or 2.50%, undivided beneficial ownership
interest in a Series E Treasury Security having a principal
amount at maturity of $1,000.
To create Stripped Common Equity Units, the minimum amount of
which is 80 Stripped Common Equity Units, you must:
|
|
|
|
|
if creating a Stripped Common Equity Unit prior to the First
Stock Purchase Date, deposit with the Collateral Agent
Series C Treasury Securities having an aggregate principal
amount at maturity of $2,000;
|
|
|
|
if creating a Stripped Common Equity Unit prior to the Second
Stock Purchase Date, deposit with the Collateral Agent
Series D Treasury Securities having an aggregate principal
amount at maturity of $2,000;
|
|
|
|
deposit with the Collateral Agent Series E Treasury
Securities having an aggregate principal amount at maturity of
$2,000; and
|
|
|
|
transfer 80 Normal Common Equity Units to the Stock Purchase
Contract Agent, accompanied by a notice stating that you have
deposited the required number of Treasury Securities with the
Collateral Agent and requesting the release to you of the
Debentures relating to the 80 Normal Common Equity Units.
|
Upon such deposit and receipt of an instruction from the Stock
Purchase Contract Agent, the Collateral Agent will release the
related Debentures from the pledge under the Pledge Agreement,
dated November 1, 2010 (the Pledge
Agreement), among MetLife, Inc., the Collateral Agent,
Deutsche Bank Trust Company Americas, as securities
intermediary (the Securities Intermediary),
and the Stock Purchase Contract Agent, free and clear of
MetLife, Inc.s security interest, to the Stock Purchase
Contract Agent on your behalf. The Stock Purchase Contract Agent
then will:
|
|
|
|
|
cancel the 80 Normal Common Equity Units;
|
|
|
|
transfer the related Debentures to you; and
|
|
|
|
authenticate, execute on your behalf and deliver 80 Stripped
Common Equity Units to you.
|
Pursuant to the Pledge Agreement, the applicable Treasury
Securities will be substituted for the Debentures and will be
pledged to MetLife, Inc. through the Collateral Agent to secure
your obligation to purchase Common Stock under your Stock
Purchase Contracts. The related Debentures released to you
thereafter will trade separately from the resulting Stripped
Common Equity Units.
How can I
recreate Normal Common Equity Units from the Stripped Equity
Units?
You will have the right (but not during the period that begins
at 5:00 p.m., New York City time, on the tenth Business Day
immediately preceding any scheduled Stock Purchase Date and ends
at 5:00 p.m., New York City time, on such scheduled Stock
Purchase Date), in accordance with the procedures described
below, to recreate a Normal Common Equity Unit from a Stripped
Common Equity Unit by substituting the Series C Debentures
(if applicable), the Series D Debentures (if applicable)
and the Series E Debentures for the applicable Treasury
Securities then held by the Collateral Agent. You may recreate
Normal Common Equity Units only in integral multiples of 80
Stripped Common Equity Units. The Series C Debentures (if
applicable), the Series D Debentures (if applicable) and
the Series E Debentures substituted for the applicable
Treasury Securities must be purchased in the open market at your
expense unless otherwise owned by you. If you elect to
substitute Debentures for your Treasury Securities, thereby
recreating Normal Common Equity Units, you will be responsible
for any fees or expenses payable in connection with the
substitution.
To recreate Normal Common Equity Units, the minimum amount of
which is 80 Normal Common Equity Units, you must:
|
|
|
|
|
if recreating a Normal Common Equity Unit prior to the First
Stock Purchase Date, deposit with the Collateral Agent
Series C Debentures having an aggregate principal amount of
$2,000;
|
|
|
|
if recreating a Normal Common Equity Unit prior to the Second
Stock Purchase Date, deposit with the Collateral Agent
Series D Debentures having an aggregate principal amount of
$2,000;
|
S-14
|
|
|
|
|
deposit with the Collateral Agent Series E Debentures
having an aggregate principal amount of $2,000; and
|
|
|
|
transfer 80 Stripped Common Equity Units to the Stock Purchase
Contract Agent, accompanied by a notice stating that you have
deposited the required number of Debentures with the Collateral
Agent and requesting the release to you of the Treasury
Securities relating to the 80 Stripped Common Equity Units.
|
Each of these substitutions will recreate Normal Common Equity
Units, and the applicable Treasury Securities will be released
to you and be separately tradeable from the Normal Common Equity
Units.
Upon such deposit and receipt of an instruction from the Stock
Purchase Contract Agent, the Collateral Agent will release the
related Treasury Securities from the pledge under the Pledge
Agreement, free and clear of MetLife, Inc.s security
interest, to the Stock Purchase Contract Agent on your behalf.
The Stock Purchase Contract Agent will then:
|
|
|
|
|
cancel the 80 Stripped Common Equity Units;
|
|
|
|
transfer the related Treasury Securities to you; and
|
|
|
|
authenticate, execute on your behalf and deliver 80 Normal
Common Equity Units to you.
|
Pursuant to the Pledge Agreement, the substituted ownership
interests in the applicable Debentures will be pledged to
MetLife, Inc. through the Collateral Agent to secure your
obligation to purchase Common Stock under the Stock Purchase
Contracts.
What is
the Settlement Rate?
On the Stock Purchase Date of each Stock Purchase Contract, the
holder thereof must purchase, and MetLife, Inc. must sell to
such holder, for a cash price of $25.00 (the Purchase
Price), a number of shares of Common Stock equal to
the Settlement Rate (as defined below). Except to the extent
described below with respect to Early Settlement or Cash Merger
Early Settlement, the Purchase Price will be paid (i) from
the proceeds of the Remarketing of, or the exercise of the Put
Right (as defined below) with respect to, the related
Debentures, in the case of Normal Common Equity Units; or
(ii) from the proceeds of the applicable maturing Treasury
Securities, in the case of Stripped Common Equity Units.
However, if, in the case of a Normal Common Equity Unit, the
applicable Remarketing is a Final Failed Remarketing and the
holder of the Normal Common Equity Unit has elected not to
exercise the related Put Right, or if the holder has duly
elected not to have the related Debentures sold pursuant to the
applicable Remarketing, then the holder must pay the applicable
Purchase Price in cash to the Collateral Agent by 5:00 p.m.
(New York City time) on the Business Day immediately preceding
the applicable Stock Purchase Date (or such earlier time as may
be required by the terms of the Stock Purchase Contract
Agreement).
Settlement Rate means, with respect to a
Stock Purchase Date of a Stock Purchase Contract, a number of
shares of Common Stock equal to the following:
(i) if the Applicable Market Value (as defined below) for
such Stock Purchase Date is equal to or less than the Reference
Price (as defined below), then the Settlement Rate for such
Stock Purchase Date will be the Maximum Settlement Rate (as
defined below);
(ii) if the Applicable Market Value for such Stock Purchase
Date is greater than the Reference Price and less than the
Threshold Appreciation Price (as defined below), then the
Settlement Rate for such Stock Purchase Date will be a fraction
whose numerator is $25.00 and whose denominator is such
Applicable Market Value, which fraction will be rounded to the
nearest one-ten-thousandth of a share of Common Stock; and
(iii) if the Applicable Market Value for such Stock
Purchase Date is equal to or greater than the Threshold
Appreciation Price, then the Settlement Rate for such Stock
Purchase Date will be the Minimum Settlement Rate (as defined
below).
However, if the Stock Purchase Date (or, with respect to an
Early Settlement Upon Cash Merger, the Cash Merger Early
Settlement Date) of a Stock Purchase Contract occurs after the
Initial Scheduled First Stock Purchase Date (in the case of a
Series C Stock Purchase Contract), the Initial Scheduled
Second Stock Purchase Date (in the
S-15
case of a Series D Stock Purchase Contract) or the Initial
Scheduled Third Stock Purchase Date (in the case of a
Series E Stock Purchase Contract), then the Settlement Rate
will be adjusted in the same manner as the Fixed Settlement
Rates are adjusted as described below under Description of
the Stock Purchase Contracts Adjustments to the
Fixed Settlement Rates for any event or transaction that
occurs on or after such Initial Scheduled First Stock Purchase
Date, Initial Scheduled Second Stock Purchase Date or Initial
Scheduled Third Stock Purchase Date, as applicable, and on or
before such Stock Purchase Date or Cash Merger Early Settlement
Date, as applicable.
Applicable Market Value means, with respect
to a Stock Purchase Date of a Stock Purchase Contract, the
average of the VWAPs (as defined below) on each Trading Day in
the Trading Day Period (as defined below) of such Stock Purchase
Date.
VWAP on any Trading Day means the
volume-weighted average price per share of Common Stock in
respect of the period from 9:30 a.m. to 4:00 p.m. (New
York City time) on such Trading Day, as displayed under the
heading Bloomberg VWAP on Bloomberg page MET.N
<equity> AQR (or its equivalent successor if
such page is not available). However, if such volume-weighted
average price will not be available on such Trading Day, then
VWAP on such Trading Day will be determined, using a
volume-weighted average method, by a nationally recognized
independent investment banking firm retained for such purpose by
MetLife, Inc.
Trading Day means any day during which both
of the following conditions are satisfied: (i) trading in
the Common Stock generally occurs on the Relevant Exchange (as
defined below); and (ii) there is no Market Disruption
Event (as defined below).
Relevant Exchange means the New York Stock
Exchange; provided, however, that if the Common
Stock is not listed for trading on the New York Stock Exchange,
then Relevant Exchange means the principal
U.S. national or regional securities exchange on which the
Common Stock is listed; provided further, that if the
Common Stock is not listed on a U.S. national or regional
securities exchange, then Relevant Exchange means
the
over-the-counter
market on which the Common Stock is traded.
Market Disruption Event means any of the
following events that MetLife, Inc., in its reasonable
discretion, determines has occurred and is material:
(i) the occurrence or existence, for an aggregate period of
at least 30 minutes or during the
one-hour
period prior to the close of trading for the regular trading
session on the Relevant Exchange, of any suspension of, or
limitation imposed on, trading by the Relevant Exchange, whether
by reason of movements in price exceeding limits permitted by
the Relevant Exchange, or otherwise:
(1) relating to the Common Stock; or
(2) in futures or options contracts relating to the Common
Stock on the Relevant Exchange;
(ii) any event (other than an event described in
clause (iii) below) that disrupts or impairs the ability of
market participants, for an aggregate period of at least 30
minutes or during the
one-hour
period prior to the close of trading for the regular trading
session on the Relevant Exchange in general:
(1) to effect transactions in, or obtain market values for,
the Common Stock on the Relevant Exchange; or
(2) to effect transactions in, or obtain market values for,
futures or options contracts relating to the Common Stock on the
Relevant Exchange; or
(iii) the failure to open of the Relevant Exchange on which
futures or options contracts relating to the Common Stock are
traded or the closure of such exchange prior to its respective
scheduled closing time for the regular trading session on such
day (without regard to after hours or any other trading outside
of the regular trading session hours) unless such earlier
closing time is announced by such exchange at least one hour
prior to the earlier of:
(1) the actual closing time for the regular trading session
on such day, and
S-16
(2) the submission deadline for orders to be entered into
such exchange for execution at the actual closing time on such
day.
Trading Day Period means, (i) with
respect to the First Stock Purchase Date, the 20 consecutive
Trading Days ending on, and including, the third Trading Day
immediately preceding the Initial Scheduled First Stock Purchase
Date; (ii) with respect to the Second Stock Purchase Date,
the 20 consecutive Trading Days ending on, and including, the
third Trading Day immediately preceding the Initial Scheduled
Second Stock Purchase Date; and (iii) with respect to the
Third Stock Purchase Date, the 20 consecutive Trading Days
ending on, and including, the third Trading Day immediately
preceding the Initial Scheduled Third Stock Purchase Date.
Maximum Settlement Rate means 0.7058, subject
to adjustments as described under Description of the Stock
Purchase Contracts Adjustments to the Fixed
Settlement Rates.
Minimum Settlement Rate means 0.5647, subject
to adjustments as described under Description of the Stock
Purchase Contracts Adjustments to the Fixed
Settlement Rates.
Fixed Settlement Rates means each of the
Maximum Settlement Rate and the Minimum Settlement Rate, subject
to adjustments as described under Description of the Stock
Purchase Contracts Adjustments to the Fixed
Settlement Rates.
Reference Price means $35.42, subject to
adjustments as described under Description of the Stock
Purchase Contracts Adjustments to the Fixed
Settlement Rates.
Threshold Appreciation Price means $44.275,
subject to adjustments as described under Description of
the Stock Purchase Contracts Adjustments to the
Fixed Settlement Rates.
What are
the Contract Payments?
MetLife, Inc. will make Contract Payments on each Stock Purchase
Contract, payable quarterly in arrears on each Contract Payment
Date. However, the Contract Payment that is scheduled to be made
on March 15, 2011 will be paid to the Selling
Securityholder as holder of record on March 1, 2011.
Contract Payments will accrue on the stated amount of $25.00 for
each Stock Purchase Contract at the following annual rates:
|
|
|
|
|
3.436% on the Series C Stock Purchase Contracts;
|
|
|
|
3.077% on the Series D Stock Purchase Contracts; and
|
|
|
|
2.537% on the Series E Stock Purchase Contracts.
|
Contract Payments will accrue from, and including, the most
recent date to which Contract Payments have been paid or
provided for (or, if no such Contract Payments have been paid or
provided for, from, and including, November 1,
2010) to, but excluding, the next Contract Payment Date. If
you purchase Common Equity Units pursuant to this offering,
Contract Payments on the Stock Purchase Contracts will accrue
from, and including, March 15, 2011. Contract Payments are
computed on the basis of a
360-day year
of twelve
30-day
months. On each Contract Payment Date, the Contract Payment on
each Stock Purchase Contract will be paid to the person in whose
name the Common Equity Unit of which the Stock Purchase Contract
is a part was registered at the close of business on the date
(the Record Date) that is the
15th calendar day immediately preceding the applicable
Contract Payment Date. However, MetLife, Inc. may, at its
option, select any other day as the Record Date, so long as such
selection is made more than 15 calendar days before the Contract
Payment Date and such Record Date selected is (A) more than
one Business Day but less than 60 Business Days before the
applicable Contract Payment Date and (B) administratively
acceptable to the Stock Purchase Contract Agent in its
reasonable judgment.
Notwithstanding the above, MetLife, Inc. may defer the Contract
Payments upon prior written notice to holders until no later
than the Third Stock Purchase Date (Deferred Contract
Payments). Deferred Contract Payments will accrue
interest, to the extent permitted by law, at an annual rate
equal to the applicable Contract Payment Deferral Rate (as
defined below).
The Contract Payment Deferral Rate means an
annual rate, determined by MetLife, Inc. as of each Contract
Payment Date and applicable to amounts that accrue from, and
including, such Contract Payment Date to, but
S-17
excluding, the next succeeding Contract Payment Date, equal to
the greater of (i) the sum of (a) the prevailing
annual market yield, on such Contract Payment Date, of the
benchmark U.S. Treasury Security having a remaining
maturity, as of such payment date, that most closely corresponds
to the period from such Contract Payment Date to (x) the
next scheduled First Stock Purchase Date, with respect to a
Series C Stock Purchase Contract, (y) the next
scheduled Second Stock Purchase Date, with respect to a
Series D Stock Purchase Contract or (z) the next
scheduled Third Stock Purchase Date, with respect to a
Series E Stock Purchase Contract; and
(b) 100 basis points; and (ii) 5.00%.
MetLife, Inc.s obligation to pay Contract Payments will be
subordinate and junior in right of payment to all of its
existing and future secured and senior debt, as described in the
accompanying prospectus under Description of Debt
Securities Subordination. In addition, your
right to receive accrued Contract Payments will terminate
automatically upon the occurrence of specified bankruptcy,
insolvency or reorganization events involving MetLife, Inc.
In the case of any Common Equity Units with respect to which
Early Settlement or Cash Merger Early Settlement (as described
under Description of the Stock Purchase
Contracts Early Settlement and
Description of the Stock Purchase Contracts
Early Settlement Upon Cash Merger) of the underlying Stock
Purchase Contracts is effected and the related Early Settlement
Date or Cash Merger Early Settlement Date, as applicable, is
after any Record Date and on or before the next succeeding
Contract Payment Date, Contract Payments otherwise payable on
such Contract Payment Date will be payable on such Contract
Payment Date notwithstanding such Early Settlement or Cash
Merger Early Settlement, and such Contract Payments will be paid
to the person in whose name the Common Equity Units are
registered at the close of business on such Record Date. Subject
to limited exceptions, if the Stock Purchase Contracts of a
Common Equity Unit are subject to Early Settlement or Cash
Merger Early Settlement, Contract Payments that would otherwise
be payable after the related Early Settlement Date or Cash
Merger Early Settlement Date, as applicable, with respect to
such Stock Purchase Contracts will not be payable.
What is a
Remarketing?
If you hold Normal Common Equity Units, to provide you with the
proceeds necessary to be applied in the settlement of your Stock
Purchase Contract obligations on each applicable Stock Purchase
Date, the Debentures of the series having an applicable
Remarketing Settlement Date (as defined below) that corresponds
to such applicable Stock Purchase Date will be remarketed,
unless you elect not to participate in that remarketing. The
cash proceeds from a successful remarketing will be used to
satisfy your obligation to purchase Common Stock on the
applicable Stock Purchase Date and any remaining proceeds (net
of any Remarketing Fee) will be remitted to you. If you hold
Debentures separately and not as part of the Common Equity
Units, you may elect to participate in remarketings as described
below.
At least 30 days before each Stock Purchase Date, MetLife,
Inc. will appoint a nationally recognized investment banking
firm as remarketing agent (the Remarketing
Agent) who will attempt to resell Debentures of the
applicable series corresponding to such Stock Purchase Date in
remarketings (each, a Remarketing), unless
you elect not to participate in such Remarketings. If you hold
the Debentures separately and not as part of Common Equity
Units, you may elect to participate in a Remarketing as
described under Description of the Debentures
Optional Remarketing of the Debentures Not Included in Normal
Common Equity Units. MetLife, Inc. may appoint different
Remarketing Agents for Remarketings for different Stock Purchase
Dates. In the case of the Series C Debentures and the
Series E Debentures, the settlement date for each
Remarketing will occur after the applicable Bifurcation Date,
and each tranche of Component Debentures will be separately
remarketed.
In each Remarketing, the Remarketing Agent will use its
commercially reasonable efforts to obtain a cash price for the
relevant series of Debentures or Component Debentures to be
Remarketed which results in gross proceeds equal to the sum of
(i) the fee to be paid to the Remarketing Agent, as agreed
between the Remarketing Agent and MetLife, Inc. (the
Remarketing Fee); (ii) 100% of the
aggregate principal amount of all Debentures or Component
Debentures to be Remarketed; (iii) the Interest Make-Whole
(as defined below) for such Debentures or Component Debentures;
and (iv) the product of five basis points and the aggregate
principal amount of such Debentures or Component Debentures (the
Success Fee). To obtain that price, the
Remarketing Agent may reset the interest rate (the
Reset Rate) on the Debentures as described
below. If the Remarketing is successful, the Reset
S-18
Rate will apply to all outstanding Debentures of the series,
whether or not the holders of such Debentures participated in
the Remarketing, and will become effective on the settlement
date of such Remarketing. A Remarketing will generally be deemed
to be successful if it actually settles during the
period specified below and it generates the gross proceeds
specified above.
Interest Make-Whole means, with respect to a
Debenture to be offered for resale in a Remarketing, an amount
equal to the unpaid interest on such Debenture that will have
accrued to, but not including, the applicable Stock Purchase
Date of such Remarketing. However, if the Remarketing Settlement
Date of such Remarketing is after the close of business on a
record date for the payment of interest on such Component
Debentures and on or before the next succeeding interest payment
date for such Component Debentures, then the Interest Make-Whole
of such Component Debentures will be an amount equal to zero.
MetLife, Inc. will conduct at least one, but no more than three,
Remarketings for each of the Series C Debenture Units, the
Series D Debentures and the Series E Debenture Units.
Notwithstanding the foregoing, MetLife, Inc. will be under no
such obligation to conduct a Remarketing at any time when none
of the Common Equity Units are outstanding.
For each series of Debentures or Component Debentures, the first
Remarketing must settle (i.e., close) during the period
beginning on, and including, the fifth Business Day immediately
preceding the applicable Initial Scheduled Stock Repurchase
Date, and ending on, and including, (i) the Initial
Scheduled First Stock Purchase Date (in the case of
Series C Debenture Units), (ii) the Initial Scheduled
Second Stock Purchase Date (in the case of Series D
Debentures), or (iii) the Initial Scheduled Third Stock
Purchase Date (in the case of Series E Debenture Units), as
applicable. Such settlement date is referred to as the
Remarketing Settlement Date. If such initial
Remarketing is not successful, then the applicable scheduled
Stock Purchase Date will be deferred by three months and a
second Remarketing will be conducted. The settlement date of the
second Remarketing must occur during the period beginning on,
and including, the fifth Business Day immediately preceding such
deferred scheduled Stock Purchase Date. If such second
Remarketing is not successful, then the applicable scheduled
Stock Purchase Date will again be deferred by three months and a
third and final Remarketing will be conducted. The settlement
date of the third Remarketing must occur during the period
beginning on, and including, the fifth Business Day immediately
preceding such deferred scheduled Stock Purchase Date.
In connection with the first two Remarketings of any series of
Debentures or Component Debentures, the Reset Rate may not
exceed the Reset Cap. For this purpose, the Reset
Cap is the prevailing market yield per annum, as
determined by the Remarketing Agent, of the benchmark
U.S. treasury security having a remaining maturity that
most closely corresponds to the remaining maturity of such
Debentures or Component Debentures, plus 750 basis points.
The Reset Cap will not apply to any third Remarketing attempt.
In the event that the third Remarketing for any series of
Debentures or Component Debentures is not successful, then the
interest rate applicable to those Debentures or Component
Debentures will not be reset.
What
happens if a Remarketing is successful?
If the Remarketing is successful, the Remarketing Agent will
deduct the applicable Remarketing Fee, and the remaining
proceeds will be applied as follows:
|
|
|
|
|
in the case of Debentures or Debenture Units forming part of any
Common Equity Unit, (i) the Interest Make-Whole and Success
Fee will be delivered to the holder of such Common Equity Unit;
and (ii) the remaining proceeds will be delivered to
MetLife, Inc. on behalf of such holder in satisfaction of such
holders obligation to pay the Purchase Price for the Stock
Purchase Contract forming part of such Common Equity Unit that
settles on the applicable Stock Purchase Date; and
|
|
|
|
in the case of Separate Debentures (as defined below), the
remaining proceeds will be remitted to the holders that tendered
such Separate Debentures for inclusion in the Remarketing.
|
S-19
What
happens if the final Remarketing of a series of Debentures is
not successful?
If the third Remarketing for any series of Debentures or
Debenture Units is not successful, a Final Failed
Remarketing will have occurred with respect to that
series of Debentures or Debenture Units. In such case, holders
of Debentures or Debenture Units of that series forming part of
any Normal Common Equity Unit will have the right (the
Put Right) to require MetLife, Inc. to
purchase such Debentures or Debenture Units on the Stock
Purchase Date for such series of Debentures or Component
Debentures, for cash in an amount equal to the principal amount
of such Debentures or Component Debentures, plus unpaid interest
thereon that has accrued to, but not including, such Stock
Purchase Date. Such Put Right of a holder of Debentures or
Debenture Units forming part of any Normal Common Equity Units
will automatically, without any action of that holder, be deemed
to be exercised on the Stock Purchase Date applicable to the
Final Failed Remarketing, unless the holder has elected cash
settlement in accordance with the Stock Purchase Contract
Agreement.
If I hold
my Debentures separately from the Common Equity Units, may I
still participate in a Remarketing?
Holders of Debentures or Debenture Units not forming part of any
Common Equity Units (Separate Debentures) may
elect to have such Separate Debentures included in a Remarketing
by delivering such Separate Debentures, along with a notice of
such election to Deutsche Bank Trust Company Americas, as
the custodial agent (the Custodial Agent),
before the close of business on the 25th Business Day
immediately before the applicable Stock Purchase Date. However,
no holder of a Separate Debenture may elect to include such
Separate Debenture in a Remarketing, unless the principal amount
of such Separate Debenture (and, if such Separate Debenture is a
Debenture Unit, the principal amount of each tranche of
Component Debentures forming part of such Debenture Unit) is an
integral multiple of $1,000. Such election may be withdrawn
before the 25th Business Day immediately preceding the
applicable Stock Purchase Date.
Can the
Debentures be Redeemed?
MetLife, Inc. will not have the right to redeem any Debentures
or Component Debentures before the Redemption Trigger Date
(as defined below). However, MetLife, Inc. has the right, at its
option, at any time, and from time to time, to redeem all or any
part of the Debentures or Component Debentures, on any date
selected by MetLife, Inc. (the
Redemption Date) on or after the
Redemption Trigger Date, at a price payable in cash equal
to the Debenture Redemption Price (as defined below). If a
Redemption Date is after the regular record date for a
payment of interest on the Debentures or Component Debentures to
be redeemed and on or before the next Interest Payment Date,
then such payment of interest will, notwithstanding the
redemption, be made, on such Interest Payment Date, to the
holder(s) of such Debentures or Component Debentures as of the
close of business on such regular record date. To exercise its
right to redeem any Debentures or Component Debentures, MetLife,
Inc. must send notice of such redemption to holders of the
Debentures or Component Debentures to be redeemed not less than
30 days nor more than 90 days before the applicable
Redemption Date.
Redemption Trigger Date means, with
respect to a series of Debentures or Debenture Units, the
following date, as applicable: (i) if a successful
Remarketing has occurred with respect to such series, the second
anniversary of the applicable Stock Purchase Date of such
Remarketing; or (ii) if a Final Failed Remarketing has
occurred with respect to such series, the Stock Purchase Date
for such series.
Debenture Redemption Price means, with
respect to each Debenture or Component Debenture to be redeemed
on a Redemption Date, the sum of (1) the greater of
(A) the principal amount of such Debenture or Component
Debenture; and (B) the present value, as of such
Redemption Date, of all remaining scheduled principal and
interest payments on such Debenture or Component Debenture from,
but excluding, such Redemption Date through, and including,
the stated maturity date of the principal of such Debenture or
Component Debenture (not including any portion of such payments
of interest that have accrued, or for which the regular record
date has occurred, as of such Redemption Date), such
present value to be calculated using discounting, on a
semi-annual basis assuming a
360-day year
consisting of twelve
30-day
months, at a discount rate equal to the lesser of (i) the
Treasury Rate (as defined below) plus 50 basis points and
(ii) 15%; and (2) (without duplication) unpaid interest
that has accrued on such Debenture or Component Debenture to,
but excluding, such Redemption Date; provided,
S-20
however, that if such Redemption Date is after the
regular record date for a payment of interest on such Debenture
or Component Debenture and on or before the next Interest
Payment Date of such Debenture or Component Debenture, then
(x) such payment of interest will, notwithstanding such
redemption, be made, on such Interest Payment Date, to the
holder of such Debenture or Component Debenture as of the close
of business on such regular record date; (y) for avoidance
of doubt, such present value in clause (1)(B) above will be
calculated excluding such payment of interest; and (z) the
amount described in clause (2) above will be deemed to be
equal to zero. The present value to be calculated pursuant to
clause (1)(B) above will be calculated assuming that the
interest rate of such Debenture or Component Debentures in
effect at the open of business on the applicable
Redemption Date will not thereafter be changed.
Treasury Rate means, with respect to any
Redemption Date for a Debenture to be redeemed, the
prevailing market yield per annum of the benchmark
U.S. treasury security having a remaining maturity, as of
such Redemption Date, that most closely corresponds to the
state maturity of the principal of such Debenture. The Treasury
Rate will be calculated on the third business day preceding the
Redemption Date.
Each series of Component Debentures may be redeemed
independently of another series of Component Debentures.
What are
the United States federal income tax consequences related to the
Normal Common Equity Units and Debentures?
Each Normal Common Equity Unit should be treated for United
States federal income tax purposes as an investment unit
comprised of (a) the undivided beneficial ownership
interests in the applicable series of Debentures and
(b) the Stock Purchase Contracts. Consequently, you must
allocate the purchase price of the Normal Common Equity Unit
between your undivided interest in the applicable series of
Debentures and the Stock Purchase Contracts in proportion to
their respective fair market values, which will establish your
initial tax basis in the Debentures and the Stock Purchase
Contracts. Although unclear, if the fair market value of any
Stock Purchase Contract is negative at the time of your purchase
of a Common Equity Unit, the amount you are treated as paying
for the ownership interests in the applicable series of
Debentures and any Stock Purchase Contracts that have a positive
value should include the amount attributable to the assumption
of the liability associated with the Stock Purchase Contract
that has a negative value (i.e., the negative value
should be added to your basis in the applicable series of
Debentures and any Stock Purchase Contracts that have a positive
value in accordance with their relative fair market values).
Interest paid on the Debentures will be taxable to you as
ordinary interest income at the time it is received or accrued,
depending upon the method of accounting applicable to you. If
you own Stripped Common Equity Units, although the Treasury
Securities will not generate current payments to you, you will
be required, for United States federal income tax purposes, to
recognize original issue discount in respect of the Treasury
Securities on a constant yield basis, or to recognize
acquisition discount on the Treasury Securities when it is
received or accrued, depending upon the method of accounting
applicable to you.
To the extent MetLife, Inc. is required to file information
returns with respect to the Contract Payments or Deferred
Contract Payments, MetLife, Inc. intends to report such payments
as income to you.
For additional information, see Certain United
States Federal Income Tax Consequences.
Will the
Common Equity Units be listed on a stock exchange?
The Normal Common Equity Units have been approved for listing on
the New York Stock Exchange under the symbol MLU,
subject to official notice. MetLife, Inc. expects trading of the
Normal Common Equity Units on the New York Stock Exchange to
begin on March 7, 2011.
Neither the Stripped Common Equity Units nor the Debentures
initially will be listed. If enough Stripped Common Equity Units
are created so that applicable exchange listing requirements are
met, we may list the Stripped Common Equity Units or the
Debentures on the same exchange as the Normal Common Equity
Units are then listed, although we are under no obligation to do
so.
S-21
What are
your expected uses of proceeds from the offering of the Common
Equity Units?
MetLife, Inc. will not receive any of the proceeds from the sale
of the Common Equity Units by the Selling Securityholder. All of
the Common Equity Units being offered and sold by the Selling
Securityholder in this offering are currently being held in the
Indemnification Collateral Account (the Indemnification
Collateral Account) under the stock purchase
agreement, dated as of March 7, 2010 (as amended, the
Stock Purchase Agreement), entered into in
connection with the Acquisition, by and among MetLife, Inc., AIG
and the Selling Securityholder.
In accordance with the amended and restated indemnification
collateral account security and control agreement, to be entered
into at or prior to the closing of this offering (the
Amended Indemnification Collateral
Agreement), by and among MetLife, Inc., the Selling
Securityholder, Deutsche Bank Trust Company Americas, as
securities intermediary, the Collateral Agent, the Stock
Purchase Contract Agent and AIG, $3.0 billion of the net
proceeds from the sale of the Common Equity Units will be
deposited in the Indemnification Collateral Account and
substituted for the applicable Common Equity Units held therein.
To the extent that the net proceeds from the sale of the Common
Equity Units exceed $3.0 billion, the Selling
Securityholder will retain any such excess. Such Common Equity
Units will be thereafter transferred to the underwriters for
delivery to you and the proceeds from their sale up to
$3.0 billion will remain in the Indemnification Collateral
Account as indemnification collateral under the Stock Purchase
Agreement.
S-22
RISK
FACTORS
Investing in the Common Equity Units involves a high degree
of risk. In addition to the other information contained in this
prospectus supplement, the accompanying prospectus and the
information incorporated by reference herein and therein, you
should consider carefully the following factors relating to us
and the Common Equity Units before making an investment in the
Common Equity Units offered hereby. In addition to the risk
factors set forth below, please read the information included or
incorporated by reference under Risk Factors in the
accompanying prospectus and the 2010
Form 10-K.
If any of the following risks or those incorporated by reference
actually occur, our business, results of operations, financial
condition, cash flows or prospects could be materially adversely
affected, which in turn could adversely affect the trading price
of the Common Equity Units and MetLife, Inc.s Common
Stock. As a result, you may lose all or part of your original
investment. The risks discussed below also include
forward-looking statements, and our actual results may differ
substantially from those discussed in these forward-looking
statements.
The Common Equity Units consist of Stock Purchase Contracts
to acquire MetLife, Inc.s Common Stock and an interest in
Debentures. When considering an investment in MetLife,
Inc.s Common Equity Units, you are making an investment
decision with respect to MetLife Inc.s Common Stock and
Debentures as well as the Common Equity Units. You should
carefully review the information in this prospectus supplement
and the accompanying prospectus about all of these
securities.
Risks
Related to our Business
Difficult
Conditions in the Global Capital Markets and the Economy
Generally May Materially Adversely Affect Our Business and
Results of Operations and These Conditions May Not Improve in
the Near Future
Our business and results of operations are materially affected
by conditions in the global capital markets and the economy
generally, both in the United States and elsewhere around the
world. Stressed conditions, volatility and disruptions in global
capital markets or in particular markets or financial asset
classes can have an adverse effect on us, in part because we
have a large investment portfolio and our insurance liabilities
are sensitive to changing market factors. Disruptions in one
market or asset class can also spread to other markets or asset
classes. Although the disruption in the global financial markets
that began in late 2007 has moderated, not all global financial
markets are functioning normally, and some remain reliant upon
government intervention and liquidity. Upheavals in the
financial markets can also affect our business through their
effects on general levels of economic activity, employment and
customer behavior. Although the recent recession in the United
States ended in June of 2009, the recovery from the recession
has been below historic averages and the unemployment rate is
expected to remain high for some time. In addition, inflation is
expected to remain at low levels for some time. Some economists
believe that some level of disinflation and deflation risk
remains in the U.S. economy. The global recession and
disruption of the financial markets has led to concerns over
capital markets access and the solvency of certain European
Union member states, including Portugal, Ireland, Italy, Greece
and Spain. The Japanese economy, to which we face increased
exposure as a result of the Acquisition, continues to experience
low nominal growth, a deflationary environment, and weak
consumer spending.
Our revenues and net investment income are likely to remain
under pressure in such circumstances and our profit margins
could erode. Also, in the event of extreme prolonged market
events, such as the recent global credit crisis, we could incur
significant capital
and/or
operating losses. Even in the absence of a market downturn, we
are exposed to substantial risk of loss due to market volatility.
We are a significant writer of variable annuity products. The
account values of these products decrease as a result of
downturns in capital markets. Decreases in account values reduce
the fees generated by our variable annuity products, cause the
amortization of deferred policy acquisition costs
(DAC) to accelerate and could increase the
level of insurance liabilities we must carry to support those
variable annuities issued with any associated guarantees.
Factors such as consumer spending, business investment,
government spending, the volatility and strength of the capital
markets, and inflation all affect the business and economic
environment and, ultimately, the amount and profitability of our
business. In an economic downturn characterized by higher
unemployment, lower family
S-23
income, lower corporate earnings, lower business investment and
lower consumer spending, the demand for our financial and
insurance products could be adversely affected. Group insurance,
in particular, is affected by the higher unemployment rate. In
addition, we may experience an elevated incidence of claims and
lapses or surrenders of policies. Our policyholders may choose
to defer paying insurance premiums or stop paying insurance
premiums altogether. Adverse changes in the economy could affect
earnings negatively and could have a material adverse effect on
our business, results of operations and financial condition. The
recent market turmoil has precipitated, and may continue to
raise the possibility of, legislative, regulatory and
governmental actions. We cannot predict whether or when such
actions may occur, or what impact, if any, such actions could
have on our business, results of operations and financial
condition. See Actions of the
U.S. Government, Federal Reserve Bank of New York and Other
Governmental and Regulatory Bodies for the Purpose of
Stabilizing and Revitalizing the Financial Markets and
Protecting Investors and Consumers May Not Achieve the Intended
Effect or Could Adversely Affect MetLifes Competitive
Position, Various Aspects of Dodd-Frank
Could Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth, Our
Insurance, Brokerage and Banking Businesses Are Heavily
Regulated, and Changes in Regulation May Reduce Our
Profitability and Limit Our Growth and
Competitive Factors May Adversely Affect Our
Market Share and Profitability.
Adverse
Capital and Credit Market Conditions May Significantly Affect
Our Ability to Meet Liquidity Needs, Access to Capital and Cost
of Capital
The capital and credit markets are sometimes subject to periods
of extreme volatility and disruption. Such volatility and
disruption could cause liquidity and credit capacity for certain
issuers to be limited.
We need liquidity to pay our operating expenses, interest on our
debt and dividends on our capital stock, maintain our securities
lending activities and replace certain maturing liabilities.
Without sufficient liquidity, we will be forced to curtail our
operations, and our business will suffer. The principal sources
of our liquidity are insurance premiums, annuity considerations,
deposit funds, and cash flow from our investment portfolio and
assets, consisting mainly of cash or assets that are readily
convertible into cash. Sources of liquidity in normal markets
also include short-term instruments such as funding agreements
and commercial paper. Sources of capital in normal markets
include long-term instruments, medium- and long-term debt,
junior subordinated debt securities, capital securities and
equity securities.
In the event market or other conditions have an adverse impact
on our capital and liquidity beyond expectations and our current
resources do not satisfy our needs, we may have to seek
additional financing. The availability of additional financing
will depend on a variety of factors such as market conditions,
regulatory considerations, the general availability of credit,
the volume of trading activities, the overall availability of
credit to the financial services industry, our credit ratings
and credit capacity, as well as the possibility that customers
or lenders could develop a negative perception of our long- or
short-term financial prospects if we incur large investment
losses or if the level of our business activity decreases due to
a market downturn. Similarly, our access to funds may be
impaired if regulatory authorities or rating agencies take
negative actions against us. Our internal sources of liquidity
may prove to be insufficient and, in such case, we may not be
able to successfully obtain additional financing on favorable
terms, or at all.
Our liquidity requirements may change if, among other things, we
are required to return significant amounts of cash collateral on
short notice under securities lending agreements.
Disruptions, uncertainty or volatility in the capital and credit
markets may also limit our access to capital required to operate
our business, most significantly our insurance operations. Such
market conditions may limit our ability to replace, in a timely
manner, maturing liabilities; satisfy regulatory capital
requirements (under both insurance and banking laws); and access
the capital necessary to grow our business. The possible impact
of Basel II and Basel III on MetLife is discussed in
the 2010
Form 10-K.
As such, we may be forced to delay raising capital, issue
different types of securities than we would otherwise, less
effectively deploy such capital, issue shorter tenor securities
than we prefer, or bear an unattractive cost of capital which
could decrease our profitability and significantly reduce our
financial flexibility. Our results of operations, financial
condition, cash flows and statutory capital position could be
materially adversely affected by disruptions in the financial
markets.
S-24
Actions
of the U.S. Government, Federal Reserve Bank of New York and
Other Governmental and Regulatory Bodies for the Purpose of
Stabilizing and Revitalizing the Financial Markets and
Protecting Investors and Consumers May Not Achieve the Intended
Effect or Could Adversely Affect MetLifes Competitive
Position
In recent years, Congress, the Federal Reserve Bank of New York,
the FDIC, the U.S. Treasury and other agencies of the
U.S. federal government took a number of increasingly
aggressive actions (in addition to continuing a series of
interest rate reductions that began in the second half of
2007) intended to provide liquidity to financial
institutions and markets, to avert a loss of investor confidence
in particular troubled institutions, to prevent or contain the
spread of the financial crisis and to spur economic growth. Most
of these programs have largely run their course or been
discontinued. More likely to be relevant to MetLife, Inc. is the
monetary policy implemented by the Federal Reserve Board, as
well as Dodd-Frank, which will significantly change financial
regulation in the U.S. in a number of areas that could
affect MetLife. Given the large number of provisions that must
be implemented through regulatory action, we cannot predict what
impact this could have on our business, results of operations
and financial condition.
It is not certain what effect the enactment of Dodd-Frank will
have on the financial markets, the availability of credit, asset
prices and MetLifes operations. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth. In addition, the U.S. federal
government (including the FDIC) and private lenders have
instituted programs to reduce the monthly payment obligations of
mortgagors
and/or
reduce the principal payable on residential mortgage loans. As a
result of such programs or of any legislation requiring loan
modifications, we may need to maintain or increase our
engagement in similar activities in order to comply with program
or statutory requirements and to remain competitive. We cannot
predict whether the funds made available by the
U.S. federal government and its agencies will be enough to
continue stabilizing or to further revive the financial markets
or, if additional amounts are necessary, whether the Federal
Reserve Board will make funds available, whether Congress will
be willing to make the necessary appropriations, what the
publics sentiment would be towards any such
appropriations, or what additional requirements or conditions
might be imposed on the use of any such additional funds.
The choices made by the U.S. Treasury, the Federal Reserve
Board and the FDIC in their distribution of funds under EESA and
any future asset purchase programs, as well as any decisions
made regarding the imposition of additional regulation on large
financial institutions may have, over time, the effect of
supporting or burdening some aspects of the financial services
industry more than others. Some of our competitors have
received, or may in the future receive, benefits under one or
more of the federal governments programs. This could
adversely affect our competitive position. See
Competitive Factors May Adversely Affect
Our Market Share and Profitability. See also
New and Impending Compensation and Corporate
Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively and Our Insurance, Brokerage
and Banking Businesses Are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth.
Our
Insurance, Brokerage and Banking Businesses Are Highly
Regulated, and Changes in Regulation and in Supervisory and
Enforcement Policies May Reduce Our Profitability and Limit Our
Growth
Our insurance operations are subject to a wide variety of
insurance and other laws and regulations. State insurance laws
regulate most aspects of our U.S. insurance businesses, and
our insurance subsidiaries are regulated by the insurance
departments of the states in which they are domiciled and the
states in which they are licensed. Our
non-U.S. insurance
operations are principally regulated by insurance regulatory
authorities in the jurisdictions in which they are domiciled or
operate.
State laws in the United States grant insurance regulatory
authorities broad administrative powers with respect to, among
other things:
|
|
|
|
|
licensing companies and agents to transact business;
|
|
|
|
calculating the value of assets to determine compliance with
statutory requirements;
|
|
|
|
mandating certain insurance benefits;
|
|
|
|
regulating certain premium rates;
|
S-25
|
|
|
|
|
reviewing and approving policy forms;
|
|
|
|
regulating unfair trade and claims practices, including through
the imposition of restrictions on marketing and sales practices,
distribution arrangements and payment of inducements;
|
|
|
|
regulating advertising;
|
|
|
|
protecting privacy;
|
|
|
|
establishing statutory capital and reserve requirements and
solvency standards;
|
|
|
|
fixing maximum interest rates on insurance policy loans and
minimum rates for guaranteed crediting rates on life insurance
policies and annuity contracts;
|
|
|
|
approving changes in control of insurance companies;
|
|
|
|
restricting the payment of dividends and other transactions
between affiliates; and
|
|
|
|
regulating the types, amounts and valuation of investments.
|
State insurance guaranty associations have the right to assess
insurance companies doing business in their state for funds to
help pay the obligations of insolvent insurance companies to
policyholders and claimants. Because the amount and timing of an
assessment is beyond our control, the liabilities that we have
currently established for these potential liabilities may not be
adequate.
State insurance regulators and the National Association of
Insurance Commissioners (NAIC) regularly
reexamine existing laws and regulations applicable to insurance
companies and their products. Changes in these laws and
regulations, or in interpretations thereof, are often made for
the benefit of the consumer at the expense of the insurer and,
thus, could have a material adverse effect on our financial
condition and results of operations.
Currently, the U.S. federal government does not directly
regulate the business of insurance. However, Dodd-Frank allows
federal regulators to compel state insurance regulators to
liquidate an insolvent insurer under some circumstances if the
state regulators have not acted within a specific period. It
also establishes the Federal Insurance Office which has the
authority to participate in the negotiations of international
insurance agreements with foreign regulators for the United
States. The Federal Insurance Office is also authorized to
collect information about the insurance industry and recommend
prudential standards.
Federal legislation and administrative policies in several areas
can significantly and adversely affect insurance companies.
These areas include financial services regulation, securities
regulation, pension regulation, health care regulation, privacy,
tort reform legislation and taxation. In addition, various forms
of direct and indirect federal regulation of insurance have been
proposed from time to time, including proposals for the
establishment of an optional federal charter for insurance
companies. Other aspects of our insurance operations could also
be affected by Dodd-Frank. For example, Dodd-Frank imposes new
restrictions on the ability of affiliates of insured depository
institutions (such as MetLife Bank) to engage in proprietary
trading or sponsor or invest in hedge funds or private equity
funds. See Various Aspects of
Dodd-Frank Could Impact Our Business Operations, Capital
Requirements and Profitability and Limit Our Growth.
As a federally chartered national association, MetLife Bank is
subject to a wide variety of banking laws, regulations and
guidelines. Federal banking laws regulate most aspects of the
business of MetLife Bank, but certain state laws may apply as
well. MetLife Bank is principally regulated by the Office of the
Comptroller of the Currency, the Federal Reserve and the FDIC.
Federal banking laws and regulations address various aspects of
MetLife Banks business and operations with respect to,
among other things:
|
|
|
|
|
chartering to carry on business as a bank;
|
|
|
|
the permissibility of certain activities;
|
|
|
|
maintaining minimum capital ratios;
|
|
|
|
capital management in relation to the banks assets;
|
S-26
|
|
|
|
|
dividend payments;
|
|
|
|
safety and soundness standards;
|
|
|
|
loan loss and other related liabilities;
|
|
|
|
liquidity;
|
|
|
|
financial reporting and disclosure standards;
|
|
|
|
counterparty credit concentration;
|
|
|
|
restrictions on related party and affiliate transactions;
|
|
|
|
lending limits (and, in addition, Dodd-Frank includes the credit
exposures arising from securities lending by MetLife Bank within
lending limits otherwise applicable to loans);
|
|
|
|
payment of interest;
|
|
|
|
unfair or deceptive acts or practices;
|
|
|
|
privacy; and
|
|
|
|
bank holding company and bank change of control.
|
Federal and state banking regulators regularly re-examine
existing laws and regulations applicable to banks and their
products. Changes in these laws and regulations, or in
interpretations thereof, are often made for the benefit of the
consumer at the expense of the bank and, thus, could have a
material adverse effect on the financial condition and results
of operations of MetLife Bank.
Since 2008, MetLife, through its MetLife Bank affiliate, has
significantly increased its mortgage servicing activities by
acquiring servicing portfolios. Currently, MetLife Bank services
approximately 1% of the aggregate principal amount of the
mortgage loans serviced in the United States.
State and federal regulatory and law enforcement authorities
have initiated various inquiries, investigations or examinations
of alleged irregularities in the foreclosure practices of the
residential mortgage servicing industry. Mortgage servicing
practices have also been the subject of Congressional attention.
Authorities have publicly stated that the scope of the
investigations extends beyond foreclosure documentation
practices to include mortgage loan modification and loss
mitigation practices.
MetLife Banks mortgage servicing has been the subject of
recent inquiries and requests by such authorities. The Acting
Comptroller of the Currency disclosed in testimony before
Congress that 14 mortgage servicing businesses affiliated with
banking organizations, including that of MetLife Bank, have been
the subject of an intra-agency confidential horizontal
examination of mortgage servicing and foreclosure
activities. The Acting Comptroller testified that federal
banking regulators expect to issue administrative enforcement
orders to such businesses and to seek civil money penalties. The
Acting Comptrollers testimony also indicated that other
federal agencies, including the Department of Justice and the
Federal Trade Commission, were examining potential actions with
respect to such businesses.
MetLife is cooperating with the authorities review of this
business. MetLife cannot predict the outcome of the pending
reviews. It is also possible that additional state or federal
authorities may pursue similar investigations or make related
inquiries.
In view of widespread attention to foreclosure practices within
the industry, MetLife Bank undertook a review of its servicing
procedures. Based on its review of its foreclosure practices and
procedures, MetLife Bank does not believe that its mortgage
servicing practices improperly adversely affected the obligors
of mortgages that it services.
Nevertheless, these inquiries or investigations could adversely
affect MetLifes reputation or result in material fines,
penalties, equitable remedies (including requiring default
servicing or other process changes), or other enforcement
actions, and result in significant legal costs in responding to
governmental investigations or other litigation. In addition,
any changes to the mortgage servicing business that are required
in connection with the resolution of such matters may affect the
profitability of such business.
S-27
In addition, Dodd-Frank establishes a new Bureau of Consumer
Financial Protection that supervises and regulates institutions
providing certain financial products and services to consumers.
Although the consumer financial services to which this
legislation applies exclude insurance business of the kind in
which we engage, the new Bureau has authority to regulate
consumer services provided by MetLife Bank and non-insurance
consumer services provided elsewhere throughout MetLife.
Dodd-Frank established a statutory standard for Federal
pre-emption of state consumer financial protection laws, which
standard will require national banks to comply with many state
consumer financial protection laws that previously were
considered preempted by Federal law. As a result, the regulatory
and compliance burden on MetLife Bank may increase and could
adversely affect its business and results of operations.
Dodd-Frank also includes provisions on mortgage lending,
anti-predatory lending and other regulatory and supervisory
provisions that could impact the business and operations of
MetLife Bank.
Dodd-Frank also authorizes the SEC to establish a standard of
conduct applicable to brokers and dealers when providing
personalized investment advice to retail and other customers.
This standard of conduct would be to act in the best interest of
the customer without regard to the financial or other interest
of the broker or dealer providing the advice. See
Changes in U.S. Federal and State
Securities Laws and Regulations, and State Insurance Regulations
Regarding Suitability of Annuity Product Sales, May Affect Our
Operations and Our Profitability.
In December 2010, the Basel Committee on Banking Supervision
published Basel III for banks and bank holding companies,
such as MetLife, Inc. Assuming regulators in the United States
endorse and adopt Basel III, it will require banks and bank
holding companies to hold greater amounts of capital, to comply
with requirements for short-term liquidity and to reduce
reliance on short-term funding sources. It is not clear how
these new requirements will compare to the enhanced prudential
standards that may apply to us under Dodd-Frank. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth.
As a bank holding company, MetLife, Inc.s ability to pay
dividends may be restricted by the Federal Reserve Bank of New
York. In addition, the ability of MetLife Bank and MetLife, Inc.
to pay dividends could be restricted by any additional capital
requirements that might be imposed as a result of the enactment
of Dodd-Frank
and/or the
endorsement and adoption by the United States of Basel III.
The FDIC has the right to assess FDIC-insured banks for funds to
help pay the obligations of insolvent banks to depositors.
Because the amount and timing of an assessment is beyond our
control, the reserves that we have currently established for
these potential liabilities may not be adequate. In addition,
Dodd-Frank will result in increased assessment for banks with
assets of $10.0 billion or more, which includes MetLife
Bank.
Our international operations are subject to regulation in the
jurisdictions in which they operate. A significant portion of
our revenues are generated through operations in foreign
jurisdictions, including many countries in early stages of
economic and political development. Our international operations
may be materially adversely affected by foreign authorities and
regulators, such as through nationalization or expropriation of
assets, the imposition of limits on foreign ownership, changes
in laws or their interpretation or application, political
instability, dividend limitations, price controls, currency
exchange controls or other restrictions that prevent us from
transferring funds from these operations out of the countries in
which they operate or converting local currencies we hold to
U.S. dollars or other currencies, as well as adverse
actions by foreign governmental authorities and regulators. This
may also impact many of our customers and independent sales
intermediaries. Changes in the regulations that affect their
operations also may affect our business relationships with them
and their ability to purchase or distribute our products.
Accordingly, these changes could have a material adverse effect
on our financial condition and results of operations.
Our international operations are subject to local laws and
regulations, and we expect the scope and extent of regulation
outside of the United States, as well as regulatory oversight,
generally to continue to increase. The authority of our
international operations to conduct business is subject to
licensing requirements, permits and approvals, and these
authorizations are subject to modification and revocation. The
regulatory environment in the countries in which we operate and
changes in laws could have a material adverse effect on us and
our foreign operations. See Our
International Operations Face Political, Legal, Operational and
Other Risks, Including Exposure to Local and Regional Economic
Conditions, that Could Negatively Affect Those Operations or Our
Profitability.
Furthermore, the increase in our international operations as a
result of the acquisition of ALICO may also subject us to
increased supervision by the Federal Reserve Board, since the
size of a bank holding companys
S-28
foreign activities is taken as an indication of the holding
companys complexity. It may also have an effect on the
manner in which MetLife, Inc. is required to calculate its
risk-based capital (RBC).
Compliance with applicable laws and regulations is time
consuming and personnel-intensive, and changes in these laws and
regulations may materially increase our direct and indirect
compliance and other expenses of doing business, thus having a
material adverse effect on our financial condition and results
of operations.
From time to time, regulators raise issues during examinations
or audits of MetLife, Inc.s regulated subsidiaries that
could, if determined adversely, have a material impact on us. We
cannot predict whether or when regulatory actions may be taken
that could adversely affect our operations. In addition, the
interpretations of regulations by regulators may change and
statutes may be enacted with retroactive impact, particularly in
areas such as accounting or statutory reserve requirements.
We are also subject to other regulations and may in the future
become subject to additional regulations.
Various
Aspects of Dodd-Frank Could Impact Our Business Operations,
Capital Requirements and Profitability and Limit Our
Growth
On July 21, 2010, President Obama signed Dodd-Frank.
Various provisions of Dodd-Frank could affect our business
operations and our profitability and limit our growth. For
example:
|
|
|
|
|
As a large, interconnected bank holding company with assets of
$50 billion or more, or possibly as an otherwise
systemically important financial company, MetLife, Inc. will be
subject to enhanced prudential standards imposed on systemically
significant financial companies. Enhanced standards will be
applied to RBC, liquidity, leverage (unless another, similar,
standard is appropriate), resolution plan and credit exposure
reporting, concentration limits, and risk management.
Off-balance sheet activities are required to be accounted for in
meeting capital requirements. In addition, if it were determined
that MetLife posed a substantial threat to U.S. financial
stability, the applicable federal regulators would have the
right to require it to take one or more other mitigating actions
to reduce that risk, including limiting its ability to merge
with or acquire another company, terminating activities,
restricting its ability to offer financial products or requiring
it to sell assets or off-balance sheet items to unaffiliated
entities. Enhanced standards would also permit, but not require,
regulators to establish requirements with respect to contingent
capital, enhanced public disclosures and short-term debt limits.
These standards are described as being more stringent than those
otherwise imposed on bank holding companies; however, the
Federal Reserve Board is permitted to apply them on an
institution-by-institution
basis, depending on its determination of the institutions
riskiness. In addition, under Dodd-Frank, all bank holding
companies that have elected to be treated as financial holding
companies, such as MetLife, Inc. will be required to be
well capitalized and well managed as
defined by the Federal Reserve Board, on a consolidated basis
and not just at their depository institution(s), a higher
standard than was applicable to financial holding companies
before Dodd-Frank.
|
|
|
|
MetLife, Inc., as a bank holding company, will have to meet
minimum leverage ratio and RBC requirements on a consolidated
basis to be established by the Federal Reserve Board that are
not less than those applicable to insured depository
institutions under so-called prompt corrective action
regulations as in effect on the date of the enactment of
Dodd-Frank. One consequence of these new rules will ultimately
be the inability of bank holding companies to include
trust-preferred securities as part of their Tier 1 capital.
Because of the phase-in period for these new rules, they should
have little practical effect on MetLifes ability to treat
its currently outstanding trust-preferred securities as part of
its Tier 1 capital, but they do prevent MetLife, Inc. from
treating the Common Equity Units as Tier 1 capital, since
the new rules apply immediately to instruments issued after
May 19, 2010.
|
|
|
|
Under the provisions of Dodd-Frank relating to the resolution or
liquidation of certain types of financial institutions,
including bank holding companies, if MetLife, Inc. were to
become insolvent or were in danger of defaulting on its
obligations, it could be compelled to undergo liquidation with
the FDIC as receiver. For this new regime to be applicable, a
number of determinations would have to be made, including that a
default by the affected company would have serious adverse
effects on financial stability in the United States. If the FDIC
were to be appointed as the receiver for such a company, the
liquidation of that company would occur under the provisions of
the new liquidation authority, and not under the
U.S. Bankruptcy Code. In such a
|
S-29
|
|
|
|
|
liquidation, the holders of such companys debt could in
certain respects be treated differently than under the
U.S. Bankruptcy Code. In particular, unsecured creditors
and shareholders are intended to bear the losses of the company
being liquidated. The FDIC is authorized to establish rules for
the priority of creditors claims and, under certain
circumstances, to treat similarly situated creditors
differently. These provisions could apply to some financial
institutions whose outstanding debt securities we hold in our
investment portfolios. Dodd-Frank also provides for the
assessment of bank holding companies with assets of
$50.0 billion or more, non-bank financial companies
supervised by the Federal Reserve Bank, and other financial
companies with assets of $50.0 billion or more to cover the
costs of liquidating any financial company subject to the new
liquidation authority. Although it is not possible to assess the
full impact of the liquidation authority at this time, it could
affect the funding costs of large bank holding companies or
financial companies that might be viewed as systemically
significant. It could also lead to an increase in secured
financings.
|
|
|
|
|
|
Dodd-Frank also includes a new framework of regulation of the
OTC derivatives markets which will require clearing of certain
types of transactions currently traded OTC and could potentially
impose additional costs, including new capital, reporting and
margin requirements and additional regulation on MetLife, Inc.
Increased margin requirements on MetLife, Inc.s part and a
smaller universe of securities that will qualify as eligible
collateral could reduce its liquidity and require an increase in
its holdings of cash and government securities with lower yields
causing a reduction in income. However, increased margin
requirements and the expanded ability to transfer trades between
MetLife, Inc.s counterparties could reduce MetLife,
Inc.s exposure to its counterparties default.
MetLife, Inc. uses derivatives to mitigate a wide range of risks
in connection with its businesses, including the impact of
increased benefit exposures from our annuity products that offer
guaranteed benefits. The derivative clearing requirements of
Dodd-Frank could increase the cost of our risk mitigation and
expose us to the risk of a default by a clearinghouse or one of
its members. In addition, we are subject to the risk that
hedging and other management procedures prove ineffective in
reducing the risks to which insurance policies expose us or that
unanticipated policyholder behavior or mortality, combined with
adverse market events, produces economic losses beyond the scope
of the risk management techniques employed. Any such losses
could be increased by any higher costs of writing derivatives
(including customized derivatives) that might result from the
enactment of Dodd-Frank.
|
|
|
|
Dodd-Frank restricts the ability of insured depository
institutions and of companies, such as MetLife, Inc., that
control an insured depository institution and their affiliates,
to engage in proprietary trading and to sponsor or invest in
funds (hedge funds and private equity funds) that rely on
certain exemptions from the Investment Company Act of 1940, as
amended (the Investment Company Act).
Dodd-Frank provides an exemption for investment activity by a
regulated insurance company or its affiliate solely for the
general account of such insurance company if such activity is in
compliance with the insurance company investments laws of the
state or jurisdiction in which such company is domiciled and the
appropriate Federal regulators after consultation with relevant
insurance commissioners have not jointly determined such laws to
be insufficient to protect the safety and soundness of the
institution or the financial stability of the
United States. Notwithstanding the foregoing, the
appropriate Federal regulatory authorities are permitted under
the legislation to impose, as part of rulemaking, additional
capital requirements and other restrictions on any exempted
activity. Dodd-Frank provided for a period of study and rule
making during which the effects of the statutory language may be
clarified. The study has been completed and has assessed and
included recommendations as to how to appropriately accommodate
the business of insurance within an insurance company subject to
regulation in accordance with relevant insurance company
investments laws. However, while these provisions of Dodd-Frank
are supposed to accommodate the business of insurance, until the
rulemaking is completed, it is unclear whether MetLife, Inc. may
have to alter any of its future investment activities to comply.
|
|
|
|
Until various studies are completed and final regulations are
promulgated pursuant to Dodd-Frank, the full impact of
Dodd-Frank on the investments and investment activities and
insurance and annuity products of MetLife, Inc. and its
subsidiaries remains unclear. For example, besides directly
limiting our future investment activities, Dodd-Frank could
potentially negatively impact the market for, the returns from,
or liquidity in, primary and secondary investments in private
equity funds and hedge funds that are connected to (either
through a fund sponsorship or investor relationship) an insured
depository institution. The number of sponsors of such funds
going forward may diminish, which may impact our available fund
investment
|
S-30
|
|
|
|
|
opportunities. Although Dodd-Frank provides for various
transition periods for coming into compliance, fund sponsors
that are subject to Dodd-Frank, and whose funds we have invested
in, may have to spin off their funds business or reduce their
ownership stakes in their funds, thereby potentially impacting
our related investments in such funds. In addition, should such
funds be required or choose to liquidate or sell their
underlying assets, the market value and liquidity of such assets
or the broader related asset classes could be negatively
affected, including securities and real estate assets that
MetLife, Inc. and its subsidiaries hold or may plan to sell.
Secondary sales of fund interests at significant discounts by
banking institutions and their affiliates, which are not fund
sponsors but nevertheless are subject to the divestment
requirements of Dodd-Frank, could reduce the returns realized by
investors such as MetLife, Inc. and its subsidiaries seeking to
access liquidity by selling their fund interests. In addition,
our existing derivatives counterparties and the financial
institutions subject to Dodd-Frank in which we have invested
also could be negatively impacted by Dodd-Frank. See also
New and Impending Compensation and Corporate
Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively.
|
|
|
|
|
|
In addition, Dodd-Frank statutorily imposes the requirement that
MetLife, Inc. serve as a source of strength for MetLife Bank.
|
The addition of a new regulatory regime over MetLife, Inc. and
its subsidiaries, the likelihood of additional regulations, and
the other changes discussed above could require changes to
MetLife, Inc.s operations. Whether such changes would
affect our competitiveness in comparison to other institutions
is uncertain, since it is possible that at least some of our
competitors, for example insurance holding companies that
control thrifts, rather than banks, will be similarly affected.
Competitive effects are possible, however, if MetLife, Inc. were
required to pay any new or increased assessments and capital
requirements are imposed, and to the extent any new prudential
supervisory standards are imposed on MetLife, Inc. but not on
its competitors. We cannot predict whether other proposals will
be adopted, or what impact, if any, the adoption of Dodd-Frank
or other proposals and the resulting studies and regulations
could have on our business, financial condition or results of
operations or on our dealings with other financial companies.
See also Our Insurance, Brokerage and
Banking Businesses are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth and New and Impending
Compensation and Corporate Governance Regulations Could Hinder
or Prevent Us From Attracting and Retaining Management and Other
Employees with the Talent and Experience to Manage and Conduct
Our Business Effectively.
Moreover, Dodd-Frank potentially affects such a wide range of
the activities and markets in which MetLife, Inc. and its
subsidiaries engage and participate that it may not be possible
to anticipate all of the ways in which it could affect us. For
example, many of our methods for managing risk and exposures are
based upon the use of observed historical market behavior or
statistics based on historical models. Historical market
behavior may be altered by the enactment of Dodd-Frank. As a
result of this enactment and otherwise, these methods may not
fully predict future exposures, which could be significantly
greater than our historical measures indicate.
The
Resolution of Several Issues Affecting the Financial Services
Industry Could Have a Negative Impact on Our Reported Results or
on Our Relations with Current and Potential
Customers
We will continue to be subject to legal and regulatory actions
in the ordinary course of our business, both in the United
States and internationally. This could result in a review of
business sold in the past under previously acceptable market
practices at the time. Regulators are increasingly interested in
the approach that product providers use to select third-party
distributors and to monitor the appropriateness of sales made by
them. In some cases, product providers can be held responsible
for the deficiencies of third-party distributors.
As a result of publicity relating to widespread perceptions of
industry abuses, there have been numerous regulatory inquiries
and proposals for legislative and regulatory reforms.
In Asia, where MetLife derives and will continue to derive a
significant portion of its income, regulatory regimes are
developing at different speeds, driven by a combination of
global factors and local considerations. New requirements may be
introduced that are retrospectively applied to sales made prior
to their introduction.
S-31
We Are
Exposed to Significant Financial and Capital Markets Risk Which
May Adversely Affect Our Results of Operations, Financial
Condition and Liquidity, and May Cause Our Net Investment Income
to Vary from Period to Period
We are exposed to significant financial and capital markets
risk, including changes in interest rates, credit spreads,
equity prices, real estate markets, foreign currency exchange
rates, market volatility, the performance of the global economy
in general, the performance of the specific obligors, including
governments, included in our portfolio and other factors outside
our control.
Our exposure to interest rate risk relates primarily to the
market price and cash flow variability associated with changes
in interest rates. Changes in interest rates will impact the net
unrealized gain or loss position of our fixed income investment
portfolio. If long-term interest rates rise dramatically within
a six to twelve month time period, certain of our life insurance
businesses and fixed annuity business may be exposed to
disintermediation risk. Disintermediation risk refers to the
risk that our policyholders may surrender their contracts in a
rising interest rate environment, requiring us to liquidate
fixed income investments in an unrealized loss position. Due to
the long-term nature of the liabilities associated with certain
of our life insurance businesses, guaranteed benefits on
variable annuities, and structured settlements, sustained
declines in long-term interest rates may subject us to
reinvestment risks and increased hedging costs. In other
situations, declines in interest rates may result in increasing
the duration of certain life insurance liabilities, creating
asset-liability duration mismatches.
Our investment portfolio also contains interest rate sensitive
instruments, such as fixed income securities, which may be
adversely affected by changes in interest rates from
governmental monetary policies, domestic and international
economic and political conditions and other factors beyond our
control. Changes in interest rates will impact both the net
unrealized gain or loss position of our fixed income portfolio
and the rates of return we receive on funds invested. Our
mitigation efforts with respect to interest rate risk are
primarily focused towards maintaining an investment portfolio
with diversified maturities that has a weighted average duration
that is approximately equal to the duration of our estimated
liability cash flow profile. However, our estimate of the
liability cash flow profile may be inaccurate and we may be
forced to liquidate fixed income investments prior to maturity
at a loss in order to cover the cash flow profile of the
liability. Although we take measures to manage the economic
risks of investing in a changing interest rate environment, we
may not be able to mitigate the interest rate risk of our fixed
income investments relative to our liabilities. See also
Changes in Market Interest Rates May
Significantly Affect Our Profitability.
Our exposure to credit spreads primarily relates to market price
volatility and cash flow variability associated with changes in
credit spreads. A widening of credit spreads will adversely
impact both the net unrealized gain or loss position of the
fixed-income investment portfolio, will increase losses
associated with credit-based non-qualifying derivatives where we
assume credit exposure, and, if issuer credit spreads increase
significantly or for an extended period of time, will likely
result in higher
other-than-temporary
impairments. Credit spread tightening will reduce net investment
income associated with new purchases of fixed maturity
securities. In addition, market volatility can make it difficult
to value certain of our securities if trading becomes less
frequent. As such, valuations may include assumptions or
estimates that may have significant period to period changes
which could have a material adverse effect on our results of
operations or financial condition. Credit spreads on both
corporate and structured securities widened significantly during
2008, resulting in continuing depressed pricing. As a result of
improved conditions, credit spreads narrowed in 2009 and changed
to a lesser extent in 2010. If there is a resumption of
significant volatility in the markets, it could cause changes in
credit spreads and defaults and a lack of pricing transparency
which, individually or in tandem, could have a material adverse
effect on our results of operations, financial condition,
liquidity or cash flows through realized investment losses,
impairments, and changes in unrealized loss positions.
Our primary exposure to equity risk relates to the potential for
lower earnings associated with certain of our insurance
businesses where fee income is earned based upon the estimated
fair value of the assets under management. Downturns and
volatility in equity markets can have a material adverse effect
on the revenues and investment returns from our savings and
investment products and services. Because these products and
services generate fees related primarily to the value of assets
under management, a decline in the equity markets could reduce
our revenues from the reduction in the value of the investments
we manage. The retail variable annuity business in particular is
highly sensitive to equity markets, and a sustained weakness in
the equity markets could decrease revenues and earnings in
variable annuity products. Furthermore, certain of our variable
annuity products offer guaranteed benefits which increase our
S-32
potential benefit exposure should equity markets decline.
MetLife, Inc. uses derivatives and reinsurance to mitigate the
impact of such increased potential benefit exposures. We are
also exposed to interest rate and equity risk based upon the
discount rate and expected long-term rate of return assumptions
associated with our pension and other postretirement benefit
obligations. Sustained declines in long-term interest rates or
equity returns likely would have a negative effect on the funded
status of these plans. Lastly, we invest a portion of our
investments in public and private equity securities, leveraged
buy-out funds, hedge funds and other private equity funds and
the estimated fair value of such investments may be impacted by
downturns or volatility in equity markets.
Our primary exposure to real estate risk relates to commercial
and agricultural real estate. Our exposure to commercial and
agricultural real estate risk stems from various factors. These
factors include, but are not limited to, market conditions
including the demand and supply of leasable commercial space,
creditworthiness of tenants and partners, capital markets
volatility and the inherent interest rate movement. In addition,
our real estate joint venture development program is subject to
risks, including, but not limited to, reduced property sales and
decreased availability of financing which could adversely impact
the joint venture developments
and/or
operations. The state of the economy and speed of recovery in
fundamental and capital market conditions in the commercial and
agricultural real estate sectors will continue to influence the
performance of our investments in these sectors. These factors
and others beyond our control could have a material adverse
effect on our results of operations, financial condition,
liquidity or cash flows through net investment income, realized
investment losses and levels of valuation allowances.
Our investment portfolio contains investments in government
bonds issued by European nations. Recently, the European Union
member states have experienced above average public debt,
inflation and unemployment as the global economic downturn has
developed. A number of member states are significantly impacted
by the economies of their more influential neighbors, such as
Germany. In addition, financial troubles of one nation can
trigger a domino effect on others. In particular, a number of
large European banks hold significant amounts of sovereign
financial institution debt of other European nations and could
experience difficulties as a result of defaults or declines in
the value of such debt. Our investment portfolio also contains
investments in revenue bonds issued under the auspices of states
and municipalities and a limited amount of general obligation
bonds of states and municipalities (collectively,
Municipal Bonds). Recently, certain states
and municipalities have faced budget deficits and financial
difficulties. There can be no assurance that the financial
difficulties of such states and municipalities would not have an
adverse impact on our Municipal Bond portfolio.
Our primary foreign currency exchange risks are described under
Fluctuations in Foreign Currency Exchange
Rates Could Negatively Affect Our Profitability. Changes
in these factors, which are significant risks to us, can affect
our net investment income in any period, and such changes can be
substantial.
A portion of our investments are made in leveraged buy-out
funds, hedge funds and other private equity funds, many of which
make private equity investments. The amount and timing of net
investment income from such investment funds tends to be uneven
as a result of the performance of the underlying investments,
including private equity investments. The timing of
distributions from the funds, which depends on particular events
relating to the underlying investments, as well as the
funds schedules for making distributions and their needs
for cash, can be difficult to predict. As a result, the amount
of net investment income that we record from these investments
can vary substantially from quarter to quarter.
Recovering private equity markets and stabilizing credit and
real estate markets during 2010 had a positive impact on returns
and net investment income on private equity funds, hedge funds
and real estate joint ventures, which are included within other
limited partnership interests and real estate and real estate
joint venture portfolios. Although volatility in most global
financial markets has moderated, if there is a resumption of
significant volatility, it could adversely impact returns and
net investment income on these alternative investment classes.
Continuing challenges include continued weakness in the
U.S. real estate market and increased residential mortgage
loan and other consumer loan delinquencies, investor anxiety
over the U.S. and European economies, rating agency
downgrades of various structured products and financial issuers,
unresolved issues with structured investment vehicles and
monoline financial guarantee insurers, deleveraging of financial
institutions and hedge funds and the continuing recovery in the
inter-bank market. If there is a resumption of significant
volatility in the markets, it could cause changes in interest
rates, declines in equity prices, and the strengthening or
weakening of foreign currencies against the U.S. dollar
which, individually or in tandem, could have a material adverse
effect on our results of
S-33
operations, financial condition, liquidity or cash flows through
realized investment losses, impairments, increased valuation
allowances and changes in unrealized gain or loss positions.
Changes
in Market Interest Rates May Significantly Affect Our
Profitability
Some of our products, principally traditional whole life
insurance, fixed annuities and guaranteed interest contracts,
expose us to the risk that changes in interest rates will reduce
our investment margin or spread, or the difference
between the amounts that we are required to pay under the
contracts in our general account and the rate of return we are
able to earn on general account investments intended to support
obligations under the contracts. Our spread is a key component
of our net income.
As interest rates decrease or remain at low levels, we may be
forced to reinvest proceeds from investments that have matured
or have been prepaid or sold at lower yields, reducing our
investment margin. Moreover, borrowers may prepay or redeem the
fixed income securities, commercial or agricultural mortgage
loans and mortgage-backed securities in our investment portfolio
with greater frequency in order to borrow at lower market rates,
which exacerbates this risk. Lowering interest crediting rates
can help offset decreases in investment margins on some
products. However, our ability to lower these rates could be
limited by competition or contractually guaranteed minimum rates
and may not match the timing or magnitude of changes in asset
yields. As a result, our spread could decrease or potentially
become negative. Our expectation for future spreads is an
important component in the amortization of DAC and value of
business acquired (VOBA), and significantly
lower spreads may cause us to accelerate amortization, thereby
reducing net income in the affected reporting period. In
addition, during periods of declining interest rates, life
insurance and annuity products may be relatively more attractive
investments to consumers, resulting in increased premium
payments on products with flexible premium features, repayment
of policy loans and increased persistency, or a higher
percentage of insurance policies remaining in force from year to
year, during a period when our new investments carry lower
returns. A decline in market interest rates could also reduce
our return on investments that do not support particular policy
obligations. Accordingly, declining interest rates may
materially affect our results of operations, financial position
and cash flows and significantly reduce our profitability. We
recognize that a low interest rate environment will adversely
affect our earnings, but we do not believe any such impact will
be material in 2011.
The sufficiency of our life insurance statutory reserves in
Taiwan is highly sensitive to interest rates and other related
assumptions. This is due to the sustained low interest rate
environment in Taiwan coupled with long-term interest rate
guarantees of approximately 6% embedded in the life and health
contracts sold prior to 2003 and the lack of availability of
long-duration investments in the Taiwanese capital markets to
match such long-duration liabilities. The key assumptions
include current Taiwan government bond yield rates increasing
approximately 1% from current levels over the next ten years,
lapse rates, mortality and morbidity levels remaining consistent
with recent experience, and U.S. dollar-denominated
investments making up to 35% of total assets backing life
insurance statutory reserves. Current reserve adequacy analysis
shows that provisions are adequate; however, adverse
changes in key assumptions for interest rates, lapse experience
and mortality and morbidity levels could lead to a need to
strengthen reserves.
Increases in market interest rates could also negatively affect
our profitability. In periods of rapidly increasing interest
rates, we may not be able to replace, in a timely manner, the
investments in MetLifes general account with higher
yielding investments needed to fund the higher crediting rates
necessary to keep interest sensitive products competitive. We,
therefore, may have to accept a lower spread and, thus, lower
profitability or face a decline in sales and greater loss of
existing contracts and related assets. In addition, policy
loans, surrenders and withdrawals may tend to increase as
policyholders seek investments with higher perceived returns as
interest rates rise. This process may result in cash outflows
requiring that we sell investments at a time when the prices of
those investments are adversely affected by the increase in
market interest rates, which may result in realized investment
losses. Unanticipated withdrawals and terminations may cause us
to accelerate the amortization of DAC, VOBA and negative VOBA,
which reduces net income. An increase in market interest rates
could also have a material adverse effect on the value of our
investment portfolio, for example, by decreasing the estimated
fair values of the fixed income securities that comprise a
substantial portion of our investment portfolio. Lastly, an
increase in interest rates could result in decreased fee income
associated with a decline in the value of variable annuity
account balances invested in fixed income funds.
S-34
Some
of Our Investments Are Relatively Illiquid and Are in Asset
Classes That Have Been Experiencing Significant Market
Valuation Fluctuations
We hold certain investments that may lack liquidity, such as
privately-placed fixed maturity securities; mortgage loans;
policy loans and leveraged leases; equity real estate, including
real estate joint ventures and funds; and other limited
partnership interests. These asset classes represented 26.6% of
the carrying value of our total cash and investments at
December 31, 2010. In recent years, even some of our very
high quality investments experienced reduced liquidity during
periods of market volatility or disruption. If we require
significant amounts of cash on short notice in excess of normal
cash requirements or are required to post or return cash
collateral in connection with our investment portfolio,
derivatives transactions or securities lending program, we may
have difficulty selling these investments in a timely manner, be
forced to sell them for less than we otherwise would have been
able to realize, or both. The reported value of our relatively
illiquid types of investments, our investments in the asset
classes described above and, at times, our high quality,
generally liquid asset classes, do not necessarily reflect the
lowest current market price for the asset. If we were forced to
sell certain of our investments in the global market, there can
be no assurance that we will be able to sell them for the prices
at which we have recorded them and we could be forced to sell
them at significantly lower prices.
Our
Participation in a Securities Lending Program Subjects Us to
Potential Liquidity and Other Risks
We participate in a securities lending program whereby blocks of
securities, which are included in fixed maturity securities and
short-term investments, are loaned to third parties, primarily
brokerage firms and commercial banks. We generally obtain
collateral in an amount equal to 102% of the estimated fair
value of the loaned securities, which is obtained at the
inception of a loan and maintained at a level greater than or
equal to 100% for the duration of the loan. Returns of loaned
securities by the third parties would require us to return the
collateral associated with such loaned securities. In addition,
in some cases, the maturity of the securities held as invested
collateral (i.e., securities that we have
purchased with cash collateral received from the third parties)
may exceed the term of the related securities on loan and the
estimated fair value may fall below the amount of cash received
as collateral and invested. If we are required to return
significant amounts of cash collateral on short notice and we
are forced to sell securities to meet the return obligation, we
may have difficulty selling such collateral that is invested in
securities in a timely manner, be forced to sell securities in a
volatile or illiquid market for less than we otherwise would
have been able to realize under normal market conditions, or
both. In addition, under stressful capital market and economic
conditions, liquidity broadly deteriorates, which may further
restrict our ability to sell securities. If we decrease the
amount of our securities lending activities over time, the
amount of net investment income generated by these activities
will also likely decline.
Our
Requirements to Pledge Collateral or Make Payments Related to
Declines in Estimated Fair Value of Specified Assets May
Adversely Affect Our Liquidity and Expose Us to Counterparty
Credit Risk
Some of our transactions with financial and other institutions
specify the circumstances under which the parties are required
to pledge collateral related to any decline in the estimated
fair value of the specified assets. In addition, under the terms
of some of our transactions, we may be required to make payments
to our counterparties related to any decline in the estimated
fair value of the specified assets. The amount of collateral we
may be required to pledge and the payments we may be required to
make under these agreements may increase under certain
circumstances, which could adversely affect our liquidity.
Gross
Unrealized Losses on Fixed Maturity and Equity Securities May Be
Realized or Result in Future Impairments, Resulting in a
Reduction in Our Net Income
Fixed maturity and equity securities classified as
available-for-sale
are reported at their estimated fair value. Unrealized gains or
losses on
available-for-sale
securities are recognized as a component of other comprehensive
income (loss) and are, therefore, excluded from net income. Our
gross unrealized losses on fixed maturity and equity securities
available for sale at December 31, 2010 were
$6.9 billion. The portion of the $6.9 billion of gross
unrealized losses for fixed maturity and equity securities where
the estimated fair value has declined and remained below
amortized cost or cost by 20% or more for six months or greater
was $2.1 billion at December 31, 2010. The accumulated
change in estimated fair value of these
available-for-sale
securities is recognized in net income when
S-35
the gain or loss is realized upon the sale of the security or in
the event that the decline in estimated fair value is determined
to be
other-than-temporary
and an impairment charge to earnings is taken. Realized losses
or impairments may have a material adverse effect on our net
income in a particular quarterly or annual period.
The
Determination of the Amount of Allowances and Impairments Taken
on Our Investments is Highly Subjective and Could Materially
Impact Our Results of Operations or Financial
Position
The determination of the amount of allowances and impairments
varies by investment type and is based upon our periodic
evaluation and assessment of known and inherent risks associated
with the respective asset class. Such evaluations and
assessments are revised as conditions change and new information
becomes available. We update our evaluations regularly and
reflect changes in allowances and impairments in net investment
losses as such evaluations are revised. Additional impairments
may need to be taken or allowances provided for in the future.
Furthermore, historical trends may not be indicative of future
impairments or allowances.
For example, the cost of our fixed maturity and equity
securities is adjusted for impairments deemed to be
other-than-temporary.
The assessment of whether impairments have occurred is based on
our
case-by-case
evaluation of the underlying reasons for the decline in
estimated fair value. The review of our fixed maturity and
equity securities for impairments includes an analysis of the
total gross unrealized losses by three categories of securities:
(i) securities where the estimated fair value has declined
and remained below cost or amortized cost by less than 20%;
(ii) securities where the estimated fair value has declined
and remained below cost or amortized cost by 20% or more for
less than six months; and (iii) securities where the
estimated fair value has declined and remained below cost or
amortized cost by 20% or more for six months or greater.
Additionally, we consider a wide range of factors about the
security issuer and use our best judgment in evaluating the
cause of the decline in the estimated fair value of the security
and in assessing the prospects for near term recovery. Inherent
in our evaluation of the security are assumptions and estimates
about the operations of the issuer and its future earnings
potential. Considerations in the impairment evaluation process
include, but are not limited to: (i) the length of time and
the extent to which the estimated fair value has been below cost
or amortized cost; (ii) the potential for impairments of
securities when the issuer is experiencing significant financial
difficulties; (iii) the potential for impairments in an
entire industry sector or
sub-sector;
(iv) the potential for impairments in certain economically
depressed geographic locations; (v) the potential for
impairments of securities where the issuer, series of issuers or
industry has suffered a catastrophic type of loss or has
exhausted natural resources; (vi) with respect to fixed
maturity securities, whether we have the intent to sell or will
more likely than not be required to sell a particular security
before recovery of the decline in estimated fair value below
amortized cost; (vii) with respect to equity securities,
whether we have the ability and intent to hold a particular
security for a period of time sufficient to allow for the
recovery of its estimated fair value to an amount at least equal
to its cost; (viii) unfavorable changes in forecasted cash
flows on mortgage-backed and asset-backed securities
(ABS); and (ix) other subjective
factors, including concentrations and information obtained from
regulators and rating agencies.
Defaults
on Our Mortgage Loans and Volatility in Performance May
Adversely Affect Our Profitability
Our mortgage loans face default risk and are principally
collateralized by commercial, agricultural and residential
properties. We establish valuation allowances for estimated
impairments at the balance sheet date. Such valuation allowances
are based on the excess carrying value of the loan over the
present value of expected future cash flows discounted at the
loans original effective interest rate, the estimated fair
value of the loans collateral if the loan is in the
process of foreclosure or otherwise collateral dependent, or the
loans observable market price. We also establish valuation
allowances for loan losses for pools of loans with similar risk
characteristics, such as property types, or loans having similar
loan-to-value
ratios and debt service coverage ratios, when based on past
experience, it is probable that a credit event has occurred and
the amount of the loss can be reasonably estimated. These
valuation allowances are based on loan risk characteristics,
historical default rates and loss severities, real estate market
fundamentals and outlook as well as other relevant factors. At
December 31, 2010, mortgage loans that were either
delinquent or in the process of foreclosure totaled less than
0.6% of our mortgage loan investments. The performance of our
mortgage loan investments, however, may fluctuate in the future.
In addition, substantially all of our mortgage loans
held-for-investment
have balloon payment maturities. An increase in the default rate
of
S-36
our mortgage loan investments could have a material adverse
effect on our business, results of operations and financial
condition through realized investment losses or increases in our
valuation allowances.
Further, any geographic or sector concentration of our mortgage
loans may have adverse effects on our investment portfolios and
consequently on our results of operations or financial
condition. While we seek to mitigate this risk by having a
broadly diversified portfolio, events or developments that have
a negative effect on any particular geographic region or sector
may have a greater adverse effect on the investment portfolios
to the extent that the portfolios are concentrated. Moreover,
our ability to sell assets relating to such particular groups of
related assets may be limited if other market participants are
seeking to sell at the same time. In addition, legislative
proposals that would allow or require modifications to the terms
of mortgage loans could be enacted. We cannot predict whether
these proposals will be adopted, or what impact, if any, such
proposals or, if enacted, such laws, could have on our business
or investments.
The
Impairment of Other Financial Institutions Could Adversely
Affect Us
We have exposure to many different industries and
counterparties, and routinely execute transactions with
counterparties in the financial services industry, including
brokers and dealers, commercial banks, investment banks, hedge
funds and other investment funds and other institutions. Many of
these transactions expose us to credit risk in the event of
default of our counterparty. In addition, with respect to
secured transactions, our credit risk may be exacerbated when
the collateral held by us cannot be realized or is liquidated at
prices not sufficient to recover the full amount of the loan or
derivative exposure due to us. We also have exposure to these
financial institutions in the form of unsecured debt
instruments, non-redeemable and redeemable preferred securities,
derivative transactions, joint venture, hedge fund and equity
investments. Further, potential action by governments and
regulatory bodies in response to the financial crisis affecting
the global banking system and financial markets, such as
investment, nationalization, conservatorship, receivership and
other intervention, whether under existing legal authority or
any new authority that may be created, could negatively impact
these instruments, securities, transactions and investments.
There can be no assurance that any such losses or impairments to
the carrying value of these investments would not materially and
adversely affect our business and results of operations.
We
Face Unforeseen Liabilities, Asset Impairments or Rating Actions
Arising from Acquisitions, Including ALICO, and Dispositions of
Businesses or Difficulties Integrating and Managing Growth of
Such Businesses
We have engaged in dispositions and acquisitions of businesses
in the past, and expect to continue to do so in the future.
Acquisition and disposition activity exposes us to a number of
risks.
There could be unforeseen liabilities or asset impairments,
including goodwill impairments, that arise in connection with
the businesses that we may sell or the businesses that we may
acquire in the future.
In addition, there may be liabilities or asset impairments that
we fail, or are unable, to discover in the course of performing
due diligence investigations on each business that we have
acquired or may acquire. Furthermore, even for obligations and
liabilities that we do discover during the due diligence
process, neither the valuation adjustment nor the contractual
protections we negotiate may be sufficient to fully protect us
from losses. For example, in connection with the acquisition of
ALICO, we may be exposed to obligations and liabilities of ALICO
that are not adequately covered, in amount, scope or duration,
by the indemnification provisions in the Stock Purchase
Agreement or reflected or reserved for in ALICOs
historical financial statements. Although we have rights to
indemnification from the Selling Securityholder under the Stock
Purchase Agreement for certain losses, our rights are limited by
survival periods for bringing claims and monetary limitations on
the amount we may recover, and we cannot be certain that
indemnification will be, among other things, collectible or
sufficient in amount, scope or duration to fully offset any loss
we may suffer. We are indemnified under the Stock Purchase
Agreement for various tax matters, including U.S. federal income
taxes attributable to periods during which the ALICO business
was included in AIGs consolidated federal income tax
return. We cannot be certain that any such indemnification will
ultimately be fully collectible.
Furthermore, the use of our own funds as consideration in any
acquisition would consume capital resources that would no longer
be available for other corporate purposes. We also may not be
able to raise sufficient funds to consummate an acquisition if,
for example, we are unable to sell our securities or close
related bridge credit facilities. Moreover, as a result of
uncertainty and risks associated with potential acquisitions and
dispositions of
S-37
businesses, rating agencies may take certain actions with
respect to the ratings assigned to MetLife, Inc.
and/or its
subsidiaries.
Our ability to achieve certain benefits we anticipate from any
acquisitions of businesses will depend in large part upon our
ability to successfully integrate such businesses in an
efficient and effective manner. We may not be able to integrate
such businesses smoothly or successfully, and the process may
take longer than expected. The integration of operations and
differences in operational culture may require the dedication of
significant management resources, which may distract
managements attention from
day-to-day
business. If we are unable to successfully integrate the
operations of such acquired businesses, we may be unable to
realize the benefits we expect to achieve as a result of such
acquisitions and our business and results of operations may be
less than expected.
The success with which we are able to integrate acquired
operations, will depend on our ability to manage a variety of
issues, including the following:
|
|
|
|
|
Loss of key personnel or higher than expected employee attrition
rates could adversely affect the performance of the acquired
business and our ability to integrate it successfully.
|
|
|
|
Customers of the acquired business may reduce, delay or defer
decisions concerning their use of its products and services as a
result of the acquisition or uncertainty related to the
consummation of the acquisition, including, for example,
potential unfamiliarity with the MetLife brand in regions where
MetLife did not have a market presence prior to the acquisition.
|
|
|
|
If the acquired business relies upon independent distributors to
distribute its products, these distributors may not continue to
generate the same volume of business for MetLife after the
acquisition. Independent distributors may reexamine the scope of
their relationship with the acquired business or MetLife as a
result of the acquisition and decide to curtail or eliminate
distribution of our products.
|
|
|
|
Integrating acquired operations with our existing operations may
require us to coordinate geographically separated organizations,
address possible differences in corporate culture and management
philosophies, merge financial processes and risk and compliance
procedures, combine separate information technology platforms
and integrate operations that were previously closely tied to
the former parent of the acquired business or other service
providers.
|
|
|
|
In cases where we or an acquired business operates in certain
markets through joint ventures, the acquisition may affect the
continued success and prospects of the joint venture. Our
ability to exercise management control or influence over these
joint venture operations and our investment in them will depend
on the continued cooperation between the joint venture
participants and on the terms of the joint venture agreements,
which allocate control among the joint venture participants. We
may face financial or other exposure in the event that any of
these joint venture partners fail to meet their obligations
under the joint venture, encounter financial difficulty or elect
to alter, modify or terminate the relationship.
|
|
|
|
We may incur significant costs in connection with any
acquisition and the related integration. The costs and
liabilities actually incurred in connection with an acquisition
and subsequent integration process may exceed those anticipated.
|
All of these challenges are present in our integration of ALICO,
which we expect to extend over a substantial period.
The prospects of our business also may be materially and
adversely affected if we are not able to manage the growth of
any acquired business successfully. For example, the life
insurance markets in many of the international markets in which
ALICO operates have experienced significant growth in recent
years. Management of ALICOs growth to date has required
significant management and operational resources and is likely
to continue to do so. Future growth of our combined business
will require, among other things, the continued development of
adequate underwriting and claim handling capabilities and
skills, sufficient capital base, increased marketing and sales
activities, and the hiring and training of new personnel.
There can be no assurance that we will be successful in managing
future growth of any acquired business, including ALICO. In
particular, there may be difficulties in hiring and training
sufficient numbers of customer
S-38
service personnel and agents to keep pace with any future growth
in the number of customers in our developing or developed
markets. In addition, we may experience difficulties in
upgrading, developing and expanding information technology
systems quickly enough to accommodate any future growth. If we
are unable to manage future growth, our prospects may be
materially and adversely affected.
There
Can Be No Assurance That the Closing Agreement American Life
Entered Into With the IRS Will Achieve Its Intended Effect, or
That American Life Will Be Able to Comply with the Related
Agreed Upon Plan
On March 4, 2010, American Life entered into a closing
agreement with the Commissioner of the IRS with respect to a
U.S. withholding tax issue arising from payments by foreign
branches of a life insurance company incorporated under
U.S. law. IRS Revenue Ruling
2004-75,
effective January 1, 2005, requires foreign branches of
U.S. life insurance companies in certain circumstances to
withhold U.S. income taxes on payments of taxable income
made with respect to certain insurance and annuity products paid
to customers resident in a foreign country. The closing
agreement provides transitional relief under
Section 7805(b) of the U.S. Internal Revenue Code of
1986, as amended (the Code), to American
Life, such that American Lifes foreign branches will not
be required to withhold U.S. income tax on the income
portion of payments made pursuant to American Lifes life
insurance and annuity contracts (Covered
Payments) under IRS Revenue Ruling
2004-75 for
any tax periods beginning on January 1, 2005 and ending on
December 31, 2013 (the Deferral Period).
In accordance with the closing agreement, American Life
submitted a plan to the IRS indicating the steps American Life
will take (on a country by country basis) to ensure that no
substantial amount of U.S. withholding tax will arise from
Covered Payments made by American Lifes foreign branches
to foreign customers after the Deferral Period. In addition, the
closing agreement requires that such plan be updated in
quarterly filings with the IRS. The closing agreement is final
and binding upon American Life and the IRS; provided, however,
that the agreement can be reopened in the event of malfeasance,
fraud or a misrepresentation of a material fact, and is subject
to change of law risk that occurs after the effective date of
the closing agreement (with certain exceptions). In addition,
the closing agreement provides that no legislative amendment to
Section 861(a)(1)(A) of the Code shall shorten the Deferral
Period, regardless of when such amendment is enacted. The plan
American Life delivered to the IRS involves the transfer of
businesses from certain of the foreign branches of American Life
to one or more existing or newly-formed foreign affiliates of
American Life; however, the plan is subject to change pursuant
to the quarterly updates that American Life will provide to the
IRS. An estimate of the costs to comply with the plan has been
recorded in the financial statements. Also the achievement of
the plan presented to the IRS within the required time frame of
December 31, 2013 is contingent upon regulatory approvals
and other requirements. Failure to achieve the plan in a timely
manner could cause American Life to be required to withhold
U.S. income taxes on the taxable portion of payments made
by American Lifes foreign branches after December 31,
2013 to customers resident in a foreign country, which could put
American Life at a competitive disadvantage with its competitors
that sell similar products through foreign entities and could
have a material adverse effect on American Lifes future
revenues or expenses or both.
There
Can Be No Assurance That Any Incremental Tax Benefit Will Result
From the Currently Planned Elections Under Section 338 of
the Code
MetLife, Inc. currently plans to make Section 338 Elections
with respect to ALICO and certain of its subsidiaries, and
MetLife, Inc. believes that ALICO and such subsidiaries should
have additional amortizable basis in their assets for
U.S. tax purposes as a result of such elections. No
assurance can be given, however, as to the incremental tax
benefit, if any, that will result from any such elections if
made.
To the
Extent MetLife, Inc. Does Not Repurchase All of the
Series B Preferred Stock, If MetLife, Inc.s
Stockholders Do Not Vote to Approve the Conversion of the
Series B Preferred Stock Into Common Stock, MetLife, Inc.
Will Be Required to Pay Up To Approximately $300 Million to the
Selling Securityholder
The Selling Securityholder received the shares of the
Series B Preferred Stock upon completion of the
Acquisition. Each share of Series B Preferred Stock will
convert into 10 shares of MetLife, Inc.s common stock
(subject to anti-dilution adjustments) if conversion is approved
by MetLife, Inc.s common stockholders. If MetLife, Inc.
fails to obtain such approval prior to the first anniversary of
the closing of the Acquisition, November 1, 2011, MetLife,
Inc. will be required to pay up to approximately
$300 million to the Selling Securityholder, assuming no
purchase price adjustments, and, upon request, register the
Series B Preferred Stock for sale by the Selling
Securityholder in a public offering and list the Series B
Preferred Stock on the NYSE.
S-39
Fluctuations
in Foreign Currency Exchange Rates Could Negatively Affect Our
Profitability
We are exposed to risks associated with fluctuations in foreign
currency exchange rates against the U.S. dollar resulting
from our holdings of
non-U.S. dollar
denominated investments, investments in foreign subsidiaries and
net income from foreign operations and issuance of
non-U.S. dollar
denominated instruments, including guaranteed interest contracts
and funding agreements. These risks relate to potential
decreases in estimated fair value and income resulting from a
strengthening or weakening in foreign exchange rates versus the
U.S. dollar. In general, the weakening of foreign
currencies versus the U.S. dollar will adversely affect the
estimated fair value of our
non-U.S. dollar
denominated investments, our investments in foreign
subsidiaries, and our net income from foreign operations.
Although we use foreign currency swaps and forward contracts to
mitigate foreign currency exchange rate risk, we cannot provide
assurance that these methods will be effective or that our
counterparties will perform their obligations.
From time to time, various emerging market countries have
experienced severe economic and financial disruptions, including
significant devaluations of their currencies. Our exposure to
foreign exchange rate risk is exacerbated by our investments in
certain emerging markets.
Historically, we have matched substantially all of our foreign
currency liabilities in our foreign subsidiaries with
investments denominated in their respective foreign currency,
which limits the effect of currency exchange rate fluctuation on
local operating results; however, fluctuations in such rates
affect the translation of these results into our
U.S. dollar basis consolidated financial statements.
Although we take certain actions to address this risk, foreign
currency exchange rate fluctuation could materially adversely
affect our reported results due to unhedged positions or the
failure of hedges to effectively offset the impact of the
foreign currency exchange rate fluctuation.
The Acquisition has increased our exposure to risks associated
with fluctuations in foreign currency exchange rates against the
U.S. dollar and increased our exposure to emerging markets.
Fluctuations in the yen/ U.S. dollar exchange rate can have
a significant effect on our reported financial position and
results of operations because ALICO has substantial operations
in Japan and a significant portion of its premiums and
investment income are received in yen. Claims and expenses are
also paid in yen and ALICO primarily purchases yen-denominated
assets to support yen-denominated policy liabilities. These and
other yen-denominated financial statement items are, however,
translated into U.S. dollars for financial reporting
purposes. Accordingly, fluctuations in the
yen/U.S. dollar
exchange rate can have a significant effect on our reported
financial position and results of operations.
Due to our significant international operations, during periods
when any foreign currency in which we derive our revenues (such
as the Japanese yen) weakens, translating amounts expressed in
that currency into U.S. dollars causes fewer
U.S. dollars to be reported. When the relevant foreign
currency strengthens, translating such currency into
U.S. dollars causes more U.S. dollars to be reported.
Between September 30, 2010 and December 31, 2010, the
Japanese yen has strengthened against the U.S. dollar,
which fluctuated from a low point of ¥80.40 to the
U.S. dollar on October 29, 2010 to a high point of
¥84.26 to the U.S. dollar on November 29, 2010,
which has been somewhat offset by the weakening of the euro,
which fluctuated from a high point of 0.7702 euro to the
U.S. dollar on November 30, 2010, to 0.7039 euro to
the U.S. dollar on November 4, 2010. Any unrealized
foreign currency translation adjustments are reported in
accumulated other comprehensive income (loss). The weakening of
a foreign currency relative to the U.S. dollar will
generally adversely affect the value of investments in
U.S. dollar terms and reduce the level of reserves
denominated in that currency.
Our
International Operations Face Political, Legal, Operational and
Other Risks, Including Exposure to Local and Regional Economic
Conditions, That Could Negatively Affect Those Operations or Our
Profitability
Our international operations face political, legal, operational
and other risks that we do not face in our domestic operations.
We face the risk of discriminatory regulation, nationalization
or expropriation of assets, price controls and exchange controls
or other restrictions that prevent us from transferring funds
from these operations out of the countries in which they operate
or converting local currencies we hold into U.S. dollars or
other currencies. Some of our foreign insurance operations are,
and are likely to continue to be, in emerging markets where
these risks are heightened. In addition, we rely on local sales
forces in these countries and may encounter labor problems
resulting from workers associations and trade unions in
some countries. In several countries, including Japan, China and
India we operate with local business partners with the resulting
risk of managing partner relationships to the
S-40
business objectives. If our business model is not successful in
a particular country, we may lose all or most of our investment
in building and training the sales force in that country.
We are expanding our international operations in certain markets
where we operate and in selected new markets. This may require
considerable management time, as well as
start-up
expenses for market development before any significant revenues
and earnings are generated. Operations in new foreign markets
may achieve low margins or may be unprofitable, and expansion in
existing markets may be affected by local economic and market
conditions. Therefore, as we expand internationally, we may not
achieve expected operating margins and our results of operations
may be negatively impacted.
In addition, in recent years, the operating environment in
Argentina has been very challenging. In Argentina, we were
formerly principally engaged in the pension business. In
December 2008, the Argentine government nationalized private
pensions and seized the pension funds investments,
eliminating the private pensions business in Argentina. As a
result, we have experienced and will continue to experience
reductions in the operations revenues and cash flows. The
Argentine government now controls all assets which previously
were managed by our Argentine pension operations. Further
governmental or legal actions related to our operations in
Argentina could negatively impact our operations in Argentina
and result in future losses.
We have market presence in over 60 different countries, and
increased exposure to risks posed by local and regional economic
conditions. Europe has recently experienced a deep recession and
countries such as Italy, Spain, Portugal and, in particular,
Greece and Ireland, have been particularly affected by the
recession, resulting in increased national debts and depressed
economic activity. We have significant operations and
investments in these countries which could be adversely affected
by economic developments such as higher taxes, growing
inflation, decreasing government spending, rising unemployment
and currency instability.
In addition to fluctuations in the yen/U.S. dollar exchange
rate discussed above, we face increased exposure to the Japanese
markets as a result of ALICOs considerable presence there.
Deterioration in Japans economic recovery could have an
adverse effect on our results of operations and financial
condition.
We also have operations in the Middle East where the legal and
political systems and regulatory frameworks are subject to
instability and disruptions. Lack of legal certainty and
stability in the region exposes our operations to increased risk
of disruption and to adverse or unpredictable actions by
regulators and may make it more difficult for us to enforce our
contracts, which may negatively impact our business in this
region. See also Changes in Market
Interest Rates May Significantly Affect Our Profitability
regarding the impact of low interest rates on our Taiwanese
operations.
As a
Holding Company, MetLife, Inc. Depends on the Ability of Its
Subsidiaries to Transfer Funds to It to Meet Its Obligations and
Pay Dividends
MetLife, Inc. is a holding company for its insurance and
financial subsidiaries and does not have any significant
operations of its own. Dividends from its subsidiaries and
permitted payments to it under its tax sharing arrangements with
its subsidiaries are its principal sources of cash to meet its
obligations and to pay preferred and common stock dividends. If
the cash MetLife, Inc. receives from its subsidiaries is
insufficient for it to fund its debt service and other holding
company obligations, MetLife, Inc. may be required to raise cash
through the incurrence of debt, the issuance of additional
equity or the sale of assets.
The payment of dividends and other distributions to MetLife,
Inc. by its insurance subsidiaries is regulated by insurance
laws and regulations. In general, dividends in excess of
prescribed limits require insurance regulatory approval. In
addition, insurance regulators may prohibit the payment of
dividends or other payments by its insurance subsidiaries to
MetLife, Inc. if they determine that the payment could be
adverse to our policyholders or contractholders. The payment of
dividends and other distributions by insurance companies is also
influenced by business conditions and rating agency
considerations. The ability of MetLife Bank to pay dividends is
also subject to regulation by the OCC.
Any payment of interest, dividends, distributions, loans or
advances by our foreign subsidiaries and branches to MetLife,
Inc. could be subject to taxation or other restrictions on
dividends or repatriation of earnings under applicable law,
monetary transfer restrictions and foreign currency exchange
regulations in the jurisdiction in which
S-41
such foreign subsidiaries operate. See
Our International Operations Face
Political, Legal, Operational and Other Risks, Including
Exposure to Local and Regional Economic Conditions, That Could
Negatively Affect Those Operations or Our Profitability.
A
Downgrade or a Potential Downgrade in Our Financial Strength or
Credit Ratings Could Result in a Loss of Business and Materially
Adversely Affect Our Financial Condition and Results of
Operations
Financial strength ratings, which various Nationally Recognized
Statistical Rating Organizations (NRSRO)
publish as indicators of an insurance companys ability to
meet contractholder and policyholder obligations, are important
to maintaining public confidence in our products, our ability to
market our products and our competitive position.
Downgrades in our financial strength ratings could have a
material adverse effect on our financial condition and results
of operations in many ways, including:
|
|
|
|
|
reducing new sales of insurance products, annuities and other
investment products;
|
|
|
|
adversely affecting our relationships with our sales force and
independent sales intermediaries;
|
|
|
|
materially increasing the number or amount of policy surrenders
and withdrawals by contractholders and policyholders;
|
|
|
|
requiring us to reduce prices for many of our products and
services to remain competitive; and
|
|
|
|
adversely affecting our ability to obtain reinsurance at
reasonable prices or at all.
|
In addition to the financial strength ratings of our insurance
subsidiaries, various NRSROs also publish credit ratings for
MetLife, Inc. and several of its subsidiaries. Credit ratings
are indicators of a debt issuers ability to meet the terms
of debt obligations in a timely manner and are important factors
in our overall funding profile and ability to access certain
types of liquidity. Downgrades in our credit ratings could have
a material adverse effect on our financial condition and results
of operations in many ways, including adversely limiting our
access to capital markets, potentially increasing the cost of
debt, and requiring us to post collateral. For example, with
respect to derivative transactions with credit ratings downgrade
triggers, a one-notch downgrade would have increased our
derivative collateral requirements by $99 million at
December 31, 2010. Also, $375 million of liabilities
associated with funding agreements and other capital market
products were subject to credit ratings downgrade triggers that
permit early termination subject to a notice period of
90 days.
In view of the difficulties experienced during 2008 and 2009 by
many financial institutions, including our competitors in the
insurance industry, we believe it is possible that the NRSROs
will continue to heighten the level of scrutiny that they apply
to such institutions, will continue to increase the frequency
and scope of their credit reviews, will continue to request
additional information from the companies that they rate, and
may adjust upward the capital and other requirements employed in
the NRSRO models for maintenance of certain ratings levels.
Rating agencies use an outlook statement of
positive, stable, negative
or developing to indicate a medium- or long-term
trend in credit fundamentals which, if continued, may lead to a
ratings change. A rating may have a stable outlook
to indicate that the rating is not expected to change; however,
a stable rating does not preclude a rating agency
from changing a rating at any time, without notice. Certain
rating agencies assign rating modifiers such as
CreditWatch or Under Review to indicate
their opinion regarding the potential direction of a rating.
These ratings modifiers are generally assigned in connection
with certain events such as potential mergers and acquisitions,
or material changes in a companys results, in order for
the rating agencies to perform their analyses to fully determine
the rating implications of the event. Certain rating agencies
have recently implemented rating actions, including downgrades,
outlook changes and modifiers, for MetLife, Inc.s and
certain of its subsidiaries insurer financial strength and
credit ratings.
Based on the announcement in February 2010 that MetLife was in
discussions to acquire ALICO, in February 2010, S&P and
A.M. Best placed the ratings of MetLife, Inc. and its
subsidiaries on CreditWatch with negative
implications and under review with negative
implications, respectively. Also in connection with the
announcement, in March 2010, Moodys changed the ratings
outlook of MetLife, Inc. and its subsidiaries from
stable to negative outlook. Upon
completion of the public financing transactions related to the
Acquisition, in August
S-42
2010, S&P affirmed the ratings of MetLife, Inc. and
subsidiaries with a negative outlook, and removed
them from CreditWatch. On November 1, 2010,
upon closing of the Acquisition, S&P changed the rating
outlook of American Life to positive from
negative and affirmed its financial strength rating;
the ratings of MetLife, Inc. and its other subsidiaries were
unaffected by this ratings action. Also on November 1,
2010, Fitch Ratings upgraded by one notch (and changed the
rating outlook from Rating Watch Positive to
stable) the financial strength rating of American
Life and affirmed all existing ratings for MetLife, Inc. and its
other subsidiaries. On November 4, 2010, A.M. Best
upgraded by one notch the financial strength rating of American
Life and changed the rating outlook from under review with
positive implications to negative.
A.M. Best also changed the outlook for MetLife, Inc. and
certain of its other subsidiaries to negative from
under review with negative implications. Effective
as of January 2011, MetLife withdrew the American Life financial
strength ratings by A.M. Best and Fitch Ratings as once it
became a subsidiary of MetLife it was not deemed necessary to
maintain stand-alone ratings.
On July 1, 2010, Moodys published revised guidance
called Revisions to Moodys Hybrid Tool Kit
(the Guidance) for assigning equity credit to
so-called hybrid securities, i.e., securities with both debt and
equity characteristics (Hybrids).
Moodys evaluates Hybrids using certain specified criteria
and then places each such security into a basket,
with a specific percentage of debt and equity being associated
with each basket, which is then used to adjust full sets of
financial statements for purposes of, among other things,
calculating the issuing companys financial leverage. Under
the Guidance, Hybrids are one element that Moodys
considers within the context of an issuers overall credit
profile. As of December 31, 2010, we have approximately
$11.1 billion of Hybrids outstanding, which includes
approximately $6.2 billion of debt securities and
$4.9 billion of equity securities. Application of the
Guidance has resulted in Moodys significantly reducing the
amount of equity credit it assigns to these securities,
including the common equity units issued to the Selling
Securityholder in connection with the Acquisition. We do not
expect at this time, as a result of the Guidance, that a
reduction in Moodys equity treatment of our Hybrids,
including the common equity units, would result in any material
negative impact on MetLife, Inc.s credit rating or the
financial strength ratings of its insurance company
subsidiaries. However, if we decided to increase our adjusted
capital as a result of the application of the Guidance, we may
seek to (i) issue additional common equity or higher equity
content Hybrids satisfying the Guidances revised rating
criteria,
and/or
(ii) redeem, repurchase or restructure existing Hybrids.
Any sale of additional common equity would have a dilutive
effect on our common stockholders.
We cannot predict what actions rating agencies may take, or what
actions we may take in response to the actions of rating
agencies, which could adversely affect our business. As with
other companies in the financial services industry, our ratings
could be downgraded at any time and without any notice by any
NRSRO.
An
Inability to Access Our Credit Facilities Could Result in a
Reduction in Our Liquidity and Lead to Downgrades in Our Credit
and Financial Strength Ratings
In October 2010, we entered into two senior unsecured credit
facilities: a three-year $3 billion facility and a
364-day
$1 billion facility. We also have other facilities which we
enter into in the ordinary course of business.
We rely on our credit facilities as a potential source of
liquidity. The availability of these facilities could be
critical to our credit and financial strength ratings and our
ability to meet our obligations as they come due in a market
when alternative sources of credit are tight. The credit
facilities contain certain administrative, reporting, legal and
financial covenants. We must comply with covenants under our
credit facilities, including a requirement to maintain a
specified minimum consolidated net worth.
Our right to make borrowings under these facilities is subject
to the fulfillment of certain important conditions, including
our compliance with all covenants, and our ability to borrow
under these facilities is also subject to the continued
willingness and ability of the lenders that are parties to the
facilities to provide funds. Our failure to comply with the
covenants in the credit facilities or fulfill the conditions to
borrowings, or the failure of lenders to fund their lending
commitments (whether due to insolvency, illiquidity or other
reasons) in the amounts provided for under the terms of the
facilities, would restrict our ability to access these credit
facilities when needed and, consequently, could have a material
adverse effect on our financial condition and results of
operations.
S-43
Defaults,
Downgrades or Other Events Impairing the Carrying Value of Our
Fixed Maturity or Equity Securities Portfolio May Reduce Our
Earnings
We are subject to the risk that the issuers, or guarantors, of
fixed maturity securities we own may default on principal and
interest payments they owe us. We are also subject to the risk
that the underlying collateral within loan-backed securities,
including mortgage-backed securities, may default on principal
and interest payments causing an adverse change in cash flows.
Fixed maturity securities represent a significant portion of our
investment portfolio. The occurrence of a major economic
downturn, acts of corporate malfeasance, widening risk spreads,
or other events that adversely affect the issuers, guarantors or
underlying collateral of these securities could cause the
estimated fair value of our fixed maturity securities portfolio
and our earnings to decline and the default rate of the fixed
maturity securities in our investment portfolio to increase. A
ratings downgrade affecting issuers or guarantors of particular
securities, or similar trends that could worsen the credit
quality of issuers, such as the corporate issuers of securities
in our investment portfolio, could also have a similar effect.
With economic uncertainty, credit quality of issuers or
guarantors could be adversely affected. Similarly, a ratings
downgrade affecting a security we hold could indicate the credit
quality of that security has deteriorated and could increase the
capital we must hold to support that security to maintain our
RBC levels. Any event reducing the estimated fair value of these
securities other than on a temporary basis could have a material
adverse effect on our business, results of operations and
financial condition. Levels of writedowns or impairments are
impacted by our assessment of intent to sell, or whether it is
more likely than not that we will be required to sell, fixed
maturity securities and the intent and ability to hold equity
securities which have declined in value until recovery. If we
determine to reposition or realign portions of the portfolio so
as not to hold certain equity securities, or intend to sell or
determine that it is more likely than not that we will be
required to sell, certain fixed maturity securities in an
unrealized loss position prior to recovery, then we will incur
an
other-than-temporary
impairment charge in the period that the decision was made not
to hold the equity security to recovery, or to sell, or the
determination was made it is more likely than not that we will
be required to sell the fixed maturity security.
Our
Risk Management Policies and Procedures May Leave Us Exposed to
Unidentified or Unanticipated Risk, Which Could Negatively
Affect Our Business
Management of risk requires, among other things, policies and
procedures to record properly and verify a large number of
transactions and events. We have devoted significant resources
to develop our risk management policies and procedures and
expect to continue to do so in the future. Nonetheless, our
policies and procedures may not be comprehensive. Many of our
methods for managing risk and exposures are based upon the use
of observed historical market behavior or statistics based on
historical models. As a result, these methods may not fully
predict future exposures, which can be significantly greater
than our historical measures indicate. Other risk management
methods depend upon the evaluation of information regarding
markets, clients, catastrophe occurrence or other matters that
is publicly available or otherwise accessible to us. This
information may not always be accurate, complete,
up-to-date
or properly evaluated.
Reinsurance
May Not Be Available, Affordable or Adequate to Protect Us
Against Losses
As part of our overall risk management strategy, we purchase
reinsurance for certain risks underwritten by our various
business segments. While reinsurance agreements generally bind
the reinsurer for the life of the business reinsured at
generally fixed pricing, market conditions beyond our control
determine the availability and cost of the reinsurance
protection for new business. In certain circumstances, the price
of reinsurance for business already reinsured may also increase.
Any decrease in the amount of reinsurance will increase our risk
of loss and any increase in the cost of reinsurance will, absent
a decrease in the amount of reinsurance, reduce our earnings.
Accordingly, we may be forced to incur additional expenses for
reinsurance or may not be able to obtain sufficient reinsurance
on acceptable terms, which could adversely affect our ability to
write future business or result in the assumption of more risk
with respect to those policies we issue.
S-44
If the
Counterparties to Our Reinsurance or Indemnification
Arrangements or to the Derivative Instruments We Use to Hedge
Our Business Risks Default or Fail to Perform, We May Be Exposed
to Risks We Had Sought to Mitigate, Which Could Materially
Adversely Affect Our Financial Condition and Results of
Operations
We use reinsurance, indemnification and derivative instruments
to mitigate our risks in various circumstances. In general,
reinsurance does not relieve us of our direct liability to our
policyholders, even when the reinsurer is liable to us.
Accordingly, we bear credit risk with respect to our reinsurers
and indemnitors. We cannot provide assurance that our reinsurers
will pay the reinsurance recoverables owed to us or that
indemnitors will honor their obligations now or in the future or
that they will pay these recoverables on a timely basis. A
reinsurers or indemnitors insolvency, inability or
unwillingness to make payments under the terms of reinsurance
agreements or indemnity agreements with us could have a material
adverse effect on our financial condition and results of
operations.
In addition, we use derivative instruments to hedge various
business risks. We enter into a variety of derivative
instruments, including options, forwards, interest rate, credit
default and currency swaps with a number of counterparties. If
our counterparties fail or refuse to honor their obligations
under these derivative instruments, our hedges of the related
risk will be ineffective. This is a more pronounced risk to us
in view of the stresses suffered by financial institutions over
the past few years. Such failure could have a material adverse
effect on our financial condition and results of operations.
Differences
Between Actual Claims Experience and Underwriting and Reserving
Assumptions May Adversely Affect Our Financial
Results
Our earnings significantly depend upon the extent to which our
actual claims experience is consistent with the assumptions we
use in setting prices for our products and establishing
liabilities for future policy benefits and claims. Our
liabilities for future policy benefits and claims are
established based on estimates by actuaries of how much we will
need to pay for future benefits and claims. For life insurance
and annuity products, we calculate these liabilities based on
many assumptions and estimates, including estimated premiums to
be received over the assumed life of the policy, the timing of
the event covered by the insurance policy, the amount of
benefits or claims to be paid and the investment returns on the
investments we make with the premiums we receive. We establish
liabilities for property and casualty claims and benefits based
on assumptions and estimates of damages and liabilities
incurred. To the extent that actual claims experience is less
favorable than the underlying assumptions we used in
establishing such liabilities, we could be required to increase
our liabilities.
Due to the nature of the underlying risks and the high degree of
uncertainty associated with the determination of liabilities for
future policy benefits and claims, we cannot determine precisely
the amounts which we will ultimately pay to settle our
liabilities. Such amounts may vary from the estimated amounts,
particularly when those payments may not occur until well into
the future. We evaluate our liabilities periodically based on
accounting requirements, which change from time to time, the
assumptions used to establish the liabilities, as well as our
actual experience. We charge or credit changes in our
liabilities to expenses in the period the liabilities are
established or re-estimated. If the liabilities originally
established for future benefit payments prove inadequate, we
must increase them. Such increases could affect earnings
negatively and have a material adverse effect on our business,
results of operations and financial condition.
Catastrophes
May Adversely Impact Liabilities for Policyholder Claims and
Reinsurance Availability
Our life insurance operations are exposed to the risk of
catastrophic mortality, such as a pandemic or other event that
causes a large number of deaths. Significant influenza pandemics
have occurred three times in the last century, but neither the
likelihood, timing, nor the severity of a future pandemic can be
predicted. A significant pandemic could have a major impact on
the global economy or the economies of particular countries or
regions, including travel, trade, tourism, the health system,
food supply, consumption, overall economic output and,
eventually, on the financial markets. In addition, a pandemic
that affected our employees or the employees of our distributors
or of other companies with which we do business could disrupt
our business operations. The effectiveness of external parties,
including governmental and non-governmental organizations, in
combating the spread and severity of such a pandemic could have
a material impact on the losses experienced by us. In our
S-45
group insurance operations, a localized event that affects the
workplace of one or more of our group insurance customers could
cause a significant loss due to mortality or morbidity claims.
These events could cause a material adverse effect on our
results of operations in any period and, depending on their
severity, could also materially and adversely affect our
financial condition.
Our Auto & Home business has experienced, and will
likely in the future experience, catastrophe losses that may
have a material adverse impact on the business, results of
operations and financial condition of the Auto & Home
segment. Although Auto & Home makes every effort to
manage our exposure to catastrophic risks through volatility
management and reinsurance programs, these efforts do not
eliminate all risk. Catastrophes can be caused by various
events, including hurricanes, windstorms, earthquakes, hail,
tornadoes, explosions, severe winter weather (including snow,
freezing water, ice storms and blizzards), fires and man-made
events such as terrorist attacks. Historically, substantially
all of our catastrophe-related claims have related to homeowners
coverages. However, catastrophes may also affect other
Auto & Home coverages. Due to their nature, we cannot
predict the incidence, timing and severity of catastrophes. In
addition, changing climate conditions, primarily rising global
temperatures, may be increasing, or may in the future increase,
the frequency and severity of natural catastrophes such as
hurricanes.
Hurricanes and earthquakes are of particular note for our
homeowners coverages. Areas of major hurricane exposure include
coastal sections of the northeastern United States (including
lower New York, Connecticut, Rhode Island and Massachusetts),
the Gulf Coast (including Alabama, Mississippi, Louisiana and
Texas) and Florida. We also have some earthquake exposure,
primarily along the New Madrid fault line in the central United
States and in the Pacific Northwest.
The extent of losses from a catastrophe is a function of both
the total amount of insured exposure in the area affected by the
event and the severity of the event. Most catastrophes are
restricted to small geographic areas; however, hurricanes,
earthquakes and man-made catastrophes may produce significant
damage or loss of life in larger areas, especially those that
are heavily populated. Claims resulting from natural or man-made
catastrophic events could cause substantial volatility in our
financial results for any fiscal quarter or year and could
materially reduce our profitability or harm our financial
condition. Also, catastrophic events could harm the financial
condition of our reinsurers and thereby increase the probability
of default on reinsurance recoveries. Our ability to write new
business could also be affected. It is possible that increases
in the value, caused by the effects of inflation or other
factors, and geographic concentration of insured property, could
increase the severity of claims from catastrophic events in the
future.
Most of the jurisdictions in which our insurance subsidiaries
are admitted to transact business require life and property and
casualty insurers doing business within the jurisdiction to
participate in guaranty associations, which are organized to pay
contractual benefits owed pursuant to insurance policies issued
by impaired, insolvent or failed insurers. These associations
levy assessments, up to prescribed limits, on all member
insurers in a particular state on the basis of the proportionate
share of the premiums written by member insurers in the lines of
business in which the impaired, insolvent or failed insurer is
engaged. In addition, certain states have government owned or
controlled organizations providing life and property and
casualty insurance to their citizens. The activities of such
organizations could also place additional stress on the adequacy
of guaranty fund assessments. Many of these organizations also
have the power to levy assessments similar to those of the
guaranty associations described above. Some states permit member
insurers to recover assessments paid through full or partial
premium tax offsets.
While in the past five years, the aggregate assessments levied
against MetLife, Inc.s insurance subsidiaries have not
been material, it is possible that a large catastrophic event
could render such guaranty funds inadequate and we may be called
upon to contribute additional amounts, which may have a material
impact on our financial condition or results of operations in a
particular period. We have established liabilities for guaranty
fund assessments that we consider adequate for assessments with
respect to insurers that are currently subject to insolvency
proceedings, but additional liabilities may be necessary.
Consistent with industry practice and accounting standards, we
establish liabilities for claims arising from a catastrophe only
after assessing the probable losses arising from the event. We
cannot be certain that the liabilities we have established will
be adequate to cover actual claim liabilities. From time to
time, states have passed legislation that has the effect of
limiting the ability of insurers to manage risk, such as
legislation restricting an
S-46
insurers ability to withdraw from catastrophe-prone areas.
While we attempt to limit our exposure to acceptable levels,
subject to restrictions imposed by insurance regulatory
authorities, a catastrophic event or multiple catastrophic
events could have a material adverse effect on our business,
results of operations and financial condition.
Our ability to manage this risk and the profitability of our
property and casualty and life insurance businesses depends in
part on our ability to obtain catastrophe reinsurance, which may
not be available at commercially acceptable rates in the future.
See Reinsurance May Not Be Available,
Affordable or Adequate to Protect Us Against Losses.
Our
Statutory Reserve Financings May Be Subject to Cost Increases
and New Financings May Be Subject to Limited Market
Capacity
To support statutory reserves for several products, including,
but not limited to, our level premium term life and universal
life with secondary guarantees and MLICs closed block, we
currently utilize capital markets solutions for financing a
portion of our statutory reserve requirements. While we have
financing facilities in place for our previously written
business and have remaining capacity in existing facilities to
support writings through the end of 2010 or later, certain of
these facilities are subject to cost increases upon the
occurrence of specified ratings downgrades of MetLife or are
subject to periodic repricing. Any resulting cost increases
could negatively impact our financial results.
Future capacity for these statutory reserve funding structures
in the marketplace is not guaranteed. If capacity becomes
unavailable for a prolonged period of time, hindering our
ability to obtain funding for these new structures, our ability
to write additional business in a cost effective manner may be
impacted.
Competitive
Factors May Adversely Affect Our Market Share and
Profitability
Our segments are subject to intense competition. We believe that
this competition is based on a number of factors, including
service, product features, scale, price, financial strength,
claims-paying ratings, credit ratings,
e-business
capabilities and name recognition. We compete with a large
number of other insurers, as well as non-insurance financial
services companies, such as banks, broker-dealers and asset
managers, for individual consumers, employers and other group
customers and agents and other distributors of insurance and
investment products. Some of these companies offer a broader
array of products, have more competitive pricing or more
attractive features in their products or, with respect to other
insurers, have higher claims paying ability ratings. Some may
also have greater financial resources with which to compete.
National banks, which may sell annuity products of life insurers
in some circumstances, also have pre-existing customer bases for
financial services products. Many of our group insurance
products are underwritten annually, and, accordingly, there is a
risk that group purchasers may be able to obtain more favorable
terms from competitors rather than renewing coverage with us.
The effect of competition may, as a result, adversely affect the
persistency of these and other products, as well as our ability
to sell products in the future.
In addition, the investment management and securities brokerage
businesses have relatively few barriers to entry and continually
attract new entrants.
Finally, the new requirements imposed on the financial industry
by Dodd-Frank could similarly have differential effects. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth.
Industry
Trends Could Adversely Affect the Profitability of Our
Businesses
Our segments continue to be influenced by a variety of trends
that affect the insurance industry, including competition with
respect to product features, price, distribution capability,
customer service and information technology. The impact on our
business and on the life insurance industry generally of the
volatility and instability of the financial markets is difficult
to predict, and our business plans, financial condition and
results of operations may be negatively impacted or affected in
other unexpected ways. In addition, the life insurance industry
is subject to state regulation, and, as complex products are
introduced, regulators may refine capital requirements and
S-47
introduce new reserving standards. Dodd-Frank, Basel III
and the market environment in general may also lead to changes
in regulation that may benefit or disadvantage us relative to
some of our competitors. See Our
Insurance, Brokerage and Banking Businesses Are Heavily
Regulated, and Changes in Regulation May Reduce Our
Profitability and Limit Our Growth and
Competitive Factors May Adversely Affect Our
Market Share and Profitability.
Consolidation
of Distributors of Insurance Products May Adversely Affect the
Insurance Industry and the Profitability of Our
Business
The insurance industry distributes many of its individual
products through other financial institutions such as banks and
broker-dealers. An increase in bank and broker-dealer
consolidation activity may negatively impact the industrys
sales, and such consolidation could increase competition for
access to distributors, result in greater distribution expenses
and impair our ability to market insurance products to our
current customer base or to expand our customer base.
Consolidation of distributors
and/or other
industry changes may also increase the likelihood that
distributors will try to renegotiate the terms of any existing
selling agreements to terms less favorable to us.
Our
Valuation of Fixed Maturity, Equity and Trading and Other
Securities and Short-Term Investments May Include Methodologies,
Estimations and Assumptions Which Are Subject to Differing
Interpretations and Could Result in Changes to Investment
Valuations That May Materially Adversely Affect Our Results of
Operations or Financial Condition
Fixed maturity, equity, and trading and other securities and
short-term investments which are reported at estimated fair
value on the consolidated balance sheets represent the majority
of our total cash and investments. We have categorized these
securities into a three-level hierarchy, based on the priority
of the inputs to the respective valuation technique.
The fair value hierarchy gives the highest priority to quoted
prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable
inputs (Level 3). An asset or liabilitys
classification within the fair value hierarchy is based on the
lowest level of significant input to its valuation. The input
levels are as follows:
Level 1 Unadjusted quoted prices in active
markets for identical assets or liabilities. We define active
markets based on average trading volume for equity securities.
The size of the bid/ask spread is used as an indicator of market
activity for fixed maturity securities.
Level 2 Quoted prices in markets that are not
active or inputs that are observable either directly or
indirectly. Level 2 inputs include quoted prices for
similar assets or liabilities other than quoted prices in
Level 1; quoted prices in markets that are not active; or
other significant inputs that are observable or can be derived
principally from or corroborated by observable market data for
substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported
by little or no market activity and are significant to the
estimated fair value of the assets or liabilities. Unobservable
inputs reflect the reporting entitys own assumptions about
the assumptions that market participants would use in pricing
the asset or liability. Level 3 assets and liabilities
include financial instruments whose values are determined using
pricing models, discounted cash flow methodologies, or similar
techniques, as well as instruments for which the determination
of the estimated fair value requires significant management
judgment or estimation.
At December 31, 2010, 7.0%, 85.8% and 7.2% of these
securities represented Level 1, Level 2 and
Level 3, respectively. The Level 1 securities
primarily consist of certain U.S. Treasury, agency and
government guaranteed fixed maturity securities; certain foreign
government fixed maturity securities; exchange-traded common
stock; certain trading securities; certain fair value option
securities and certain short-term investments. The Level 2
assets include fixed maturity and equity securities priced
principally through independent pricing services using
observable inputs. These fixed maturity securities include most
U.S. Treasury, agency and government guaranteed securities,
as well as the majority of U.S. and foreign corporate
securities, RMBS, CMBS, state and political subdivision
securities, foreign government securities, and ABS. Equity
securities classified as Level 2 primarily consist of non-
redeemable preferred securities and certain equity securities
where market quotes are available but
S-48
are not considered actively traded and are priced by independent
pricing services. We review the valuation methodologies used by
the independent pricing services on an ongoing basis and ensure
that any changes to valuation methodologies are justified.
Level 3 assets include fixed maturity securities priced
principally through independent non-binding broker quotations or
market standard valuation methodologies using inputs that are
not market observable or cannot be derived principally from or
corroborated by observable market data. Level 3 consists of
less liquid fixed maturity securities with very limited trading
activity or where less price transparency exists around the
inputs to the valuation methodologies including: U.S. and
foreign corporate securities including below
investment grade private placements; RMBS; CMBS; and
ABS including all of those supported by
sub-prime
mortgage loans. Equity securities classified as Level 3
securities consist principally of nonredeemable preferred stock
and common stock of companies that are privately held or
companies for which there has been very limited trading activity
or where less price transparency exists around the inputs to the
valuation.
Prices provided by independent pricing services and independent
non-binding broker quotations can vary widely even for the same
security.
The determination of estimated fair values by management in the
absence of quoted market prices is based on: (i) valuation
methodologies; (ii) securities we deem to be comparable;
and (iii) assumptions deemed appropriate given the
circumstances. The fair value estimates are made at a specific
point in time, based on available market information and
judgments about financial instruments, including estimates of
the timing and amounts of expected future cash flows and the
credit standing of the issuer or counterparty. Factors
considered in estimating fair value include: coupon rate,
maturity, estimated duration, call provisions, sinking fund
requirements, credit rating, industry sector of the issuer, and
quoted market prices of comparable securities. The use of
different methodologies and assumptions may have a material
effect on the estimated fair value amounts. During periods of
market disruption including periods of significantly rising or
high interest rates, rapidly widening credit spreads or
illiquidity, it may be difficult to value certain of our
securities, for example
sub-prime
mortgage-backed securities, mortgage-backed securities where the
underlying loans are Alt-A and CMBS, if trading becomes less
frequent
and/or
market data becomes less observable. In times of financial
market disruption, certain asset classes that were in active
markets with significant observable data may become illiquid. In
such cases, more securities may fall to Level 3 and thus
require more subjectivity and management judgment. As such,
valuations may include inputs and assumptions that are less
observable or require greater estimation, as well as valuation
methods which are more sophisticated or require greater
estimation thereby resulting in estimated fair values which may
be greater or less than the amount at which the investments may
be ultimately sold. Further, rapidly changing and unprecedented
credit and equity market conditions could materially impact the
valuation of securities as reported within our consolidated
financial statements and the
period-to-period
changes in estimated fair value could vary significantly.
Decreases in value may have a material adverse effect on our
results of operations or financial condition.
If Our
Business Does Not Perform Well, We May Be Required to Recognize
an Impairment of Our Goodwill or Other Long-Lived Assets or to
Establish a Valuation Allowance Against the Deferred Income Tax
Asset, Which Could Adversely Affect Our Results of Operations or
Financial Condition
Goodwill represents the excess of the amounts we paid to acquire
subsidiaries and other businesses over the estimated fair value
of their net assets at the date of acquisition. As of
December 31, 2010, our goodwill was $11,781 million,
of which $6,959 million of goodwill was established in
connection with the acquisition of ALICO. We test goodwill at
least annually for impairment. Impairment testing is performed
based upon estimates of the estimated fair value of the
reporting unit to which the goodwill relates. The
reporting unit is the operating segment or a business one level
below that operating segment if discrete financial information
is prepared and regularly reviewed by management at that level.
The estimated fair value of the reporting unit is impacted by
the performance of the business. The performance of our
businesses may be adversely impacted by prolonged market
declines. If it is determined that the goodwill has been
impaired, we must write down the goodwill by the amount of the
impairment, with a corresponding charge to net income. Such
writedowns could have an adverse effect on our results of
operation or financial position. For example, our goodwill has
increased substantially as a result of the Acquisition. Market
factors, the failure of ALICO to perform well, or issues
relating to the integration of ALICO could result in the
reporting units containing parts of ALICO having fair values
lower than their respective carrying values, which
S-49
would result in a writedown of goodwill and, consequently, it
could have a material adverse effect on our results of
operations.
Long-lived assets, including assets such as real estate, also
require impairment testing to determine whether changes in
circumstances indicate that MetLife will be unable to recover
the carrying amount of the asset group through future operations
of that asset group or market conditions that will impact the
estimated fair value of those assets. Such writedowns could have
a material adverse effect on our results of operations or
financial position.
Deferred income tax represents the tax effect of the differences
between the book and tax basis of assets and liabilities.
Deferred tax assets are assessed periodically by management to
determine if they are realizable. Factors in managements
determination include the performance of the business including
the ability to generate future taxable income. If based on
available information, it is more likely than not that the
deferred income tax asset will not be realized then a valuation
allowance must be established with a corresponding charge to net
income. Such charges could have a material adverse effect on our
results of operations or financial position.
If Our
Business Does Not Perform Well or if Actual Experience Versus
Estimates Used in Valuing and Amortizing DAC, Deferred Sales
Inducements (DSI) and VOBA Vary Significantly, We
May Be Required to Accelerate the Amortization and/or Impair the
DAC, DSI and VOBA Which Could Adversely Affect Our Results of
Operations or Financial Condition
We incur significant costs in connection with acquiring new and
renewal business. Those costs that vary with and are primarily
related to the production of new and renewal business are
deferred and referred to as DAC. Bonus amounts credited to
certain policyholders, either immediately upon receiving a
deposit or as excess interest credits for a period of time, are
referred to as DSI. The recovery of DAC and DSI is dependent
upon the future profitability of the related business. The
amount of future profit or margin is dependent principally on
investment returns in excess of the amounts credited to
policyholders, mortality, morbidity, persistency, interest
crediting rates, dividends paid to policyholders, expenses to
administer the business, creditworthiness of reinsurance
counterparties and certain economic variables, such as
inflation. Of these factors, we anticipate that investment
returns are most likely to impact the rate of amortization of
such costs. The aforementioned factors enter into
managements estimates of gross profits or margins, which
generally are used to amortize such costs.
If the estimates of gross profits or margins were overstated,
then the amortization of such costs would be accelerated in the
period the actual experience is known and would result in a
charge to income. Significant or sustained equity market
declines could result in an acceleration of amortization of the
DAC and DSI related to variable annuity and variable universal
life contracts, resulting in a charge to income. Such
adjustments could have a material adverse effect on our results
of operations or financial condition.
VOBA is an intangible asset that represents the excess of book
value over the estimated fair value of acquired insurance,
annuity, and investment-type contracts in-force at the
acquisition date. The estimated fair value of the acquired
liabilities is based on actuarially determined projections, by
each block of business, of future policy and contract charges,
premiums, mortality and morbidity, separate account performance,
surrenders, operating expenses, investment returns,
nonperformance risk adjustment and other factors. Actual
experience on the purchased business may vary from these
projections. Revisions to estimates result in changes to the
amounts expensed in the reporting period in which the revisions
are made and could result in a charge to income. Also, as VOBA
is amortized similarly to DAC and DSI, an acceleration of the
amortization of VOBA would occur if the estimates of gross
profits or margins were overstated. Accordingly, the
amortization of such costs would be accelerated in the period in
which the actual experience is known and would result in a
charge to net income. Significant or sustained equity market
declines could result in an acceleration of amortization of the
VOBA related to variable annuity and variable universal life
contracts, resulting in a charge to income. Such adjustments
could have a material adverse effect on our results of
operations or financial condition.
Changes
in Accounting Standards Issued by the Financial Accounting
Standards Board or Other
Standard-Setting
Bodies May Adversely Affect Our Financial
Statements
Our financial statements are subject to the application of GAAP
(as defined below), which is periodically revised
and/or
expanded. Accordingly, from time to time we are required to
adopt new or revised accounting
S-50
standards issued by recognized authoritative bodies, including
the Financial Accounting Standards Board. Market conditions have
prompted accounting standard setters to expose new guidance
which further interprets or seeks to revise accounting
pronouncements related to financial instruments, structures or
transactions, as well as to issue new standards expanding
disclosures. The impact of accounting pronouncements that have
been issued but not yet implemented is disclosed in the 2010
Form 10-K
and in our quarterly reports on
Form 10-Q.
An assessment of proposed standards is not provided as such
proposals are subject to change through the exposure process
and, therefore, the effects on our financial statements cannot
be meaningfully assessed. It is possible that future accounting
standards we are required to adopt could change the current
accounting treatment that we apply to our consolidated financial
statements and that such changes could have a material adverse
effect on our financial condition and results of operations.
Changes
in Our Discount Rate, Expected Rate of Return and Expected
Compensation Increase Assumptions for Our Pension and Other
Postretirement Benefit Plans May Result in Increased Expenses
and Reduce Our Profitability
We determine our pension and other postretirement benefit plan
costs based on our best estimates of future plan experience.
These assumptions are reviewed regularly and include discount
rates, expected rates of return on plan assets and expected
increases in compensation levels and expected medical inflation.
Changes in these assumptions may result in increased expenses
and reduce our profitability.
Guarantees
Within Certain of Our Products that Protect Policyholders
Against Significant Downturns in Equity Markets May Decrease Our
Earnings, Increase the Volatility of Our Results if Hedging or
Risk Management Strategies Prove Ineffective, Result in Higher
Hedging Costs and Expose Us to Increased Counterparty
Risk
Certain of our variable annuity products include guaranteed
benefits. These include guaranteed death benefits, guaranteed
withdrawal benefits, lifetime withdrawal guarantees, guaranteed
minimum accumulation benefits, and guaranteed minimum income
benefits. Periods of significant and sustained downturns in
equity markets, increased equity volatility, or reduced interest
rates could result in an increase in the valuation of the future
policy benefit or policyholder account balance liabilities
associated with such products, resulting in a reduction to net
income. We use reinsurance in combination with derivative
instruments to mitigate the liability exposure and the
volatility of net income associated with these liabilities, and
while we believe that these and other actions have mitigated the
risks related to these benefits, we remain liable for the
guaranteed benefits in the event that reinsurers or derivative
counterparties are unable or unwilling to pay. In addition, we
are subject to the risk that hedging and other management
procedures prove ineffective or that unanticipated policyholder
behavior or mortality, combined with adverse market events,
produces economic losses beyond the scope of the risk management
techniques employed. These, individually or collectively, may
have a material adverse effect on net income, financial
condition or liquidity. We are also subject to the risk that the
cost of hedging these guaranteed minimum benefits increases as
implied volatilities increase
and/or
interest rates decrease, resulting in a reduction to net income.
The valuation of certain of the foregoing liabilities (carried
at fair value) includes an adjustment for nonperformance risk
that reflects the credit standing of the issuing entity. This
adjustment, which is not hedged, is based in part on publicly
available information regarding credit spreads related to
MetLife, Inc.s debt, including credit default swaps. In
periods of extreme market volatility, movements in these credit
spreads can have a significant impact on net income.
Guarantees
Within Certain of Our Life and Annuity Products May Increase Our
Exposure to Foreign Exchange Risk, and Decrease Our
Earnings
Certain of our life and annuity products are exposed to foreign
exchange risk. Payments under these contracts may be required to
be made in different currencies, depending on the circumstances.
Therefore, payments may be required in a different currency than
the currency upon which the liability valuation is based. If the
currency upon which expected future payments are made
strengthens relative to the currency upon which the liability
valuation is based, the liability valuation may increase,
resulting in a reduction of net income.
S-51
We May
Need to Fund Deficiencies in Our Closed Block; Assets
Allocated to the Closed Block Benefit Only the Holders of Closed
Block Policies
MLICs plan of reorganization, as amended (the
Plan of Reorganization), required that we
establish and operate an accounting mechanism, known as a closed
block, to ensure that the reasonable dividend expectations of
policyholders who own certain individual insurance policies of
MLIC are met. We allocated assets to the closed block in an
amount that will produce cash flows which, together with
anticipated revenue from the policies included in the closed
block, are reasonably expected to be sufficient to support
obligations and liabilities relating to these policies,
including, but not limited to, provisions for the payment of
claims and certain expenses and tax, and to provide for the
continuation of the policyholder dividend scales in effect for
1999, if the experience underlying such scales continues, and
for appropriate adjustments in such scales if the experience
changes. We cannot provide assurance that the closed block
assets, the cash flows generated by the closed block assets and
the anticipated revenue from the policies included in the closed
block will be sufficient to provide for the benefits guaranteed
under these policies. If they are not sufficient, we must fund
the shortfall. Even if they are sufficient, we may choose, for
competitive reasons, to support policyholder dividend payments
with our general account funds.
The closed block assets, the cash flows generated by the closed
block assets and the anticipated revenue from the policies in
the closed block will benefit only the holders of those
policies. In addition, to the extent that these amounts are
greater than the amounts estimated at the time the closed block
was funded, dividends payable in respect of the policies
included in the closed block may be greater than they would be
in the absence of a closed block. Any excess earnings will be
available for distribution over time only to closed block
policyholders.
Litigation
and Regulatory Investigations Are Increasingly Common in Our
Businesses and May Result in Significant Financial Losses and/or
Harm to Our Reputation
We face a significant risk of litigation and regulatory
investigations and actions in the ordinary course of operating
our businesses, including the risk of class action lawsuits. Our
pending legal and regulatory actions include proceedings
specific to us and others generally applicable to business
practices in the industries in which we operate. In connection
with our insurance operations, plaintiffs lawyers may
bring or are bringing class actions and individual suits
alleging, among other things, issues relating to sales or
underwriting practices, claims payments and procedures, product
design, disclosure, administration, denial or delay of benefits
and breaches of fiduciary or other duties to customers.
Plaintiffs in class action and other lawsuits against us may
seek very large or indeterminate amounts, including punitive and
treble damages, and the damages claimed and the amount of any
probable and estimable liability, if any, may remain unknown for
substantial periods of time.
Due to the vagaries of litigation, the outcome of a litigation
matter and the amount or range of potential loss at particular
points in time may normally be difficult to ascertain.
Uncertainties can include how fact finders will evaluate
documentary evidence and the credibility and effectiveness of
witness testimony, and how trial and appellate courts will apply
the law in the context of the pleadings or evidence presented,
whether by motion practice, or at trial or on appeal.
Disposition valuations are also subject to the uncertainty of
how opposing parties and their counsel will themselves view the
relevant evidence and applicable law.
On a quarterly and annual basis, we review relevant information
with respect to litigation and contingencies to be reflected in
our consolidated financial statements. The review includes
senior legal and financial personnel. Estimates of possible
losses or ranges of loss for particular matters cannot in the
ordinary course be made with a reasonable degree of certainty.
Liabilities are established when it is probable that a loss has
been incurred and the amount of the loss can be reasonably
estimated.
Liabilities have been established for a number of matters. It is
possible that some of the matters could require us to pay
damages or make other expenditures or establish accruals in
amounts that could not be estimated at December 31, 2010.
MLIC and its affiliates are currently defendants in numerous
lawsuits including class actions and individual suits, alleging
improper marketing or sales of individual life insurance
policies, annuities, mutual funds or other products.
S-52
In addition, MLIC is a defendant in a large number of lawsuits
seeking compensatory and punitive damages for personal injuries
allegedly caused by exposure to asbestos or asbestos-containing
products. These lawsuits principally have focused on allegations
with respect to certain research, publication and other
activities of one or more of MLICs employees during the
period from the 1920s through approximately the
1950s and have alleged that MLIC learned or should have
learned of certain health risks posed by asbestos and, among
other things, improperly publicized or failed to disclose those
health risks. Additional litigation relating to these matters
may be commenced in the future. The ability of MLIC to estimate
its ultimate asbestos exposure is subject to considerable
uncertainty, and the conditions impacting its liability can be
dynamic and subject to change. The availability of reliable data
is limited and it is difficult to predict with any certainty the
numerous variables that can affect liability estimates,
including the number of future claims, the cost to resolve
claims, the disease mix and severity of disease in pending and
future claims, the impact of the number of new claims filed in a
particular jurisdiction and variations in the law in the
jurisdictions in which claims are filed, the possible impact of
tort reform efforts, the willingness of courts to allow
plaintiffs to pursue claims against MLIC when exposure took
place after the dangers of asbestos exposure were well known,
and the impact of any possible future adverse verdicts and their
amounts. The number of asbestos cases that may be brought or the
aggregate amount of any liability that MLIC may incur, and the
total amount paid in settlements in any given year are uncertain
and may vary significantly from year to year. Accordingly, it is
reasonably possible that our total exposure to asbestos claims
may be materially greater than the liability recorded by us in
our consolidated financial statements and that future charges to
income may be necessary. The potential future charges could be
material in the particular quarterly or annual periods in which
they are recorded.
We are also subject to various regulatory inquiries, such as
information requests, subpoenas and books and record
examinations, from state and federal regulators and other
authorities. A substantial legal liability or a significant
regulatory action against us could have a material adverse
effect on our business, financial condition and results of
operations. Moreover, even if we ultimately prevail in the
litigation, regulatory action or investigation, we could suffer
significant reputational harm, which could have a material
adverse effect on our business, financial condition and results
of operations, including our ability to attract new customers,
retain our current customers and recruit and retain employees.
Regulatory inquiries and litigation may cause volatility in the
price of stocks of companies in our industry.
The New York Attorney General announced on July 29, 2010
that his office had launched a major fraud investigation into
the life insurance industry for practices related to the use of
retained asset accounts as a settlement option for death
benefits and that subpoenas requesting comprehensive data
related to retained asset accounts have been served on MetLife
and other insurance carriers. We received the subpoena on
July 30, 2010. We also have received requests for documents
and information from U.S. congressional committees and
members as well as various state regulatory bodies, including
the New York Insurance Department. It is possible that other
state and federal regulators or legislative bodies may pursue
similar investigations or make related inquiries. We cannot
predict what effect any such investigations might have on our
earnings or the availability of our retained asset account,
known as the Total Control Account (TCA), but
we believe that our financial statements taken as a whole would
not be materially affected. We believe that any allegations that
information about the TCA is not adequately disclosed or that
the accounts are fraudulent or violate state or federal laws are
without merit.
We cannot give assurance that current claims, litigation,
unasserted claims probable of assertion, investigations and
other proceedings against us will not have a material adverse
effect on our business, financial condition or results of
operations. It is also possible that related or unrelated
claims, litigation, unasserted claims probable of assertion,
investigations and proceedings may be commenced in the future,
and we could become subject to further investigations and have
lawsuits filed or enforcement actions initiated against us. In
addition, increased regulatory scrutiny and any resulting
investigations or proceedings could result in new legal actions
and precedents and industry-wide regulations that could
adversely affect our business, financial condition and results
of operations.
We May
Not be Able to Protect Our Intellectual Property and May be
Subject to Infringement Claims
We rely on a combination of contractual rights with third
parties and copyright, trademark, patent and trade secret laws
to establish and protect our intellectual property. Although we
endeavor to protect our rights, third parties may infringe or
misappropriate our intellectual property. We may have to
litigate to enforce and protect our
S-53
copyrights, trademarks, patents, trade secrets and know-how or
to determine their scope, validity or enforceability. This would
represent a diversion of resources that may be significant and
our efforts may not prove successful. The inability to secure or
protect our intellectual property assets could have a material
adverse effect on our business and our ability to compete.
We may be subject to claims by third parties for
(i) patent, trademark or copyright infringement,
(ii) breach of copyright, trademark or license usage
rights, or (iii) misappropriation of trade secrets. Any
such claims and any resulting litigation could result in
significant expense and liability for damages. If we were found
to have infringed or misappropriated a third-party patent or
other intellectual property right, we could in some
circumstances be enjoined from providing certain products or
services to our customers or from utilizing and benefiting from
certain methods, processes, copyrights, trademarks, trade
secrets or licenses. Alternatively, we could be required to
enter into costly licensing arrangements with third parties or
implement a costly work around. Any of these scenarios could
have a material adverse effect on our business and results of
operations.
New
and Impending Compensation and Corporate Governance Regulations
Could Hinder or Prevent Us From Attracting and Retaining
Management and Other Employees with the Talent and Experience to
Manage and Conduct Our Business Effectively
The compensation and corporate governance practices of financial
institutions have become and will continue to be subject to
increasing regulation and scrutiny. Dodd-Frank includes new
requirements that will affect our corporate governance and
compensation practices, including some that have resulted in (or
are likely to lead to) shareholders having the limited right to
use MetLife, Inc.s proxy statement to solicit proxies to
vote for their own candidates for director, impose additional
requirements for membership on Board committees, requirements
for additional shareholder votes on compensation matters,
requirements for policies to recover compensation previously
paid to certain executives under certain circumstances,
elimination of broker discretionary voting on compensation
matters, requirements for additional performance and
compensation disclosure, and other requirements. See
Various Aspects of Dodd-Frank Could Impact
Our Business Operations, Capital Requirements and Profitability
and Limit Our Growth. In addition, the Federal Reserve
Board, the FDIC and other U.S. bank regulators have
released guidelines on incentive compensation that may apply to
or impact MetLife, Inc. as a bank holding company. These
requirements and restrictions, and others Congress or regulators
may propose or implement, could hinder or prevent us from
attracting and retaining management and other employees with the
talent and experience to manage and conduct our business
effectively.
Although AIG has received assurances from the Troubled Asset
Relief Program Special Master for Executive Compensation that
neither we nor ALICO will be subject to compensation related
requirements and restrictions under programs established in
whole or in part under EESA, there can be no assurance that the
Acquisition will not lead to greater public or governmental
scrutiny, regulation, or restrictions on our compensation
practices as a result of the Acquisition and expansion into new
markets outside the United States, whether in connection with
AIGs having received U.S. government funding or as a
result of other factors.
Legislative
and Regulatory Activity in Health Care and Other Employee
Benefits Could Increase the Costs or Administrative Burdens of
Providing Benefits to Our Employees or Hinder or Prevent Us From
Attracting and Retaining Employees, or Affect our Profitability
As a Provider of Life Insurance, Annuities, and Non-Medical
Health Insurance Benefit Products
The Patient Protection and Affordable Care Act, signed into law
on March 23, 2010, and The Health Care and Education
Reconciliation Act of 2010, signed into law on March 30,
2010 (together, the Health Care Act), may
lead to fundamental changes in the way that employers, including
us, provide health care benefits, other benefits, and other
forms of compensation to their employees and former employees.
Among other changes, and subject to various effective dates, the
Health Care Act generally restricts certain limits on benefits,
mandates coverage for certain kinds of care, extends the
required coverage of dependent children through age 26,
eliminates pre-existing condition exclusions or limitations,
requires cost reporting and, in some cases, requires premium
rebates to participants under certain circumstances, limits
coverage waiting periods, establishes several penalties on
employers who fail to offer sufficient coverage to their
full-time employees, and requires employers under certain
circumstances to provide employees with vouchers to purchase
their own health care coverage. The Health Care Act
S-54
also provides for increased taxation of high cost
coverage, restricts the tax deductibility of certain
compensation paid by health insurers, reduces the tax
deductibility of retiree health care costs to the extent of any
retiree prescription drug benefit subsidy provided to the
employer by the federal government, increases Medicare taxes on
certain high earners, and establishes health insurance
exchanges for individual purchases of health
insurance.
The impact of the Health Care Act on us as an employer and on
the benefit plans we sponsor for employees or retirees and their
dependents, whether those benefits remain competitive or
effective in meeting their business objectives, and our costs to
provide such benefits and our tax liabilities in connection with
benefits or compensation, cannot be predicted. Furthermore, we
cannot predict the impact of choices that will be made by
various regulators, including the United States Treasury, the
IRS, the United States Department of Health and Human Services,
and state regulators, to promulgate regulations or guidance, or
to make determinations under or related to the Health Care Act.
Either the Health Care Act or any of these regulatory actions
could adversely affect our ability to attract, retain, and
motivate talented associates. They could also result in
increased or unpredictable costs to provide employee benefits,
and could harm our competitive position if we are subject to
fees, penalties, tax provisions or other limitations in the
Health Care Act and our competitors are not.
The Health Care Act also imposes requirements on us as a
provider of non-medical health insurance benefit products,
subject to various effective dates. It also imposes requirements
on the purchasers of certain of these products and has
implications for certain other MLIC products, such as annuities.
We cannot predict the impact of the Act or of regulations,
guidance or determinations made by various regulators, on the
various products that we offer. Either the Health Care Act or
any of these regulatory actions could adversely affect our
ability to offer certain of these products in the same manner as
we do today. They could also result in increased or
unpredictable costs to provide certain products, and could harm
our competitive position if the Health Care Act has a disparate
impact on our products compared to products offered by our
competitors.
The Preservation of Access to Care for Medicare Beneficiaries
and Pension Relief Act of 2010 also includes certain provisions
for defined benefit pension plan funding relief. These
provisions may impact the likelihood
and/or
timing of corporate plan sponsors terminating their plans
and/or
engaging in transactions to partially or fully transfer pension
obligations to an insurance company. As part of our Corporate
Benefit Funding segment, we offer general account and separate
account group annuity products that enable a plan sponsor to
transfer these risks, often in connection with the termination
of defined benefit pension plans. Consequently, this legislation
could indirectly affect the mix of our business, with fewer
closeouts and more non-guaranteed funding products, and
adversely impact our results of operations.
Changes
in U.S. Federal and State Securities Laws and Regulations, and
State Insurance Regulations Regarding Suitability of Annuity
Product Sales, May Affect Our Operations and Our
Profitability
Federal and state securities laws and regulations apply to
insurance products that are also securities,
including variable annuity contracts and variable life insurance
policies. As a result, some of MetLife, Inc.s subsidiaries
and their activities in offering and selling variable insurance
contracts and policies are subject to extensive regulation under
these securities laws. These subsidiaries issue variable annuity
contracts and variable life insurance policies through separate
accounts that are registered with the SEC as investment
companies under the Investment Company Act. Each registered
separate account is generally divided into
sub-accounts,
each of which invests in an underlying mutual fund which is
itself a registered investment company under the Investment
Company Act. In addition, the variable annuity contracts and
variable life insurance policies issued by the separate accounts
are registered with the SEC under the Securities Act. Other
subsidiaries are registered with the SEC as broker-dealers under
the Exchange Act, and are members of and subject to regulation
by FINRA. Further, some of our subsidiaries are registered as
investment advisers with the SEC under the Investment Advisers
Act of 1940, and are also registered as investment advisers in
various states, as applicable.
Federal and state securities laws and regulations are primarily
intended to ensure the integrity of the financial markets and to
protect investors in the securities markets, as well as protect
investment advisory or brokerage clients. These laws and
regulations generally grant regulatory agencies broad rulemaking
and enforcement powers, including the power to limit or restrict
the conduct of business for failure to comply with the
securities laws and regulations. A number of changes have
recently been suggested to the laws and regulations that govern
the conduct
S-55
of our variable insurance products business and our distributors
that could have a material adverse effect on our financial
condition and results of operations. For example, Dodd-Frank
authorizes the SEC to establish a standard of conduct applicable
to brokers and dealers when providing personalized investment
advice to retail and other customers. This standard of conduct
would be to act in the best interest of the customer without
regard to the financial or other interest of the broker or
dealer providing the advice. Further, proposals have been made
that the SEC establish a self-regulatory organization with
respect to registered investment advisers, which could increase
the level of regulatory oversight over such investment advisers.
In addition, state insurance regulators are becoming more active
in adopting and enforcing suitability standards with respect to
sales of annuities, both fixed and variable. In particular, the
NAIC has adopted a revised Suitability in Annuity Transactions
Model Regulation (SAT), that will, if enacted
by the states, place new responsibilities upon issuing insurance
companies with respect to the suitability of annuity sales,
including responsibilities for training agents. Several states
have already enacted laws based on the SAT.
We also may be subject to similar laws and regulations in the
foreign countries in which we offer products or conduct other
activities similar to those described above.
Changes
in Tax Laws, Tax Regulations, or Interpretations of Such Laws or
Regulations Could Increase Our Corporate Taxes; Changes in Tax
Laws Could Make Some of Our Products Less Attractive to
Consumers
Changes in tax laws, Treasury and other regulations promulgated
thereunder, or interpretations of such laws or regulations could
increase our corporate taxes. The Obama Administration has
proposed corporate tax changes. Changes in corporate tax rates
could affect the value of deferred tax assets and deferred tax
liabilities. Furthermore, the value of deferred tax assets could
be impacted by future earnings levels.
Changes in tax laws could make some of our products less
attractive to consumers. A shift away from life insurance and
annuity contracts and other tax-deferred products would reduce
our income from sales of these products, as well as the assets
upon which we earn investment income. The Obama Administration
has proposed certain changes to individual income tax rates and
rules applicable to certain policies.
We cannot predict whether any tax legislation impacting
corporate taxes or insurance products will be enacted, what the
specific terms of any such legislation will be or whether, if at
all, any legislation would have a material adverse effect on our
financial condition and results of operations.
Changes
to Regulations Under the Employee Retirement Income Security Act
of 1974 Could Adversely Affect Our Distribution Model by
Restricting Our Ability to Provide Customers With
Advice
The prohibited transaction rules of the U.S. Employee
Retirement Income Security Act of 1974, as amended
(ERISA), and the Code generally restrict the
provision of investment advice to ERISA plans and participants
and Individual Retirement Accounts (IRAs) if
the investment recommendation results in fees paid to the
individual advisor, his or her firm or their affiliates that
vary according to the investment recommendation chosen. In March
2010, the United States Department of Labor (the
DOL) issued proposed regulations which
provide limited relief from these investment advice
restrictions. If the proposed rules are issued in final form and
no additional relief is provided regarding these investment
advice restrictions, the ability of our affiliated
broker-dealers and their registered representatives to provide
investment advice to ERISA plans and participants, and with
respect to IRAs, would likely be significantly restricted. Also,
the fee and revenue arrangements of certain advisory programs
may be required to be revenue neutral, resulting in potential
lost revenues for these broker-dealers and their affiliates.
Other proposed regulatory initiatives under ERISA also may
negatively impact the current business model of our
broker-dealers. In particular, the DOL issued a proposed
regulation in October 2010 that would, if adopted as proposed,
significantly broaden the circumstances under which a person or
entity providing investment advice with respect to ERISA plans
or IRAs would be deemed a fiduciary under ERISA or the Code. If
adopted, the proposed regulations may make it easier for the DOL
in enforcement actions, and for plaintiffs attorneys in
ERISA litigation, to attempt to extend fiduciary status to
advisors who would not be deemed fiduciaries under current
regulations.
In addition, the DOL has issued a number of regulations recently
that increase the level of disclosure that must be provided to
plan sponsors and participants, and may issue additional such
regulations in 2011. These ERISA
S-56
disclosure requirements will likely increase the regulatory and
compliance burden upon MetLife, resulting in increased costs.
We May
Be Unable to Attract and Retain Sales Representatives for Our
Products
We must attract and retain productive sales representatives to
sell our insurance, annuities and investment products. Strong
competition exists among insurers for sales representatives with
demonstrated ability. In addition, there is competition for
representatives with other types of financial services firms,
such as independent broker-dealers.
We compete with other insurers for sales representatives
primarily on the basis of our financial position, support
services and compensation and product features. We continue to
undertake several initiatives to grow our career agency force
while continuing to enhance the efficiency and production of our
existing sales force. We cannot provide assurance that these
initiatives will succeed in attracting and retaining new agents.
Sales of individual insurance, annuities and investment products
and our results of operations and financial condition could be
materially adversely affected if we are unsuccessful in
attracting and retaining agents.
MetLife,
Inc.s Board of Directors May Control the Outcome of
Stockholder Votes on Many Matters Due to the Voting Provisions
of the MetLife Policyholder Trust
Under the Plan of Reorganization, we established the MetLife
Policyholder Trust (the Trust) to hold the
shares of MetLife, Inc. common stock allocated to eligible
policyholders not receiving cash or policy credits under the
Plan of Reorganization. As of February 18, 2011, the Trust
held 220,255,199 shares, or 22.3%, of the outstanding
shares of MetLife, Inc. common stock. Because of the number of
shares held in the Trust and the voting provisions of the Trust,
the Trust may affect the outcome of matters brought to a
stockholder vote.
Except on votes regarding certain fundamental corporate actions
described below, the trustee will vote all of the shares of
common stock held in the Trust in accordance with the
recommendations given by MetLife, Inc.s Board of Directors
to its stockholders or, if the Board gives no such
recommendations, as directed by the Board. As a result of the
voting provisions of the Trust, the Board of Directors may be
able to control votes on matters submitted to a vote of
stockholders, excluding those fundamental corporate actions, so
long as the Trust holds a substantial number of shares of common
stock.
If the vote relates to fundamental corporate actions specified
in the Trust, the trustee will solicit instructions from the
Trust beneficiaries and vote all shares held in the Trust in
proportion to the instructions it receives. These actions
include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s Board of Directors
or a vote on a stockholders proposal to oppose a Board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution, of MetLife, Inc., in each case requiring a vote of
stockholders under applicable Delaware law;
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the Trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s Board of Directors
to amend or redeem the rights under MetLife, Inc.s
stockholder rights plan, other than a proposal with respect to
which we have received advice of nationally-recognized legal
counsel to the effect that the proposal is not a proper subject
for stockholder action under Delaware law. MetLife, Inc. does
not currently have a stockholder rights plan.
|
If a vote concerns any of these fundamental corporate actions,
the trustee will vote all of the shares of common stock held by
the Trust in proportion to the instructions it received, which
will give disproportionate weight to the instructions actually
given by Trust beneficiaries.
S-57
The Selling Securityholder has agreed to vote all shares of
MetLife, Inc. common stock acquired by it in connection with the
Acquisition in proportion to the votes cast by all other
stockholders of MetLife, Inc., including the Trust.
State
Laws, Federal Laws, Our Certificate of Incorporation and Our
By-Laws May Delay, Deter or Prevent Takeovers and Business
Combinations that Stockholders Might Consider in Their Best
Interests
State laws and our certificate of incorporation and by-laws may
delay, deter or prevent a takeover attempt that stockholders
might consider in their best interests. For instance, they may
prevent stockholders from receiving the benefit from any premium
over the market price of MetLife, Inc.s common stock
offered by a bidder in a takeover context. Even in the absence
of a takeover attempt, the existence of these provisions may
adversely affect the prevailing market price of MetLife,
Inc.s common stock if they are viewed as discouraging
takeover attempts in the future.
Any person seeking to acquire a controlling interest in us would
face various regulatory obstacles which may delay, deter or
prevent a takeover attempt that stockholders of MetLife, Inc.
might consider in their best interests. First, the insurance
laws and regulations of the various states in which MetLife,
Inc.s insurance subsidiaries are organized may delay or
impede a business combination involving us. State insurance laws
prohibit an entity from acquiring control of an insurance
company without the prior approval of the domestic insurance
regulator. Under most states statutes, an entity is
presumed to have control of an insurance company if it owns,
directly or indirectly, 10% or more of the voting stock of that
insurance company or its parent company. We are also subject to
banking regulations, and may in the future become subject to
additional regulations. Dodd-Frank contains provisions that
could restrict or impede consolidation, mergers and acquisitions
by systemically significant firms
and/or large
bank holding companies. In addition, the Investment Company Act
would require approval by the contract owners of our variable
contracts in order to effectuate a change of control of any
affiliated investment adviser to a mutual fund underlying our
variable contracts. Finally, FINRA approval would be necessary
for a change of control of any FINRA registered broker-dealer
that is a direct or indirect subsidiary of MetLife, Inc.
In addition, Section 203 of the Delaware General
Corporation Law may affect the ability of an interested
stockholder to engage in certain business combinations,
including mergers, consolidations or acquisitions of additional
shares, for a period of three years following the time that the
stockholder becomes an interested stockholder. An
interested stockholder is defined to include persons
owning, directly or indirectly, 15% or more of the outstanding
voting stock of a corporation.
MetLife, Inc.s certificate of incorporation and by-laws
also contain provisions that may delay, deter or prevent a
takeover attempt that stockholders might consider in their best
interests. These provisions may adversely affect prevailing
market prices for MetLife, Inc.s common stock and include:
classification of MetLife, Inc.s Board of Directors into
three classes; a prohibition on the calling of special meetings
by stockholders; advance notice procedures for the nomination of
candidates to the Board of Directors and stockholder proposals
to be considered at stockholder meetings; and supermajority
voting requirements for the amendment of certain provisions of
the certificate of incorporation and by-laws.
The
Continued Threat of Terrorism and Ongoing Military Actions May
Adversely Affect the Level of Claim Losses We Incur and the
Value of Our Investment Portfolio
The continued threat of terrorism, both within the United States
and abroad, ongoing military and other actions and heightened
security measures in response to these types of threats may
cause significant volatility in global financial markets and
result in loss of life, property damage, additional disruptions
to commerce and reduced economic activity. Some of the assets in
our investment portfolio may be adversely affected by declines
in the credit and equity markets and reduced economic activity
caused by the continued threat of terrorism. We cannot predict
whether, and the extent to which, companies in which we maintain
investments may suffer losses as a result of financial,
commercial or economic disruptions, or how any such disruptions
might affect the ability of those companies to pay interest or
principal on their securities or mortgage loans. The continued
threat of terrorism also could result in increased reinsurance
prices and reduced insurance coverage and potentially cause us
to retain more risk than we otherwise would retain if we were
able to obtain reinsurance at lower prices. Terrorist actions
also could
S-58
disrupt our operations centers in the United States or abroad.
In addition, the occurrence of terrorist actions could result in
higher claims under our insurance policies than anticipated.
See Difficult Conditions in the Global
Capital Markets and the Economy Generally May Materially
Adversely Affect Our Business and Results of Operations and
These Conditions May Not Improve in the Near Future.
The
Occurrence of Events Unanticipated in Our Disaster Recovery
Systems and Management Continuity Planning Could Impair Our
Ability to Conduct Business Effectively
In the event of a disaster such as a natural catastrophe, an
epidemic, an industrial accident, a blackout, a computer virus,
a terrorist attack or war, unanticipated problems with our
disaster recovery systems could have a material adverse impact
on our ability to conduct business and on our results of
operations and financial position, particularly if those
problems affect our computer-based data processing,
transmission, storage and retrieval systems and destroy valuable
data. We depend heavily upon computer systems to provide
reliable service. Despite our implementation of a variety of
security measures, our computer systems could be subject to
physical and electronic break-ins, and similar disruptions from
unauthorized tampering. In addition, in the event that a
significant number of our managers were unavailable in the event
of a disaster, our ability to effectively conduct business could
be severely compromised. These interruptions also may interfere
with our suppliers ability to provide goods and services
and our employees ability to perform their job
responsibilities.
Our
Associates May Take Excessive Risks Which Could Negatively
Affect Our Financial Condition and Business
As an insurance enterprise, we are in the business of being paid
to accept certain risks. The associates who conduct our
business, including executive officers and other members of
management, sales managers, investment professionals, product
managers, sales agents, and other associates, do so in part by
making decisions and choices that involve exposing us to risk.
These include decisions such as setting underwriting guidelines
and standards, product design and pricing, determining what
assets to purchase for investment and when to sell them, which
business opportunities to pursue, and other decisions. Although
we endeavor, in the design and implementation of our
compensation programs and practices, to avoid giving our
associates incentives to take excessive risks, associates may
take such risks regardless of the structure of our compensation
programs and practices. Similarly, although we employ controls
and procedures designed to monitor associates business
decisions and prevent us from taking excessive risks, there can
be no assurance that these controls and procedures are or may be
effective. If our associates take excessive risks, the impact of
those risks could have a material adverse effect on our
financial condition or business operations.
Risks
Relating to the Common Equity Units
You
Assume the Risk that the Market Value of MetLife, Inc.s
Common Stock May Decline
As a holder of Normal Common Equity Units or Stripped Common
Equity Units, you will have an obligation to buy shares of
MetLife, Inc.s Common Stock pursuant to the Stock Purchase
Contracts that are part of the Normal Common Equity Units or
Stripped Common Equity Units. On each Stock Purchase Date,
unless you pay cash to satisfy your obligation under the Stock
Purchase Contract or the Stock Purchase Contracts are terminated
due to our bankruptcy, insolvency or reorganization, (i) in
the case of Normal Common Equity Units, either the proceeds
attributable to the applicable ownership interest in a Debenture
derived from the successful Remarketing or, if a Final Failed
Remarketing has occurred, the put price paid upon the automatic
put of a Debenture to us, or (ii) in the case of Stripped
Common Equity Units, the principal of the applicable ownership
interests in the Treasury Securities, will automatically be used
to purchase a specified number of shares of Common Stock on your
behalf.
The number of shares of Common Stock that you will receive upon
the settlement of a Stock Purchase Contract is not fixed but
instead will depend on the average of the VWAPs on each of the
20 consecutive Trading Days ending on, and including, the third
scheduled Trading Day immediately preceding the applicable
Initial Scheduled Stock Purchase Date. There can be no assurance
that the market value of each share of Common Stock received by
you on the applicable Stock Purchase Date or applicable Early
Settlement Date will be equal to or greater than the average
VWAP used to calculate how many shares are due to you.
Accordingly, you assume the risk that the market value of the
Common Stock may decline, and that the decline could be
substantial.
S-59
The
Issuance of Common Stock Pursuant to the Stock Purchase
Contracts Forming Part of the Common Equity Units Being Offered
By the Selling Securityholder in This Offering and the Issuance
of the Common Stock Pursuant to the Conversion of the
Series B Preferred Stock, to the Extent that the Any of the
Shares of the Series B Preferred Stock are Not Repurchased
and Cancelled by MetLife, Inc., Will Have a Dilutive Impact on
MetLife, Inc.s Stockholders
The Common Equity Units consist of (x) Stock Purchase
Contracts obligating the holder to purchase a variable number of
shares of MetLife, Inc.s common stock on each of three
specified future settlement dates (approximately two, three and
four years after the closing of the Acquisition, subject to
deferral under certain circumstances) for a fixed amount per
Stock Purchase Contract (an aggregate of $1.0 billion on
each settlement date) and (y) an interest in each of three
series of debt securities of MetLife, Inc. The aggregate amount
of MetLife, Inc.s common stock expected to be issued upon
settlement of the Stock Purchase Contracts is expected to be
approximately 67,764,000 to 84,696,000 shares.
In addition, to the extent that MetLife, Inc. does not
Repurchase (as defined in this prospectus supplement) and cancel
all of the shares of the Series B Preferred Stock pursuant
to the Coordination Agreement, dated as of March 1, 2011
(the Coordination Agreement), by and among
MetLife, Inc., the Selling Securityholder and AIG, MetLife, Inc.
will issue 10 shares of common stock for every share of the
6,857,000 shares of the Series B Preferred Stock that
is not so Repurchased and cancelled.
As a result of the issuance of these securities, more shares of
common stock will be outstanding and each existing stockholder
will own a smaller percentage of our common stock then
outstanding.
Following
This Offering and the Concurrent Offerings, to the Extent the
Selling Securityholder Will Hold Any of MetLife, Inc.s
Equity Securities, the Selling Securityholder Will Be Able to
Sell Such Securities at Any Time From and After the Date 365
Days After the Closing of the Acquisition, Which Could Cause
MetLife, Inc.s Stock Price to Decrease
The Selling Securityholder has agreed pursuant to the Investor
Rights Agreement, dated November 1, 2010 (the
Investor Rights Agreement), among MetLife,
Inc., the Selling Securityholder and AIG, entered into in
connection with the Acquisition, not to transfer any of MetLife,
Inc.s securities received pursuant to the terms of the
Stock Purchase Agreement, at any time up to the date
365 days after the closing of the Acquisition, without the
consent of MetLife, Inc. However, from and after such date, the
Selling Securityholder will be able to transfer up to half of
such equity securities, and from and after the first anniversary
of the closing of the Acquisition, the Selling Securityholder
will be able to transfer all of such securities, subject in each
case to certain limited volume and timing restrictions set forth
in the Investor Rights Agreement. Moreover, the Selling
Stockholder will agree to use commercially reasonable efforts to
transfer, and it will cause its affiliates to so transfer, all
of MetLife, Inc.s securities received in connection with
the Acquisition prior to the later of (i) the fifth
anniversary of the closing of the Acquisition, and (ii) the
first anniversary of the third stock purchase date under the
stock purchase contracts. Subject to certain conditions, we have
agreed to register the resale of MetLife, Inc.s equity and
other securities to be issued to the Selling Securityholder
under the Securities Act.
In connection with this offering of Common Equity Units, the
Concurrent Offerings and the repurchase of the Series B
Preferred Stock, MetLife, Inc. has entered into a limited waiver
of the Investor Rights Agreement with the Selling Securityholder
and AIG in order to permit the Selling Securityholder to offer
and sell the Common Equity Units and the common stock it
received in the Acquisition in this offering and the Concurrent
Offerings, respectively, and to sell the Series B Preferred
Stock to MetLife, Inc. pursuant to the Coordination Agreement.
The sale or transfer of a substantial number of these securities
within a short period of time could cause MetLife, Inc.s
stock price to decrease, make it more difficult for us to raise
funds through future offerings of MetLife, Inc.s common
stock or acquire other businesses using MetLife, Inc.s
common stock as consideration.
S-60
The
Opportunity for Equity Appreciation Provided by an Investment in
the Common Equity Units is Less Than That Provided by a Direct
Investment in MetLife, Inc.s Common Stock
Your opportunity for equity appreciation afforded by investing
in the Common Equity Units is less than your opportunity for
equity appreciation if you directly invested in the Common
Stock. If the Applicable Market Value of the Common Stock equals
or exceeds the Reference Price but falls below the Threshold
Appreciation Price of $44.275 (subject to adjustment), you will
realize no equity appreciation of the Common Stock for the
period during which the applicable Stock Purchase Contract forms
a part of the Common Equity Unit.
If an
Applicable Stock Purchase Date is Deferred, the Value of the
Common Stock That You Are Required to Purchase May Decline
Between the Determination of the Settlement Rate and the
Applicable Stock Purchase Date
Once we have determined the Settlement Rate in anticipation of a
Stock Purchase Date, the market value of the Common Stock that
you are required to purchase upon settlement of your Stock
Purchase Contracts may rise or fall with changes in the price of
the Common Stock between the determination of the Settlement
Rate and the applicable Stock Purchase Date. The applicable
Stock Purchase Date can be deferred for up to six months. Even
if the price of the Common Stock subsequently declines, you will
be required to purchase a number of shares of the Common Stock
equal to the previously fixed Settlement Rate.
The
Common Equity Units Provide Limited Settlement Rate
Adjustments
The number of shares of Common Stock that you are entitled to
receive on each Stock Purchase Date, or as a result of Early
Settlement, is subject to adjustment for certain events arising
from stock splits and combinations, stock dividends, cash
dividends and certain other actions by MetLife, Inc. that modify
its capital structure. See Description of the Stock
Purchase Contracts. MetLife, Inc. will not adjust the
number of shares of Common Stock that you are to receive on the
applicable Stock Purchase Date or as a result of Early
Settlement of a Stock Purchase Contract for other events,
including the Concurrent Offerings or other offerings of Common
Stock by MetLife, Inc. for cash. There can be no assurance that
an event that adversely affects the value of the Common Equity
Units, but does not result in an adjustment to the Settlement
Rate, will not occur. Further, MetLife, Inc. is not restricted
from issuing additional Common Stock during the term of the
Stock Purchase Contracts and has no obligation to consider your
interests. If MetLife, Inc. issues additional shares of Common
Stock, it may materially and adversely affect the price of the
Common Stock and the trading price of the Common Equity Units.
MetLife,
Inc. May Defer Contract Payments under the Stock Purchase
Contracts, and this May Have an Adverse Effect on the Trading
Prices of the Common Equity Units
MetLife, Inc. may at its option, and will at the direction of
the Federal Reserve Board, defer the payments of any or all of
the Contract Payments under the Stock Purchase Contracts. If
MetLife, Inc. exercises its right to defer Contract Payments,
the market price of the Common Equity Units is likely to be
adversely affected. As a result of the existence of these
deferral rights, the market price of the Common Equity Units may
be more volatile than the market prices of other securities that
are not subject to these optional deferrals. Furthermore, you
will be subject to the risk that MetLife, Inc. may not be able
to pay such Deferred Contract Payments (including compounded
Contract Payments thereon) in the future.
In addition, if MetLife, Inc. elects to defer the payment of
Contract Payments on the Stock Purchase Contracts, and the
Deferred Contract Payments are not paid prior to the applicable
Stock Purchase Date, then MetLife, Inc. will pay you such
Deferred Contract Payments in either shares of its Common Stock
or unsecured junior subordinated notes, at its sole discretion.
See Description of the Stock Purchase
ContractsOption to Defer Contract Payments for a
discussion of the valuation methods MetLife, Inc. will use to
determine the payment of Deferred Contract Payments.
If You
Hold Common Equity Units, You Will Not be Entitled to any Rights
with Respect to Common Stock, but You Will Be Subject to All
Changes Made with Respect to Common Stock
If you hold Common Equity Units, you will not be entitled to any
rights with respect to MetLife, Incs Common Stock
(including, without limitation, voting rights and rights to
receive any dividends or other
S-61
distributions on the Common Stock), but you will be subject to
all changes affecting the Common Stock. You will only be
entitled to rights on the Common Stock if and when MetLife, Inc.
delivers shares of Common Stock upon settlement of Stock
Purchase Contracts on the applicable Stock Purchase Date, or as
a result of Early Settlement. For example, in the event that an
amendment is proposed to our certificate of incorporation or
by-laws requiring stockholder approval and the record date for
determining the stockholders of record entitled to vote on the
amendment occurs prior to delivery of the Common Stock, you will
not be entitled to vote on the amendment, although you will
nevertheless be subject to any changes in the powers,
preferences or special rights of the Common Stock.
The
Trading Price of the Common Stock, the General Level of Interest
Rates and our Credit Quality Will Directly Affect the Trading
Prices for the Common Equity Units
The trading prices of the Common Equity Units will be directly
affected by, among other things, the trading price of Common
Stock, interest rates generally and MetLife, Inc.s credit
quality. It is impossible to predict whether the price of the
Common Stock or interest rates will rise or fall. Our operating
results and prospects and economic, financial and other factors
will affect trading prices of the Common Stock and the Common
Equity Units. In addition, market conditions can affect the
capital markets generally, thereby affecting the price of the
Common Equity Units and the Common Stock. These conditions may
include the level of, and fluctuations in, the trading prices of
stocks generally.
Fluctuations
in Interest Rates May Give Rise to Arbitrage Opportunities,
Which Would Affect the Trading Prices of the Normal Common
Equity Units, Stripped Common Equity Units, Debentures and
Common Stock
Fluctuations in interest rates may give rise to arbitrage
opportunities based upon changes in the relative value of the
Common Stock underlying the Stock Purchase Contracts and of the
other components of the Common Equity Units. Any such arbitrage
could, in turn, affect the trading prices of the Normal Common
Equity Units, Stripped Common Equity Units, Debentures and
Common Stock.
The
Contract Payments are Subordinated to Any Existing or Future
Senior Debt of MetLife, Inc.; Contract Payments and Debentures
Indebtedness Are Subordinated to Secured Indebtedness to the
Extent of the Value of the Assets Securing Such
Indebtedness
The Contract Payments are subordinated and junior in right of
payment to MetLife, Incs obligations under any existing
and future senior debt, including trade payables. The Debentures
constitute and will constitute senior unsecured obligations of
MetLife, Inc., ranking equally with other existing and future
senior unsecured indebtedness and ranking senior to any existing
or future subordinated indebtedness. The Contract Payments and
the Debentures are subordinated and junior in right of payment
to MetLife, Inc.s secured indebtedness to the extent of
the value of the assets securing such indebtedness. The
Indenture does not restrict MetLife, Inc. or its subsidiaries
from incurring substantial additional indebtedness in the
future. As of December 31, 2010, MetLifes total
consolidated indebtedness was approximately $36.4 billion.
MetLife, Inc.s obligations with respect to Contract
Payments and payments on its junior subordinated debt securities
will be pari passu, and will be subordinate and junior in
right of payment to its obligations under its existing and
future secured and senior debt, but senior to payments of
dividends on MetLife, Inc.s preferred stock. At
December 31, 2010, MetLife, Inc.s secured and senior
debt totaled approximately $25.2 billion, excluding the
liabilities of our subsidiaries.
MetLife, Inc. receives substantially all of its revenue from
dividends from its subsidiaries. Because MetLife, Inc. is a
holding company, its right to participate in any distribution of
the assets of its subsidiaries, upon a subsidiarys
dissolution,
winding-up,
liquidation or reorganization or otherwise, and thus your
ability to benefit indirectly from such distribution, is subject
to the prior claims of creditors of that subsidiary, except to
the extent that MetLife, Inc. may be a creditor of that
subsidiary and MetLife, Inc.s claims are recognized. There
are legal limitations on the extent to which some of the
subsidiaries may extend credit, pay dividends or otherwise
supply funds to, or engage in transactions with, MetLife, Inc.
or some of its other subsidiaries. This includes state laws in
the United States that grant insurance regulatory authorities
broad administrative powers with respect to, among
S-62
other things, the payment of dividends and other transactions
among affiliates. See Our Insurance,
Brokerage and Banking Businesses Are Heavily Regulated, and
Changes in Regulation May Reduce Our Probability and Limit
Our Growth. MetLife, Inc.s subsidiaries are separate
and distinct legal entities and have no obligation, contingent
or otherwise, to pay amounts due under the Stock Purchase
Contracts or otherwise to make any funds available to MetLife,
Inc. Accordingly, the Contract Payments and payments on the
Debentures, effectively, will be subordinated to all existing
and future liabilities of MetLife, Inc.s subsidiaries.
Our
Financial Performance and Other Factors Could Adversely Impact
MetLife, Inc.s Ability to Make Contract Payments and
Payments on the Debentures
MetLife, Inc.s ability to make scheduled payments with
respect to its indebtedness and contractual obligations,
including amounts due on the Debentures and Stock Purchase
Contracts, will depend on our financial and operating
performance, which, in turn, is subject to prevailing economic
conditions and to financial, business and other factors beyond
our control.
The
Cash Merger Early Settlement May Not Adequately Compensate
You
If a Cash Merger Early Settlement (as described under
Description of the Stock Purchase Contracts) occurs
and you exercise your Cash Merger Early Settlement right, you
will be entitled to settle your Stock Purchase Contract at the
Cash Merger Early Settlement Amount subject to certain
conditions. Although the Cash Merger Early Settlement is
designed to compensate you for the lost option value of your
Common Equity Units as a result of the Cash Merger, this feature
may not adequately compensate you for such loss.
MetLife,
Inc.s Normal Common Equity Units, Stripped Common Equity
Units and Debentures Have no Prior Public Market, and We Cannot
Assure You That an Active Trading Market Will
Develop
Prior to this offering, there has not been a market for MetLife,
Inc.s Normal Common Equity Units, Stripped Common Equity
Units or Debentures. While we have applied for listing of the
Normal Common Equity Units on the New York Stock Exchange, an
active trading market in the Normal Common Equity Units might
not develop or continue. If you purchase Normal Common Equity
Units in this offering, you will pay a price that was not
established in a competitive market. Rather, you will pay a
price that was determined by negotiations with the underwriters
based upon an assessment of the market for similar securities
and other factors, including economic conditions and our
financial condition, performance and prospects. The public
market may not agree with or accept this valuation, in which
case you may not be able to sell your Normal Common Equity Units
at or above the initial offering price. If the Stripped Common
Equity Units or the Debentures are separately traded to a
sufficient extent that applicable exchange listing requirements
are met, we will endeavor to list the Stripped Common Equity
Units or the Debentures on the same exchange as the Normal
Common Equity Units. However, an active trading market in those
securities also may not develop. In addition, if you were to
substitute Treasury Securities for Debentures or Debentures for
Treasury Securities, thereby converting your Stripped Common
Equity Units to Normal Common Equity Units or your Normal Common
Equity Units to Stripped Common Equity Units, as the case may
be, the liquidity of Normal Common Equity Units or Stripped
Common Equity Units could be adversely affected. We cannot
assure you that the Normal Common Equity Units will not be
delisted from the New York Stock Exchange or that trading in the
Normal Common Equity Units will not be suspended as a result of
your election to create Stripped Common Equity Units by
substituting collateral, which could cause the number of Normal
Common Equity Units to fall below the requirement for listing
securities on the New York Stock Exchange.
Your
Rights to the Pledged Securities Will Be Subject to MetLife,
Inc.s Security Interest and May Be Affected by a
Bankruptcy Proceeding
Although you will be the beneficial owner of the applicable
ownership interests in Debentures or Treasury Securities, those
securities will be pledged to MetLife, Inc. through the
Collateral Agent to secure your obligations under the related
Stock Purchase Contracts. Thus, your rights to the pledged
securities will be subject to MetLife, Inc.s security
interest. Therefore, for so long as your Stock Purchase
Contracts remain in effect, you will not be allowed to withdraw
your ownership interest in the pledged Debentures or Treasury
Securities from this pledge arrangement, except upon
substitution of other securities as described in this prospectus
supplement. Additionally,
S-63
notwithstanding the automatic termination of the Stock Purchase
Contracts, in the event that MetLife, Inc. becomes the subject
of a case under the U.S. Bankruptcy Code, the delivery of
the pledged securities to you may be delayed by the imposition
of the automatic stay under the U.S. Bankruptcy Code or by
exercise of the bankruptcy courts power under the
U.S. Bankruptcy Code and claims arising out of the
Debentures, like all other claims in bankruptcy proceedings,
will be subject to the equitable jurisdiction and powers of the
bankruptcy court.
The
Stock Purchase Contract Agreement and Pledge Agreement Will Not
Be Qualified Under the Trust Indenture Act and the
Obligations of the Stock Purchase Contract Agent Are
Limited
The Stock Purchase Contract Agreement and Pledge Agreement will
not be qualified as an indenture under the Trust Indenture
Act of 1939, as amended (the Trust Indenture
Act), and the Stock Purchase Contract Agent will not
be required to qualify as a trustee under the
Trust Indenture Act. Thus, you will not have the benefit of
the protection of the Trust Indenture Act with respect to
the Stock Purchase Contract and Pledge Agreement or the Stock
Purchase Contract Agent. The Debentures constituting a part of
the Normal Common Equity Units were issued pursuant to the
Indenture, which is qualified under the Trust Indenture
Act. Accordingly, if you hold Normal Common Equity Units, you
will have the benefit of the protections of the
Trust Indenture Act only to the extent applicable to the
Debentures included in the Normal Common Equity Units. The
protections generally afforded the holder of a security issued
under an indenture that has been qualified under the
Trust Indenture Act include:
|
|
|
|
|
disqualification of the indenture trustee for conflicting
interests, as defined under the Trust Indenture Act;
|
|
|
|
provisions preventing a trustee that is also a creditor of the
issuer from improving its own credit position at the expense of
the security holders immediately prior to or after a default
under such indenture; and
|
|
|
|
the requirement that the indenture trustee deliver reports at
least annually with respect to certain matters concerning the
indenture trustee and the securities.
|
You
Should Not Expect the Payment of Cash Dividends on MetLife,
Inc.s Common Stock
Our dividend policy is subject to the discretion of our Board of
Directors and depends upon a number of factors, including our
earnings, financial condition, cash and capital needs and
general economic or business conditions. In the future, there
can be no assurance that the Board of Directors will declare a
dividend.
MetLife,
Inc. May Redeem the Component Debentures and the Debentures at
Its Option Following Certain Events
MetLife, Inc. has the right, at MetLife, Inc.s option, at
any time, and from time to time, to redeem all or any part of
the Debentures or Component Debentures, on any date selected by
MetLife, Inc. (the Redemption Date) on
or after the Redemption Trigger Date (as described under
Description of the Stock Purchase Contracts
Redemption), at a price payable in cash equal to the
Debenture Redemption Price (as defined under
Description of the Stock Purchase Contracts
Redemption).
Upon a
Successful Remarketing of the Debentures, the Terms of Your
Debentures May Be Modified Even If You Elect Not to Participate
in the Remarketing
When MetLife, Inc. attempts to remarket the Debentures, the
Remarketing Agent will agree to use its commercially reasonable
efforts to sell the Debentures included in the Remarketing. In
connection with the Remarketing, MetLife, Inc. and the
Remarketing Agent may materially change the Interest Rate of
such Debenture. If the Remarketing is successful, the modified
terms will apply to all the Debentures, even if they were not
included in the Remarketing. However, holders of the Debentures
must elect to participate in the Remarketing before knowing what
the modified terms of the Debentures will be. You may determine
that the revised terms are not as favorable to you as you would
deem appropriate.
S-64
Recent
Developments in the Equity-linked and Convertible Securities
Markets May Adversely Affect the Market Value of the Common
Equity Units
Governmental actions that interfere with the ability of
equity-linked and convertible securities investors to effect
short sales of the underlying shares of common stock could
significantly affect the market value of the Common Equity
Units. Such government actions could make the convertible
arbitrage strategy that many equity- linked and convertible
securities investors employ difficult to execute for outstanding
equity-linked or convertible securities of any company whose
shares of common stock are subject to such actions. The SEC has
adopted a short sale price test which will restrict short
selling only when a stock price has triggered a circuit
breaker by falling at least 10 percent from the prior
days closing price, at which point short sale orders can
be displayed or executed only if the order price is above the
current national best bid for the remainder of the day and the
next trading day, subject to certain limited exceptions. If such
new price test precludes, or is perceived to preclude,
equity-linked and convertible securities investors from
executing the convertible arbitrage strategy that they employ or
other limitations are instituted by the SEC or any other
regulatory agencies, the market value of the Common Equity Units
could be adversely affected.
MetLife,
Inc. Will Withhold Tax on any Contract Payments and Deferred
Contract Payments to the Extent Required by Law
MetLife, Inc. will withhold any tax on Contract Payments and
Deferred Contract Payments to the extent required by law, which
will be remitted to the appropriate taxing jurisdiction. See
Certain United States Federal Income Tax
Consequences.
You
May Have To Include Deferred Contract Payments in Your Taxable
Income Before You Receive Such Contract Payments
If MetLife, Inc. defers a Contract Payment and you use the
accrual method of tax accounting, you may be required to
recognize income for United States federal income tax purposes
in respect of the Deferred Contract Payment in advance of your
receipt of any corresponding cash distributions. See
Certain United States Federal Income Tax
Consequences.
S-65
SELECTED
HISTORICAL CONSOLIDATED FINANCIAL INFORMATION FOR
METLIFE
The following selected financial data has been derived from
MetLifes audited consolidated financial statements. The
statement of operations data for the years ended
December 31, 2010, 2009 and 2008, and the balance sheet
data at December 31, 2010 and 2009 have been derived from
MetLifes audited financial statements included in the 2010
Form 10-K.
The statement of operations data for the years ended
December 31, 2007 and 2006, and the balance sheet data at
December 31, 2008, 2007 and 2006 have been derived from
MetLifes audited financial statements not included herein.
This selected consolidated financial data should be read in
conjunction with and is qualified by reference to these
consolidated financial statements and the related notes and the
2010
Form 10-K.
The following consolidated statements of operations and
consolidated balance sheet data have been prepared in conformity
with accounting principles generally accepted in the United
States of America (GAAP).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Statement of Operations Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
27,394
|
|
|
$
|
26,460
|
|
|
$
|
25,914
|
|
|
$
|
22,970
|
|
|
$
|
22,052
|
|
Universal life and investment-type product policy fees
|
|
|
6,037
|
|
|
|
5,203
|
|
|
|
5,381
|
|
|
|
5,238
|
|
|
|
4,711
|
|
Net investment income
|
|
|
17,615
|
|
|
|
14,837
|
|
|
|
16,289
|
|
|
|
18,055
|
|
|
|
16,239
|
|
Other revenues
|
|
|
2,328
|
|
|
|
2,329
|
|
|
|
1,586
|
|
|
|
1,465
|
|
|
|
1,301
|
|
Net investment gains (losses)
|
|
|
(392
|
)
|
|
|
(2,906
|
)
|
|
|
(2,098
|
)
|
|
|
(318
|
)
|
|
|
(1,174
|
)
|
Net derivative gains (losses)
|
|
|
(265
|
)
|
|
|
(4,866
|
)
|
|
|
3,910
|
|
|
|
(260
|
)
|
|
|
(208
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
52,717
|
|
|
|
41,057
|
|
|
|
50,982
|
|
|
|
47,150
|
|
|
|
42,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
29,545
|
|
|
|
28,336
|
|
|
|
27,437
|
|
|
|
23,783
|
|
|
|
22,869
|
|
Interest credited to policyholder account balances
|
|
|
4,925
|
|
|
|
4,849
|
|
|
|
4,788
|
|
|
|
5,461
|
|
|
|
4,899
|
|
Policyholder dividends
|
|
|
1,486
|
|
|
|
1,650
|
|
|
|
1,751
|
|
|
|
1,723
|
|
|
|
1,698
|
|
Other expenses
|
|
|
12,803
|
|
|
|
10,556
|
|
|
|
11,947
|
|
|
|
10,405
|
|
|
|
9,514
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
48,759
|
|
|
|
45,391
|
|
|
|
45,923
|
|
|
|
41,372
|
|
|
|
38,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before provision for
income tax
|
|
|
3,958
|
|
|
|
(4,334
|
)
|
|
|
5,059
|
|
|
|
5,778
|
|
|
|
3,941
|
|
Provision for income tax expense (benefit)
|
|
|
1,181
|
|
|
|
(2,015
|
)
|
|
|
1,580
|
|
|
|
1,675
|
|
|
|
1,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations, net of income tax
|
|
|
2,777
|
|
|
|
(2,319
|
)
|
|
|
3,479
|
|
|
|
4,103
|
|
|
|
2,914
|
|
Income (loss) from discontinued operations, net of income tax
|
|
|
9
|
|
|
|
41
|
|
|
|
(201
|
)
|
|
|
362
|
|
|
|
3,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
2,786
|
|
|
|
(2,278
|
)
|
|
|
3,278
|
|
|
|
4,465
|
|
|
|
6,440
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
|
(4
|
)
|
|
|
(32
|
)
|
|
|
69
|
|
|
|
148
|
|
|
|
147
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
|
2,790
|
|
|
|
(2,246
|
)
|
|
|
3,209
|
|
|
|
4,317
|
|
|
|
6,293
|
|
Less: Preferred stock dividends
|
|
|
122
|
|
|
|
122
|
|
|
|
125
|
|
|
|
137
|
|
|
|
134
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,668
|
|
|
$
|
(2,368
|
)
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In millions)
|
|
|
Balance Sheet Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General account assets (2)
|
|
$
|
547,569
|
|
|
$
|
390,273
|
|
|
$
|
380,839
|
|
|
$
|
399,007
|
|
|
$
|
383,758
|
|
Separate account assets
|
|
|
183,337
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
730,906
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder liabilities and other policy-related balances (3)
|
|
$
|
401,905
|
|
|
$
|
283,759
|
|
|
$
|
282,261
|
|
|
$
|
261,442
|
|
|
$
|
252,099
|
|
Payables for collateral under securities loaned and other
transactions
|
|
|
27,272
|
|
|
|
24,196
|
|
|
|
31,059
|
|
|
|
44,136
|
|
|
|
45,846
|
|
Bank deposits
|
|
|
10,316
|
|
|
|
10,211
|
|
|
|
6,884
|
|
|
|
4,534
|
|
|
|
4,638
|
|
Short-term debt
|
|
|
306
|
|
|
|
912
|
|
|
|
2,659
|
|
|
|
667
|
|
|
|
1,449
|
|
Long-term debt (2)
|
|
|
27,586
|
|
|
|
13,220
|
|
|
|
9,667
|
|
|
|
9,100
|
|
|
|
8,822
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
|
|
5,192
|
|
|
|
4,882
|
|
|
|
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
3,758
|
|
|
|
4,075
|
|
|
|
3,381
|
|
Other (2)
|
|
|
22,583
|
|
|
|
15,989
|
|
|
|
15,374
|
|
|
|
33,186
|
|
|
|
32,277
|
|
Separate account liabilities
|
|
|
183,337
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
681,793
|
|
|
|
505,816
|
|
|
|
477,693
|
|
|
|
522,164
|
|
|
|
492,861
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable noncontrolling interests in partially owned
consolidated securities
|
|
|
117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
Convertible preferred stock, at par value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, at par value
|
|
|
10
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
Additional paid-in capital
|
|
|
26,423
|
|
|
|
16,859
|
|
|
|
15,811
|
|
|
|
17,098
|
|
|
|
17,454
|
|
Retained earnings
|
|
|
21,363
|
|
|
|
19,501
|
|
|
|
22,403
|
|
|
|
19,884
|
|
|
|
16,574
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(190
|
)
|
|
|
(236
|
)
|
|
|
(2,890
|
)
|
|
|
(1,357
|
)
|
Accumulated other comprehensive income (loss)
|
|
|
1,000
|
|
|
|
(3,058
|
)
|
|
|
(14,253
|
)
|
|
|
1,078
|
|
|
|
1,118
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total MetLife, Inc.s stockholders equity
|
|
|
48,625
|
|
|
|
33,121
|
|
|
|
23,734
|
|
|
|
35,179
|
|
|
|
33,798
|
|
Noncontrolling interests
|
|
|
371
|
|
|
|
377
|
|
|
|
251
|
|
|
|
1,806
|
|
|
|
1,448
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
48,996
|
|
|
|
33,498
|
|
|
|
23,985
|
|
|
|
36,985
|
|
|
|
35,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
730,906
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
|
(In millions, except per share data)
|
|
Other Data (1), (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,668
|
|
|
$
|
(2,368
|
)
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
Return on MetLife, Inc.s common equity
|
|
|
6.9
|
%
|
|
|
(9.0
|
)%
|
|
|
11.2
|
%
|
|
|
12.9
|
%
|
|
|
20.9
|
%
|
Return on MetLife, Inc.s common equity, excluding
accumulated other comprehensive income (loss)
|
|
|
7.0
|
%
|
|
|
(6.8
|
)%
|
|
|
9.1
|
%
|
|
|
13.3
|
%
|
|
|
22.1
|
%
|
EPS Data (1), (5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss) from Continuing Operations Available to MetLife,
Inc.s Common Shareholders Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.01
|
|
|
$
|
(2.94
|
)
|
|
$
|
4.60
|
|
|
$
|
5.32
|
|
|
$
|
3.64
|
|
Diluted
|
|
$
|
2.99
|
|
|
$
|
(2.94
|
)
|
|
$
|
4.54
|
|
|
$
|
5.19
|
|
|
$
|
3.59
|
|
Income (Loss) from Discontinued Operations Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
(0.41
|
)
|
|
$
|
0.30
|
|
|
$
|
4.45
|
|
Diluted
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
(0.40
|
)
|
|
$
|
0.29
|
|
|
$
|
4.40
|
|
Net Income (Loss) Available to MetLife, Inc.s Common
Shareholders Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.02
|
|
|
$
|
(2.89
|
)
|
|
$
|
4.19
|
|
|
$
|
5.62
|
|
|
$
|
8.09
|
|
Diluted
|
|
$
|
3.00
|
|
|
$
|
(2.89
|
)
|
|
$
|
4.14
|
|
|
$
|
5.48
|
|
|
$
|
7.99
|
|
Cash Dividends Declared Per Common Share
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.59
|
|
|
|
|
(1) |
|
On November 1, 2010, MetLife, Inc. acquired ALICO. The
results of the Acquisition are reflected in the 2010 selected
financial data. |
|
(2) |
|
At December 31, 2010, general account assets, long-term
debt and other liabilities include amounts relating to variable
interest entities of $11,080 million, $6,902 million
and $93 million, respectively. |
|
(3) |
|
Policyholder liabilities and other policy-related balances
include future policy benefits, policyholder account balances,
other policy-related balances, policyholder dividends payable
and the policyholder dividend obligation. |
|
(4) |
|
Return on MetLife, Inc.s common equity is defined as net
income (loss) available to MetLife, Inc.s common
shareholders divided by MetLife, Inc.s average common
stockholders equity. |
|
(5) |
|
For the year ended December 31, 2009, shares related to the
assumed exercise or issuance of stock-based awards have been
excluded from the calculation of diluted earnings per common
share as these assumed shares are anti-dilutive. |
S-68
UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
On November 1, 2010, MetLife, Inc. acquired all of the
outstanding shares of capital stock of ALICO, pursuant to the
Stock Purchase Agreement, for a total purchase price of
approximately $16.4 billion, subject to adjustment, which
included cash of $7.2 billion and securities of MetLife,
Inc. valued at $9.2 billion.
The unaudited pro forma condensed combined statement of
operations and accompanying notes present the impact of the
Acquisition on MetLife, Inc.s results of operations under
the acquisition method of accounting. The unaudited pro forma
condensed combined statement of operations for the year ended
December 31, 2010 combines the historical consolidated
statement of operations of MetLife, Inc. for the year ended
December 31, 2010 (which includes ALICOs operations
for the month of November 2010) with the historical
combined statement of income of ALICO for the eleven months
ended October 31, 2010, giving effect to the Acquisition as
if it had been completed on January 1, 2010. The historical
financial information has been adjusted in the unaudited pro
forma condensed combined statement of operations to give effect
to pro forma events that are directly attributable to the
Acquisition and factually supportable, and are expected to have
a continuing impact on the combined results.
The unaudited pro forma condensed combined statement of
operations should be read in conjunction with the accompanying
notes and in conjunction with the audited historical
consolidated financial statements of MetLife, Inc. as of and for
the year ended December 31, 2010 and the related notes,
included in the 2010 Form 10-K.
The unaudited pro forma condensed combined statement of
operations is not intended to reflect the results of operations
that would have resulted had the Acquisition been effective
during the period presented or the results that may be obtained
by the combined company in the future. The unaudited pro forma
condensed combined statement of operations for the period
presented does not reflect future events that may occur after
the Acquisition, including, but not limited to, expense
efficiencies or revenue enhancements arising from the
Acquisition. It also does not give effect to certain one-time
charges that MetLife, Inc. expects to incur such as
restructuring and integration costs. Future results may vary
significantly from the results reflected in the unaudited pro
forma condensed combined statement of operations.
S-69
MetLife,
Inc.
Unaudited
Pro Forma Condensed Combined Statement of Operations
For the
Year Ended December 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Historical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife
|
|
|
ALICO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eleven
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
Pro
|
|
|
|
|
|
|
|
Pro
|
|
|
|
December 31,
|
|
|
October 31,
|
|
|
Forma
|
|
|
Reclassification
|
|
|
|
|
Forma
|
|
|
|
2010
|
|
|
2010
|
|
|
Adjustments
|
|
|
Adjustments
|
|
|
Notes
|
|
Combined
|
|
|
|
(In millions, except per share data)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
27,394
|
|
|
$
|
9,463
|
|
|
$
|
(160
|
)
|
|
$
|
(1,123
|
)
|
|
5(a); 6(a)
|
|
$
|
35,574
|
|
Universal life and investment-type product policy fees
|
|
|
6,037
|
|
|
|
|
|
|
|
(107
|
)
|
|
|
1,123
|
|
|
4(p); 5(a)
|
|
|
7,053
|
|
Net investment income
|
|
|
17,615
|
|
|
|
3,734
|
|
|
|
(857
|
)
|
|
|
|
|
|
4(a)
|
|
|
20,492
|
|
Other revenues
|
|
|
2,328
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,333
|
|
Net investment gains (losses)
|
|
|
(657
|
)
|
|
|
(98
|
)
|
|
|
(229
|
)
|
|
|
|
|
|
4(s); 4(t); 6(a); 6(b)
|
|
|
(984
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
52,717
|
|
|
|
13,104
|
|
|
|
(1,353
|
)
|
|
|
|
|
|
|
|
|
64,468
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
29,545
|
|
|
|
7,596
|
|
|
|
(324
|
)
|
|
|
(2,135
|
)
|
|
4(q); 4(r); 4(v); 5(b); 6(a)
|
|
|
34,682
|
|
Interest credited to policyholder account balances
|
|
|
4,925
|
|
|
|
|
|
|
|
|
|
|
|
2,135
|
|
|
5(b)
|
|
|
7,060
|
|
Policyholder dividends
|
|
|
1,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,486
|
|
Other expenses
|
|
|
12,803
|
|
|
|
3,790
|
|
|
|
(1,186
|
)
|
|
|
|
|
|
4(b)
|
|
|
15,407
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
48,759
|
|
|
|
11,386
|
|
|
|
(1,510
|
)
|
|
|
|
|
|
|
|
|
58,635
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before provision for income tax
|
|
|
3,958
|
|
|
|
1,718
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
5,833
|
|
Provision for income tax expense
|
|
|
1,181
|
|
|
|
554
|
|
|
|
98
|
|
|
|
|
|
|
4(u)
|
|
|
1,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax
|
|
|
2,777
|
|
|
|
1,164
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
4,000
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
|
(4
|
)
|
|
|
36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax,
attributable to shareholders
|
|
|
2,781
|
|
|
|
1,128
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
3,968
|
|
Less: Preferred stock dividends
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of income tax,
attributable to common shareholders
|
|
$
|
2,659
|
|
|
$
|
1,128
|
|
|
$
|
59
|
|
|
$
|
|
|
|
|
|
$
|
3,846
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share from continuing operations, net of income tax,
attributable to common shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
2.99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,056
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to unaudited pro forma condensed combined
statement of operations
S-70
MetLife,
Inc.
Notes to
Unaudited Pro Forma Condensed Combined Statement of
Operations
|
|
1.
|
Description
of Transaction
|
Under the terms of the Stock Purchase Agreement, on
November 1, 2010, MetLife, Inc. (i) paid
$7.2 billion to the Selling Securityholder in cash, and
(ii) issued to the Selling Securityholder
(a) 78,239,712 shares of Common Stock,
(b) 6,857,000 shares of Series B Contingent
Convertible Junior Participating Non-Cumulative Perpetual
Preferred Stock (the Series B Preferred Stock)
of MetLife, Inc., and (c) 40,000,000 Common Equity Units
with an aggregate stated amount at issuance of
$3.0 billion, initially consisting of (x) the Stock
Purchase Contracts; and (y) the Debentures.
The unaudited pro forma condensed combined statement of
operations is based on the historical financial statements of
MetLife, Inc. and ALICO and combines the condensed consolidated
statement of operations for the year ended December 31,
2010, for MetLife, Inc. (which includes ALICOs operations
for the month of November 2010) and the combined statement
of income for the eleven months ended October 31, 2010, for
ALICO. For ease of reference, all pro forma adjustments
reference MetLife, Inc.s December 31, 2010 year
end date and no adjustments were made to ALICOs reported
information for its different period-end date. Certain
adjustments and reclassifications have been recorded in the
unaudited pro forma condensed combined statement of operations
to conform to MetLife, Inc.s accounting policies and are
more fully described in Notes 4 and 5. The unaudited pro
forma condensed combined statement of operations gives effect to
the Acquisition as if it had occurred on January 1, 2010.
The unaudited pro forma condensed combined statement of
operations is presented in accordance with the requirements of
Article 11 of
Regulation S-X
published by the SEC. In accordance with Article 11 of
Regulation S-X,
discontinued operations and the related earnings per share data
have been excluded from the presentation of the unaudited pro
forma condensed combined statement of operations.
The unaudited pro forma condensed combined statement of
operations and accompanying notes present the impact of the
Acquisition on MetLife, Inc.s results of operations under
the acquisition method of accounting. The acquisition method of
accounting requires, among other things, that the consideration
transferred be measured at fair value at the acquisition date
and that assets acquired and liabilities assumed be recognized
at their fair values as of the acquisition date. Accordingly,
for purposes of determining the pro forma adjustments in the
condensed combined statement of operations, the assets acquired
and liabilities assumed were assumed to have been recorded as of
the acquisition date of January 1, 2010 at their respective
fair values.
The pro forma adjustments reflecting the acquisition are based
on certain estimates and assumptions. MetLife, Inc.s
management believes that the pro forma adjustments give
appropriate effect to those assumptions and are properly applied
in the unaudited pro forma condensed combined statement of
operations.
The unaudited pro forma condensed combined statement of
operations is not intended to reflect the results of operations
of the combined company that would have resulted had the
Acquisition been effective during the period presented or the
results that may be obtained by the combined company in the
future.
|
|
3.
|
Acquisition-Related
Costs
|
During the year ended December 31, 2010, MetLife, Inc.
incurred acquisition-related transaction costs, consisting
primarily of investment banking and legal fees, of
$106 million. This amount is reflected in MetLife,
Inc.s historical consolidated statement of operations for
the year ended December 31, 2010 and was included in other
expenses. A pro forma adjustment has been made to eliminate
these costs from the unaudited pro forma condensed combined
statement of operations for the year ended December 31,
2010 due to their non-recurring nature.
S-71
The following pro forma adjustments are included in the
unaudited pro forma condensed combined statement of operations:
(a) Adjustments to reflect the increase/(decrease) in net
investment income for the year ended December 31, 2010 as
follows:
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
Note
|
|
|
|
December 31, 2010
|
|
|
Reference
|
|
|
|
(In millions)
|
|
|
Adjustment to income associated with commercial mortgage-backed
securities
|
|
$
|
6
|
|
|
|
4(c
|
)
|
Adjustment to amortization/accretion of fixed maturities
available-for-sale portfolio
|
|
|
(777
|
)
|
|
|
4(c
|
)
|
Elimination of interest income on investment in MetLife, Inc.
debt securities
|
|
|
(8
|
)
|
|
|
4(c
|
)
|
Adjustment to net investment income associated with reclass of
investment securities
|
|
|
(35
|
)
|
|
|
4(d
|
)
|
Adjustment to commercial mortgage loan income
|
|
|
45
|
|
|
|
4(e
|
)
|
Adjustment to income associated with policy loans
|
|
|
(43
|
)
|
|
|
4(f
|
)
|
Recognition of income on indemnification asset
|
|
|
2
|
|
|
|
4(g
|
)
|
Adjustment to depreciation expense on investment real estate
|
|
|
1
|
|
|
|
4(l
|
)
|
Elimination of net investment income associated with Peru joint
ventures
|
|
|
(48
|
)
|
|
|
6(a
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(857
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(b) Adjustments to reflect the (decrease)/increase in other
expenses for the year ended December 31, 2010 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
Note
|
|
|
|
December 31, 2010
|
|
|
Reference
|
|
|
|
(In millions)
|
|
|
Adjustment to remove acquisition-related transaction costs
incurred in 2010
|
|
$
|
(106
|
)
|
|
|
3
|
|
Elimination of interest expense on MetLife, Inc. debt securities
|
|
|
(8
|
)
|
|
|
4(c
|
)
|
Elimination of amortization on historical DAC
|
|
|
(1,808
|
)
|
|
|
4(h
|
)
|
Adjustment to DAC amortization related to new business
|
|
|
242
|
|
|
|
4(h
|
)
|
Amortization of VOBA, VODA and VOCRA
|
|
|
1,202
|
|
|
|
4(i
|
)
|
Amortization of negative VOBA
|
|
|
(806
|
)
|
|
|
4(j
|
)
|
Elimination of expense associated with historical deferred sales
inducements
|
|
|
(26
|
)
|
|
|
4(k
|
)
|
Adjustment to amortization of trademark assets
|
|
|
8
|
|
|
|
4(m
|
)
|
Adjustment to depreciation/amortization expense associated with
fixed assets and software capitalization
|
|
|
(13
|
)
|
|
|
4(n
|
)
|
Recognition of interest expense on debt securities issued in
connection with Acquisition
|
|
|
129
|
|
|
|
4(o
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(1,186
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) An adjustment to decrease certain fixed maturity
securities relating to commercial mortgage-backed securities to
fair value based on MetLife, Inc.s valuation methodology
was assumed to have been made as of January 1, 2010. The
associated increase in net investment income is $6 million
for the year ended December 31, 2010 related primarily to
the net change in premium/discount of those securities. In
addition,
S-72
an adjustment to recognize the reduction of $777 million
for the year ended December 31, 2010 was recorded to
reflect the new cost basis and related amortization/accretion of
the acquired fixed maturities available-for-sale portfolio.
The elimination of ALICOs investment in MetLife,
Inc.s bonds resulted in the related elimination of
intercompany interest income/interest expense of $8 million
for the year ended December 31, 2010.
(d) An adjustment to reclassify trading securities to fixed
maturity securities
available-for-sale,
short term investments and cash in accordance with MetLife,
Inc.s intention not to hold the securities principally for
the purpose of selling in the near term resulted in a reduction
in net investment income of $35 million for the year ended
December 31, 2010.
(e) An adjustment to decrease mortgage loans to fair value
resulted in an increase in net investment income of
$45 million for the year ended December 31, 2010.
(f) An adjustment to increase policy loans to fair value
resulted in a reduction in net investment income of
$43 million for the year ended December 31, 2010,
related to the amortization of premium.
(g) An adjustment related to the change in value of
indemnification assets established for potential recoveries
related to the deterioration of fixed maturity securities
(including commercial mortgage-backed securities), mortgage
loans and certain investment funds resulted in an increase in
net investment income of $2 million for the year ended
December 31, 2010.
(h) An adjustment to eliminate ALICOs historical DAC,
resulted in an amortization decrease of $1,808 million for
the year ended December 31, 2010. In addition, the
adjustment to increase other expenses for the DAC amortization
related to new business in the period presented in conformity
with MetLife, Inc.s accounting policy is $242 million
for the year ended December 31, 2010.
(i) Adjustments to establish the VOBA, the value of
distribution agreements acquired (VODA) and
the value of customer relationships acquired
(VOCRA) arising from the Acquisition resulted
in an adjustment for the related amortization for VOBA, VODA and
VOCRA of $1,202 million for the year ended
December 31, 2010.
(j) For certain acquired blocks of business, the estimated
fair value of acquired liabilities exceeded the initial policy
reserves assumed at the acquisition date, resulting in a
negative VOBA which resulted in an adjustment for the related
amortization for negative VOBA of $806 million for the year
ended December 31, 2010.
(k) An adjustment to eliminate ALICOs deferred sales
inducement assets resulted in a reduction in amortization of
$26 million for the year ended December 31, 2010.
(l) An adjustment to increase investment real estate to
fair value resulted in an increase in net investment income of
$1 million for the year ended December 31, 2010.
(m) An adjustment to recognize the trademark values
acquired as an identifiable intangible asset arising from the
Acquisition resulted in an adjustment for trademark amortization
of $8 million for the year ended December 31, 2010.
(n) An adjustment to reduce fixed assets and capitalized
software to conform to MetLife, Inc.s capitalization
policy resulted in a reduction in depreciation expense of
$13 million for the year ended December 31, 2010.
(o) An adjustment to reflect the issuance of the Debentures
of $3.0 billion and the public offering of senior notes
issued in August, 2010 of $3.0 billion in connection with
the Acquisition was assumed to have been made as of
January 1, 2010 and the increase in other expenses related
to interest expense related to the Debentures and the senior
notes is $129 million for the year ended December 31,
2010. Interest expense on the Debentures was based on an average
annual contractual rate of 1.98%. Interest expense on the public
offering of senior debt was calculated based on actual borrowing
rates for the $3.0 billion in aggregate principal amount of
senior notes.
(p) An adjustment to eliminate ALICOs historical
unearned revenue is $107 million for the year ended
December 31, 2010.
S-73
(q) Adjustment to remove the effects of changes in embedded
derivatives on certain U.K. unit linked business contracts which
reduce earnings by $99 million for the year ended
December 31, 2010 since the related guarantees will not
impact MetLife, Inc.s future earnings based on the
provisions of the Stock Purchase Agreement.
(r) Adjustment to decrease policyholder benefits and claims
incurred by $107 million for the year ended
December 31, 2010 for the estimated effects of unlocking
actuarial assumptions used in determining future net benefit
premiums for certain traditional life insurance blocks of
business and to reverse the mark to market effects of the fair
value option used by ALICO for certain single premium variable
life products in Japan as MetLife, Inc. did not exercise such a
fair value election.
(s) Adjustment to reverse realized investment losses of
$83 million for the year ended December 31, 2010, to
conform to MetLife, Inc.s policy related to foreign
exchange.
(t) Adjustment to realize a net investment loss of
$9 million related to the release of unrealized
gains/losses to realized gains/losses on foreign currency
denominated fixed maturity securities for the year ended
December 31, 2010.
(u) The unaudited pro forma condensed combined statement of
operations pre-tax adjustments were tax effected at the
U.S. tax rate of 35%. For purposes of the unaudited pro
forma condensed statements of operations, it has been assumed
that earnings of foreign subsidiaries will not be permanently
reinvested. For the year ended December 31, 2010, the pro
forma pre-tax adjustments resulted in an increase to income tax
expense of $98 million.
(v) Adjustment to record an increase in indemnification
assets of $138 million associated with certain litigation
matters, which offsets the related litigation charge reflected
in ALICOs statement of income for the eleven months ended
October 31, 2010.
|
|
5.
|
Reclassification
Adjustments
|
The following reclassification adjustments have been made to
conform ALICOs accounting policies to those of MetLife,
Inc. which have been recorded in the unaudited pro forma
condensed combined statement of operations:
(a) Adjustment to reclassify universal life and
investment-type product policy fees of $1,123 million from
premiums for the year ended December 31, 2010.
(b) Adjustment to reclassify interest credited to
policyholder account balances of $2,135 million from
policyholder benefits and claims for the year ended
December 31, 2010.
|
|
6.
|
Pre
Closing Activities
|
(a) On October 27, 2010, ALICO sold its investments in
two joint ventures in Peru resulting in a gain of
$83 million which has been eliminated in the unaudited pro
forma condensed combined statement of operations. In addition,
the statement of operations items related to the Peru joint
ventures have been eliminated in the unaudited pro forma
condensed combined statement of operations for the year ended
December 31, 2010 and are presented below.
|
|
|
|
|
|
|
Eleven Months Ended
|
|
|
October 31, 2010
|
|
|
(In millions)
|
|
Revenues
|
|
|
|
|
Premiums
|
|
$
|
160
|
|
Net investment income
|
|
|
48
|
|
Net investment gains
|
|
|
5
|
|
Expenses
|
|
|
|
|
Policyholder benefits and claims
|
|
|
178
|
|
Net income attributable to noncontrolling interests
|
|
|
22
|
|
S-74
(b) Prior to the closing of the Acquisition, AIG was
required to complete certain transactions that affect ALICO, as
required by the Stock Purchase Agreement. As a result, the
following adjustments to eliminate gains were made in the
unaudited pro forma condensed combined statement of operations
for the year ended December 31, 2010:
(i) a gain of $29 million for the year ended
December 31, 2010 associated with an intercompany
settlement of a foreign currency derivative between the ALICO
and AIG;
(ii) a gain of $78 million for the year ended
December 31, 2010, associated with the intercompany
settlement of swap positions between the ALICO and AIG Financial
Products; and
(iii) a gain of $108 million for the year ended
December 31, 2010, associated with the sale of AIG common
stock to AIG.
|
|
7.
|
Pro Forma
Earnings Per Share
|
The pro forma basic and diluted earnings per share amounts
presented in the unaudited pro forma condensed combined
statement of operations are based upon the estimated weighted
average number of common shares outstanding, as adjusted for the
following items:
(i) the public offering of 86,250,000 shares of Common
Stock issued on August 6, 2010, in connection with
financing the cash portion of the transaction;
(ii) the issuance of 78,239,712 shares of Common Stock
to the Selling Securityholder; and
(iii) conversion of the Series B Preferred Stock into
68,570,000 shares of Common Stock.
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31, 2010
|
|
|
|
(in millions)
|
|
|
Basic
|
|
|
|
|
Weighted average common shares outstanding, as reported(1)
|
|
|
823
|
|
Common shares issued in connection with the Acquisition(2)
|
|
|
164
|
|
Common shares upon conversion of Series B Preferred Stock(3)
|
|
|
69
|
|
|
|
|
|
|
Weighted average common shares outstanding, pro forma
|
|
|
1,056
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
Weighted average common shares outstanding, as reported(1)
|
|
|
830
|
|
Common shares issued in connection with the Acquisition(2)
|
|
|
164
|
|
Common shares upon conversion of Series B Preferred Stock(3)
|
|
|
69
|
|
|
|
|
|
|
Weighted average common shares outstanding, pro forma
|
|
|
1,063
|
|
|
|
|
|
|
|
|
|
(1) |
|
Weighted average common shares, as reported for both basic and
diluted, are adjusted to remove the incremental common shares
associated with Common Stock issued on August 6, 2010, as
well as the incremental common shares associated with the Common
Stock and the Series B Preferred Stock issued to the
Selling Securityholder on November 1, 2010 in connection
with the Acquisition. The shares associated with Common Stock
are included in the total Common shares issued in
connection with the Acquisition and assumed to be
outstanding for the entire 2010 year. The shares associated
with the Series B Preferred Stock are included in the total
Common shares upon conversion of Series B Preferred
Stock and are assumed to be outstanding for the entire
2010 year. |
|
(2) |
|
Includes shares issued on August 6, 2010 as well as shares
of Common Stock issued to the Selling Securityholder on
November 1, 2010. |
|
(3) |
|
For purposes of the earnings per share calculation, the
Series B Preferred Stock is treated on an as-converted
basis for both basic and diluted weighted average shares. |
S-75
USE OF
PROCEEDS
MetLife, Inc. will not receive any proceeds from the sale of the
Common Equity Units by the Selling Securityholder. All of the
Common Equity Units being offered and sold by the Selling
Securityholder in this offering are currently being held in the
Indemnification Collateral Account under the Stock Purchase
Agreement, entered into in connection with the Acquisition.
In accordance with the Amended Indemnification Collateral
Agreement, $3.0 billion of the net proceeds from the sale
of the Common Equity Units will be deposited in the
Indemnification Collateral Account and substituted for the
applicable Common Equity Units held therein. To the extent that
the net proceeds from the sale of the Common Equity Units exceed
$3.0 billion, the Selling Securityholder will retain any
such excess. Such Common Equity Units will be thereafter
transferred to the underwriters for delivery to you and the
proceeds from their sale up to $3.0 billion will remain in
the Indemnification Collateral Account as indemnification
collateral under the Stock Purchase Agreement.
S-76
CAPITALIZATION
The following table sets forth our consolidated capitalization
at December 31, 2010, on an actual basis and as adjusted to
give effect to the Concurrent Offering and the repurchase (the
Repurchase) from the Selling Securityholder
of the Series B Preferred Stock. This information should be
read in conjunction with our consolidated financial statements
at December 31, 2010, including the notes thereto, and
other financial information pertaining to us incorporated herein
by reference as well as the unaudited pro forma financial
information included in Unaudited Pro Forma Condensed
Combined Statement of Operations.
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2010
|
|
|
|
|
|
|
As Adjusted for
|
|
|
|
|
|
|
the Concurrent
|
|
|
|
|
|
|
Offering and the
|
|
|
|
Actual
|
|
|
Repurchase (1)(2)
|
|
|
|
(In millions)
|
|
|
Short-term debt
|
|
$
|
306
|
|
|
$
|
306
|
|
Long-term debt(3)
|
|
|
27,586
|
|
|
|
27,586
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
36,380
|
|
|
|
36,380
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s Stockholders Equity:
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
Convertible preferred stock, at par value
|
|
|
|
|
|
|
|
|
Common stock, at par value
|
|
|
10
|
|
|
|
11
|
|
Additional paid-in capital
|
|
|
26,423
|
|
|
|
26,567
|
|
Retained earnings
|
|
|
21,363
|
|
|
|
21,218
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(172
|
)
|
Accumulated other comprehensive income
|
|
|
1,000
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
Total MetLife, Inc.s stockholders equity
|
|
|
48,625
|
|
|
|
48,625
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
85,005
|
|
|
$
|
85,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
There is no adjustment in this column to reflect the offering of
40,000,000 of Common Equity Units. |
|
(2) |
|
Adjusted for the MetLife Concurrent Offering of
68,570,000 shares of Common Stock and ALICO Holdings
Concurrent Offering of 78,239,712 shares of MetLife,
Incs Common Stock and the elimination of
6,857,000 shares of the Series B Preferred Stock
resulting from the Repurchase. These adjustments reflect
managements best estimate of the forms and amounts
involved in the Concurrent Offerings and the Repurchase at the
time of this offering. |
|
(3) |
|
Includes $6,902 million of long-term debt relating to
variable interest entities. |
S-77
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth MetLifes historical ratio
of earnings to fixed charges for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For The Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
Ratio of Earnings to Fixed Charges (1),(2)
|
|
|
1.52
|
|
|
|
|
|
|
|
1.92
|
|
|
|
1.74
|
|
|
|
1.60
|
|
|
|
|
(1) |
|
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, non-controlling interest and fixed charges,
excluding capitalized interest. Fixed charges are the sum of
interest and debt issue costs, interest credited to bank
deposits, interest credited to policyholder account balances, an
estimated interest component of rent expense and preferred stock
dividends. Interest costs of $411 million related to
consolidated securitization entities are included in this
computation for the year ended December 31, 2010. |
|
(2) |
|
Earnings were insufficient to cover fixed charges at a 1:1 ratio
by $2,861 million for the year ended December 31,
2009, primarily due to increased net investment losses on
freestanding derivatives, partially offset by gains on embedded
derivatives. |
S-78
COMMON
STOCK PRICE RANGE AND DIVIDENDS
MetLife, Inc.s common stock is listed on the New York
Stock Exchange. Trading, as reported on the New York Stock
Exchange, and dividend information follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Price Range
|
|
Cash Dividend
|
|
|
High
|
|
Low
|
|
per Share
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter (through March 2, 2011)
|
|
$
|
48.63
|
|
|
$
|
43.41
|
|
|
$
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
44.92
|
|
|
$
|
37.74
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
42.73
|
|
|
$
|
36.49
|
|
|
|
|
|
Second Quarter
|
|
$
|
47.10
|
|
|
$
|
37.76
|
|
|
|
|
|
First Quarter
|
|
$
|
43.34
|
|
|
$
|
33.64
|
|
|
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
38.35
|
|
|
$
|
33.22
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
40.83
|
|
|
$
|
26.90
|
|
|
|
|
|
Second Quarter
|
|
$
|
35.50
|
|
|
$
|
23.43
|
|
|
|
|
|
First Quarter
|
|
$
|
35.97
|
|
|
$
|
12.10
|
|
|
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
48.15
|
|
|
$
|
16.48
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
63.00
|
|
|
$
|
43.75
|
|
|
|
|
|
Second Quarter
|
|
$
|
62.88
|
|
|
$
|
52.77
|
|
|
|
|
|
First Quarter
|
|
$
|
61.52
|
|
|
$
|
54.62
|
|
|
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
70.87
|
|
|
$
|
60.46
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
69.92
|
|
|
$
|
59.62
|
|
|
|
|
|
Second Quarter
|
|
$
|
69.04
|
|
|
$
|
63.29
|
|
|
|
|
|
First Quarter
|
|
$
|
65.92
|
|
|
$
|
59.10
|
|
|
|
|
|
The reported last sale price for our common stock on the New
York Stock Exchange on March 2, 2011 was $43.41 per share.
As of February 18, 2011 there were 986,585,463 shares
of common stock outstanding. As of February 18, 2011, our
outstanding shares of common stock were held by 90,250
stockholders of record.
S-79
ACCOUNTING
TREATMENT
Earnings
Per Share
Before the issuance of Common Stock upon settlement of the Stock
Purchase Contracts, the Stock Purchase Contracts will be
reflected in MetLife, Inc.s diluted earnings per share
calculations using the treasury stock method. Under this method,
the number of shares of MetLife, Inc.s Common Stock used
in calculating diluted earnings per share is deemed to be
increased by the excess, if any, of the number of shares that
would be issued upon settlement of the Stock Purchase Contracts
less the number of shares that could be purchased by MetLife,
Inc. in the market using the proceeds receivable upon settlement.
Other
Matters
Both the FASB and its Emerging Issues Task Force continue to
study the accounting for financial and derivative instruments,
including instruments such as the Common Equity Units. It is
possible that our accounting for the Stock Purchase Contracts
and the Debentures could be affected by any new accounting rules
that might be issued by these groups.
S-80
SELLING
SECURITYHOLDER
The Selling Securityholder, a subsidiary of AIG, proposes to
offer and sell up to 40,000,000 Common Equity Units with an
aggregate stated value of $3.0 billion. Following
completion of this offering, the Selling Securityholder will own
no Common Equity Units.
The Selling Securityholder received the 40,000,000 Common Equity
Units offered by this prospectus supplement pursuant to the
Acquisition. Total consideration for the Acquisition also
included $7.2 billion of cash, 6,857,000 shares of the
Series B Preferred Stock (convertible into
68,570,000 shares of Common Stock (subject to anti-dilution
adjustments) upon a favorable vote of MetLife, Inc.s
common shareholders) and 78,239,712 shares of Common Stock.
For a discussion of certain relationships between MetLife, Inc.,
AIG and the Selling Securityholder, see Corporate
Governance Related Party Transactions in
MetLife, Inc.s Form 10-K/A filed on March 1, 2011, which
is incorporated by reference herein.
S-81
COORDINATION
AGREEMENT
On March 1, 2011, MetLife, Inc. entered into the
Coordination Agreement with the Selling Stockholder and AIG,
pursuant to which MetLife, Inc. agreed to repurchase from the
Selling Stockholder the number of shares of Series B
Preferred Stock equal to the lesser of
(i) 6,857,000 shares of Series B Preferred Stock
and (ii) the actual number of shares of MetLife,
Inc.s common stock, up to 68,570,000 shares, actually
sold and delivered by MetLife, Inc. in the concurrent offering
of common stock, divided by ten. The Series B Preferred
Stock was previously issued by MetLife, Inc. to the Selling
Stockholder at the closing of the Acquisition in accordance with
the Stock Purchase Agreement. The aggregate consideration to be
paid for the Repurchase will equal MetLife, Inc.s net
proceeds from the offering by MetLife, Inc. of up to
68,570,000 shares of its common stock.
The 6,857,000 shares of Series B Preferred Stock are
convertible into 68,570,000 shares of MetLife, Inc.s
common stock, subject to a favorable vote of MetLife,
Inc.s stockholders at its 2011 annual meeting. Pursuant to
the terms of the Stock Purchase Agreement, MetLife, Inc. is
obligated to pay a $300 million compensatory payment to the
Selling Stockholder in the event that MetLife, Inc.s
stockholders do not approve the conversion of the Series B
Preferred Stock. Pursuant to the Coordination Agreement, the
$300 million compensatory payment will be reduced in
proportion to the number of shares of Series B Preferred
Stock repurchased by MetLife.
The consummation of the Repurchase, which is expected to occur
concurrently with, or immediately following, the closing of this
offering of Common Equity Units, is subject to the satisfaction
of customary closing conditions, including the receipt of any
required governmental approvals and third party contractual
consents. Additionally, the consummation of the Repurchase is
subject to the successful consummation of the offering by
MetLife, Inc. of up to 68,570,000 shares of its common
stock as contemplated by a prospectus supplement and the receipt
of a letter from the United States Department of the Treasury,
the Selling Stockholder and AIA Aurora LLC, confirming, among
other things, the release of all encumbrances on the shares of
Series B Preferred Stock to be repurchased in the
Repurchase.
In addition to customary termination provisions, MetLife, Inc.
may, prior to the execution of the underwriting agreement for
the offering concurrent of common stock, terminate the
Coordination Agreement in the event that MetLife, Inc.s
board of directors (or a committee thereof), determines that the
offering of up to 68,570,000 shares of its common stock
cannot be completed on terms acceptable to MetLife, Inc. in its
sole discretion. Similarly, AIG may, prior to the execution of
the underwriting agreement for the offering of common stock,
terminate the Coordination Agreement in the event that
AIGs board of directors (or a committee thereof),
determines that the offering of common stock or this offering of
Common Equity Units cannot be completed on terms acceptable to
AIG in its sole discretion. Additionally, either AIG or MetLife,
Inc. may terminate the Coordination Agreement between the
pricing of the offering of common stock and the consummation of
the offering, in the event that the underwriting agreement for
the offering of common stock is terminated in accordance with
its terms.
The Coordination Agreement amends the Stock Purchase Agreement
with respect to certain indemnification-related obligations of
AIG and the Selling Stockholder. As of the date of this
prospectus supplement, 40,000,000 Common Equity Units of
MetLife, Inc. being offered in this offering are currently held
in an indemnification collateral account in order to secure the
Selling Stockholders indemnification obligations to
MetLife, Inc. pursuant to the Stock Purchase Agreement. Pursuant
to the Coordination Agreement, in the event that the net
proceeds from this offering equal at least $3.0 billion,
then $3.0 billion (which is the aggregate stated amount of
the Common Equity Units) will be placed in the indemnification
collateral account and any proceeds above such amount will be
distributed to the Selling Stockholder. In such case, any unsold
Common Equity Units will be released from the indemnification
collateral account to the Selling Stockholder. In the event that
less than all of the Common Equity Units are sold in this
offering, and this offering generates net proceeds of less than
$3.0 billion, an amount equal to the aggregate stated
amount of the Common Equity Units sold in this offering will be
deposited in the indemnification collateral account, and any net
proceeds from this offering above such aggregate stated amount
will be distributed to the Selling Stockholder, with the unsold
Common Equity Units remaining in the indemnification collateral
account. If the Selling Stockholder sells all of the Common
Equity Units in this offering but the net proceeds from the
offering are less than $3.0 billion, the entire net
proceeds from this offering will be deposited in the
indemnification collateral account. In that case, the amount
that the Selling Stockholder is entitled to withdraw from the
indemnification collateral account on certain scheduled release
dates pursuant to the terms of the Stock
S-82
Purchase Agreement will be reduced by the amount by which the
net proceeds from this offering are less than $3.0 billion.
The Coordination Agreement also provides, among other things,
(i) for mechanics that govern the release from the
indemnification collateral account of such Common Equity Units
sold in this offering and the allocation of the net proceeds
from this offering to the indemnification collateral account and
the Selling Stockholder, (ii) that the Selling Stockholder
will only be permitted to substitute cash for any collateral
held in the indemnification collateral account, (iii) that
the Selling Stockholder will not be permitted to make
indemnification payments under the Stock Purchase Agreement
utilizing MetLife, Inc.s common stock or any shares of
Series B Preferred Stock, (iv) that indemnification
payments to be made by the Selling Stockholder by utilizing the
collateral held in the indemnification collateral account will
be satisfied first by delivery of cash held in such account and,
to the extent such cash collateral is insufficient, by delivery
of equity units held in such account, (v) that Common
Equity Units will first be released from the indemnification
collateral account on the scheduled release dates as provided in
the Stock Purchase Agreement, followed by any cash held in such
account and (vi) that a portion of the net proceeds from
this offering and, to the extent such proceeds are insufficient,
a sufficient amount of the net proceeds from the offering by the
Selling Stockholder of up to 78,239,712 shares of MetLife,
Inc.s common stock, will be delivered to MetLife, Inc. in
connection with the payment of certain tax liabilities in
connection with the Acquisition pursuant to the terms of the
Coordination Agreement.
The Coordination Agreement provides for, among other things, the
release of the Selling Stockholder from the transfer
restrictions under the Investor Rights Agreement solely to the
extent necessary to permit this offering of common stock and the
concurrent offering to proceed. These restrictions include the
lock-up,
which prevents the Selling Stockholder from transferring any of
MetLife, Inc.s securities it received in the Acquisition
before the end of July 2011, and limitations on the amount of
MetLife, Inc. securities held by the Selling Stockholder that
can be sold in any one offering or in any period of
180 days. In the event that the Selling Stockholder is
unable to dispose of all of MetLife, Inc.s common stock
and Common Equity Units that it holds in the offerings,
respectively, any unsold securities will remain subject to the
lock-up
until November 1, 2011, and any unsold shares of common
stock or Common Equity Units that are not sold in the offerings,
respectively, and any shares of Series B Preferred Stock
not repurchased in the Repurchase will remain subject in all
respects to the terms, conditions and restrictions of the
Investor Rights Agreement.
The representations and warranties in the Coordination Agreement
are the product of negotiations among the parties thereto and
are for the sole benefit of the parties thereto. Any
inaccuracies in such representations and warranties are subject
to waiver by the parties thereto in accordance with the
Coordination Agreement without notice or liability to any other
person. In some instances, the representations and warranties in
the Coordination Agreement may represent an allocation among the
parties thereto of risks associated with particular matters
regardless of the knowledge of any of the parties thereto.
Consequently, persons other than the parties to the Coordination
Agreement may not rely upon the representations and warranties
in the Coordination Agreement as characterizations of actual
facts or circumstances as of the date of the Coordination
Agreement or as of any other date.
Pursuant to the terms of the Coordination Agreement, the parties
have agreed to enter into an Amended and Restated
Indemnification Collateral Account Security and Control
Agreement with Deutsche Bank Trust Company Americas, as
securities intermediary, pledge collateral agent and stock
purchase contract agent (the Amended Indemnification
Control Agreement). The Amended Indemnification
Control Agreement makes conforming changes to the
Indemnification Collateral Account Security and Control
Agreement, dated as of November 1, 2010, by and among
MetLife, Inc., the Selling Stockholder, Deutsche Bank
Trust Company Americas, as securities intermediary, pledge
collateral agent and stock purchase contract agent, and AIG, as
necessary to reflect the agreements and understandings in the
Coordination Agreement described above.
S-83
DESCRIPTION
OF THE COMMON EQUITY UNITS
The following description of the terms of the Common Equity
Units supplements the description of the general terms and
provisions of such securities set forth under Description
of Units beginning on page 25 in the accompanying
prospectus. This summary, together with the summary of some of
the provisions of the related documents described below,
contains a description of the material terms of the Common
Equity Units but is not necessarily complete. We refer you to
the copies of those documents that have been or will be filed
and incorporated by reference in the registration statement of
which this prospectus supplement and the accompanying prospectus
form a part. See Where You Can Find More Information
in this prospectus supplement and the accompanying prospectus.
In addition, to the extent that the following description is not
consistent with the descriptions contained in the accompanying
prospectus, you should rely on the following description.
The common equity units (each, a Common Equity
Unit) were issued by MetLife, Inc. to the Selling
Securityholder under the Stock Purchase Contract Agreement,
dated November 1, 2010 (the Stock Purchase
Contract Agreement), between MetLife, Inc. and
Deutsche Bank Trust Company Americas, as stock purchase
contract agent (the Stock Purchase Contract
Agent). The Common Equity Units may be either normal
Common Equity Units (each, a Normal Common Equity
Unit) or stripped Common Equity Units (each, a
Stripped Common Equity Unit). Unless
indicated otherwise, the term Common Equity
Units will include both Normal Common Equity Units and
Stripped Common Equity Units. The Common Equity Units initially
consisted of 40,000,000 Normal Common Equity Units. Each Common
Equity Unit has a stated amount of (i) $75.00 from, and
including, the issue date of the Common Equity Units to, but
excluding, the First Stock Purchase Date (as defined below),
(ii) $50.00 from, and including the First Stock Purchase
Date to, but excluding, the Second Stock Purchase Date (as
defined below), and (iii) $25.00 from, and including, the
Second Stock Purchase Date to, but excluding, the Third Stock
Purchase Date (as defined below).
Normal
Common Equity Units
Each Normal Common Equity Unit initially consists of the
following:
(a) three stock purchase contracts (each a Stock
Purchase Contract and together the Stock
Purchase Contracts), as described below:
(1) Under the first Stock Purchase Contract (the
Series C Stock Purchase Contract), you
will agree to purchase from MetLife, Inc., and MetLife, Inc.
will agree to sell to you, on a specified date (the
First Stock Purchase Date), for $25.00 in
cash, a variable number of shares of Common Stock equal to the
settlement rate described under Description of the Stock
Purchase Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. See
Description of the Stock Purchase
Contracts Adjustments to the Fixed Settlement
Rate. The First Stock Purchase Date is expected to occur
on October 10, 2012 (the Initial Scheduled First
Stock Purchase Date) but can be deferred for up to two
three-month periods in the event of a failed Remarketing.
(2) Under the second Stock Purchase Contract (the
Series D Stock Purchase Contract), you
will agree to purchase from MetLife, Inc., and MetLife, Inc.
will agree to sell to you, on a specified date (the
Second Stock Purchase Date), for $25.00 in
cash, a variable number of shares of Common Stock equal to the
settlement rate described under Description of the Stock
Purchase Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. The Second
Stock Purchase Date will be on the later of (x) the date
that is six calendar months after the First Stock Purchase Date
and (y) September 11, 2013 (such date in this clause
(y), the Initial Scheduled Second Stock Purchase
Date). However, the Second Stock Purchase Date can be
deferred for up to two three-month periods in the event of a
failed Remarketing.
(3) Under the third Stock Purchase Contract (the
Series E Stock Purchase Contract), you will
agree to purchase from MetLife, Inc., and MetLife, Inc. will
agree to sell to you, on a specified date (the Third
Stock Purchase Date), for $25.00 in cash, a variable
number of shares of Common Stock equal to the settlement rate
described under Description of the Stock Purchase
Contracts Settlement at Each Stock Purchase
Date, subject to anti-dilution adjustments. The Third
Stock Purchase Date will be on the
S-84
later of (x) the date that is six calendar months after the
Second Stock Purchase Date and (y) October 8, 2014
such date in this clause (y), the Initial Scheduled
Third Stock Purchase Date). However, the Third Stock
Purchase Date can be deferred for up to two three-month periods
in the event of a failed Remarketing.
(4) MetLife, Inc. will make quarterly payments on each
Stock Purchase Contract as described under Description of
the Stock Purchase Contracts Contract Payments.
(b) prior to the First Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series C Senior Debenture due 2023 of MetLife, Inc.
(collectively, the Series C Debentures)
having a principal amount of $1,000;
(c) prior to the Second Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series D Senior Debenture due 2024 of MetLife, Inc.
(collectively, the Series D Debentures)
having a principal amount of $1,000; and
(d) a 1/40, or 2.50%, undivided beneficial ownership
interest in a Series E Senior Debenture due 2045 of
MetLife, Inc. (collectively, the Series E
Debenture, and, together with the Series C
Debentures and the Series D Debentures, the
Debentures) having a principal amount of
$1,000.
As long as a Common Equity Unit is in the form of a Normal
Common Equity Unit, your applicable ownership interest in the
Debentures forming a part of the Normal Common Equity Unit will
be pledged to MetLife, Inc. through Deutsche Bank
Trust Company Americas, acting as the collateral agent (the
Collateral Agent), to secure your obligation
to purchase Common Stock under your Stock Purchase Contracts.
Creating
Stripped Common Equity Units
You will have the right (but not during the period that begins
at 5:00 p.m., New York City time, on the tenth Business Day
immediately preceding any scheduled Stock Purchase Date and ends
at 5:00 p.m., New York City time, on such scheduled Stock
Purchase Date), in accordance with the procedures described
below, to create Stripped Common Equity Units by substituting
(i) for the Series C Debentures, zero coupon
Series C Treasury Securities, (ii) for the
Series D Debentures, zero coupon Series D Treasury
Securities, and (iii) for the Series E Debentures,
zero coupon Series E Treasury Securities (each such zero
coupon treasury security, a Treasury
Security), that mature on the respective dates set
forth in the table below, in a total principal amount at
maturity equal to the aggregate principal amount of such
Debentures for which substitution is being made. Because the
Series C Debentures and the Series E Debentures were
issued in integral multiples of $2,000, you may make this
substitution only in integral multiples of 80 Normal Common
Equity Units. Each of these substitutions will create Stripped
Common Equity Units, and the ownership interest in the
Debentures will be released to you and be separately tradeable
from the Stripped Common Equity Units.
If you choose to create Stripped Common Equity Units, you must
substitute Treasury Securities for each series of Debentures
then underlying the Normal Common Equity Units that are being
made into Stripped Common Equity Units. The Treasury Securities
substituted for the Debentures of each series must be purchased
in the open market at your expense unless otherwise owned by
you. If you elect to substitute Treasury Securities for your
Debentures, thereby creating Stripped Common Equity Units, you
will be responsible for any fees or expenses payable in
connection with the substitution.
The following table sets forth the CUSIP numbers of the Treasury
Securities maturing on the dates indicated.
|
|
|
|
|
Treasury Security
|
|
Maturity Date
|
|
CUSIP No.
|
|
Series C Treasury Securities
|
|
September 30, 2012
|
|
912833Y61
|
Series D Treasury Securities
|
|
August 31, 2013
|
|
912834AF5
|
Series E Treasury Securities
|
|
September 30, 2014
|
|
912834BE7
|
If any of the Treasury Securities underlying Stripped Common
Equity Units mature prior to the applicable Stock Purchase Date,
the proceeds from such maturity will be invested at the sole
discretion of MetLife, Inc. and the applicable Treasury
Securities will, subject to limited exceptions, be deemed to
have matured on the applicable Stock Purchase Date.
S-85
Each Stripped Common Equity Unit consists of the following:
(a) prior to the First Stock Purchase Date, one
Series C Stock Purchase Contract;
(b) prior to the Second Stock Purchase Date, one
Series D Stock Purchase Contract;
(c) one Series E Stock Purchase Contract;
(d) prior to the First Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series C Treasury Security having a principal amount at
maturity of $1,000;
(e) prior to the Second Stock Purchase Date, a 1/40, or
2.50%, undivided beneficial ownership interest in a
Series D Treasury Security having a principal amount at
maturity of $1,000; and
(f) a 1/40, or 2.50%, undivided beneficial ownership
interest in a Series E Treasury Security having a principal
amount at maturity of $1,000.
To create Stripped Common Equity Units, the minimum amount of
which is 80 Stripped Common Equity Units, you must:
|
|
|
|
|
if creating a Stripped Common Equity Unit prior to the First
Stock Purchase Date, deposit with the Collateral Agent
Series C Treasury Securities having an aggregate principal
amount at maturity of $2,000;
|
|
|
|
if creating a Stripped Common Equity Unit prior to the Second
Stock Purchase Date, deposit with the Collateral Agent
Series D Treasury Securities having an aggregate principal
amount at maturity of $2,000;
|
|
|
|
deposit with the Collateral Agent Series E Treasury
Securities having an aggregate principal amount at maturity of
$2,000; and
|
|
|
|
transfer 80 Normal Common Equity Units to the Stock Purchase
Contract Agent, accompanied by a notice stating that you have
deposited the required number of Treasury Securities with the
Collateral Agent and requesting the release to you of the
Debentures relating to the 80 Normal Common Equity Units.
|
Upon such deposit and receipt of an instruction from the Stock
Purchase Contract Agent, the Collateral Agent will release the
related Debentures from the pledge under the Pledge Agreement,
dated November 1, 2010 (the Pledge
Agreement), among MetLife, Inc., the Collateral Agent,
Deutsche Bank Trust Company Americas, as securities
intermediary (the Securities Intermediary),
and the Stock Purchase Contract Agent, free and clear of
MetLife, Inc.s security interest, to the Stock Purchase
Contract Agent on your behalf. The Stock Purchase Contract Agent
then will:
|
|
|
|
|
cancel the 80 Normal Common Equity Units;
|
|
|
|
transfer the related Debentures to you; and
|
|
|
|
authenticate, execute on your behalf and deliver 80 Stripped
Common Equity Units to you.
|
Pursuant to the Pledge Agreement, the applicable Treasury
Securities will be substituted for the Debentures and will be
pledged to MetLife, Inc. through the Collateral Agent to secure
your obligation to purchase Common Stock under your Stock
Purchase Contracts. The related Debentures released to you
thereafter will trade separately from the resulting Stripped
Common Equity Units.
Recreating
Normal Common Equity Units
You will have the right (but not during the period that begins
at 5:00 p.m., New York City time, on the tenth Business Day
immediately preceding any scheduled Stock Purchase Date and ends
at 5:00 p.m., New York City time, on such scheduled Stock
Purchase Date), in accordance with the procedures described
below, to recreate a Normal Common Equity Unit from a Stripped
Common Equity Unit by substituting the Series C Debentures
(if applicable), the Series D Debentures (if applicable)
and the Series E Debentures for the applicable Treasury
Securities then held by the Collateral Agent. Because the
Series C Debentures and the Series E Debentures were
issued in integral multiples of $2,000, you may recreate Normal
Common Equity Units only in integral multiples of 80 Stripped
Common Equity Units. The Series C Debentures (if
applicable), the Series D Debentures (if applicable)
S-86
and the Series E Debentures substituted for the applicable
Treasury Securities must be purchased in the open market at your
expense unless otherwise owned by you. If you elect to
substitute Debentures for your Treasury Securities, thereby
recreating Normal Common Equity Units, you will be responsible
for any fees or expenses payable in connection with the
substitution.
To recreate Normal Common Equity Units, the minimum amount of
which is 80 Normal Common Equity Units, you must:
|
|
|
|
|
if recreating a Normal Common Equity Unit prior to the First
Stock Purchase Date, deposit with the Collateral Agent
Series C Debentures having an aggregate principal amount of
$2,000;
|
|
|
|
if recreating a Normal Common Equity Unit prior to the Second
Stock Purchase Date, deposit with the Collateral Agent
Series D Debentures having an aggregate principal amount of
$2,000;
|
|
|
|
deposit with the Collateral Agent Series E Debentures
having an aggregate principal amount of $2,000; and
|
|
|
|
transfer 80 Stripped Common Equity Units to the Stock Purchase
Contract Agent, accompanied by a notice stating that you have
deposited the required number of Debentures with the Collateral
Agent and requesting the release to you of the Treasury
Securities relating to the 80 Stripped Common Equity Units.
|
Each of these substitutions will recreate Normal Common Equity
Units, and the applicable Treasury Securities will be released
to you and be separately tradeable from the Normal Common Equity
Units.
Upon such deposit and receipt of an instruction from the Stock
Purchase Contract Agent, the Collateral Agent will release the
related Treasury Securities from the pledge under the Pledge
Agreement, free and clear of MetLife, Inc.s security
interest, to the Stock Purchase Contract Agent on your behalf.
The Stock Purchase Contract Agent will then:
|
|
|
|
|
cancel the 80 Stripped Common Equity Units;
|
|
|
|
transfer the related Treasury Securities to you; and
|
|
|
|
authenticate, execute on your behalf and deliver 80 Normal
Common Equity Units to you.
|
Pursuant to the Pledge Agreement, the substituted ownership
interests in the applicable Debentures will be pledged to
MetLife, Inc. through the Collateral Agent to secure your
obligation to purchase Common Stock under the Stock Purchase
Contracts.
Absence
of Voting and Certain Other Rights
Holders of the Stock Purchase Contracts forming part of the
Normal Common Equity Units or Stripped Common Equity Units, in
their capacities as such, will have no voting or other rights in
respect of Common Stock.
Listing
of the Securities
The Normal Common Equity Units have been approved for listing on
the New York Stock Exchange (the NYSE) under
the symbol MLU, subject to official notice. MetLife,
Inc. expects trading of the Normal Common Equity Units on the
NYSE to begin on March 7, 2011. Unless and until
substitution has been made as described in
Creating Stripped Common Equity Units,
no series of the Debentures will trade separately from the
Normal Common Equity Units. The Debentures will trade as a unit
with the Stock Purchase Contract component of the Normal Common
Equity Units. If the Stripped Common Equity Units or the
Debentures are separately traded to a sufficient extent that
applicable exchange listing requirements are met, MetLife, Inc.
may at its option list the Stripped Common Equity Units or the
Debentures on the same exchange on which the Normal Common
Equity Units are then listed, although MetLife, Inc. is under no
obligation to do so.
Miscellaneous
MetLife, Inc. or its affiliates may from time to time purchase
any of the securities offered by this prospectus supplement that
are then outstanding by tender, in the open market or by private
agreement.
S-87
DESCRIPTION
OF THE STOCK PURCHASE CONTRACTS
The Stock Purchase Contracts underlying a Common Equity Unit
will obligate you to purchase, and us to sell, for $25.00, on
each of the First Stock Purchase Date, the Second Stock Purchase
Date and the Third Stock Purchase Date, a variable number of
newly issued or treasury shares of Common Stock per Common
Equity Unit equal to the applicable Settlement Rate. Each
Settlement Rate will be calculated based on the VWAP during a
specified period preceding the applicable Initial Scheduled
Stock Purchase Date, as described below.
Contract
Payments
MetLife, Inc. will make payments (Contract
Payments) on each Stock Purchase Contract, payable
quarterly in arrears on each March 15, June 15,
September 15 and December 15 of each year (each such date, a
Contract Payment Date). However, the Contract
Payment that is scheduled to be made on March 15, 2011 will
be paid to the Selling Securityholder as holder of record on
March 1, 2011. Contract Payments will accrue on the stated
amount of $25.00 for each Stock Purchase Contract at the
following annual rates:
|
|
|
|
|
3.436% on the Series C Stock Purchase Contracts;
|
|
|
|
3.077% on the Series D Stock Purchase Contracts; and
|
|
|
|
2.537% on the Series E Stock Purchase Contracts.
|
Contract Payments will accrue from, and including, the most
recent date to which Contract Payments have been paid or
provided for (or, if no such Contract Payments have been paid or
provided for, from, and including, November 1,
2010) to, but excluding, the next Contract Payment Date. If
you purchase Common Equity Units pursuant to this offering,
Contract Payments on the Stock Purchase Contracts will accrue
from, and including, March 15, 2011. Contract Payments are
computed on the basis of a
360-day year
of twelve
30-day
months. Contract Payments on each Stock Purchase Contract will
be paid to the person in whose name the Common Equity Unit of
which the Stock Purchase Contract is a part was registered at
the close of business on the date (the Record
Date) that is the 15th calendar day immediately
preceding the applicable Contract Payment Date. However,
MetLife, Inc. may, at its option, select any other day as the
Record Date, so long as such selection is made more than 15
calendar days before the Contract Payment Date and such Record
Date selected is (A) more than one Business Day but less
than 60 Business Days before the applicable Contract Payment
Date and (B) administratively acceptable to the Stock
Purchase Contract Agent in its reasonable judgment. On each
Stock Purchase Date of each Stock Purchase Contract, MetLife,
Inc. will make Contract Payments accruing from, and including,
the most recent Contract Payment Date, to but excluding, such
Stock Purchase Date.
MetLife, Inc.s obligation to pay Contract Payments will be
subordinate and junior in right of payment to all of its
existing and future secured and senior debt, as described in the
accompanying prospectus under Description of Debt
Securities Subordination. In addition, your
right to receive accrued Contract Payments will terminate
automatically upon the occurrence of specified bankruptcy,
insolvency or reorganization events involving MetLife, Inc.
In the case of any Common Equity Units with respect to which
Early Settlement or Cash Merger Early Settlement (as described
under Early Settlement and
Early Settlement Upon Cash Merger) of
the underlying Stock Purchase Contracts is effected and the
related Early Settlement Date or Cash Merger Early Settlement
Date, as applicable, is after any Record Date and on or before
the next succeeding Contract Payment Date, Contract Payments
otherwise payable on such Contract Payment Date will be payable
on such Contract Payment Date notwithstanding such Early
Settlement or Cash Merger Early Settlement, and such Contract
Payments will be paid to the person in whose name the Common
Equity Units are registered at the close of business on such
Record Date. Subject to limited exceptions, if the Stock
Purchase Contracts of a Common Equity Unit are subject to Early
Settlement or Cash Merger Early Settlement, Contract Payments
that would otherwise be payable after the related Early
Settlement Date or Cash Merger Early Settlement Date, as
applicable, with respect to such Stock Purchase Contracts will
not be payable.
S-88
Option to
Defer Contract Payments
MetLife, Inc. may, at its option, and will at the direction of
the Federal Reserve Board, upon prior written notice to the
holders of Common Equity Units and the Stock Purchase Contract
Agent, defer Contract Payments on the Stock Purchase Contracts.
Any such Deferred Contract Payments will accrue interest, to the
extent permitted by law, at an annual rate equal to the
applicable Contract Payment Deferral Rate (as defined below),
compounded quarterly on each succeeding Payment Date, until paid
in full. If the Stock Purchase Contracts are terminated upon the
occurrence of a Termination Event (as defined below), the right
to receive Deferred Contract Payments, on or after such
Termination Event, will also terminate.
If MetLife, Inc. elects to defer the payment of Contract
Payments on the Stock Purchase Contracts until a Payment Date
that is prior to a Stock Purchase Date, then all Deferred
Contract Payments, if any, will be payable to the holders as of
the close of business on the Record Date immediately preceding
such Payment Date.
If MetLife, Inc elects to defer the payment of Contract Payments
on the Stock Purchase Contracts, and the Deferred Contract
Payments are not paid prior to the applicable Stock Purchase
Date, then MetLife, Inc. will pay the Deferred Contract Payments
in either shares of Common Stock or unsecured junior
subordinated notes, in its sole discretion.
If MetLife, Inc. pays Deferred Contract Payments in shares of
Common Stock, the number of shares of its Common Stock that you
will be entitled to receive will be equal to:
|
|
|
|
|
the aggregate amount of Deferred Contract Payments payable to
you, divided by
|
|
|
|
VWAP per share of Common Stock on the Trading Day immediately
preceding such Stock Purchase Date
|
If MetLife, Inc. elects to pay Deferred Contract Payments in
unsecured junior subordinated notes, the junior subordinated
notes you will receive will:
|
|
|
|
|
have a principal amount equal to the aggregate amount of
Deferred Contract Payments payable to you,
|
|
|
|
mature on April 8, 2016,
|
|
|
|
bear interest at an annual rate equal to the then market rate of
interest for similar instruments (not to exceed 10%), as
determined by a nationally recognized investment banking firm
selected by MetLife, Inc.,
|
|
|
|
be subordinate and rank junior in right of payment to all of
MetLife, Incs existing and future secured and senior debt
on the same basis as the Contract Payments, and
|
|
|
|
not be redeemable by MetLife, Inc. prior to their stated
maturity.
|
MetLife, Inc. will not issue any fractional shares of its Common
Stock with respect to the payment of Deferred Contract Payments.
In lieu of fractional shares that MetLife, Inc. would otherwise
have to issue to you, you will receive an amount in cash equal
to the applicable fraction of a share multiplied by VWAP per
share of Common Stock on the Trading Day immediately preceding
the applicable Stock Purchase Date.
If we elect or are directed by the Federal Reserve Board to
defer Contract Payments, then until the earlier of the date on
which (i) any Termination Event occurs or (ii) the
Deferred Contract Payments have been paid, MetLife, Inc. will
not (A) declare or pay dividends on, make distributions
with respect to, or redeem, purchase or acquire, or make a
liquidation payment with respect to, any of MetLife, Inc.s
capital stock; (B) make any payment of principal of, or
interest or premium, if any, on or repay, repurchase or redeem
any debt securities issued by MetLife, Inc. that rank equally
with or junior to MetLife, Inc.s junior subordinated debt
securities; and (C) make any payment under any guarantee
that ranks equally with junior subordinated debt securities of
MetLife Inc., in each case other than:
(i) any repurchase, redemption or other acquisition of
shares of capital stock of MetLife, Inc. in connection with
(x) any employment contract, benefit plan or other similar
arrangement with or for the benefit of any one or more
employees, officers, directors, consultants or independent
contractors, (y) a dividend reinvestment or stockholder
purchase plan, or (z) the issuance of capital stock of
MetLife, Inc., or
S-89
securities convertible into or exercisable for such capital
stock, as consideration in an acquisition transaction entered
into before the date MetLife, Inc. first exercises its option to
defer Contract Payments;
(ii) any exchange, redemption or conversion of any class or
series of capital stock of MetLife, Inc., or the capital stock
of one of MetLife, Inc.s subsidiaries, for any other class
or series of capital stock of MetLife, Inc., or any class or
series of MetLife, Inc.s indebtedness for any class or
series of capital stock of MetLife, Inc.;
(iii) any purchase of, or payment of cash in lieu of,
fractional interests in shares of capital stock of MetLife, Inc.
pursuant to the conversion or exchange provisions of such
capital stock or the securities being converted or exchanged;
(iv) any declaration of a dividend in connection with any
rights plan, or the issuance of rights, stock or other property
under any rights plan, or the redemption or repurchase of rights
pursuant thereto; and
(v) any dividend in the form of stock, warrants, options or
other rights where the dividend stock or stock issuable upon
exercise of such warrants, options or other rights is the same
stock as that on which the dividend is being paid or ranks equal
with or junior to such stock.
The Contract Payment Deferral Rate means an
annual rate, determined by MetLife, Inc. as of each Contract
Payment Date and applicable to amounts that accrue from, and
including, such Contract Payment Date to, but excluding, the
next succeeding Contract Payment Date, equal to the greater of
(i) the sum of (a) the prevailing annual market yield,
on such Contract Payment Date, of the benchmark
U.S. Treasury Security having a remaining maturity, as of
such payment date, that most closely corresponds to the period
from such Contract Payment Date to (x) the next scheduled
First Stock Purchase Date, with respect to a Series C Stock
Purchase Contract, (y) the next scheduled Second Stock
Purchase Date, with respect to a Series D Stock Purchase
Contract or (z) the next scheduled Third Stock Purchase
Date, with respect to a Series E Stock Purchase Contract;
and (b) 100 basis points; and (ii) 5.00%.
Settlement
at Each Stock Purchase Date
On the Stock Purchase Date of each Stock Purchase Contract, the
holder thereof must purchase, and MetLife, Inc. must sell to
such holder, for a cash price of $25.00 (the Purchase
Price), a number of shares of Common Stock equal to
the Settlement Rate (as defined below). Except to the extent
described below with respect to Early Settlement or Cash Merger
Early Settlement (each as defined below), the Purchase Price
will be paid (i) from the proceeds of the Remarketing of,
or the exercise of the Put Right with respect to, the related
Debentures, in the case of Normal Common Equity Units; or
(ii) from the proceeds of the applicable maturing Treasury
Securities, in the case of Stripped Common Equity Units.
However, if, in the case of a Normal Common Equity Unit, the
applicable Remarketing is a Final Failed Remarketing and the
holder of the Normal Common Equity Unit has elected not to
exercise the related Put Right, or if the holder has duly
elected not to have the related Debentures sold pursuant to the
applicable Remarketing, then the holder must pay the applicable
Purchase Price in cash to the Collateral Agent by 5:00 p.m.
(New York City time) on the Business Day immediately preceding
the applicable Stock Purchase Date (or such earlier time as may
be required by the terms of the Stock Purchase Contract
Agreement).
Settlement Rate means, with respect to a
Stock Purchase Date of a Stock Purchase Contract, a number of
shares of Common Stock equal to the following:
(i) if the Applicable Market Value (as defined below) for
such Stock Purchase Date is equal to or less than the Reference
Price (as defined below), then the Settlement Rate for such
Stock Purchase Date will be the Maximum Settlement Rate (as
defined below);
(ii) if the Applicable Market Value for such Stock Purchase
Date is greater than the Reference Price and less than the
Threshold Appreciation Price (as defined below), then the
Settlement Rate for such Stock Purchase Date will be a fraction
whose numerator is $25.00 and whose denominator is such
Applicable Market Value, which fraction will be rounded to the
nearest one-ten-thousandth of a share of Common Stock; and
(iii) if the Applicable Market Value for such Stock
Purchase Date is equal to or greater than the Threshold
Appreciation Price, then the Settlement Rate for such Stock
Purchase Date will be the Minimum Settlement Rate (as defined
below).
S-90
However, if the Stock Purchase Date (or, with respect to an
Early Settlement Upon Cash Merger, the Cash Merger Early
Settlement Date) of a Stock Purchase Contract occurs after the
Initial Scheduled First Stock Purchase Date (in the case of a
Series C Stock Purchase Contract), the Initial Scheduled
Second Stock Purchase Date (in the case of a Series D Stock
Purchase Contract) or the Initial Scheduled Third Stock Purchase
Date (in the case of a Series E Stock Purchase Contract),
then the Settlement Rate will be adjusted in the same manner as
the Fixed Settlement Rates are adjusted as described below under
Adjustments to the Fixed Settlement
Rates for any event or transaction that occurs on or after
such Initial Scheduled First Stock Purchase Date, Initial
Scheduled Second Stock Purchase Date or Initial Scheduled Third
Stock Purchase Date, as applicable, and on or before such Stock
Purchase Date or Cash Merger Early Settlement Date, as
applicable.
Applicable Market Value means, with respect
to a Stock Purchase Date of a Stock Purchase Contract, the
average of the VWAPs (as defined below) on each Trading Day (as
defined below) in the Trading Day Period (as defined below) of
such Stock Purchase Date.
VWAP on any Trading Day means the
volume-weighted average price per share of Common Stock in
respect of the period from 9:30 a.m. to 4:00 p.m. (New
York City time) on such Trading Day, as displayed under the
heading Bloomberg VWAP on Bloomberg page MET.N
<equity> AQR (or its equivalent successor if
such page is not available). However, if such volume-weighted
average price will not be available on such Trading Day, then
VWAP on such Trading Day will be determined, using a
volume-weighted average method, by a nationally recognized
independent investment banking firm retained for such purpose by
MetLife, Inc.
Trading Day means any day during which both
of the following conditions are satisfied: (i) trading in
the Common Stock generally occurs on the Relevant Exchange (as
defined below); and (ii) there is no Market Disruption
Event (as defined below).
Relevant Exchange means the New York Stock
Exchange; provided, however, that if the Common
Stock is not listed for trading on the New York Stock Exchange,
then Relevant Exchange means the principal
U.S. national or regional securities exchange on which the
Common Stock is listed; provided further, that if the
Common Stock is not listed on a U.S. national or regional
securities exchange, then Relevant Exchange means
the
over-the-counter
market on which the Common Stock is traded.
Market Disruption Event means any of the
following events that MetLife, Inc., in its reasonable
discretion, determines has occurred and is material:
(i) the occurrence or existence, for an aggregate period of
at least 30 minutes or during the
one-hour
period prior to the close of trading for the regular trading
session on the Relevant Exchange, of any suspension of, or
limitation imposed on, trading by the Relevant Exchange, whether
by reason of movements in price exceeding limits permitted by
the Relevant Exchange, or otherwise:
(1) relating to the Common Stock; or
(2) in futures or options contracts relating to the Common
Stock on the Relevant Exchange;
(ii) any event (other than an event described in
clause (iii) below) that disrupts or impairs the ability of
market participants, for an aggregate period of at least 30
minutes or during the
one-hour
period prior to the close of trading for the regular trading
session on the Relevant Exchange in general:
(1) to effect transactions in, or obtain market values for,
the Common Stock on the Relevant Exchange; or
(2) to effect transactions in, or obtain market values for,
futures or options contracts relating to the Common Stock on the
Relevant Exchange; or
(iii) the failure to open of the Relevant Exchange on which
futures or options contracts relating to the Common Stock are
traded or the closure of such exchange prior to its respective
scheduled closing time for the regular trading session on such
day (without regard to after hours or any other trading outside
of the regular
S-91
trading session hours) unless such earlier closing time is
announced by such exchange at least one hour prior to the
earlier of:
(1) the actual closing time for the regular trading session
on such day, and
(2) the submission deadline for orders to be entered into
such exchange for execution at the actual closing time on such
day.
Trading Day Period means, (i) with
respect to the First Stock Purchase Date, the 20 consecutive
Trading Days ending on, and including, the third Trading Day
immediately preceding the Initial Scheduled First Stock Purchase
Date; (ii) with respect to the Second Stock Purchase Date,
the 20 consecutive Trading Days ending on, and including, the
third Trading Day immediately preceding the Initial Scheduled
Second Stock Purchase Date; and (iii) with respect to the
Third Stock Purchase Date, the 20 consecutive Trading Days
ending on, and including, the third Trading Day immediately
preceding the Initial Scheduled Third Stock Purchase Date.
Maximum Settlement Rate means 0.7058, subject
to adjustments as described under Adjustments
to the Fixed Settlement Rates.
Minimum Settlement Rate means 0.5647, subject
to adjustments as described under Adjustments
to the Fixed Settlement Rates.
Fixed Settlement Rates means each of the
Maximum Settlement Rate and the Minimum Settlement Rate, subject
to adjustments as described under Adjustments
to the Fixed Settlement Rates.
Reference Price means $35.42, subject to
adjustments as described under Adjustments to
the Fixed Settlement Rates.
Threshold Appreciation Price means $44.275,
subject to adjustments as described under
Adjustments to the Fixed Settlement
Rates.
Early
Settlement
Stock Purchase Contracts may be settled early (Early
Settlement) at the option of the holder thereof.
However, Early Settlement may be effected only in integral
multiples of 80 Common Equity Units. If Early Settlement is
elected, it will apply to each remaining Stock Purchase Contract
forming a part of the applicable Common Equity Unit whose Stock
Purchase Date has not occurred before the applicable Early
Settlement Date. No Early Settlement will be permitted unless,
at the time such Early Settlement is effected, there is an
effective registration statement under the Securities Act with
respect to the securities to be issued and delivered in
connection with such Early Settlement, if such a registration
statement is required. If such a registration statement is so
required, MetLife, Inc. covenants and agrees to use commercially
reasonable efforts to (i) have in effect such a
registration statement covering the settlement of the Stock
Purchase Contracts being settled and (ii) provide a
prospectus in connection therewith.
A holder may not exercise its right to settle early unless it
has notified MetLife, Inc. and the Stock Purchase Contract Agent
in writing at least 61 days before the Early Settlement
Date that it may exercise such right. After providing such
notice, a holder of a Common Equity Unit that seeks to exercise
its right to effect Early Settlement must, at any time other
than the periods beginning from 5:00 p.m. (New York City
time) on the 10th Business Day immediately preceding each
scheduled Stock Purchase Date and ending on the open of business
on the Business Day immediately following such scheduled Stock
Purchase Date, deliver the certificate evidencing such Common
Equity Unit to the Stock Purchase Contract Agent, duly endorsed
for transfer to MetLife, Inc. or in blank, with the
Election to Settle Early form on the reverse thereof
duly completed. In addition, the holder must provide a cash
payment in an amount (the Early Settlement
Amount) equal to the sum of:
(i) the product of (A) the stated amount of each
Common Equity Unit to be subject to such Early Settlement; and
(B) the number of such Common Equity Units to be subject to
such Early Settlement; and
(ii) if the Early Settlement Date for such Early Settlement
occurs after any Record Date and before the next Contract
Payment Date, an amount equal to the Contract Payments payable
on such Contract Payment Date with respect to such Stock
Purchase Contracts.
S-92
If the foregoing requirements are first satisfied with respect
to Stock Purchase Contracts subject to an Early Settlement by
5:00 p.m. (New York City time) on a Business Day, then such
day will be the Early Settlement Date with
respect to such Stock Purchase Contracts. If such requirements
are first satisfied after 5:00 p.m. (New York City time) on
a Business Day or on a day that is not a Business Day, then the
Early Settlement Date with respect to the applicable Stock
Purchase Contracts will be the next succeeding Business Day.
No later than the third Business Day after the applicable Early
Settlement Date of a Common Equity Unit, MetLife, Inc. will
cause to be delivered to the applicable holder:
(i) a number of shares of Common Stock equal to the Minimum
Settlement Rate; and
(ii) the pledged Debentures or Treasury Securities, as
applicable, forming part of such Common Equity Unit to be
released from the pledge by the Collateral Agent, free and clear
of MetLife, Inc.s security interest therein.
Cash
Settlement
Unless an Early Settlement, a Cash Merger Early Settlement (as
defined below) or a Termination Event (as defined below) has
occurred prior to the applicable Stock Purchase Date, each
holder of a Normal Common Equity Unit will have the right to
satisfy its obligations under the related Stock Purchase
Contract on such Stock Purchase Date in cash by
(i) providing the Stock Purchase Contract Agent, no later
than 5:00 p.m. (New York City time) on the
11th Business Day immediately preceding the related
scheduled Stock Purchase Date, with a notice (Cash
Settlement); and (ii) paying, concurrently with
providing such notice, the Purchase Price for such Stock
Purchase Contract for deposit in the Collateral Account, in
lawful money of the United States, by certified or
cashiers check or wire transfer of immediately available
funds payable to or upon the order of the Securities
Intermediary; provided, however, that holders of Normal Common
Equity Units may effect Cash Settlement only in integral
multiples of 80 Normal Common Equity Units.
Promptly following 5:00 p.m. (New York City time) on the
11th Business Day immediately preceding each scheduled
Stock Purchase Date, the Stock Purchase Contract Agent shall
notify the Collateral Agent of the receipt of such notices from
holders intending to make a Cash Settlement. Notwithstanding the
foregoing, in no event may a holder elect a Cash Settlement from
the time any Remarketing has priced to, and including, the Stock
Purchase Date relating to such Remarketing. A holder that has
duly elected Cash Settlement to apply to any Normal Common
Equity Units shall, if the related Remarketing is a Final Failed
Remarketing, be deemed to have elected not to exercise its Put
Right with respect to the Debentures forming part of such Normal
Common Equity Units.
Except in the event of a failed Remarketing that is not a Final
Failed Remarketing, any cash received pursuant to a duly elected
Cash Settlement shall be paid to MetLife, Inc. on the applicable
Stock Purchase Date in settlement of such Stock Purchase
Contract.
If a holder of a Normal Common Equity Unit does not duly elect
Cash Settlement, then such holder shall be deemed to have
consented to the disposition of its pledged Debentures pursuant
to the next applicable Remarketing.
Early
Settlement upon Cash Merger
If a Cash Merger (as defined below) occurs before the Third
Stock Purchase Date, then, at the option of the holder thereof,
Stock Purchase Contracts may be settled early (Cash
Merger Early Settlement). However, holders of Common
Equity Units may effect Cash Merger Early Settlement only in
integral multiples of 80 Common Equity Units. If Cash Merger
Early Settlement is elected, it will apply to each remaining
Stock Purchase Contract forming a part of the applicable Common
Equity Unit whose Stock Purchase Date has not occurred before
the applicable Cash Merger Early Settlement Date. No Cash Merger
Early Settlement will be permitted unless, at the time such Cash
Merger Early Settlement is effected, there is an effective
registration statement under the Securities Act with respect to
the securities to be issued and delivered in connection with
such Cash Merger Early Settlement, if such a registration
statement is required. If such a registration statement is so
required, MetLife, Inc. covenants and agrees to use commercially
reasonable efforts to (i) have in effect such a
registration statement covering the settlement of the Stock
Purchase Contracts being settled and (ii) provide a
prospectus in connection therewith.
S-93
Cash Merger means any Reorganization Event
(as described under Effect of Reorganization
Events below) where (1) pursuant to such
Reorganization Event, the Common Stock is converted into or
exchanged for, or constitutes solely the right to receive, cash,
securities or other property (such cash, securities, or other
property, the Common Stock Consideration);
and (2) at least 30% of such Common Stock Consideration
consists of cash or cash equivalents.
Within five Business Days of the completion of a Cash Merger,
MetLife, Inc. must provide written notice to holders of Common
Equity Units, the Stock Purchase Contract Agent and the
Collateral Agent of the completion of such Cash Merger.
In order to exercise the right to effect a Cash Merger Early
Settlement, the holder of the certificate evidencing the Common
Equity Units of which such Stock Purchase Contracts are a part
must, no later than 5:00 p.m. (New York City time) on the
third Business Day immediately preceding the applicable Cash
Merger Early Settlement Date, deliver such certificate to the
Stock Purchase Contract Agent, duly endorsed for transfer to
MetLife, Inc, or in blank, with the Election to Settle
Early form on the reverse thereof duly completed. The
holder must also provide payment in an amount (the Cash
Merger Early Settlement Amount) equal to (I) the
product of (A) the stated amount of each Common Equity Unit
to be subject to such Cash Merger Early Settlement; and
(B) the number of such Common Equity Units to be subject to
such Cash Merger Early Settlement, less (II) the aggregate
amount of any unpaid Contract Payments on such Stock Purchase
Contracts that MetLife, Inc. is required to credit against such
amount pursuant to the immediately following paragraph. However,
if such Common Equity Unit is a Normal Common Equity Unit, then
such holder may, in lieu of such payment, elect (by checking the
appropriate box in such Election to Settle Early
form) to have the Debentures forming part of such Normal Common
Equity Units transferred to MetLife, Inc. in full satisfaction
of such holders obligation to deliver the Cash Merger
Early Settlement Amount with respect to such Normal Common
Equity Units (an In Kind Settlement Upon Cash Merger
Early Settlement).
If a holder effects a Cash Merger Early Settlement of any of its
Stock Purchase Contracts, then the holder will be entitled to
receive the aggregate amount of any unpaid Contract Payments
that have accrued, on such Stock Purchase Contracts, from, and
including, the Contract Payment Date immediately preceding the
related Cash Merger Early Settlement Date to, but excluding,
such Cash Merger Early Settlement Date. This amount will either
be credited against the amount otherwise payable by the holder
to effect the Cash Merger Early Settlement or be paid, on such
Cash Merger Early Settlement Date, to the holder. However, if
the Cash Merger Early Settlement Date occurs after a Record Date
and on or before the next Contract Payment Date, then Contract
Payments otherwise payable on such Contract Payment Date will be
payable on such Contract Payment Date notwithstanding such Cash
Merger Early Settlement, and such Contract Payments will be paid
to the person in whose name the certificate evidencing the
applicable Common Equity Units is registered at the close of
business on such Record Date.
Upon payment of the applicable Cash Merger Early Settlement
Amount with respect to a Cash Merger Early Settlement of Common
Equity Units, the holder thereof will be entitled to receive, no
later than the third Business Day after the applicable Cash
Merger Early Settlement Date, a number of Reference Property
Units equal to the Applicable Cash Merger Early Settlement Rate
(as defined below).
Applicable Cash Merger Early Settlement Rate
means, with respect to a Stock Purchase Contract subject to a
Cash Merger Early Settlement upon a Cash Merger, a number of
Reference Property Units equal to the amount, set forth in the
applicable table below.
S-94
With respect to Series C Stock Purchase Contracts, the
following table is used to determine the Applicable Cash Merger
Early Settlement Rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
Applicable Price
|
|
Date
|
|
$5.00
|
|
|
$10.00
|
|
|
$15.00
|
|
|
$20.00
|
|
|
$22.50
|
|
|
$25.00
|
|
|
$27.50
|
|
|
$30.00
|
|
|
$32.50
|
|
|
$35.42
|
|
|
$38.00
|
|
|
$40.00
|
|
|
$42.00
|
|
|
$44.28
|
|
|
$46.00
|
|
|
$48.00
|
|
|
$50.00
|
|
|
$52.50
|
|
|
$55.00
|
|
|
$60.00
|
|
|
$65.00
|
|
|
$70.00
|
|
|
$80.00
|
|
|
$100.00
|
|
|
$200.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-10-11
|
|
|
1.0173
|
|
|
|
0.8575
|
|
|
|
0.7981
|
|
|
|
0.7554
|
|
|
|
0.7355
|
|
|
|
0.7164
|
|
|
|
0.6983
|
|
|
|
0.6816
|
|
|
|
0.6665
|
|
|
|
0.6509
|
|
|
|
0.6390
|
|
|
|
0.6310
|
|
|
|
0.6239
|
|
|
|
0.6169
|
|
|
|
0.6123
|
|
|
|
0.6076
|
|
|
|
0.6035
|
|
|
|
0.5992
|
|
|
|
0.5956
|
|
|
|
0.5901
|
|
|
|
0.5863
|
|
|
|
0.5835
|
|
|
|
0.5798
|
|
|
|
0.5758
|
|
|
|
0.5679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-10-11
|
|
|
0.9606
|
|
|
|
0.8301
|
|
|
|
0.7825
|
|
|
|
0.7475
|
|
|
|
0.7302
|
|
|
|
0.7128
|
|
|
|
0.6957
|
|
|
|
0.6793
|
|
|
|
0.6642
|
|
|
|
0.6484
|
|
|
|
0.6362
|
|
|
|
0.6279
|
|
|
|
0.6206
|
|
|
|
0.6134
|
|
|
|
0.6087
|
|
|
|
0.6039
|
|
|
|
0.5998
|
|
|
|
0.5955
|
|
|
|
0.5919
|
|
|
|
0.5866
|
|
|
|
0.5830
|
|
|
|
0.5805
|
|
|
|
0.5773
|
|
|
|
0.5739
|
|
|
|
0.5672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-10-11
|
|
|
0.9026
|
|
|
|
0.8018
|
|
|
|
0.7659
|
|
|
|
0.7392
|
|
|
|
0.7249
|
|
|
|
0.7096
|
|
|
|
0.6938
|
|
|
|
0.6779
|
|
|
|
0.6628
|
|
|
|
0.6465
|
|
|
|
0.6338
|
|
|
|
0.6251
|
|
|
|
0.6174
|
|
|
|
0.6099
|
|
|
|
0.6050
|
|
|
|
0.6000
|
|
|
|
0.5958
|
|
|
|
0.5915
|
|
|
|
0.5879
|
|
|
|
0.5828
|
|
|
|
0.5795
|
|
|
|
0.5773
|
|
|
|
0.5747
|
|
|
|
0.5719
|
|
|
|
0.5665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-10-11
|
|
|
0.8433
|
|
|
|
0.7727
|
|
|
|
0.7482
|
|
|
|
0.7301
|
|
|
|
0.7194
|
|
|
|
0.7068
|
|
|
|
0.6926
|
|
|
|
0.6775
|
|
|
|
0.6624
|
|
|
|
0.6455
|
|
|
|
0.6319
|
|
|
|
0.6226
|
|
|
|
0.6143
|
|
|
|
0.6062
|
|
|
|
0.6009
|
|
|
|
0.5957
|
|
|
|
0.5913
|
|
|
|
0.5869
|
|
|
|
0.5834
|
|
|
|
0.5786
|
|
|
|
0.5757
|
|
|
|
0.5739
|
|
|
|
0.5718
|
|
|
|
0.5698
|
|
|
|
0.5658
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-10-12
|
|
|
0.8880
|
|
|
|
0.7955
|
|
|
|
0.7643
|
|
|
|
0.7448
|
|
|
|
0.7342
|
|
|
|
0.7216
|
|
|
|
0.7070
|
|
|
|
0.6908
|
|
|
|
0.6739
|
|
|
|
0.6547
|
|
|
|
0.6391
|
|
|
|
0.6283
|
|
|
|
0.6188
|
|
|
|
0.6096
|
|
|
|
0.6038
|
|
|
|
0.5981
|
|
|
|
0.5934
|
|
|
|
0.5887
|
|
|
|
0.5852
|
|
|
|
0.5805
|
|
|
|
0.5778
|
|
|
|
0.5761
|
|
|
|
0.5741
|
|
|
|
0.5717
|
|
|
|
0.5671
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-10-12
|
|
|
0.8288
|
|
|
|
0.7664
|
|
|
|
0.7456
|
|
|
|
0.7340
|
|
|
|
0.7280
|
|
|
|
0.7200
|
|
|
|
0.7090
|
|
|
|
0.6948
|
|
|
|
0.6781
|
|
|
|
0.6572
|
|
|
|
0.6392
|
|
|
|
0.6265
|
|
|
|
0.6152
|
|
|
|
0.6045
|
|
|
|
0.5979
|
|
|
|
0.5916
|
|
|
|
0.5867
|
|
|
|
0.5822
|
|
|
|
0.5790
|
|
|
|
0.5752
|
|
|
|
0.5734
|
|
|
|
0.5723
|
|
|
|
0.5710
|
|
|
|
0.5695
|
|
|
|
0.5664
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-10-12
|
|
|
0.7683
|
|
|
|
0.7366
|
|
|
|
0.7261
|
|
|
|
0.7208
|
|
|
|
0.7189
|
|
|
|
0.7165
|
|
|
|
0.7122
|
|
|
|
0.7038
|
|
|
|
0.6899
|
|
|
|
0.6671
|
|
|
|
0.6438
|
|
|
|
0.6261
|
|
|
|
0.6104
|
|
|
|
0.5960
|
|
|
|
0.5878
|
|
|
|
0.5809
|
|
|
|
0.5763
|
|
|
|
0.5729
|
|
|
|
0.5710
|
|
|
|
0.5695
|
|
|
|
0.5689
|
|
|
|
0.5685
|
|
|
|
0.5679
|
|
|
|
0.5672
|
|
|
|
0.5656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-10-12
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.6579
|
|
|
|
0.6250
|
|
|
|
0.5952
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
With respect to Series D Stock Purchase Contracts, the
following table is used to determine the Applicable Cash Merger
Early Settlement Rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
Applicable Price
|
|
Date
|
|
$5.00
|
|
|
$10.00
|
|
|
$15.00
|
|
|
$20.00
|
|
|
$22.50
|
|
|
$25.00
|
|
|
$27.50
|
|
|
$30.00
|
|
|
$32.50
|
|
|
$35.42
|
|
|
$38.00
|
|
|
$40.00
|
|
|
$42.00
|
|
|
$44.28
|
|
|
$46.00
|
|
|
$48.00
|
|
|
$50.00
|
|
|
$52.50
|
|
|
$55.00
|
|
|
$60.00
|
|
|
$65.00
|
|
|
$70.00
|
|
|
$80.00
|
|
|
$100.00
|
|
|
$200.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12-11-10
|
|
|
1.1369
|
|
|
|
0.9128
|
|
|
|
0.8250
|
|
|
|
0.7655
|
|
|
|
0.7409
|
|
|
|
0.7191
|
|
|
|
0.6998
|
|
|
|
0.6829
|
|
|
|
0.6683
|
|
|
|
0.6536
|
|
|
|
0.6427
|
|
|
|
0.6353
|
|
|
|
0.6289
|
|
|
|
0.6224
|
|
|
|
0.6181
|
|
|
|
0.6137
|
|
|
|
0.6098
|
|
|
|
0.6056
|
|
|
|
0.6020
|
|
|
|
0.5962
|
|
|
|
0.5919
|
|
|
|
0.5886
|
|
|
|
0.5840
|
|
|
|
0.5787
|
|
|
|
0.5684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03-11-11
|
|
|
1.0821
|
|
|
|
0.8870
|
|
|
|
0.8109
|
|
|
|
0.7576
|
|
|
|
0.7348
|
|
|
|
0.7141
|
|
|
|
0.6955
|
|
|
|
0.6791
|
|
|
|
0.6646
|
|
|
|
0.6501
|
|
|
|
0.6392
|
|
|
|
0.6318
|
|
|
|
0.6254
|
|
|
|
0.6189
|
|
|
|
0.6147
|
|
|
|
0.6103
|
|
|
|
0.6064
|
|
|
|
0.6023
|
|
|
|
0.5987
|
|
|
|
0.5932
|
|
|
|
0.5891
|
|
|
|
0.5860
|
|
|
|
0.5818
|
|
|
|
0.5770
|
|
|
|
0.5678
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06-11-11
|
|
|
1.0267
|
|
|
|
0.8606
|
|
|
|
0.7963
|
|
|
|
0.7497
|
|
|
|
0.7288
|
|
|
|
0.7094
|
|
|
|
0.6916
|
|
|
|
0.6756
|
|
|
|
0.6613
|
|
|
|
0.6468
|
|
|
|
0.6359
|
|
|
|
0.6285
|
|
|
|
0.6220
|
|
|
|
0.6155
|
|
|
|
0.6113
|
|
|
|
0.6069
|
|
|
|
0.6031
|
|
|
|
0.5990
|
|
|
|
0.5955
|
|
|
|
0.5901
|
|
|
|
0.5862
|
|
|
|
0.5833
|
|
|
|
0.5795
|
|
|
|
0.5753
|
|
|
|
0.5671
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09-11-11
|
|
|
0.9707
|
|
|
|
0.8337
|
|
|
|
0.7812
|
|
|
|
0.7416
|
|
|
|
0.7229
|
|
|
|
0.7049
|
|
|
|
0.6880
|
|
|
|
0.6723
|
|
|
|
0.6582
|
|
|
|
0.6437
|
|
|
|
0.6327
|
|
|
|
0.6252
|
|
|
|
0.6186
|
|
|
|
0.6121
|
|
|
|
0.6078
|
|
|
|
0.6034
|
|
|
|
0.5996
|
|
|
|
0.5955
|
|
|
|
0.5921
|
|
|
|
0.5869
|
|
|
|
0.5832
|
|
|
|
0.5806
|
|
|
|
0.5771
|
|
|
|
0.5735
|
|
|
|
0.5665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12-11-11
|
|
|
1.0180
|
|
|
|
0.8579
|
|
|
|
0.7984
|
|
|
|
0.7556
|
|
|
|
0.7357
|
|
|
|
0.7166
|
|
|
|
0.6985
|
|
|
|
0.6817
|
|
|
|
0.6666
|
|
|
|
0.6510
|
|
|
|
0.6391
|
|
|
|
0.6311
|
|
|
|
0.6240
|
|
|
|
0.6170
|
|
|
|
0.6124
|
|
|
|
0.6077
|
|
|
|
0.6036
|
|
|
|
0.5993
|
|
|
|
0.5957
|
|
|
|
0.5902
|
|
|
|
0.5863
|
|
|
|
0.5835
|
|
|
|
0.5799
|
|
|
|
0.5758
|
|
|
|
0.5679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03-11-12
|
|
|
0.9593
|
|
|
|
0.8294
|
|
|
|
0.7820
|
|
|
|
0.7472
|
|
|
|
0.7299
|
|
|
|
0.7125
|
|
|
|
0.6954
|
|
|
|
0.6791
|
|
|
|
0.6640
|
|
|
|
0.6482
|
|
|
|
0.6360
|
|
|
|
0.6277
|
|
|
|
0.6205
|
|
|
|
0.6133
|
|
|
|
0.6086
|
|
|
|
0.6038
|
|
|
|
0.5997
|
|
|
|
0.5954
|
|
|
|
0.5918
|
|
|
|
0.5865
|
|
|
|
0.5829
|
|
|
|
0.5804
|
|
|
|
0.5772
|
|
|
|
0.5738
|
|
|
|
0.5672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06-11-12
|
|
|
0.9013
|
|
|
|
0.8011
|
|
|
|
0.7655
|
|
|
|
0.7389
|
|
|
|
0.7246
|
|
|
|
0.7093
|
|
|
|
0.6935
|
|
|
|
0.6777
|
|
|
|
0.6626
|
|
|
|
0.6463
|
|
|
|
0.6336
|
|
|
|
0.6249
|
|
|
|
0.6173
|
|
|
|
0.6097
|
|
|
|
0.6048
|
|
|
|
0.5999
|
|
|
|
0.5957
|
|
|
|
0.5913
|
|
|
|
0.5878
|
|
|
|
0.5827
|
|
|
|
0.5794
|
|
|
|
0.5772
|
|
|
|
0.5746
|
|
|
|
0.5718
|
|
|
|
0.5665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09-11-12
|
|
|
0.8433
|
|
|
|
0.7727
|
|
|
|
0.7483
|
|
|
|
0.7301
|
|
|
|
0.7194
|
|
|
|
0.7068
|
|
|
|
0.6926
|
|
|
|
0.6776
|
|
|
|
0.6624
|
|
|
|
0.6455
|
|
|
|
0.6319
|
|
|
|
0.6226
|
|
|
|
0.6143
|
|
|
|
0.6062
|
|
|
|
0.6009
|
|
|
|
0.5957
|
|
|
|
0.5913
|
|
|
|
0.5869
|
|
|
|
0.5834
|
|
|
|
0.5786
|
|
|
|
0.5757
|
|
|
|
0.5739
|
|
|
|
0.5718
|
|
|
|
0.5698
|
|
|
|
0.5658
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12-11-12
|
|
|
0.8887
|
|
|
|
0.7959
|
|
|
|
0.7646
|
|
|
|
0.7450
|
|
|
|
0.7343
|
|
|
|
0.7218
|
|
|
|
0.7071
|
|
|
|
0.6909
|
|
|
|
0.6740
|
|
|
|
0.6548
|
|
|
|
0.6392
|
|
|
|
0.6284
|
|
|
|
0.6189
|
|
|
|
0.6097
|
|
|
|
0.6039
|
|
|
|
0.5981
|
|
|
|
0.5934
|
|
|
|
0.5888
|
|
|
|
0.5853
|
|
|
|
0.5806
|
|
|
|
0.5778
|
|
|
|
0.5761
|
|
|
|
0.5741
|
|
|
|
0.5718
|
|
|
|
0.5671
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03-11-13
|
|
|
0.8274
|
|
|
|
0.7657
|
|
|
|
0.7451
|
|
|
|
0.7337
|
|
|
|
0.7277
|
|
|
|
0.7197
|
|
|
|
0.7088
|
|
|
|
0.6946
|
|
|
|
0.6779
|
|
|
|
0.6570
|
|
|
|
0.6390
|
|
|
|
0.6263
|
|
|
|
0.6151
|
|
|
|
0.6043
|
|
|
|
0.5977
|
|
|
|
0.5914
|
|
|
|
0.5866
|
|
|
|
0.5820
|
|
|
|
0.5788
|
|
|
|
0.5751
|
|
|
|
0.5733
|
|
|
|
0.5722
|
|
|
|
0.5710
|
|
|
|
0.5694
|
|
|
|
0.5663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06-11-13
|
|
|
0.7669
|
|
|
|
0.7360
|
|
|
|
0.7256
|
|
|
|
0.7205
|
|
|
|
0.7185
|
|
|
|
0.7162
|
|
|
|
0.7119
|
|
|
|
0.7036
|
|
|
|
0.6897
|
|
|
|
0.6669
|
|
|
|
0.6436
|
|
|
|
0.6259
|
|
|
|
0.6102
|
|
|
|
0.5958
|
|
|
|
0.5876
|
|
|
|
0.5807
|
|
|
|
0.5762
|
|
|
|
0.5727
|
|
|
|
0.5709
|
|
|
|
0.5694
|
|
|
|
0.5688
|
|
|
|
0.5684
|
|
|
|
0.5679
|
|
|
|
0.5671
|
|
|
|
0.5655
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09-11-13
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.6579
|
|
|
|
0.6250
|
|
|
|
0.5952
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
With respect to Series D Stock Purchase Contracts, the
following table is used to determine the Applicable Cash Merger
Early Settlement Rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
Applicable Price
|
|
Date
|
|
$5.00
|
|
|
$10.00
|
|
|
$15.00
|
|
|
$20.00
|
|
|
$22.50
|
|
|
$25.00
|
|
|
$27.50
|
|
|
$30.00
|
|
|
$32.50
|
|
|
$35.42
|
|
|
$38.00
|
|
|
$40.00
|
|
|
$42.00
|
|
|
$44.28
|
|
|
$46.00
|
|
|
$48.00
|
|
|
$50.00
|
|
|
$52.50
|
|
|
$55.00
|
|
|
$60.00
|
|
|
$65.00
|
|
|
$70.00
|
|
|
$80.00
|
|
|
$100.00
|
|
|
$200.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-08-11
|
|
|
1.2460
|
|
|
|
0.9619
|
|
|
|
0.8487
|
|
|
|
0.7766
|
|
|
|
0.7487
|
|
|
|
0.7250
|
|
|
|
0.7047
|
|
|
|
0.6875
|
|
|
|
0.6727
|
|
|
|
0.6582
|
|
|
|
0.6475
|
|
|
|
0.6403
|
|
|
|
0.6339
|
|
|
|
0.6276
|
|
|
|
0.6233
|
|
|
|
0.6189
|
|
|
|
0.6150
|
|
|
|
0.6107
|
|
|
|
0.6070
|
|
|
|
0.6009
|
|
|
|
0.5962
|
|
|
|
0.5925
|
|
|
|
0.5872
|
|
|
|
0.5807
|
|
|
|
0.5684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-08-11
|
|
|
1.1946
|
|
|
|
0.9381
|
|
|
|
0.8358
|
|
|
|
0.7688
|
|
|
|
0.7424
|
|
|
|
0.7196
|
|
|
|
0.7000
|
|
|
|
0.6831
|
|
|
|
0.6687
|
|
|
|
0.6544
|
|
|
|
0.6438
|
|
|
|
0.6367
|
|
|
|
0.6304
|
|
|
|
0.6242
|
|
|
|
0.6200
|
|
|
|
0.6157
|
|
|
|
0.6118
|
|
|
|
0.6077
|
|
|
|
0.6040
|
|
|
|
0.5982
|
|
|
|
0.5937
|
|
|
|
0.5902
|
|
|
|
0.5852
|
|
|
|
0.5792
|
|
|
|
0.5679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-08-11
|
|
|
1.1420
|
|
|
|
0.9137
|
|
|
|
0.8225
|
|
|
|
0.7610
|
|
|
|
0.7362
|
|
|
|
0.7144
|
|
|
|
0.6954
|
|
|
|
0.6790
|
|
|
|
0.6648
|
|
|
|
0.6508
|
|
|
|
0.6403
|
|
|
|
0.6333
|
|
|
|
0.6271
|
|
|
|
0.6209
|
|
|
|
0.6168
|
|
|
|
0.6125
|
|
|
|
0.6087
|
|
|
|
0.6046
|
|
|
|
0.6011
|
|
|
|
0.5954
|
|
|
|
0.5912
|
|
|
|
0.5879
|
|
|
|
0.5832
|
|
|
|
0.5778
|
|
|
|
0.5675
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-08-11
|
|
|
1.0880
|
|
|
|
0.8882
|
|
|
|
0.8085
|
|
|
|
0.7529
|
|
|
|
0.7297
|
|
|
|
0.7090
|
|
|
|
0.6908
|
|
|
|
0.6748
|
|
|
|
0.6609
|
|
|
|
0.6470
|
|
|
|
0.6366
|
|
|
|
0.6297
|
|
|
|
0.6235
|
|
|
|
0.6174
|
|
|
|
0.6133
|
|
|
|
0.6091
|
|
|
|
0.6054
|
|
|
|
0.6014
|
|
|
|
0.5980
|
|
|
|
0.5925
|
|
|
|
0.5884
|
|
|
|
0.5853
|
|
|
|
0.5810
|
|
|
|
0.5762
|
|
|
|
0.5669
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-08-12
|
|
|
1.1374
|
|
|
|
0.9131
|
|
|
|
0.8252
|
|
|
|
0.7656
|
|
|
|
0.7410
|
|
|
|
0.7192
|
|
|
|
0.6999
|
|
|
|
0.6830
|
|
|
|
0.6683
|
|
|
|
0.6537
|
|
|
|
0.6428
|
|
|
|
0.6354
|
|
|
|
0.6289
|
|
|
|
0.6225
|
|
|
|
0.6182
|
|
|
|
0.6138
|
|
|
|
0.6099
|
|
|
|
0.6056
|
|
|
|
0.6020
|
|
|
|
0.5962
|
|
|
|
0.5919
|
|
|
|
0.5886
|
|
|
|
0.5840
|
|
|
|
0.5787
|
|
|
|
0.5684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-08-12
|
|
|
1.0833
|
|
|
|
0.8876
|
|
|
|
0.8113
|
|
|
|
0.7579
|
|
|
|
0.7350
|
|
|
|
0.7143
|
|
|
|
0.6958
|
|
|
|
0.6793
|
|
|
|
0.6648
|
|
|
|
0.6503
|
|
|
|
0.6393
|
|
|
|
0.6320
|
|
|
|
0.6255
|
|
|
|
0.6191
|
|
|
|
0.6148
|
|
|
|
0.6104
|
|
|
|
0.6066
|
|
|
|
0.6024
|
|
|
|
0.5989
|
|
|
|
0.5933
|
|
|
|
0.5892
|
|
|
|
0.5861
|
|
|
|
0.5818
|
|
|
|
0.5770
|
|
|
|
0.5678
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-08-12
|
|
|
1.0280
|
|
|
|
0.8612
|
|
|
|
0.7967
|
|
|
|
0.7500
|
|
|
|
0.7291
|
|
|
|
0.7097
|
|
|
|
0.6919
|
|
|
|
0.6758
|
|
|
|
0.6615
|
|
|
|
0.6470
|
|
|
|
0.6360
|
|
|
|
0.6287
|
|
|
|
0.6221
|
|
|
|
0.6157
|
|
|
|
0.6114
|
|
|
|
0.6070
|
|
|
|
0.6032
|
|
|
|
0.5991
|
|
|
|
0.5956
|
|
|
|
0.5902
|
|
|
|
0.5863
|
|
|
|
0.5834
|
|
|
|
0.5796
|
|
|
|
0.5753
|
|
|
|
0.5672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-08-12
|
|
|
0.9713
|
|
|
|
0.8340
|
|
|
|
0.7814
|
|
|
|
0.7417
|
|
|
|
0.7230
|
|
|
|
0.7050
|
|
|
|
0.6881
|
|
|
|
0.6724
|
|
|
|
0.6583
|
|
|
|
0.6438
|
|
|
|
0.6328
|
|
|
|
0.6253
|
|
|
|
0.6187
|
|
|
|
0.6122
|
|
|
|
0.6079
|
|
|
|
0.6035
|
|
|
|
0.5997
|
|
|
|
0.5956
|
|
|
|
0.5922
|
|
|
|
0.5869
|
|
|
|
0.5833
|
|
|
|
0.5806
|
|
|
|
0.5772
|
|
|
|
0.5735
|
|
|
|
0.5665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-08-13
|
|
|
1.0173
|
|
|
|
0.8575
|
|
|
|
0.7981
|
|
|
|
0.7554
|
|
|
|
0.7355
|
|
|
|
0.7164
|
|
|
|
0.6983
|
|
|
|
0.6816
|
|
|
|
0.6665
|
|
|
|
0.6509
|
|
|
|
0.6390
|
|
|
|
0.6310
|
|
|
|
0.6239
|
|
|
|
0.6169
|
|
|
|
0.6123
|
|
|
|
0.6076
|
|
|
|
0.6035
|
|
|
|
0.5992
|
|
|
|
0.5956
|
|
|
|
0.5901
|
|
|
|
0.5863
|
|
|
|
0.5835
|
|
|
|
0.5798
|
|
|
|
0.5758
|
|
|
|
0.5679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-08-13
|
|
|
0.9606
|
|
|
|
0.8301
|
|
|
|
0.7825
|
|
|
|
0.7475
|
|
|
|
0.7302
|
|
|
|
0.7128
|
|
|
|
0.6957
|
|
|
|
0.6793
|
|
|
|
0.6642
|
|
|
|
0.6484
|
|
|
|
0.6362
|
|
|
|
0.6279
|
|
|
|
0.6206
|
|
|
|
0.6134
|
|
|
|
0.6087
|
|
|
|
0.6039
|
|
|
|
0.5998
|
|
|
|
0.5955
|
|
|
|
0.5919
|
|
|
|
0.5866
|
|
|
|
0.5830
|
|
|
|
0.5805
|
|
|
|
0.5773
|
|
|
|
0.5739
|
|
|
|
0.5672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-08-13
|
|
|
0.9026
|
|
|
|
0.8018
|
|
|
|
0.7659
|
|
|
|
0.7392
|
|
|
|
0.7249
|
|
|
|
0.7096
|
|
|
|
0.6938
|
|
|
|
0.6779
|
|
|
|
0.6628
|
|
|
|
0.6465
|
|
|
|
0.6338
|
|
|
|
0.6251
|
|
|
|
0.6174
|
|
|
|
0.6099
|
|
|
|
0.6050
|
|
|
|
0.6000
|
|
|
|
0.5958
|
|
|
|
0.5915
|
|
|
|
0.5879
|
|
|
|
0.5828
|
|
|
|
0.5795
|
|
|
|
0.5773
|
|
|
|
0.5747
|
|
|
|
0.5719
|
|
|
|
0.5665
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-08-13
|
|
|
0.8433
|
|
|
|
0.7727
|
|
|
|
0.7482
|
|
|
|
0.7301
|
|
|
|
0.7194
|
|
|
|
0.7068
|
|
|
|
0.6926
|
|
|
|
0.6775
|
|
|
|
0.6624
|
|
|
|
0.6455
|
|
|
|
0.6319
|
|
|
|
0.6226
|
|
|
|
0.6143
|
|
|
|
0.6062
|
|
|
|
0.6009
|
|
|
|
0.5957
|
|
|
|
0.5913
|
|
|
|
0.5869
|
|
|
|
0.5834
|
|
|
|
0.5786
|
|
|
|
0.5757
|
|
|
|
0.5739
|
|
|
|
0.5718
|
|
|
|
0.5698
|
|
|
|
0.5658
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01-08-14
|
|
|
0.8880
|
|
|
|
0.7955
|
|
|
|
0.7643
|
|
|
|
0.7448
|
|
|
|
0.7342
|
|
|
|
0.7216
|
|
|
|
0.7070
|
|
|
|
0.6908
|
|
|
|
0.6739
|
|
|
|
0.6547
|
|
|
|
0.6391
|
|
|
|
0.6283
|
|
|
|
0.6188
|
|
|
|
0.6096
|
|
|
|
0.6038
|
|
|
|
0.5981
|
|
|
|
0.5934
|
|
|
|
0.5887
|
|
|
|
0.5852
|
|
|
|
0.5805
|
|
|
|
0.5778
|
|
|
|
0.5761
|
|
|
|
0.5741
|
|
|
|
0.5717
|
|
|
|
0.5671
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-08-14
|
|
|
0.8288
|
|
|
|
0.7664
|
|
|
|
0.7456
|
|
|
|
0.7340
|
|
|
|
0.7280
|
|
|
|
0.7200
|
|
|
|
0.7090
|
|
|
|
0.6948
|
|
|
|
0.6781
|
|
|
|
0.6572
|
|
|
|
0.6392
|
|
|
|
0.6265
|
|
|
|
0.6152
|
|
|
|
0.6045
|
|
|
|
0.5979
|
|
|
|
0.5916
|
|
|
|
0.5867
|
|
|
|
0.5822
|
|
|
|
0.5790
|
|
|
|
0.5752
|
|
|
|
0.5734
|
|
|
|
0.5723
|
|
|
|
0.5710
|
|
|
|
0.5695
|
|
|
|
0.5664
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07-08-14
|
|
|
0.7683
|
|
|
|
0.7366
|
|
|
|
0.7261
|
|
|
|
0.7208
|
|
|
|
0.7189
|
|
|
|
0.7165
|
|
|
|
0.7122
|
|
|
|
0.7038
|
|
|
|
0.6899
|
|
|
|
0.6671
|
|
|
|
0.6438
|
|
|
|
0.6261
|
|
|
|
0.6104
|
|
|
|
0.5960
|
|
|
|
0.5878
|
|
|
|
0.5809
|
|
|
|
0.5763
|
|
|
|
0.5729
|
|
|
|
0.5710
|
|
|
|
0.5695
|
|
|
|
0.5689
|
|
|
|
0.5685
|
|
|
|
0.5679
|
|
|
|
0.5672
|
|
|
|
0.5656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10-08-14
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.7058
|
|
|
|
0.6579
|
|
|
|
0.6250
|
|
|
|
0.5952
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
|
|
0.5647
|
|
Applicable Price has the following meaning
with respect to a Cash Merger: (a) if the consideration for
the Common Stock in such Cash Merger consists solely of cash,
then the Applicable Price with respect to such Cash Merger means
the cash amount paid per share of Common Stock in such Cash
Merger; and (b) in all other circumstances, the Applicable
Price with respect to such Cash Merger will be equal to the
average of the VWAPs on each of the five consecutive Trading
Days immediately preceding the Cash Merger Effective Date of
such Cash Merger.
Cash Merger Effective Date means, with
respect to a Cash Merger, the effective date of such Cash Merger.
S-95
Notwithstanding the foregoing:
(1) if the Cash Merger Effective Date occurs on or after
the Initial Scheduled First Stock Purchase Date (if such Stock
Purchase Contract is a Series C Stock Purchase Contract),
the Initial Scheduled Second Stock Purchase Date (if such Stock
Purchase Contract is a Series D Stock Purchase Contract) or
the Initial Scheduled Third Stock Purchase Date (if such Stock
Purchase Contract is a Series E Stock Purchase Contract),
then the Applicable Cash Merger Early Settlement Rate for such
Stock Purchase Contract will be the Settlement Rate, calculated
as described above under Settlement at Each
Stock Purchase Date;
(2) if the Applicable Price of the Cash Merger is between
two prices listed in the applicable table above in the row
immediately below the title Applicable Price, or if
the Cash Merger Effective Date of the Cash Merger is between two
dates listed in the applicable table above under the column
titled Cash Merger Effective Date, then the
Applicable Cash Merger Early Settlement Rate for the applicable
Stock Purchase Contract will be determined by linear
interpolation between the settlement rates set forth for such
two prices, or for such two dates based on a 365- or
366-day
year, as applicable;
(3) if the Applicable Price of the Cash Merger is equal to
or greater than the highest price (as adjusted as described
below) listed in the applicable table above in the row
immediately below the title Applicable Price, then
the Applicable Cash Merger Early Settlement Rate for the
applicable Stock Purchase Contract is the Minimum Settlement
Rate;
(4) if the Applicable Price of the Cash Merger is equal to
or less than the lowest price (as adjusted as described below)
listed in the applicable table above in the row immediately
below the title Applicable Price, then the
Applicable Cash Merger Early Settlement Rate for the applicable
Stock Purchase Contract will be the Maximum Settlement
Rate; and
(5) if an event occurs that requires an adjustment to the
Fixed Settlement Rates, then, on the date and at the time such
adjustment is so required to be made, (A) each price set
forth in the tables above in the row immediately below the title
Applicable Price will be deemed to be adjusted so
that such price, at and after such time, will be equal to the
product of (1) such price as in effect immediately before
such adjustment to such price and (2) a fraction whose
numerator is the Maximum Settlement Rate in effect immediately
before such adjustment to the Fixed Settlement Rates and whose
denominator is the Maximum Settlement Rate to be in effect
immediately after such adjustment to the Fixed Settlement Rates;
and (B) each settlement rate set forth in the tables above
will be deemed to be adjusted so that such settlement rate, at
and after such time, will be equal to the product of
(1) such settlement rate as in effect immediately before
such adjustment to such settlement rate and (2) a fraction
whose numerator is the Maximum Settlement Rate to be in effect
immediately after such adjustment to the Fixed Settlement Rates
and whose denominator is the Maximum Settlement Rate in effect
immediately before such adjustment to the Fixed Settlement Rates.
Effect of
Reorganization Events
If there occurs any Reorganization Event (as defined below)
pursuant to which the Common Stock is converted into or
exchanged for, or constitutes solely the right to receive, cash,
securities or other property, then, at and after the effective
time of such Reorganization Event, the obligation of MetLife,
Inc. to deliver, and the obligation of each holder to purchase,
each share of Common Stock upon settlement of each Stock
Purchase Contract on each Stock Purchase Date will be changed to
the obligation of MetLife, Inc. to deliver, and the obligation
of each holder to purchase, the kind and amount of cash,
securities or other property (collectively, Reference
Property) (without any interest thereon, and without
any right to dividends or distributions thereon which have a
record date that is prior to the applicable Stock Purchase Date)
receivable pursuant to such Reorganization Event by a
Representative Holder (as defined below). After such
Reorganization Event, the Applicable Market Value will be
measured based on the value of a unit of Reference Property (a
Reference Property Unit) receivable pursuant
to such Reorganization Event by a Representative Holder of one
share of Common Stock. Following a Reorganization Event,
references to the purchase or delivery of shares of Common Stock
pursuant to Stock Purchase Contracts will be construed to be
references to the purchase or delivery of Reference Property,
and references to the purchase or delivery of a specified number
of shares of Common Stock upon settlement of the Stock Purchase
Contracts will be construed to be references to the purchase and
delivery of the same number of Reference Property Units.
S-96
A Reorganization Event means (A) any
consolidation or merger of MetLife, Inc. with or into another
person; (B) any sale, transfer, lease or conveyance to
another person of the property of MetLife, Inc. as an entirety
or substantially as an entirety; (C) any statutory exchange
of securities of MetLife, Inc. with another person or any
binding share exchange which reclassifies or changes its
outstanding Common Stock (other than a change in par value, or
from par value to no par value, or from no par value to par
value, or a reorganization effected solely to change MetLife,
Inc.s jurisdiction of organization); or (D) any
liquidation, dissolution or winding up of MetLife, Inc., other
than as a result of or after the occurrence of a Termination
Event (as defined below).
A Representative Holder in relation to a
Reorganization Event means a holder of one share of Common Stock
who (A) is not a person with which MetLife, Inc.
consolidated or into which MetLife, Inc. merged or which merged
into MetLife, Inc. or to which such sale, transfer, lease or
conveyance was made, as the case may be, in such Reorganization
Event (any such person, a Constituent
Person), or an affiliate of a Constituent Person, to
the extent such Reorganization Event provides for different
treatment of Common Stock held by affiliates of MetLife, Inc.
and non-affiliates, and (B) failed to exercise his or her
rights of election, if any, as to the kind or amount of
Reference Property (provided that if the kind or amount
of Reference Property is not the same for each share of Common
Stock held by a person (other than a Constituent Person or an
affiliate thereof) who has not exercised such rights of election
(Non-Electing Share), then the kind and
amount of Reference Property in respect of each Non-Electing
Share is deemed to be the weighted average of the kinds and
amounts of Reference Property receivable per share of Common
Stock pursuant to such Reorganization Event in respect of all
Non-Electing Shares).
Termination Event means the occurrence of any
of the following events:
(i) at any time on or prior to the Third Stock Purchase
Date, a judgment, decree or order of a court has been entered
granting relief under the U.S. Bankruptcy Code or any other
similar applicable federal or state law, adjudicating MetLife,
Inc. to be insolvent, or approving as properly filed a petition
seeking reorganization or liquidation of MetLife, Inc., and, if
such judgment, decree or order has been entered more than
60 days prior to the Third Stock Purchase Date, such
judgment, decree or order has continued undischarged and
unstayed for a period of 60 days;
(ii) at any time on or prior to the Third Stock Purchase
Date, a judgment, decree or order of a court for the appointment
of a receiver or liquidator or trustee or assignee in bankruptcy
or insolvency of MetLife, Inc. or of its property, or for the
termination or liquidation of its affairs, has been entered,
and, if such judgment, decree or order has been entered more
than 60 days prior to the Third Stock Purchase Date, such
judgment, decree or order has continued undischarged and
unstayed for a period of 60 days; or
(iii) at any time on or prior to the Third Stock Purchase
Date, MetLife, Inc. files a petition for relief under the
U.S. Bankruptcy Code, or shall consent to the filing of a
bankruptcy proceeding against it, or files a petition or answer
or consent seeking reorganization or liquidation under the
U.S. Bankruptcy Code or any other similar applicable
federal or state law, or shall consent to the filing of any such
petition, or consents to the appointment of a receiver or
liquidator or trustee or assignee in bankruptcy or insolvency of
it or of its property, or makes an assignment for the benefit of
creditors, or admits in writing its inability to pay its debts
generally as they become due.
Adjustment
to the Fixed Settlement Rates
Each of the Fixed Settlement Rates will be subject to customary
anti-dilution adjustments, without duplication, for the
following events:
Adjustments
for Dividends, Distributions, Stock Splits
Adjustment
for Change in Capital Stock
If MetLife, Inc. (A) pays a dividend or makes another
distribution on Common Stock to all holders of Common Stock
payable exclusively in shares of Common Stock;
(B) subdivides or splits the outstanding shares of Common
Stock into a greater number of shares; or (C) combines the
outstanding shares of Common Stock into a smaller number of
shares, then each Fixed Settlement Rate will be adjusted by
multiplying each Fixed Settlement Rate in effect immediately
prior to such adjustment by the number of shares of Common Stock
(such number, the Adjustment Factor) which a
person who owns only one share of Common Stock immediately
before the record
S-97
date or effective date, as applicable, of such stock dividend,
stock distribution, subdivision, split or combination and who is
entitled to participate in such stock dividend, stock
distribution, subdivision, split or combination would own
immediately after giving effect to such stock dividend, stock
distribution, subdivision, split or combination (without giving
effect to any arrangement pursuant to such stock dividend, stock
distribution, subdivision, split or combination not to issue
fractional shares of Common Stock). Such adjustment will become
effective immediately after such record date, in the case of a
stock dividend or stock distribution, and will become effective
at the open of business on such effective date, in the case of a
subdivision, split or combination.
Adjustment
for Rights Issue
If MetLife, Inc. distributes any rights, options or warrants
(other than pursuant to any dividend reinvestment, share
purchase or similar plans) to all holders of Common Stock,
entitling them to purchase or subscribe for, for a period
expiring within 60 days from the date of issuance of such
rights, options or warrants, shares of Common Stock at a price
per share less than the average of the VWAPs per share of Common
Stock on each Trading Day during the 10 consecutive Trading Days
ending on, and including, the Trading Day immediately preceding
the date MetLife, Inc. initially publicly announces such
distribution, then each Fixed Settlement Rate will be adjusted
by multiplying each Fixed Settlement Rate in effect immediately
prior to such adjustment by a fraction:
(i) the numerator of which is the sum of (1) the
number of shares of Common Stock outstanding on the record date
for such distribution and (2) the total number of
additional shares of Common Stock (the Underlying
Shares) underlying such rights, options or
warrants; and
(ii) the denominator of which is the sum of (1) the
number of shares of Common Stock outstanding on such record date
and (2) a fraction (x) the numerator of which is the
aggregate exercise, conversion, exchange or other price at which
the Underlying Shares may be subscribed for or purchased
pursuant to such rights, options or warrants and (y) the
denominator of which is the average of the VWAPs per share of
Common Stock on each Trading Day during the ten
(10) consecutive Trading Days ending on, and including, the
Trading Day immediately preceding the date the Company initially
publicly announces such distribution.
Such adjustment will become effective immediately after such
record date. To the extent that such rights, options or warrants
are not exercised prior to their expiration (and, as a result,
no additional shares of Common Stock are delivered or issued
pursuant to such rights or warrants), the Fixed Settlement Rates
will be readjusted to the Fixed Settlement Rates that would then
be in effect had the adjustments made upon the issuance of such
rights, options or warrants been made on the basis of delivery
or issuance of only the number of shares of Common Stock
actually delivered or issued.
In determining whether any rights, options or warrants entitle
the holders thereof to purchase or subscribe for shares of
Common Stock at a price per share less than such average VWAP
per share of Common Stock, and in determining the aggregate
exercise, conversion, exchange or other price at which the
Underlying Shares may be subscribed for or purchased pursuant to
such rights, options or warrants, there will be taken into
account any consideration received by MetLife, Inc. for such
rights, options or warrants and any amount payable upon
exercise, conversion or exchange thereof, with the value of such
consideration, if other than cash, to be determined in good
faith by MetLife, Inc.s Board of Directors.
Adjustments
for Other Distributions
If MetLife, Inc. dividends or distributes to all or
substantially all holders of its Common Stock any of its debt,
capital stock, securities or assets or any rights, warrants or
options to purchase securities of MetLife, Inc. (including
securities or cash, but excluding dividends or distributions
relating to a change in capital stock, rights issues or cash
dividends and distributions), then each Fixed Settlement Rate
will be adjusted, subject to the provisions of the last
paragraph of this section, by multiplying each Fixed Settlement
Rate in effect immediately prior to such adjustment by a
fraction:
(i) the numerator of which is the Current Market Price (as
defined in the Stock Purchase Contract Agreement) per share of
Common Stock on the record date for such dividend or
distribution; and
S-98
(ii) the denominator of which is such Current Market Price
per share of Common Stock minus the fair market value (as
determined in good faith by MetLife, Inc.s Board of
Directors) of the portion of such debt, capital stock,
securities, assets, rights, warrants or options dividended or
distributed in respect of each share of Common Stock.
Such adjustment will become effective immediately after such
record date. Notwithstanding anything to the contrary in the
preceding paragraph, in no event will any adjustment be made,
pursuant to the immediately preceding paragraph, to any Fixed
Settlement Rate to the extent, and only to the extent, such
adjustment will cause such Fixed Settlement Rate to be negative
or an amount that is greater than a fraction whose numerator is
$25.00 and whose denominator is the par value per share of
Common Stock.
Notwithstanding the preceding two paragraphs, if MetLife, Inc.
dividends or distributes to all or substantially all holders of
its Common Stock any shares of capital stock of any class or
series, or similar equity interests, of or relating to a
subsidiary or other business unit of MetLife, Inc. (a
Spin-off), then, in lieu of the foregoing
adjustment, each Fixed Settlement Rate will be adjusted by
multiplying each Fixed Settlement Rate in effect immediately
prior to such adjustment by a fraction:
(i) the numerator of which is the sum of (A) the
average of the VWAPs of such shares or equity interests
distributed to holders of Common Stock applicable to one share
of Common Stock (determined, for purposes of the definition of
VWAP, as if such shares or equity interests were
Common Stock) on each Trading Day in the 10 consecutive Trading
Day period (the Spin-off Valuation Period)
beginning on, and including, the 3rd Trading Day after the
effective date of such Spin-off; and (B) the average of the
VWAPs per share of Common Stock on each Trading Day in such
Spin-off Valuation Period; and
(ii) the denominator of which is the average of the VWAPs
per share of Common Stock on each Trading Day in such Spin-off
Valuation Period.
Each adjustment pursuant to the immediately preceding paragraph
will become effective immediately after the close of business on
the last Trading Day of the applicable Spin-off Valuation
Period; provided, however, that if a Stock
Purchase Date occurs during such Spin-off Valuation Period, then
references to 10 Trading Days in the immediately preceding
paragraph will be deemed, for purposes of determining the
Settlement Rate applicable to the Stock Purchase Contracts
relating to such Stock Purchase Date, to be replaced with such
lesser number of Trading Days as have elapsed from, and
including, the 3rd Trading Day after the effective date of
such Spin-off to, and including, such Stock Purchase Date.
Cash
Dividends and Distributions
If MetLife, Inc., by dividend or otherwise, pays regular annual
cash dividends, or makes any other distributions consisting
exclusively of cash, to all holders of Common Stock (excluding
any regular annual cash dividend or distribution on the Common
Stock to the extent that the aggregate cash dividend or
distribution per share of Common Stock in any fiscal year does
not exceed the Dividend Threshold Amount (as defined below))
then each Fixed Settlement Rate will be adjusted as follows:
(i) in the event of a regular annual cash dividend, each
Fixed Settlement Rate will be adjusted by multiplying each Fixed
Settlement Rate in effect immediately prior to such adjustment
by a fraction, (A) the numerator of which is the Current
Market Price per share of Common Stock on the record date of
such dividend, and (B) the denominator of which is such
Current Market Price per share of Common Stock, minus the
excess, if any, of the cash amount per share of such dividend
over the Dividend Threshold Amount; and
(ii) in the event of a cash dividend or distribution that
is not a regular annual cash dividend, each Fixed Settlement
Rates will be adjusted by multiplying each Fixed Settlement Rate
in effect immediately prior to such adjustment by a fraction,
(A) the numerator of which is the Current Market Price per
share of Common Stock on the record date of such dividend or
distribution, and (B) the denominator of which is such
Current Market Price per share of Common Stock minus the cash
amount per share of such dividend or distribution.
In either case, the adjustment will become effective immediately
after the Ex Date (as defined below) for such dividend or
distribution. In the event that any such dividend or
distribution is not so paid or made, each Fixed
S-99
Settlement Rate will again be adjusted to be the Fixed
Settlement Rates that would then be in effect if such dividend
or distribution had not been declared. Notwithstanding anything
to the contrary in this section in no event will any adjustment
be made, pursuant to this section, to any Fixed Settlement Rate
to the extent, and only to the extent, such adjustment will
cause such Fixed Settlement Rate to be negative or an amount
that is greater than a fraction whose numerator is $25.00 and
whose denominator is the par value per share of Common Stock.
Adjustment
for Company Tender Offer
If (A) MetLife, Inc. or any of its subsidiaries pay cash or
other consideration to holders of Common Stock in respect of a
tender or exchange offer (other than an odd-lot offer) by
MetLife, Inc. or any of its subsidiaries for Common Stock; and
(B) the sum of the aggregate amount of such cash paid and
the aggregate fair market value (as determined in good faith by
MetLife, Inc.s Board of Directors), as of the Tender Offer
Expiration Time (as defined below), of such other consideration
paid (such sum, the Aggregate Amount)
expressed as an amount per share of Common Stock validly
tendered or exchanged, and not withdrawn, pursuant to such
tender or exchange offer as of the Tender Offer Expiration Time
(such tendered or exchanged shares of Common Stock, the
Purchased Shares) exceeds the VWAP per share
of Common Stock on the first Trading Day after the last date
(such last date, the Tender Offer Expiration
Date) on which tenders or exchanges could have been
made pursuant to such tender or exchange offer (as the same may
be amended through the Tender Offer Expiration Date), then each
Fixed Settlement Rate will be adjusted by multiplying each Fixed
Settlement Rate in effect immediately prior to such adjustment
by a fraction:
(i) the numerator of which is equal to the sum of
(I) the Aggregate Amount and (II) the product of
(a) the average of the VWAPs per share of Common Stock on
each Trading Day in the 10 consecutive Trading Day period (the
Offer Valuation Period) commencing on, and
including, the Trading Day immediately after Tender Offer
Expiration Date and (b) an amount equal to (i) the
number of shares of Common Stock outstanding as of the last time
(the Tender Offer Expiration Time) at which
tenders or exchanges could have been made pursuant to such
tender or exchange offer (including all Purchased Shares) less
(ii) the Purchased Shares; and
(ii) the denominator of which is equal to the product of
(I) the number of shares of Common Stock outstanding as of
the Tender Offer Expiration Time (including all Purchased
Shares) and (II) such average VWAP per share of Common
Stock.
Such adjustment will become effective immediately after the
close of business on the last Trading Day of the applicable
Offer Valuation Period; provided, however, that if
any Stock Purchase Date occurs during the Offer Valuation
Period, then references to the 10 Trading Days in
clause (i) above will be deemed, for purposes of
determining the Settlement Rate applicable to the Stock Purchase
Contracts relating to such Stock Purchase Date, replaced with
such lesser number of Trading Days as have elapsed from, and
including, the Trading Day immediately after the Tender Offer
Expiration Date to, and including, any such Stock Purchase Date.
Notwithstanding anything to the contrary above, if MetLife, Inc.
or any of its subsidiaries is obligated to purchase shares of
Common Stock pursuant to any such tender or exchange offer, but
MetLife, Inc. or such subsidiary is permanently prevented by
applicable law from effecting any such purchases, or all such
purchases are rescinded, then each Fixed Settlement Rate will
again be adjusted to be the Fixed Settlement Rate which would
then be in effect if such tender or exchange offer had not been
made.
Calculation
of Adjustments
All adjustments to the Fixed Settlement Rates will be calculated
by MetLife, Inc. to the nearest one-ten-thousandth (1/10,000th)
of one share of Common Stock (or if there is not a nearest
one-ten-thousandth (1/10,000th) of a share, to the next lower
one-ten-thousandth (1/10,000th) of a share). No adjustment to
the Settlement Rate will be required unless such adjustment
would require an increase or a decrease of at least 1%;
provided, however, that each adjustment not made
will be carried forward and taken into account in any subsequent
adjustment, and all such adjustments not made will be made on
each Stock Purchase Date, Cash Merger Early Settlement Date or
Early Settlement Date.
S-100
Adjustments
to the Reference Price and Threshold Appreciation
Price
If any adjustment is made to the Fixed Settlement Rates in
accordance with the terms of the Stock Purchase Contract
Agreement, then, at the time such adjustment becomes effective,
each of the Reference Price and the Threshold Appreciation Price
will be adjusted to an amount equal to the product of
(1) Reference Price or Threshold Appreciation Price, as
applicable, as in effect immediately before such adjustment to
such price and (2) a fraction whose numerator is the
Maximum Settlement Rate in effect immediately before such
adjustment to the Fixed Settlement Rates and whose denominator
is the Maximum Settlement Rate to be in effect immediately after
such adjustment to the Fixed Settlement Rates.
When No
Adjustment Required
Notwithstanding anything in the Stock Purchase Contract
Agreement to the contrary, no adjustment of the Fixed Settlement
Rates, and the number of shares to be delivered on Early
Settlement need be made as a result of: (1) the issuance of
rights pursuant to MetLife, Inc.s stockholder rights plan
existing on the date of the Stock Purchase Contract Agreement,
as such plan may be amended, modified, or supplemented from time
to time, or any newly adopted stockholder rights plans;
(2) the distribution of separate certificates representing
such rights; (3) the exercise or redemption of such rights
in accordance with such rights plan(s); or (4) the
termination or invalidation of such rights; provided,
however, that to the extent that MetLife, Inc. has a
stockholder rights plan in effect upon settlement of a Stock
Purchase Contract (including MetLife, Inc.s rights plan
existing on the date of the Stock Purchase Contract Agreement),
you will receive, in addition to the shares of Common Stock
deliverable upon such settlement, the rights under such rights
plan, unless, prior to such settlement, the rights have
separated from the Common Stock, in which case the Fixed
Settlement Rates will be adjusted, as described above under
Adjustment for Rights Issue, at the time
of separation as if MetLife, Inc. made a distribution, to all
holders of Common Stock, that is subject to the issuance of such
rights, subject to readjustment in the event of the expiration,
termination or redemption of such rights. In addition,
notwithstanding anything in the Stock Purchase Contract
Agreement to the contrary, no adjustment to the Fixed Settlement
Rates need be made:
(i) upon the issuance of any shares of Common Stock
pursuant to any present or future plan providing for the
reinvestment of dividends or interest payable on securities of
MetLife, Inc. and the investment of additional optional amounts
in Common Stock under any plan;
(ii) upon the issuance of any shares of Common Stock or
options or rights to purchase those shares pursuant to any
present or future employee, director or consultant benefit plan
or program of or assumed by MetLife, Inc. or any of its
subsidiaries;
(iii) upon the issuance of any shares of Common Stock
pursuant to any option, warrant, right, or exercisable,
exchangeable or convertible security outstanding as of the date
the Common Equity Units are first issued; or
(iv) for a change in the par value (including causing the
Common Stock to have no par value).
Notwithstanding anything in the Stock Purchase Agreement to the
contrary, no adjustment to the Fixed Settlement Rates need be
made for a transaction as described above under
Adjustment for Change in Capital Stock,
Adjustment for Rights Issue,
Adjustments for Other Distributions,
Cash Dividends and Distributions, or
Adjustment for Company Tender Offer if
you may participate in the transaction on a basis and with
notice that MetLife, Inc.s Board of Directors determines
to be fair and appropriate in light of the basis and notice on
which holders of Common Stock participate in the transaction.
Adjustments
to VWAP to Account for Stock Dividends, Splits, Combinations or
Subdivisions or Similar Events
If, in accordance with the provisions of the Stock Purchase
Contract Agreement, an average VWAP is to be measured over a
period of multiple Trading Days and a stock dividend, split,
combination or subdivision or other event requiring an
adjustment to the Fixed Settlement Rates as described above
under Adjustment for Change in Capital
Stock occurs, or becomes effective, at any time during
such period, then, for purposes of calculating such average, the
VWAP per share on each Trading Day in such period prior to such
occurrence or effectiveness will be
S-101
multiplied by the reciprocal of the Adjustment Factor applicable
to such stock dividend, split, combination or subdivision or
other event.
Adjustment
for Consolidation, Merger or Other Reorganization
Event
If, after the date of the Stock Purchase Contract Agreement,
(1) there occurs a Reorganization Event; and
(2) pursuant to such Reorganization Event, the Common Stock
is converted into or exchanged for, or constitutes solely the
right to receive, cash, securities or other property, then, at
and after the effective time of such Reorganization Event, the
obligation of MetLife, Inc. to deliver, and the obligation of
each holder to purchase, each share of Common Stock upon
settlement of each Stock Purchase Contract on each Stock
Purchase Date will be changed to the obligation of MetLife, Inc.
to deliver, and the obligation of each holder to purchase the
Reference Property (without any interest thereon, and without
any right to dividends or distribution thereon which have a
record date that is prior to the applicable Stock Purchase Date)
receivable pursuant to such Reorganization Event by the
Representative Holder. After such Reorganization Event, the
Applicable Market Value will be measured based on the value of a
Reference Property Unit receivable pursuant to such
Reorganization Event by a Representative Holder of one share of
Common Stock. Following a Reorganization Event, references in
the Stock Purchase Contract Agreement to the purchase or
delivery of shares of Common Stock pursuant to Stock Purchase
Contracts will be construed to be references to the purchase or
delivery of Reference Property, and references to the purchase
or delivery of a specified number of shares of Common Stock upon
settlement of the Stock Purchase Contracts will be construed to
be references to the purchase and delivery of the same number of
Reference Property Units.
In the event of such a Reorganization Event, the Person formed
by such consolidation, merger or exchange or the Person which
acquires the assets of MetLife, Inc. or, in the event of a
liquidation or dissolution of MetLife, Inc., MetLife, Inc. or a
liquidating trust created in connection therewith will execute
and deliver to the Stock Purchase Contract Agent an agreement
supplemental to the Stock Purchase Contract Agreement providing
that the holder of each Outstanding Common Equity Unit will have
the rights provided by this section. Such supplemental agreement
will provide for adjustments which, for events subsequent to the
effective date of such supplemental agreement, will be as nearly
equivalent as may be practicable to the adjustments provided for
in this section. This section will similarly apply to successive
Reorganization Events.
Successive
Adjustments
After an adjustment to a Fixed Settlement Rate under these
provisions, any subsequent event requiring an adjustment under
these provisions will cause an adjustment to such Fixed
Settlement Rate as so adjusted.
Multiple
Adjustments
For the avoidance of doubt, if an event occurs that would
trigger an adjustment to a Fixed Settlement Rate pursuant to
these provisions under more than one subsection hereof, such
event, to the extent fully taken into account in a single
adjustment, will not result in multiple adjustments hereunder.
Notice of
Adjustments and Certain Other Events
Whenever a Fixed Settlement Rate is adjusted in accordance with
the Stock Purchase Contract Agreement, MetLife, Inc. will,
within 10 Business Days following the occurrence of the event
that requires such adjustment (or of MetLife, Inc. is not aware
of such occurrence, as soon as reasonably practicable after
becoming so aware) (or, in the case of a Spin-off, within 10
Business Days after the last Trading Day in the Spin-off
Valuation Period):
(i) compute the adjusted applicable Fixed Settlement Rates
in accordance with the Stock Purchase Contract Agreement and
prepare and transmit to the Stock Purchase Contract Agent an
officers certificate setting forth the Fixed Settlement
Rates, the method of calculation thereof in reasonable detail,
and the facts requiring such adjustment and upon which such
adjustment is based; and
(ii) provide a written notice to the holders of the Common
Equity Units of the occurrence of such event and a statement in
reasonable detail setting forth the method by which the
adjustment to the Fixed Settlement Rates was determined and
setting forth the adjusted Fixed Settlement Rates.
S-102
The Stock Purchase Contract Agent will not at any time be under
any duty or responsibility to any holder of Common Equity Units
to determine whether any facts exist which may require any
adjustment of the Fixed Settlement Rates or with respect to the
nature or extent or calculation of any such adjustment when
made, or with respect to the method employed in making the same.
The Stock Purchase Contract Agent will be fully authorized and
protected in relying on any officers certificate delivered
in accordance with the Stock Purchase Contract Agreement and any
adjustment contained therein, and the Stock Purchase Contract
Agent will not be deemed to have knowledge of any adjustment
unless and until it has received such certificate. The Stock
Purchase Contract Agent will not be accountable with respect to
the validity or value (or the kind or amount) of any shares of
Common Stock, or of any securities or property, which may at the
time be issued or delivered with respect to any Stock Purchase
Contract; and the Stock Purchase Contract Agent makes no
representation with respect thereto. The Stock Purchase Contract
Agent will not be responsible for any failure of MetLife, Inc.
to issue, transfer or deliver any shares of Common Stock
pursuant to a Stock Purchase Contract or to comply with any of
the duties, responsibilities or covenants of MetLife, Inc.
contained in the Stock Purchase Contract Agreement.
An Ex Date means (i) when used with
respect to any issuance or distribution, means the first date on
which the Common Stock trades the regular way on the Relevant
Exchange without the right to receive such issuance or
distribution and (ii) when used with respect to any
subdivision or combination of shares of Common Stock, means the
first date on which the Common Stock trades the regular way on
the Relevant Exchange after the time at which subdivision or
combination becomes effective.
A Dividend Threshold Amount means $0.74.
However, the Dividend Threshold Amount will be subject to
adjustment in the same manner and under the same circumstances
as the Reference Price is adjusted pursuant to the immediately
following paragraph, except that the Dividend Threshold Amount
will not be adjusted on account of any event that requires an
adjustment to the Fixed Settlement Rates pursuant to the fourth
bullet point above.
Termination
The Stock Purchase Contracts and all rights and obligations of
MetLife, Inc. and the holders thereunder, including the rights
of the holders to receive and the obligation of MetLife, Inc. to
pay any Contract Payments (including any accrued and unpaid
Contract Payments), and the rights and obligations of holders to
purchase Common Stock on each Stock Purchase Date occurring
after MetLife, Inc.s bankruptcy, insolvency or
reorganization, will immediately and automatically terminate as
a result of our bankruptcy, insolvency or reorganization. In the
event of a termination of the Stock Purchase Contracts as a
result of our bankruptcy, insolvency or reorganization, holders
of the Stock Purchase Contracts will not have a claim in
bankruptcy under the Stock Purchase Contracts with respect to
our issuance of shares of Common Stock or the right to receive
Contract Payments.
Upon any termination, the Collateral Agent will release the
Debentures or the Treasury Securities, as the case may be, held
by it to the Stock Purchase Contract Agent for distribution to
the holders. Upon any termination, however, the release and
distribution may be subject to the automatic stay under
Section 362 of the U.S. Bankruptcy Code, and claims
arising out of the Debentures like all other claims in
bankruptcy proceedings, will be subject to the equitable
jurisdiction and powers of the bankruptcy court. In the event
that we become the subject of a case under the
U.S. Bankruptcy Code, the delay may occur as a result of
the automatic stay under the U.S. Bankruptcy Code and
continue until the automatic stay has been lifted. We expect any
such delay to be limited. The automatic stay will not be lifted
until such time as the bankruptcy court agrees to lift it and
return your pledged securities to you.
If your Stock Purchase Contract is terminated as a result of our
bankruptcy, insolvency or reorganization, you will have no right
to receive any accrued Contract Payments.
S-103
CERTAIN
PROVISIONS OF THE STOCK PURCHASE CONTRACTS, THE STOCK PURCHASE
CONTRACT AGREEMENT AND THE PLEDGE AGREEMENT
This section summarizes some of the other provisions of the
Stock Purchase Contracts, the Stock Purchase Contract Agreement
and the Pledge Agreement. This summary should be read together
with those agreements, forms of which have been filed and
incorporated by reference as exhibits to the registration
statement of which this prospectus supplement and the
accompanying prospectus form a part. See Where You Can
Find More Information in this prospectus supplement and
the accompanying prospectus.
General
Except as described under Book-Entry System,
payments on the Common Equity Units will be made, the Stock
Purchase Contracts (and documents relating to the Common Equity
Units and the Stock Purchase Contracts) will be settled, and
transfers of the Common Equity Units will be registrable, at the
office of the Stock Purchase Contract Agent in the Borough of
Manhattan, New York City. In addition, if the Common Equity
Units do not remain in book-entry form, payment on the Common
Equity Units may be made, at MetLife, Inc.s option, by
check mailed to the address of the holder entitled to payment as
shown on the security register or by a wire transfer to the
account designated by the holder in a prior written notice.
Shares of Common Stock will be delivered on the applicable Stock
Purchase Date (or earlier upon early settlement) or, if the
Stock Purchase Contracts have terminated, the related pledged
Debentures or Treasury Securities, as applicable, will be
delivered at the office of the Stock Purchase Contract Agent
upon presentation and surrender of the applicable certificate.
If you fail to present and (in the case of the Third Stock
Purchase Date) surrender the certificate evidencing the Common
Equity Units to the Stock Purchase Contract Agent on or prior to
the applicable Stock Purchase Date, the shares of MetLife,
Inc.s Common Stock issuable upon settlement of the
applicable Stock Purchase Contract will be registered in the
name of the Stock Purchase Contract Agent. The shares, together
with any distributions, will be held by the Stock Purchase
Contract Agent, as agent for your benefit, until the certificate
is presented and (in the case of the Third Stock Purchase Date)
surrendered or you provide satisfactory evidence that the
certificate has been destroyed, lost or stolen, together with
any indemnity that may be required by the Stock Purchase
Contract Agent and MetLife, Inc.
If the Stock Purchase Contracts terminate prior to the
applicable Stock Purchase Date, the related pledged Debentures
or Treasury Securities, as applicable, are transferred to the
Stock Purchase Contract Agent for distribution to the holders,
and you fail to present and surrender the certificate evidencing
your Common Equity Units to the Stock Purchase Contract Agent,
the related pledged Debentures or Treasury Securities, as
applicable, delivered to the Stock Purchase Contract Agent and
payments on the pledged Debentures or Treasury Securities, as
applicable, will be held by the Stock Purchase Contract Agent as
agent for your benefit until the applicable certificate is
presented and surrendered or you provide the evidence and
indemnity described above.
The Stock Purchase Contract Agent will have no obligation to
invest or to pay interest on any amounts held by the Stock
Purchase Contract Agent pending payment to any holder.
No service charge will be made for any registration of transfer
or exchange of the Common Equity Units, except for any tax or
other governmental charge that may be imposed in connection with
a transfer or exchange.
Modification
The Stock Purchase Contract Agreement and the Pledge Agreement
contain provisions permitting MetLife, Inc., the Stock Purchase
Contract Agent or the Collateral Agent, as the case may be, to
modify the Stock Purchase Contract Agreement or the Pledge
Agreement without the consent of the holders for any of the
following purposes:
|
|
|
|
|
to evidence the succession of another person to MetLife,
Inc.s obligations;
|
|
|
|
to add to the covenants for the benefit of holders or to
surrender any of MetLife, Inc.s rights or powers under
those agreements;
|
S-104
|
|
|
|
|
to evidence and provide for the acceptance of appointment of a
successor Stock Purchase Contract Agent or a successor
Collateral Agent or Securities Intermediary;
|
|
|
|
to make provision with respect to the rights of holders pursuant
to adjustments in the Settlement Rate due to Reorganization
Events;
|
|
|
|
to cure any ambiguity, to correct or supplement any provisions
that may be inconsistent; and
|
|
|
|
to make any other provisions with respect to such matters or
questions, provided that such action will not adversely affect
the interest of the holders in any material respect.
|
The Stock Purchase Contract Agreement and the Pledge Agreement
contain provisions permitting MetLife, Inc. and the Stock
Purchase Contract Agent, and in the case of the Pledge
Agreement, the Collateral Agent, with the consent of the holders
of not less than a majority of the Stock Purchase Contracts at
the time outstanding, to modify the terms of the Stock Purchase
Contracts, the Stock Purchase Contract Agreement or the Pledge
Agreement. However, no such modification may, without the
consent of the holder of each outstanding Stock Purchase
Contract affected by the modification:
|
|
|
|
|
change any Contract Payment Date;
|
|
|
|
change the amount or type of pledged Debentures or Treasury
Securities, as applicable, related to the Stock Purchase
Contracts, impair the right of the holder of any pledged
Debentures or Treasury Securities, as applicable, to receive
distributions on the pledged Debentures or Treasury Securities,
as applicable, or otherwise adversely affect the holders
rights in or to the pledged Debentures or Treasury Securities,
as applicable;
|
|
|
|
change the place or currency of payment or reduce any Contract
Payments;
|
|
|
|
impair the right to institute suit for the enforcement of the
Stock Purchase Contract or payment of any Contract Payments;
|
|
|
|
reduce the number of shares of MetLife, Inc.s Common Stock
to be purchased under the Stock Purchase Contracts, increase the
price to purchase shares of MetLife, Inc.s Common Stock
upon settlement of the Stock Purchase Contracts, change any
Stock Purchase Date, the right to Early Settlement or the
holders Cash Merger Early Settlement right or otherwise
adversely affect the holders rights under the Stock
Purchase Contracts; or
|
|
|
|
reduce the above-stated percentage of outstanding Stock Purchase
Contracts the consent of the holders of which is required for
the modification or amendment of the provisions of the Stock
Purchase Contracts, the Stock Purchase Contract Agreement or the
Pledge Agreement.
|
If any amendment or proposal referred to above would adversely
affect only the Normal Common Equity Units or only the Stripped
Common Equity Units, then only the affected class of holders
will be entitled to vote on the amendment or proposal, and the
amendment or proposal will not be effective except with the
consent of the holders of not less than a majority of the
affected class or of all of the holders of the affected class,
as applicable.
No
Consent to Assumption
Each holder of Common Equity Units, by acceptance of these
securities, will under the terms of the Stock Purchase Contract
Agreement and the Common Equity Units, as applicable, be deemed
expressly to have withheld any consent to the assumption
(i.e., affirmance) of the Stock Purchase Contracts
by MetLife, Inc. or its trustee if MetLife, Inc. become the
subject of a case under the U.S. Bankruptcy Code or other
similar state or federal law provision for reorganization or
liquidation.
S-105
Consolidation,
Merger, Sale or Conveyance
MetLife, Inc. covenanted in the Stock Purchase Contract
Agreement that MetLife, Inc. will not merge with and into,
consolidate with or convert into any other entity or sell,
assign, transfer, lease or convey all or substantially all of
its properties and assets to any person or entity, unless:
|
|
|
|
|
either MetLife, Inc. shall be the continuing corporation, or the
successor entity (if other than MetLife, Inc.) is a corporation
organized and existing under the laws of the United States of
America or a U.S. state or the District of Columbia and
that entity expressly assumes MetLife, Inc.s obligations
under the Stock Purchase Contracts, the Stock Purchase Contract
Agreement, the Pledge Agreement, each Supplemental Indenture and
the Indenture and each applicable Remarketing Agreement; and
|
|
|
|
MetLife, Inc. or such successor entity is not, immediately after
the merger, consolidation, conversion, sale, assignment,
transfer, lease or conveyance, in default of its payment
obligations under the Stock Purchase Contracts, the Stock
Purchase Contract Agreement, the Pledge Agreement, or the
Remarketing Agreement or in material default in the performance
of any other covenants under these agreements.
|
Title
MetLife, Inc., the Stock Purchase Contract Agent and the
Collateral Agent may treat the registered owner of any Common
Equity Unit as the absolute owner of such Common Equity Unit for
the purpose of making payment and settling the Stock Purchase
Contracts and for all other purposes.
Replacement
of Common Equity Units Certificates
In the event that physical certificates have been issued, any
mutilated Common Equity Units certificate will be replaced by
MetLife, Inc. at the expense of the holder upon surrender of the
certificate to the Stock Purchase Contract Agent. Common Equity
Units certificates that become destroyed, lost or stolen will be
replaced by MetLife, Inc. at the expense of the holder upon
delivery to MetLife, Inc. and the Stock Purchase Contract Agent
of evidence of their destruction, loss or theft satisfactory to
MetLife, Inc. and the Stock Purchase Contract Agent. In the case
of a destroyed, lost or stolen Common Equity Units certificate,
an indemnity satisfactory to the Stock Purchase Contract Agent
and MetLife, Inc. may be required at the expense of the holder
of the Common Equity Units evidenced by the certificate before a
replacement will be issued.
Notwithstanding the foregoing, MetLife, Inc. will not be
obligated to issue any certificates representing Common Equity
Units on or after the Business Day immediately preceding the
Third Stock Purchase Date (or after Early Settlement) or after
the Stock Purchase Contracts have terminated. The Stock Purchase
Contract Agreement provides that, in lieu of the delivery of a
replacement Common Equity Units certificate following the Third
Stock Purchase Date, the Stock Purchase Contract Agent, upon
delivery of the evidence and indemnity described above, will
deliver the shares of Common Stock issuable pursuant to the
Stock Purchase Contracts included in the Common Equity Units
evidenced by the certificate or, if the Stock Purchase Contracts
have terminated prior to the Third Stock Purchase Date, transfer
the pledged Debentures or Treasury Securities, as applicable,
included in the Common Equity Units evidenced by the certificate.
Governing
Law
The Stock Purchase Contract Agreement, the Pledge Agreement and
the Stock Purchase Contracts are governed by, and construed in
accordance with, the laws of the State of New York.
Information
Concerning the Stock Purchase Contract Agent
Deutsche Bank Trust Company Americas is currently the Stock
Purchase Contract Agent. The Stock Purchase Contract Agent acts
as the agent for the holders of the Common Equity Units from
time to time. The Stock Purchase Contract Agreement will not
obligate the Stock Purchase Contract Agent to exercise any
discretionary actions in connection with a default under the
terms of the Common Equity Units or the Stock Purchase Contract
Agreement.
S-106
The Stock Purchase Contract Agreement contains provisions
limiting the liability of the Stock Purchase Contract Agent. The
Stock Purchase Contract Agreement contains provisions under
which the Stock Purchase Contract Agent may resign or be
replaced. Any such resignation or replacement would be effective
upon the acceptance of appointment by a successor.
Deutsche Bank Trust Company Americas and its affiliates are
among a number of financial institutions with which MetLife,
Inc. and its subsidiaries maintain ordinary banking and trust
relationships.
Information
Concerning the Collateral Agent
Deutsche Bank Trust Company Americas serves as the
Collateral Agent and Securities Intermediary for each series of
Debentures. The Collateral Agent acts solely as MetLife,
Inc.s agent and does not assume any obligation or
relationship of agency or trust for or with any of the holders
of the Common Equity Units except for the obligations owed by a
pledgee of property to the owner of the property under the
Pledge Agreement and applicable law.
The Pledge Agreement contains provisions limiting the liability
of the Collateral Agent. The Pledge Agreement contains
provisions under which the Collateral Agent may resign or be
replaced. Any such or replacement would be effective upon the
acceptance of appointment by a successor.
Miscellaneous
Should you elect to substitute the related pledged Debentures
and Treasury Securities, as applicable, to create Stripped
Common Equity Units or recreate Normal Common Equity Units, you
will be responsible for any fees or expenses payable in
connection with that substitution, as well as any commissions,
fees or other expenses incurred in acquiring the pledged
Debentures and Treasury Securities, as applicable, to be
substituted, and MetLife, Inc. will not be responsible for any
of those fees or expenses.
S-107
DESCRIPTION
OF THE DEBENTURES
A description of the specific terms of the Debentures forming
part of the Common Equity Units is set forth below. The
description is qualified in its entirety by reference to the
Indenture, dated as of November 9, 2001 (the
Indenture), between MetLife, Inc. and The Bank of
New York Mellon Trust Company, N.A. (as successor in
interest to J.P. Morgan Trust Company, National
Association (as successor in interest to Bank One
Trust Company, N.A.)), as trustee (the
Trustee), as supplemented by (i) the Twentieth
Supplemental Indenture, dated as of November 1, 2010, with
respect to the Series C Senior Debentures due 2023 (the
Series C Debentures), (ii) the
Twenty-First Supplemental Indenture, dated as of
November 1, 2010, with respect to the Series D Senior
Debentures due 2024 (the Series D Debentures),
and (iii) the Twenty-Second Supplemental Indenture, dated
as of November 1, 2010, with respect to the Series E
Senior Debentures due 2045 (the Series E
Debentures, and collectively with the Series C
Debentures and the Series D Debentures, the
Debentures), between MetLife, Inc. and the Trustee,
under which the Debentures have been issued. The Indenture has
been qualified as an indenture under the Trust Indenture
Act. The terms of the Debentures are those provided in the
Indenture as supplemented by the applicable supplemental
indenture, and those made part of the Indenture by the
Trust Indenture Act. MetLife, Inc. has filed a copy of the
Indenture with the SEC under the Exchange Act, and the Indenture
is incorporated by reference as an exhibit to the registration
statement of which this prospectus supplement forms a part.
The following description of the particular terms of the
Debentures supplements the description of the general terms and
provisions of such securities set forth under Description
of Debt Securities beginning on page 6 in the
accompanying prospectus. This summary contains a description of
all of the material terms of the Debentures but is not
necessarily complete. To the extent that the following
description is not consistent with the description contained in
the accompanying prospectus, you should rely on the following
description.
Certain
Terms of the Debentures
The Debentures consist of senior debt securities, as described
in the accompanying prospectus, divided into three series.
MetLife, Inc. issued the Debentures under the Indenture, as
supplemented by the Twentieth Supplemental Indenture, the
Twenty-First Supplemental Indenture and the Twenty-Second
Supplemental Indenture. The Series C Debentures, the
Series D Debentures and the Series E Debentures were
each issued with an initial aggregate principal amount of
$1,000,000,000. There is no limit on the aggregate principal
amount of each series of the Debentures that MetLife, Inc. may
issue. The Series C Debentures and the Series E
Debentures are denominated only in principal amounts equal to an
integral multiple of $2,000 and following a bifurcation of
either such series, as described below under
Bifurcation, Component Debentures (as
defined below) of either such series may be denominated only in
principal amounts equal to an integral multiple of $1,000. The
Series D Debentures may be denominated only in principal
amounts equal to an integral multiple of $1,000.
None of the Debentures will be entitled to any sinking fund.
Each series of Debentures and each supplemental indenture and
the Indenture are governed by, and construed in accordance with,
the laws of the State of New York.
Business Day means any day other than a
Saturday, Sunday or other day on which banking institutions in
New York, New York are authorized or required by law or
executive order to remain closed.
Interest
Interest will initially accrue on the principal amount of the
Series C Debentures at a rate per annum equal to 1.564%.
Interest will initially accrue on the principal amount of the
Series D Debentures at a rate per annum equal to 1.923%.
Interest will initially accrue on the principal amount of the
Series E Debentures at a rate per annum equal to 2.463%.
The interest rate on each series of Debentures will be reset in
connection with a successful Remarketing of that series of
Debentures, as described below under
Remarketing.
Interest on the Debentures will be payable quarterly in arrears
on March 15, June 15, September 15 and December 15 of
each year (each such date, an Interest Payment
Date). Interest that is due on any Debentures on any
March 15, June 15, September 15, or December 15
will be paid to the person who is the holder of such Debentures
as of the close of business on the immediately preceding March
1, June 1, September 1 or December 1,
S-108
respectively (whether or not such date is a Business Day).
Interest on the Debentures will accrue on the principal amount
of such Debentures from, and including, the most recent date to
which interest has been paid or provided for to, but excluding,
the next Interest Payment Date or the stated maturity date of
the principal of such Debenture, as the case may be. Interest
will be computed on the basis of a
360-day year
of twelve
30-day
months. For the avoidance of doubt, the interest payment that is
scheduled to be made on March 15, 2011 will be paid to the
Selling Securityholder as holder of record on March 1,
2011. If you purchase Common Equity Units pursuant to this
offering interest payments attributable to your ownership
interests in the Debentures will accrue from, and including,
March 15, 2011.
Maturity
As described below under Bifurcation, on
the Series C Bifurcation Date, the Series C Debentures
will automatically bifurcate into two tranches, the First
Series C Tranche Debentures and the Second
Series C Tranche Debentures. The First Series C
Tranche Debentures will mature on June 15, 2018,
unless there is a successful Remarketing or a Final Failed
Remarketing (as defined below), in which case the First
Series C Tranche Debentures will mature on the date
that is the 21st Interest Payment Date immediately
following the First Stock Purchase Date. The Second
Series C Tranche Debentures will mature on
June 15, 2023, unless there is a successful Remarketing or
a Final Failed Remarketing, in which case the Second
Series C Tranche Debentures will mature on the date
that is the 41st Interest Payment Date immediately
following the First Stock Purchase Date.
The Series D Debentures will mature on the date that is the
41st Interest Payment Date immediately following the Second
Stock Purchase Date.
As described below under Bifurcation, on
the Series E Bifurcation Date, the Series E Debentures
will automatically bifurcate into two tranches, the First
Series E Tranche Debentures and the Second
Series E Tranche Debentures. The First Series E
Tranche Debentures will mature on June 15, 2018,
unless there is a successful Remarketing or a Final Failed
Remarketing, in which case the First Series E
Tranche Debentures will mature on the date that is the
13th Interest Payment Date immediately following the Third
Stock Purchase Date. The Second Series E
Tranche Debentures will mature on June 15, 2045,
unless there is a successful Remarketing or a Final Failed
Remarketing, in which case the Second Series E
Tranche Debentures will mature on the date that is the
121st Interest Payment Date immediately following the Third
Stock Purchase Date.
Further
Issues
MetLife, Inc. may, from time to time and without the consent of
the holders of Debentures, create further securities having the
same terms and conditions as any series of the Debentures in all
respects (or in all respects except for the issue date, the date
of the first payment of interest thereon, the issue price or the
initial interest accrual date), so that such further issue will
be consolidated and form a single series with the outstanding
Debentures of such series, provided that such further securities
are fungible with the outstanding Debentures of such series for
United States federal income tax purposes.
Bifurcation
On the Interest Payment Date occurring on or immediately
preceding the Initial Scheduled First Stock Purchase Date (such
Interest Payment Date, the Series C Debenture
Bifurcation Date), the Series C Debentures will
automatically convert, without any act of any holder, into units
(each, a Series C Debenture Unit)
consisting of two tranches, with each $2,000 principal amount of
Series C Debentures thereafter consisting of $1,000
principal amount of a first tranche debenture (the
First Series C Tranche Debentures)
and $1,000 principal amount of a second tranche debenture (the
Second Series C Tranche Debentures,
and, together with the First Series C
Tranche Debentures, the Series C Component
Debentures). On the Interest Payment Date occurring on
or immediately preceding the Initial Third Stock Purchase Date
(as defined below) (such Interest Payment Date, the
Series E Debenture Bifurcation Date,
and, together with the Series C Debenture Bifurcation Date,
the Bifurcation Dates), the Series E
Debentures will automatically convert, without any act of any
holder, into units (each, a Series E Debenture
Unit, and, together with the Series C Debenture
Units, the Debenture Units) consisting of two
tranches, with each $2,000 principal amount of Series E
Debentures thereafter consisting of $1,000 principal amount of a
first tranche debenture (the First Series E
Tranche Debentures) and $1,000
S-109
principal amount of a second tranche debenture (the
Second Series E Tranche Debentures,
and, together with the First Series E
Tranche Debentures, the Series E Component
Debentures). The Series C Component Debentures
and the Series E Component Debentures are collectively
referred to as Component Debentures. For
purposes hereof, the term Debentures includes
Component Debentures after the applicable
Bifurcation Date.
Initial Third Stock Purchase Date means the
later of (1) the date that is six calendar months after the
Second Stock Purchase Date; and (2) the Initial Scheduled
Third Stock Purchase Date (as defined in the Stock Purchase
Contract Agreement).
The terms of each Component Debenture for the Series C
Debentures and the Series E Debentures will be identical to
the terms of the applicable predecessor Debentures with the
following exceptions:
|
|
|
|
|
In connection with a successful Remarketing, the interest rate
of each tranche of Component Debentures need not, but may, be
equal to each other.
|
|
|
|
Each tranche has different stated maturity dates, as described
above under Maturity.
|
|
|
|
The holder of a Debenture Unit that consists of Component
Debentures will be deemed to be the holder of such Component
Debentures.
|
|
|
|
No Component Debenture will be separated from the Debenture Unit
of which such Component Debenture forms a part, except pursuant
to a redemption or Remarketing, and a Component Debenture can be
separated from the Debenture Unit of which such Component
Debenture forms part only in integral multiples of $1,000 in
principal amount of such Component Debenture.
|
Remarketing
At least 30 days before each Stock Purchase Date, MetLife,
Inc. will appoint a nationally recognized investment banking
firm as the remarketing agent (the Remarketing
Agent) that will attempt to resell Debentures of the
applicable series corresponding to such Stock Purchase Date in
remarketings (each, a Remarketing), unless
you elect not to participate in such Remarketings. If you hold
the Debentures separately and not as part of Common Equity
Units, you may elect to participate in a Remarketing as
described below under Optional Remarketing of
the Debentures Not Included in Normal Common Equity Units.
MetLife, Inc. may appoint different Remarketing Agents for
Remarketings for different Stock Purchase Dates. In the case of
the Series C Debentures and the Series D Debentures,
the settlement date for each Remarketing will occur after the
applicable Bifurcation Date, and each tranche of Component
Debentures will be separately remarketed.
In each Remarketing, the Remarketing Agent will use its
commercially reasonable efforts to obtain a cash price for the
relevant series of Debentures or Component Debentures to be
remarketed which results in gross proceeds equal to the sum of
(i) the fee to be paid to the Remarketing Agent, as agreed
between the Remarketing Agent and MetLife, Inc. (the
Remarketing Fee); (ii) 100% of the
aggregate principal amount of all Debentures or Component
Debentures to be remarketed; (iii) the Interest Make-Whole
(as defined below) for such Debentures or Component Debentures;
and (iv) the product of five basis points and the aggregate
principal amount of such Debentures or Component Debentures (the
Success Fee). To obtain that price, the
Remarketing Agent may reset the interest rate (the
Reset Rate) on the Debentures as described
below. If the Remarketing is successful, the Reset Rate will
apply to all outstanding Debentures of the series, whether or
not the holders of such Debentures participated in the
Remarketing, and will become effective on the settlement date of
such Remarketing. A Remarketing will generally be deemed to be
successful if it actually settles during the period
specified below and it generates the gross proceeds specified
above.
Interest Make-Whole means, with respect to a
Debenture to be offered for resale in a Remarketing, an amount
equal to the unpaid interest on such Debenture that will have
accrued to, but not including, the applicable Stock Purchase
Date of such Remarketing. However, if the Remarketing Settlement
Date of such Remarketing is after the close of business on a
record date for the payment of interest on such Component
Debentures and on or before the next succeeding interest payment
date for such Component Debentures, then the Interest Make-Whole
of such Component Debentures will be an amount equal to zero.
MetLife, Inc. will conduct at least one, but no more than three,
Remarketings for each of the Series C Debenture Units, the
Series D Debentures and the Series E Debenture Units.
Notwithstanding the foregoing,
S-110
MetLife, Inc. will be under no such obligation to conduct a
Remarketing at any time when none of the Common Equity Units are
outstanding.
For each series of Debentures or Component Debentures, the first
Remarketing must settle (i.e., close) during the period
beginning on, and including, the fifth Business Day immediately
preceding, and ending on, and including, the Initial Scheduled
First Stock Purchase Date (in the case of Series C
Debenture Units), the Initial Scheduled Second Stock Purchase
Date (in the case of Series D Debentures) or the Initial
Scheduled Third Stock Purchase Date (in the case of
Series E Debenture Units), as applicable. Such settlement
date is referred to as the Remarketing Settlement
Date. If such initial Remarketing is not successful,
then the applicable scheduled Stock Purchase Date will be
deferred by three months and a second Remarketing will be
conducted. The settlement date of the second Remarketing must
occur during the period beginning on, and including, the fifth
Business Day immediately preceding such deferred scheduled Stock
Purchase Date. If such second Remarketing is not successful,
then the applicable scheduled Stock Purchase Date will again be
deferred by three months and a third and final Remarketing will
be conducted. The settlement date of the third Remarketing must
occur during the period beginning on, and including, the fifth
Business Day immediately preceding such deferred scheduled Stock
Purchase Date.
In connection with the first two Remarketings of any series of
Debentures or Component Debentures, the Reset Rate may not
exceed the Reset Cap. For this purpose, the Reset
Cap is the prevailing market yield per annum, as
determined by the Remarketing Agent, of the benchmark
U.S. treasury security having a remaining maturity that
most closely corresponds to the remaining maturity of such
Debentures or Component Debentures, plus 750 basis points.
The Reset Cap will not apply to any third Remarketing attempt.
If the Remarketing is successful, the Remarketing Agent will
deduct the applicable Remarketing Fee, and the remaining
proceeds will be applied as follows:
|
|
|
|
|
in the case of Debentures or Debenture Units forming part of any
Common Equity Unit, (i) the Interest Make-Whole and Success
Fee will be delivered to the holder of such Common Equity Unit;
and (ii) the remaining proceeds will be delivered to
MetLife, Inc. on behalf of such holder in satisfaction of such
holders obligation to pay the Purchase Price for the Stock
Purchase Contract forming part of such Common Equity Unit that
settles on the applicable Stock Purchase Date; and
|
|
|
|
in the case of Separate Debentures (as defined below), the
remaining proceeds will be remitted to the holders that tendered
such Separate Debentures for inclusion in the Remarketing.
|
In the event that the third Remarketing for any series of
Debentures or Component Debentures is not successful, then the
interest rate applicable to those Debentures or Component
Debentures will not be reset.
Optional
Remarketing of the Debentures Not Included in Normal Common
Equity Units
Holders of Debentures or Debenture Units not forming part of any
Common Equity Units (Separate Debentures) may
elect to have such Separate Debentures included in a Remarketing
by delivering such Separate Debentures, along with a notice of
such election, to the Custodial Agent before the close of
business on the 25th Business Day immediately before the
applicable Stock Purchase Date. However, no holder of a Separate
Debenture may elect to include such Separate Debenture in a
Remarketing, unless the principal amount of such Separate
Debenture (and, if such Separate Debenture is a Debenture Unit,
the principal amount of each tranche of Component Debentures
forming part of such Debenture Unit) is an integral multiple of
$1,000. Such election may be withdrawn before the
25th Business Day immediately preceding the applicable
Stock Purchase Date.
Final
Failed Remarketing
If the third Remarketing for any series of Debentures or
Debenture Units is not successful a final failed Remarketing
will have occurred with respect to that series of Debentures or
Debenture Units (a Final Failed Remarketing).
In such case, holders of Debentures or Debenture Units of that
series forming part of any Normal Common Equity Unit will have
the right (the Put Right) to require MetLife,
Inc. to purchase such Debentures or Debenture Units on the Stock
Purchase Date for such series of Debentures or Component
Debentures, for cash in an amount equal to the principal amount
of such Debentures or Component Debentures, plus unpaid interest
thereon
S-111
that has accrued to, but not including, such Stock Purchase
Date. Such Put Right of a holder of Debentures or Debenture
Units forming part of any Normal Common Equity Units will
automatically, without any action of that holder, be deemed to
be exercised on the Stock Purchase Date applicable to the Final
Failed Remarketing, unless the holder has elected cash
settlement in accordance with the Stock Purchase Contract
Agreement.
Redemption
MetLife, Inc. will not have the right to redeem any Debentures
or Component Debentures before the Redemption Trigger Date
(as defined below). MetLife, Inc. has the right, at its option,
at any time, and from time to time, to redeem all or any part of
the Debentures or Component Debentures, on any date selected by
MetLife, Inc. (the Redemption Date) on
or after the Redemption Trigger Date, at a price payable in
cash equal to the Debenture Redemption Price (as defined
below). If a Redemption Date is after the regular record
date for a payment of interest on the Debentures or Component
Debentures to be redeemed and on or before the next Interest
Payment Date, then such payment of interest will,
notwithstanding the redemption, be made, on such Interest
Payment Date, to the holder(s) of such Debentures or Component
Debentures as of the close of business on such regular record
date. To exercise its right to redeem any Debentures or
Component Debentures, MetLife, Inc. must send notice of such
redemption to holders of the Debentures or Component Debentures
to be redeemed not less than 30 days nor more than
90 days before the applicable Redemption Date.
Redemption Trigger Date means, with
respect to a series of Debentures or Debenture Units, the
following date, as applicable: (i) if a successful
Remarketing has occurred with respect to such series, the second
anniversary of the applicable Stock Purchase Date of such
Remarketing; or (ii) if a Final Failed Remarketing has
occurred with respect to such series, the Stock Purchase Date
for such series.
Debenture Redemption Price means, with
respect to each Debenture or Component Debenture to be redeemed
on a Redemption Date, the sum of (1) the greater of
(A) the principal amount of such Debenture or Component
Debenture; and (B) the present value, as of such
Redemption Date, of all remaining scheduled principal and
interest payments on such Debenture or Component Debenture from,
but excluding, such Redemption Date through, and including,
the stated maturity date of the principal of such Debenture or
Component Debenture (not including any portion of such payments
of interest that have accrued, or for which the regular record
date has occurred, as of such Redemption Date), such
present value to be calculated using discounting, on a
semi-annual basis assuming a
360-day year
consisting of twelve
30-day
months, at a discount rate equal to the lesser of (i) the
Treasury Rate (as defined below) plus 50 basis points and
(ii) 15%; and (2) (without duplication) unpaid interest
that has accrued on such Debenture or Component Debenture to,
but excluding, such Redemption Date; provided,
however, that if such Redemption Date is after the
regular record date for a payment of interest on such Debenture
or Component Debenture and on or before the next Interest
Payment Date of such Debenture or Component Debenture, then
(x) such payment of interest will, notwithstanding such
redemption, be made, on such Interest Payment Date, to the
holder of such Debenture or Component Debenture as of the close
of business on such regular record date; (y) for avoidance
of doubt, such present value in clause (1)(B) above will be
calculated excluding such payment of interest; and (z) ) the
amount described in clause ( (2) above will be deemed to be
equal to zero. The present value to be calculated pursuant to
clause (1)(B) above will be calculated assuming that the
interest rate of such Debenture or Component Debentures in
effect at the open of business on the applicable
Redemption Date will not thereafter be changed.
Treasury Rate means, with respect to any
Redemption Date for a Debenture to be redeemed, the
prevailing market yield per annum of the benchmark
U.S. Treasury Security having a remaining maturity, as of
such Redemption Date, that most closely corresponds to the
state maturity of the principal of such Debenture. The Treasury
Rate will be calculated on the third business day preceding the
Redemption Date.
Each series of Component Debentures may be redeemed
independently of another series of Component Debentures.
S-112
Events of
Default
An event of default, when used in a Debenture
with respect to the applicable series of Debentures, means any
of the following:
|
|
|
|
|
MetLife, Inc. defaults in the payment of any installment of
interest upon the Debentures, as and when the same becomes due
and payable, and the continuance of such default for a period of
30 consecutive days;
|
|
|
|
MetLife, Inc. defaults in the payment of the principal of the
Debentures as and when the same becomes due and payable, whether
at maturity, upon redemption or otherwise;
|
|
|
|
MetLife, Inc. fails to observe or perform any other of its
covenants or agreements with respect to the Debentures contained
in the Indenture (other than a covenant or agreement that has
been expressly included in the Indenture solely for the benefit
of one or more series of Securities other than the Debentures)
for a period of 90 days after the date on which written
notice of such failure, requiring the same to be remedied and
stating that such notice is a Notice of Default
under the Indenture, is given to MetLife, Inc. by the Trustee,
by registered or certified mail, or to MetLife, Inc. and the
Trustee by the holders of at least 25% in principal amount of
the Debentures at the time Outstanding;
|
|
|
|
the entry by a court of competent jurisdiction of:
|
|
|
|
|
|
a decree or order for relief in respect of MetLife, Inc. in an
involuntary proceeding under any applicable Bankruptcy Law, and
such decree or order will remain unstayed and in effect for a
period of 60 consecutive days;
|
|
|
|
a decree or order adjudging MetLife, Inc. to be insolvent, or
approving a petition seeking reorganization, arrangement,
adjustment or composition of MetLife, Inc., and such decree or
order will remain unstayed and in effect for a period of 60
consecutive days; or
|
|
|
|
a final and non-appealable order appointing a custodian of
MetLife, Inc., or of any substantial part of the property of
MetLife, Inc., or ordering the winding up or liquidation of the
affairs of MetLife, Inc.; or
|
|
|
|
|
|
MetLife, Inc., pursuant to or within the meaning of any
Bankruptcy Law, either (1) commences a voluntary case or
proceeding; (2) consents to the entry of an order for
relief against it in an involuntary case or proceeding;
(3) files a petition or answer or consent seeking
reorganization or relief or consents to such filing or to the
appointment of or taking possession by a custodian of it or for
all or substantially all of its property, and such custodian is
not discharged within 60 days; (4) makes a general
assignment for the benefit of its creditors; or (5) admits
in writing its inability to pay its debts generally as they
become due.
|
S-113
BOOK-ENTRY
SYSTEM
The Common Equity Units were originally issued to the Selling
Securityholder as certificated securities. Prior to the closing
of this offering, MetLife, Inc. will enter into an arrangement
with The Depository Trust Company to act as securities
depositary for the Normal Common Equity Units, Stripped Common
Equity Units and Separate Debentures. One or more global
security certificates representing the total aggregate number of
Normal Common Equity Units, Stripped Common Equity Units and the
aggregate principal amount of the Separate Debentures, from time
to time, will be exchanged for the certificates currently
representing the Common Equity Units held by the Selling
Securityholder sold in this offering. Accordingly, the Normal
Common Equity Units, the Stripped Common Equity Units and
Separate Debentures will be received by the purchasers of the
Common Equity Units in this offering only as beneficial
interests in the global security certificates representing the
applicable Normal Common Equity Units, Stripped Common Equity
Units and Separate Debentures. The Normal Common Equity Units,
the Stripped Common Equity Units and Separate Debentures will be
deposited with the depositary, or its custodian, and registered
in the name of Cede & Co., the depositarys
nominee.
The laws of some jurisdictions may require that some purchasers
of securities take physical delivery of securities in definitive
form. These laws may impair the ability to transfer beneficial
interests in the Normal Common Equity Units, the Stripped Common
Equity Units or Separate Debentures so long as the Normal Common
Equity Units, the Stripped Common Equity Units or Separate
Debentures are represented by global security certificates.
The depositary has advised us that it is a limited purpose trust
company organized under the laws of the State of New York, a
member of the Federal Reserve System, a clearing
corporation within the meaning of the Uniform Commercial
Code and a Clearing Agency registered pursuant to
the provisions of Section 17A of the Securities Exchange
Act of 1934, as amended (the Exchange Act).
The depositary was created to hold securities for its
participants and facilitate the clearance and settlement of
securities transactions between participants through electronic
book-entry changes in accounts of its participants, thereby
eliminating the need for physical movement of certificates.
Participants include securities brokers and dealers, banks,
trust companies and clearing corporations and certain other
organizations. Indirect access to the depositarys system
is available to others such as banks, brokers, dealers and trust
companies that clear through or maintain a custodial
relationship with a participant, either directly, or indirectly.
In the event that:
|
|
|
|
|
the depositary notifies us that it is unwilling or unable to
continue as a depositary with respect to the Common Equity Units
and no successor depositary has been appointed within
90 days after this notice;
|
|
|
|
the depositary at any time ceases to be a clearing
agency registered under the Section 17A of the
Exchange Act when the depositary is required to be so registered
to act as the depositary and so notifies MetLife, Inc., and no
successor depositary has been appointed within 90 days
after MetLife, Inc. learns that the depositary has ceased to be
so registered;
|
|
|
|
any default has occurred and is continuing under the Stock
Purchase Contract Agreement or the Indenture; or
|
|
|
|
a beneficial owner of an interest in a global security
certificate representing the Common Equity Units provides to
MetLife, Inc. and the Stock Purchase Contract Agent a written
request, upon 60 days prior notice, that such beneficial
owners interest in the Common Equity Units is to be
exchanged for an equivalent interest in the Common Equity Units
represented by a definitive certificate,
|
certificates for the Normal Common Equity Units, Stripped Common
Equity Units, or Separate Debentures may be printed and
delivered in exchange for beneficial interests in the global
security certificates. Any Normal Common Equity Units, Stripped
Common Equity Units or Separate Debentures represented by global
security certificates that are exchangeable pursuant to the
preceding sentence will be exchangeable for Normal Common Equity
Units, Stripped Common Equity Units or Separate Debentures
represented by individual security certificates and registered
in the names directed by the depositary. MetLife, Inc. expects
that these instructions will be based upon directions received
by the depositary from its participants with respect to
ownership of beneficial interests in the global security
certificates.
S-114
As long as the depositary or its nominee is the registered owner
of the global security certificates, the depositary or its
nominee, as the case may be, will be considered the sole owner
and holder of the global security certificates and all Normal
Common Equity Units, Stripped Common Equity Units or Separate
Debentures represented by these certificates for all purposes
under the Normal Common Equity Units, Stripped Common Equity
Units or Separate Debentures and the Stock Purchase Contract
Agreement. Except in the limited circumstances referred to
above, owners of beneficial interests in the global security
certificates representing Common Equity Units:
|
|
|
|
|
will not be entitled to have such global security certificates
or the Normal Common Equity Units, Stripped Common Equity Units
or Separate Debentures represented by these certificates
registered in their names;
|
|
|
|
will not receive or be entitled to receive physical delivery of
Normal Common Equity Units, Stripped Common Equity Units or
Separate Debentures certificates in exchange for beneficial
interests in such global security certificates; and
|
|
|
|
will not be considered to be owners or holders of the global
security certificates or any Normal Common Equity Units,
Stripped Common Equity Units or Separate Debentures represented
by these certificates for any purpose under the Normal Common
Equity Units, Stripped Common Equity Units and, the Stock
Purchase Contract Agreement.
|
All payments on the Common Equity Units and the Debentures
represented by the global security certificates and all
transfers and deliveries of related Debentures, treasury
securities and shares of Common Stock will be made to the
depositary or its nominee, as the case may be, as the registered
holder of the securities.
Ownership of beneficial interests in the global security
certificates will be limited to participants or persons that may
hold beneficial interests through institutions that have
accounts with the depositary or its nominee. Ownership of
beneficial interests in global security certificates will be
shown only on, and the transfer of those ownership interests
will be effected only through, records maintained by the
depositary or its nominee, with respect to participants
interests, or any participant, with respect to interests of
persons held by the participant on their behalf. Procedures for
settlement of Stock Purchase Contracts on each Stock Purchase
Date or upon early settlement will be governed by arrangements
among the depositary, participants and persons that may hold
beneficial interests through participants designed to permit
settlement without the physical movement of certificates.
Payments, transfers, deliveries, exchanges and other matters
relating to beneficial interests in global security certificates
may be subject to various policies and procedures adopted by the
depositary from time to time. None of us, the Stock Purchase
Contract Agent or any agent of ours or of the Stock Purchase
Contract Agent will have any responsibility or liability for any
aspect of the depositarys or any participants
records relating to, or for payments made on account of,
beneficial interests in global security certificates, or for
maintaining, supervising or reviewing any of the
depositarys records or any participants records
relating to these beneficial ownership interests.
Although the depositary has agreed to the foregoing procedures
in order to facilitate transfer of interests in the global
security certificates among participants, the depositary is
under no obligation to perform or continue to perform these
procedures, and these procedures may be discontinued at any
time. MetLife, Inc. will not have any responsibility for the
performance by the depositary or its direct participants or
indirect participants under the rules and procedures governing
the depositary.
The information in this section concerning the depositary and
its book-entry system has been obtained from sources that we
believe to be reliable, but we have not attempted to verify the
accuracy of this information.
S-115
CERTAIN
UNITED STATES FEDERAL INCOME TAX CONSEQUENCES
This section describes certain of the material United States
federal income tax consequences of the purchase, ownership and
disposition of the Common Equity Units, the Debentures, the
Treasury Securities and Stock Purchase Contracts, and the Common
Stock acquired pursuant to the Stock Purchase Contracts
(collectively, the Securities). This summary
does not purport to be a complete analysis of all of the tax
considerations that may be applicable to a decision to acquire
the Common Equity Units. This summary applies only to United
States holders and
non-United
States holders (each as defined below) who purchase the Common
Equity Units in this offering and hold the Securities as capital
assets within the meaning of section 1221 of the Code. This
summary does not address alternative minimum taxes or state,
local or foreign taxes. Please consult your own tax advisors to
determine what state, local or foreign tax consequences could
result from the purchase, ownership and disposition of the
Securities.
This summary does not describe all the United States federal
income tax consequences that may be relevant to a holder in
light of its particular circumstances or to holders subject to
special rules, such as:
|
|
|
|
|
dealers and certain traders in securities,
|
|
|
|
banks, regulated investment companies, real estate investment
trusts, and financial institutions,
|
|
|
|
insurance companies,
|
|
|
|
tax-exempt organizations,
|
|
|
|
persons holding Securities as part of a straddle,
hedge, conversion or similar transaction,
|
|
|
|
persons that are classified as, or who hold their Securities
through, partnerships for United States federal income tax
purposes, or
|
|
|
|
a United States holder (as defined below) whose functional
currency for tax purposes is not the U.S. dollar.
|
This summary is based on current law and is for general
information purposes only. Future legislative, judicial or
administrative changes or interpretations could be retroactive
and could affect the information, beliefs and conclusions in
this discussion. There can be no assurances that the IRS will
not challenge one or more of the tax consequences discussed
herein. The tax treatment applicable to you may vary depending
upon your particular tax situation or status. Please consult
your own tax advisor concerning the tax consequences of
purchasing, owning and disposing of Securities in your
particular circumstances under the Code and the laws of any
other taxing jurisdiction.
United
States Holders
This subsection describes certain material United States federal
income tax consequences to a United States holder. For the
purposes of this discussion, you are a United States
holder if you are a beneficial owner of Securities and you
are for United States federal income tax purposes:
|
|
|
|
|
an individual who is a citizen or resident of the United States,
|
|
|
|
a corporation (or another entity classified as a corporation)
created or organized in or under the laws of the United States
of any state thereof or the District of Columbia,
|
|
|
|
an estate the income of which is includible in gross income for
United States federal income tax purposes regardless of its
source, or
|
|
|
|
a trust if a court within the United States is able to exercise
primary supervision over the administration of the trust and one
or more United States persons are authorized to control all
substantial decisions of the trust.
|
If you are not a United States holder, this subsection does not
apply to you and you should refer to
Non-United
States Holders below.
S-116
Common
Equity Units
Characterization
of Normal Common Equity Units
Each Normal Common Equity Unit should be treated for United
States federal income tax purposes as an investment unit
comprised of (a) the undivided beneficial ownership
interests in the applicable series of Debentures and
(b) the Stock Purchase Contracts. Consequently, your
purchase price for a Normal Common Equity Unit will be allocated
between these two components in proportion to their respective
fair market values at the time of purchase. This allocation will
establish your initial United States federal income tax basis in
your undivided beneficial interest in the applicable series of
Debentures and in the Stock Purchase Contracts. Although
unclear, if the fair market value of any Stock Purchase Contract
is negative at the time of your purchase of a Common Equity
Unit, the amount you are treated as paying for the ownership
interests in the applicable series of Debentures and any Stock
Purchase Contracts that have a positive value should include the
amount attributable to the assumption of the liability
associated with the Stock Purchase Contract that has a negative
value (i.e., the negative value should be added to your
basis in the applicable series of Debentures and any Stock
Purchase Contracts that have a positive value in accordance with
their relative fair market values).
Sales,
Exchanges or Other Taxable Dispositions of the Common Equity
Units
Upon a sale, exchange or other taxable disposition of a Common
Equity Unit, you will be treated as having sold, exchanged or
disposed of the applicable Stock Purchase Contracts and your
undivided beneficial ownership interests in the applicable
series of Debentures (in the case of a Normal Common Equity
Unit) or Treasury Securities (in the case of a Stripped Common
Equity Unit) that constitute such Common Equity Unit. The
proceeds realized in such disposition will be allocated between
the applicable Stock Purchase Contracts and the undivided
beneficial ownership interests in the applicable series of
Debentures (or in the case of a Stripped Common Equity Unit, the
applicable Treasury Securities) that constitute such Common
Equity Unit in proportion to their respective fair market values
at the time of disposition. You generally will recognize gain or
loss equal to the difference between the portion of the proceeds
allocable to each applicable series of Debentures and each
applicable Stock Purchase Contract and your respective adjusted
United States federal income tax basis in each such Security.
Gain or loss from the sale of the Common Equity Unit generally
will be capital gain or loss (except that amounts properly
allocable to accrued but unpaid interest and accrued market
discount in respect of the Debentures will be treated as
ordinary income to the extent not previously included in income,
and amounts allocable to accrued or Deferred Contract Payments
could be treated as giving rise to ordinary income), and such
gain or loss generally will be long-term capital gain or loss in
respect of positions held for more than one year at the time of
such disposition. The deductibility of capital losses is subject
to significant limitations, which vary between corporate and
non-corporate taxpayers. You should consult your own tax
advisors for purposes of determining the amount and character of
any gain or loss that may be generated from the sale of a Common
Equity Unit, including without limitation the character of any
amounts that are attributable to Contract Payments.
If you dispose of a Common Equity Unit when an applicable Stock
Purchase Contract has a negative value, you should be considered
to have received additional consideration for the undivided
beneficial interest in the applicable series of Debentures or
applicable Treasury Securities, as the case may be, and any
applicable Stock Purchase Contracts having positive value in an
amount equal to such negative value (allocated in accordance
with the fair market values of such ownership interests and such
Stock Purchase Contracts having positive value); thus, the
amount treated as realized on the disposition of the components
of the Common Equity Units that have a positive value should
include the value attributable to the release from your
obligation under such Stock Purchase Contract (i.e., the
negative value of such Stock Purchase Contract). If, upon the
disposition of a Common Equity Unit, you recognize gain on the
disposition of a Debenture that has market discount and loss on
the disposition of another Debenture or a Stock Purchase
Contract, such gain will be treated as ordinary income to the
extent of the accrued market discount on such Debenture that has
not previously been included in income and the loss on the
disposition of such other Debenture or such Stock Purchase
Contract generally will be a capital loss, such that the loss
may not be used to offset the gain attributable to such market
discount.
S-117
In determining gain or loss, your characterization of the
Contract Payments could affect your tax basis in the Stock
Purchase Contracts. You should consult your tax advisor
regarding how your tax basis may be affected by the Contract
Payments.
Debentures
Interest
By purchasing a Normal Common Equity Unit you have agreed to
treat the Debentures as indebtedness for United States federal
income tax purposes. Interest paid on the Debentures will be
taxable to you as ordinary interest income at the time it is
received or accrued, depending upon the method of accounting
applicable to you, and MetLife, Inc. will report such interest
accordingly.
Market
Discount
If the portion of the purchase price for a Common Equity Unit
properly allocable to an ownership interest in a Debenture is
less than the stated principal amount of such Debenture, the
difference will be considered market discount unless it
qualifies under a statutory de minimis exception. Under
the de minimis exception, market discount will be treated
as zero if the market discount is less than
1/4
of one percent of the stated principal amount of the Debenture
multiplied by the number of complete years to maturity on the
Debenture. If a United States holder acquires an ownership
interest in a Debenture with market discount, such holder will
be required to treat as ordinary income (rather than capital
gain) any gain recognized on the disposition of that Debenture
to the extent of any accrued market discount not previously
included in income.
Market discount will be treated as accruing ratably during the
period from the date of acquisition of the ownership interest in
a Debenture to the maturity date of the Debenture, unless you
elect to use a constant yield method. You may elect to include
market discount in income currently as it accrues on either a
ratable or constant yield method. This election to include
market discount in income currently, once made, will also apply
to all market discount obligations acquired by such holder on or
after the first taxable year to which the election applies and
may not be revoked without the consent of the IRS.
Bifurcation
On each Bifurcation Date, the applicable series of Debentures
will automatically convert into Debenture Units consisting of
two tranches of Component Debentures. These conversions should
not constitute taxable events for United States federal income
tax purposes. On each Bifurcation Date, the basis in your
ownership interests in the applicable Debentures should be
allocated between your ownership interests in the applicable
Component Debentures received in exchange therefor in accordance
with each such Component Debentures fair market value.
Although unclear, if you acquire your ownership interests in the
applicable Debentures at a market discount, then, subject to a
de minimis exception, (i) your ownership interest in each
applicable Component Debenture should be treated as acquired at
a market discount if the stated principal amount of such
Component Debenture exceeds the basis allocated thereto as
described above and (ii) if you do not elect to include
market discount on the applicable Debentures in income on a
current basis, any accrued market discount on such Debentures
not previously included in income should carry over to your
ownership interests in the applicable Component Debentures
(allocated in accordance with each such Component
Debentures fair market value). Not all aspects of the tax
treatment of the bifurcations are clear. Accordingly, you should
consult your tax advisors concerning the tax consequences of the
bifurcations. For the purposes of the remainder of this
discussion, the term Debentures includes Component Debentures
after the applicable Bifurcation Date.
Sales,
Exchanges or Other Taxable Dispositions of the
Debentures
You will recognize gain or loss on a sale, exchange or other
taxable disposition of a Debenture (including upon the
remarketing thereof) in an amount equal to the difference
between the amount realized on the disposition of such Debenture
(less any portion allocable to accrued but unpaid interest or
accrued market discount, which will be treated as ordinary
income to the extent not previously included in income) and your
adjusted United States federal
S-118
income tax basis in such Debenture. See
Sales, Exchanges or Other Taxable
Dispositions of the Common Equity Units above for a
discussion regarding the character of any gain or loss from such
a disposition.
Substitution
of Treasury Securities to Create Stripped Common Equity
Units
If you hold Normal Common Equity Units and deliver Treasury
Securities to the collateral agent in substitution for
Debentures, you generally will not recognize gain or loss upon
the delivery of such Treasury Securities or the release of such
Debentures. You will continue to take into account items of
income or deduction otherwise includible or deductible,
respectively, by you with respect to such Debentures, and your
adjusted United States federal income tax bases in and your
holding period of the applicable Treasury Securities, Debentures
and Stock Purchase Contracts will not be affected by such
delivery and release.
Although the Treasury Securities will not generate current
payments to you, you will be required, for United States
federal income tax purposes, to recognize original issue
discount in respect of the Treasury Securities on a constant
yield basis, or to recognize acquisition discount on the
Treasury Securities when it is paid or accrues, generally in
accordance with your regular method of tax accounting.
You should consult your tax advisor concerning the tax
consequences of purchasing, owning and disposing of the Treasury
Securities so delivered to the collateral agent.
Substitution
of Debentures to Recreate Normal Common Equity Units
If you hold a Stripped Common Equity Unit and deliver Debentures
to the collateral agent in substitution for Treasury Securities,
you generally will not recognize gain or loss upon the delivery
of such Debentures or the release of the underlying Treasury
Securities to you. You will continue to take into account items
of income or deduction otherwise includible or deductible,
respectively, by you with respect to such Treasury Securities
and Debentures, and your adjusted United States federal income
tax bases in and your holding period of the applicable Treasury
Securities, Debentures and Stock Purchase Contracts will not be
affected by such delivery and release.
Stock
Purchase Contracts
Contract
Payments
There is no direct authority addressing the treatment, under
current law, of the Contract Payments or Deferred Contract
Payments, and such treatment is, therefore, unclear. Contract
Payments and Deferred Contract Payments may constitute taxable
ordinary income to a United States holder when received or
accrued, in accordance with such United States holders
regular method of tax accounting. Consequently, if MetLife, Inc.
defers a Contract Payment and you use the accrual method of tax
accounting, you may be required to recognize income for United
States federal income tax purposes in respect of the Deferred
Contract Payment in advance of your receipt of any corresponding
cash distributions. To the extent MetLife, Inc. is required to
file information returns with respect to the Contract Payments
or Deferred Contract Payments, MetLife, Inc. intends to report
such payments as taxable ordinary income to United States
holders. In the event that MetLife, Inc. elects to pay Contract
Payments in the form of Common Stock or unsecured junior
subordinated notes, MetLife, Inc. will take the position that
such payments constitute ordinary income to you in the amount of
the fair market value of such stock or notes as of the time of
the payments. Nevertheless, you should consult with your tax
advisor regarding possible alternative characterizations of the
Contract Payments (including Deferred Contract Payments).
The characterization of Contract Payments and Deferred Contract
Payments could affect (i) a United States holders
adjusted tax basis in a Stock Purchase Contract or the Common
Stock received under a Stock Purchase Contract or (ii) the
amount and character of gain or loss realized or recognized by a
United States holder upon the sale, termination or disposition
of a Common Equity Unit or the termination of a Stock Purchase
Contract.
Acquisition
of Common Stock Under a Stock Purchase Contract
You generally will not recognize gain or loss on the purchase of
Common Stock under a Stock Purchase Contract, including upon an
early settlement, except with respect to any cash paid in lieu
of a fractional share of Common Stock and generally, your
aggregate initial United States federal income tax basis in the
Common Stock
S-119
received under a Stock Purchase Contract should equal the
purchase price paid for such Common Stock, plus the properly
allocable portion of your adjusted tax basis in such Stock
Purchase Contract, less the portion of such purchase price
allocable to a fractional share. However, the manner in which
you characterize the Contract Payments may affect whether you
recognize taxable gain upon the purchase of Common Stock
pursuant to a Stock Purchase Contract
and/or your
tax basis in such stock. You should consult your tax advisor to
determine how the Contract Payments may affect your tax
consequences upon purchasing Common Stock pursuant to a Stock
Purchase Contract. The holding period for Common Stock received
under a Stock Purchase Contract will commence on the date
following the acquisition of such Common Stock.
Ownership
of Common Stock Acquired Under a Stock Purchase
Contract
Any distribution with respect to Common Stock that MetLife, Inc.
pays out of its current or accumulated earnings and profits (as
determined for United States federal income tax purposes) will
constitute a dividend and will be includible in income by you
when received. Any such dividends will be eligible for the
dividends received deduction if you are an otherwise qualifying
corporate United States holder that meets the holding period and
other requirements for the dividends received deduction. Upon a
disposition of Common Stock, you generally will recognize gain
or loss equal to the difference between the amount realized and
your adjusted United States federal income tax basis in the
Common Stock. See Sales, Exchanges or
Other Taxable Dispositions of the Common Equity Units
above for a discussion regarding the character of any gain or
loss from such a disposition.
Termination
of Stock Purchase Contract.
If a Stock Purchase Contract terminates, a United States holder
of a Common Equity Unit will recognize gain or loss equal to the
difference between the amount realized (if any) and such United
States holders adjusted tax basis (if any) in such Stock
Purchase Contract at the time of such termination. Any such gain
or loss generally will be capital gain or loss and generally
will be long-term capital gain or loss if the United States
holder held the Stock Purchase Contract for more than one year
prior to such termination. Additionally, tax consequences may
vary upon a termination depending upon how you have
characterized the Contract Payments for United States federal
income tax purposes. You should consult your tax advisor with
respect to any such issues.
Adjustment
to Settlement Rate.
As a holder of a Common Equity Unit, an adjustment to the
Settlement Rate could under certain circumstances be treated as
a constructive payment of a taxable amount. In such cases an
increase in the Settlement Rate might give rise to taxable
income or gain to you in accordance with the applicable
provisions of the Code even though you would not receive any
cash related thereto.
You should consult your tax advisor concerning the tax
consequences resulting from adjustments made to the Settlement
Rate.
Backup
Withholding and Information Reporting
In general, you will be subject to backup withholding with
respect to payments made on or with respect to the Securities,
the proceeds received with respect to a fractional share of
Common Stock upon a settlement of a Stock Purchase Contract, and
the proceeds received from the sale of Securities unless you:
|
|
|
|
|
are an entity that is exempt from backup withholding and, when
required, demonstrate this fact; or
|
|
|
|
provide your Taxpayer Identification Number
(TIN) (which, if you are an individual, is
your Social Security Number), and further
|
|
|
|
|
|
you certify that (i) the TIN you provide is correct,
(ii) you are a United States person and (iii) that
(a) you are exempt from backup withholding, (b) you
have not been notified by the IRS that you are subject to backup
withholding due to underreporting of interest or dividends or
(c) you have been notified by the IRS that you are no
longer subject to backup withholding, and
|
|
|
|
|
|
you otherwise comply with the applicable requirements of the
backup withholding rules.
|
S-120
In addition, such payments or proceeds received by you if you
are not an exempt recipient generally will be subject to
information reporting requirements.
Backup withholding is not an additional tax. The amount of any
backup withholding from a payment to you will be allowed as a
credit against your federal income tax liability and may entitle
you to a refund, provided that you timely furnish the required
information to the IRS.
Non-United
States Holders
The following summary is addressed to
non-United
States holders. For the purposes of this discussion, a
non-United
States holder is a holder that is neither a partnership (or an
entity classified as a partnership for United States
federal income tax purposes) nor a United States person for
United States federal income tax purposes.
United
States Federal Withholding Tax
United States federal withholding tax will not apply to any
interest paid on the Debentures provided that:
|
|
|
|
|
you do not actually (or constructively) own 10% or more of the
total combined voting power of all classes of MetLife,
Inc.s voting stock within the meaning of the Code and the
Treasury Regulations, and you are not a controlled foreign
corporation that is related to MetLife, Inc. through stock
ownership or a bank receiving interest on a Debenture pursuant
to a loan agreement entered into in the ordinary course of your
trade or business; and
|
|
|
|
either (a) you provide your name, address and certain other
information on an IRS
Form W-8BEN
(or a suitable substitute form), and certify, under penalties of
perjury, that you are not a United States person or (b) you
hold the Debentures through certain foreign intermediaries or
certain foreign partnerships and certain certification
requirements are satisfied.
|
In general, United States federal withholding tax at a rate of
30% will apply to the dividends, if any, (and generally any
deemed dividends resulting from certain adjustments or failures
to make an adjustment as described under Stock
Purchase Contracts Adjustment to Settlement
Rate) paid on the shares of Common Stock acquired under a
Stock Purchase Contract. It is possible that United States
withholding tax on deemed dividends would be withheld from
interest paid to you under the Debentures.
Although the United States federal income tax treatment of the
Contract Payments is not clear, MetLife, Inc. intends to
withhold at a rate of 30% on any Contract Payments made with
respect to a Stock Purchase Contract unless the recipient
qualifies for an exemption from or reduced rate of withholding,
as discussed below.
If a tax treaty applies, you may be eligible for an exemption
from or reduced rate of withholding. Additionally, Contract
Payments or dividends that are effectively connected with the
conduct of a trade or business by you in the United States (and,
where an applicable tax treaty so provides, are also
attributable to a United States permanent establishment
maintained by you) are not subject to the United States federal
withholding tax, but instead are subject to United States
federal income tax, as described below. In order to claim any
such exemption from or reduction in the 30% withholding tax, you
should provide a properly executed IRS
Form W-8BEN
(or suitable substitute form) claiming a reduction of or an
exemption from withholding under an applicable tax treaty or a
properly executed IRS
Form W-8ECI
(or a suitable substitute form) stating that such payments are
not subject to withholding tax because they are effectively
connected with your conduct of a trade or business in the United
States.
United
States Federal Income Tax
If you are engaged in a trade or business in the United States
(and, if a tax treaty applies, if you maintain a permanent
establishment within the United States) and (i) payments on
the Debentures, (ii) dividends on the Common Stock and,
(iii) to the extent they constitute taxable income,
Contract Payments made with respect to the Stock Purchase
Contracts are, in each case, effectively connected with the
conduct of such trade or business (and, if a tax treaty applies,
attributable to such permanent establishment), you will be
subject to United States federal income tax (but not withholding
tax), on such payments, dividends and Contract Payments on a net
income basis in
S-121
the same manner as if you were a United States holder. In
addition, in certain circumstances, if you are a corporation for
United States federal income tax purposes, you may be subject to
a 30% (or, if a tax treaty applies, such lower rate as provided)
branch profits tax.
Except as discussed below, any gain realized on the disposition
of the Securities will not be subject to United States
federal income tax (including any United States federal income
withholding taxes) unless:
|
|
|
|
|
such gain or income is effectively connected with your conduct
of a trade or business in the United States (and, where an
applicable tax treaty so provides, are also attributable to a
United States permanent establishment maintained by you); or
|
|
|
|
you are an individual who is present in the United States for
183 days or more in the taxable year of the disposition and
certain other conditions are met.
|
Notwithstanding the above statement regarding when United States
federal income tax may be imposed on gain derived from the
disposition of Securities, because of the lack of legal guidance
regarding how Contract Payments are taxed for United States
federal income tax purposes it is not clear whether proceeds
derived from the disposition of the Securities could be subject
to United States federal withholding tax to the extent such
proceeds could be attributable to the Contract Payments.
Accordingly,
non-United
States holders should consult their tax advisor to determine
whether United States federal withholding tax may be imposed
upon the disposition of the Securities.
Backup
Withholding and Information Reporting
Unless you are an exempt recipient, payments made with respect
to the Securities, the proceeds received with respect to a
fractional share of Common Stock upon the settlement of a Stock
Purchase Contract, and the proceeds received from a sale of
Securities may be subject to information reporting and may also
be subject to United States federal backup withholding at the
applicable rate if you fail to comply with applicable United
States information reporting or certification requirements. Any
amounts so withheld under the backup withholding rules may be
allowed as a credit against your United States federal income
tax liability and may entitle you to a refund, provided you
timely furnish the required information to the IRS.
S-122
ERISA
CONSIDERATIONS
The following is a summary of certain considerations associated
with the purchase of Common Equity Units by employee benefit
plans and retirement arrangements
and/or
Section 4975 of the Code and entities whose underlying
assets are considered to include plan assets of any
such plans and arrangements.
Title I of ERISA and Section 4975 of the Code impose
certain restrictions on:
|
|
|
|
|
employee benefit plans (as defined in Section 3(3) of
ERISA) subject to Title I of ERISA (ERISA
Plans);
|
|
|
|
plans described in Section 4975(e)(1) of the Code,
including individual retirement accounts and Keogh plans;
|
|
|
|
entities whose underlying assets include plan assets pursuant to
29 C.F.R. Section 2510.3-101 (as modified by
Section 3(42) of ERISA) by reason of a plans
investment in such entities (together with ERISA Plans and plans
described in Section 4975(e)(1) of the Code, referred to as
a Plan); and
|
|
|
|
persons who have certain specified relationships to a Plan
(Parties in Interest under ERISA and
Disqualified Persons under the Code).
|
ERISA and the Code impose certain duties on persons who are
fiduciaries of a Plan and prohibit certain transactions
involving Plan assets and fiduciaries or other Parties in
Interest and Disqualified Persons. Under ERISA and the Code, any
person who exercises any discretionary authority or control over
the administration of such a Plan or the management or
disposition of assets of such a Plan, or who renders to such a
Plan investment advice for a fee or other compensation is
generally considered a fiduciary of the Plan. A Plan may
purchase Common Equity Units subject to the investing
fiduciarys determination that the investment satisfies
ERISAs fiduciary standards and other requirements under
ERISA and the Code applicable to investments by the Plan.
Accordingly, among other factors, the investing fiduciary should
consider whether:
|
|
|
|
|
the investment would satisfy the prudence and diversification
requirements of ERISA;
|
|
|
|
the investment would be consistent with the documents and
instruments governing the Plan;
|
|
|
|
the investment is made solely in the interest of participants
and beneficiaries of the Plan;
|
|
|
|
the acquisition and holding of Common Equity Units (and the
securities underlying such Common Equity Units) does not result
in a prohibited transaction under Section 406 of
ERISA or Section 4975 of the Code for which there is no
applicable exemption; and
|
|
|
|
the investment does not violate ERISAs prohibition on
improper delegation of control over or responsibility for
plan assets.
|
The Common Equity Units held by a Plan will be deemed to
constitute plan assets of the Plan, and the
securities underlying the Common Equity Units may also be deemed
to constitute plan assets of the Plan. If MetLife,
Inc., the Selling Securityholder, any underwriter or the
Remarketing Agent is or becomes a Party in Interest or
Disqualified Person with respect to a Plan, such Plans
acquisition, holding or disposition of the Common Equity Units
(and the securities underlying such Common Equity Units) may
constitute or result in a prohibited transaction under
Section 406 of ERISA or Section 4975 of the Code
(e.g., the extension of credit between a Plan and a Party in
Interest or Disqualified Person), unless the Common Equity Units
(and the securities underlying such Corporate Units) are
acquired and are held pursuant to and in accordance with an
applicable exemption. In this regard, the DOL has issued
prohibited transaction class exemptions
(PTCEs) that may apply to the acquisition,
holding and holding and disposition of Common Equity Units (and
the securities underlying such Common Equity Units). These class
exemptions are
PTCE 84-14
(respecting transactions determined by independent qualified
professional asset managers),
PTCE 90-1
(respecting transactions involving insurance company separate
accounts),
PTCE 91-38
(respecting transactions involving bank collective investment
funds),
PTCE 95-60
(respecting transactions involving insurance company general
accounts) and
PTCE 96-23
(respecting transactions determined by in-house asset managers).
In addition, certain statutory prohibited transaction exemptions
may be available to provide exemptive relief for a Plan,
including, without limitation, the statutory exemption set forth
in Section 408(b)(17) of ERISA and Section 4975(d)(20)
of the Code regarding transactions with certain service
providers.
S-123
Certain of the exemptions, however, do not afford relief from
the prohibition on self-dealing contained in ERISA
Section 406(b) and Code
Sections 4975(c)(l)(E)-(F).
In addition to the prohibited transaction class or statutory
exemptions, an individual exemption may apply to the initial
purchase, holding and disposition of Common Equity Units (and
the securities underlying such Common Equity Units) by a Plan,
provided certain specified conditions are met. There can be no
assurance that any of these administrative exemptions will be
available with respect to any particular transaction involving
the Common Equity Units (and the securities underlying such
Common Equity Units).
Special considerations apply to insurance company general
accounts. Based on the reasoning of the U.S. Supreme Court
in John Hancock Life Ins. Co. v. Harris Trust and Sav.
Bank, 510 U.S. 86 (1993), an insurance companys
general account may be deemed to include assets of the Plans
investing in the general account (e.g., through the purchase of
an annuity contract), and the insurance company might be treated
as a Party in Interest or Disqualified Person with respect to a
Plan by virtue of such investment. Any investor that is an
insurance company using the assets of an insurance company
general account should note that the Small Business Job
Protection Act of 1996 added Section 401(c) of ERISA
relating to the status of the assets of insurance company
general accounts under Title I of ERISA and
Section 4975 of the Code. Pursuant to Section 401(c),
the DOL issued final regulations effective January 5, 2000
(the General Account Regulations), with
respect to insurance policies issued on or before
December 31, 1998, that are supported by an insurers
general account. As a result of the General Account Regulations,
assets of an insurance companys general account will not
be treated as plan assets for purposes of
Title I of ERISA and Section 4975 of the Code to the
extent such assets relate to contracts issued to employee
benefit plans on or before December 31, 1998, and the
insurer satisfies certain conditions. The plan asset status of
an insurance companys separate accounts is unaffected by
Section 401(c) of ERISA, and separate account assets
continue to be treated as the plan assets of any such Plan
invested in a separate account.
Governmental plans, foreign plans and certain church plans (each
as defined or described under ERISA) are not subject to the
provisions of Title I of ERISA or Section 4975 of the
Code. Such plans, however, may be subject to other federal,
state, local or
non-U.S. laws
or regulations that may affect their investment in the Common
Equity Units (and the securities underlying such Common Equity
Units). Any fiduciary of such a governmental, foreign or church
plan considering a purchase of Common Equity Units (and the
securities underlying such Common Equity Units) must determine
the need for, and the availability of, if necessary, any
exemptive relief under any such laws or regulations.
The Common Equity Units (and the securities underlying such
Common Equity Units) should not be acquired by any person
investing assets of a Plan unless the acquisition, holding and
disposition of the Common Equity Units (and the securities
underlying such Common Equity Units) will not constitute or
result in a prohibited transaction under Section 406 of
ERISA and Section 4975 of the Code that is not covered by
an applicable statutory or administrative exception.
Accordingly, by its acquisition of the Common Equity Units (and
the securities underlying such Common Equity Units), or any
interest therein, each purchaser, transferee or holder of the
Common Equity Units will be deemed to have represented and
warranted that either:
|
|
|
|
|
it is not acquiring the Common Equity Units (and the securities
underlying such Common Equity Units) with the assets of any Plan
(or any governmental plan, foreign plan or church plan subject
to laws or regulations similar to the provisions of Title I
of ERISA or Section 4975 of the Code); or
|
|
|
|
its acquisition, holding and disposition of the Common Equity
Units (and the securities underlying such Common Equity Units)
will not constitute or result in a non-exempt prohibited
transaction under Section 406 of ERISA or Section 4975
Code, or a violation of any similar federal, state, local or
non-U.S. laws
or regulations.
|
Additionally, each purchaser of the Common Equity Units (and the
securities underlying such Common Equity Units) will be deemed
to have directed the Remarketing Agent to take the actions set
forth in this prospectus
S-124
supplement. Any Plan fiduciary or person that proposes to cause
a Plan (or act on behalf of a Plan) to acquire the Common Equity
Units (and the securities underlying such Common Equity Units)
should consult with its counsel with respect to the potential
applicability of ERISA and the Code to such investment, the
potential consequences in their specific circumstances, and
whether any exemption would be applicable, and determine on its
own whether all conditions of such exemption or exemptions have
been satisfied.
The sale of the Common Equity Units (and the securities
underlying such Common Equity Units) to a Plan is in no respect
a representation by any person that this investment meets all
relevant legal requirements with respect to investments by Plans
generally or by any particular Plan or that this investment is
appropriate for Plans generally or any particular Plan.
S-125
UNDERWRITING
Goldman, Sachs & Co. and Citigroup Global Markets Inc.
are acting as representatives of the underwriters named below.
Subject to the terms and conditions set forth in an underwriting
agreement among MetLife, Inc., AIG, the Selling Securityholder
and the underwriters, the Selling Securityholder has agreed to
sell to each of the underwriters named below, and each of the
underwriters has severally agreed to purchase, the respective
number of Common Equity Units set forth in the following table:
|
|
|
|
|
|
|
Number of
|
|
|
|
Common
|
|
Underwriters
|
|
Equity Units
|
|
|
Goldman, Sachs & Co.
|
|
|
10,700,000
|
|
Citigroup Global Markets Inc.
|
|
|
8,000,000
|
|
Credit Suisse Securities (USA) LLC
|
|
|
3,800,000
|
|
Barclays Capital Inc.
|
|
|
2,500,000
|
|
Deutsche Bank Securities Inc.
|
|
|
2,500,000
|
|
J.P. Morgan Securities LLC
|
|
|
2,500,000
|
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated
|
|
|
2,500,000
|
|
Morgan Stanley & Co. Incorporated
|
|
|
2,500,000
|
|
UBS Securities LLC
|
|
|
2,500,000
|
|
Wells Fargo Securities, LLC
|
|
|
2,500,000
|
|
|
|
|
|
|
Total
|
|
|
40,000,000
|
|
|
|
|
|
|
Subject to the terms and conditions set forth in the
underwriting agreement, the underwriters have agreed, severally
and not jointly, to purchase all of the Common Equity Units sold
under the underwriting agreement if any of these Common Equity
Units are purchased. If an underwriter defaults, the
underwriting agreement provides that the purchase commitments of
the non-defaulting underwriters may be increased or the
underwriting agreement may be terminated.
MetLife, Inc., AIG and the Selling Securityholder have agreed to
indemnify the several underwriters against certain liabilities,
including liabilities under the Securities Act, or to contribute
to payments the underwriters may be required to make in respect
of those liabilities.
The underwriters are offering the Common Equity Units, subject
to prior sale, when, as and if issued to and accepted by them,
subject to the conditions contained in the underwriting
agreement, such as the receipt by the underwriters of
officers certificates and legal opinions. It is a
condition to the closing of the offering of the Common Equity
Units that the Coordination Agreement is in full force and
effect. The underwriters reserve the right to withdraw, cancel
or modify offers to the public and to reject orders in whole or
in part.
Commissions
and Discounts
The representatives have advised MetLife, Inc. and the Selling
Securityholder that the underwriters propose initially to offer
the Common Equity Units to the public at the public offering
price set forth on the cover page of this prospectus supplement
and to dealers at that price less a concession not in excess of
$0.2486 per Common Equity Unit. After the initial offering, the
public offering price, concession or any other term of the
offering may be changed.
S-126
The following table shows the public offering price,
underwriting discounts and commissions and proceeds before
expenses.
|
|
|
|
|
|
|
|
|
|
|
Per
|
|
|
|
|
|
|
Common
|
|
|
|
|
|
|
Equity Unit
|
|
|
Total
|
|
|
Public offering price
|
|
$
|
82.8800
|
|
|
$
|
3,315,200,000.00
|
|
Underwriting discounts and commissions
|
|
$
|
0.4144
|
|
|
$
|
16,576,000.00
|
|
Proceeds, before expenses, to the Selling Securityholder
|
|
$
|
82.4656
|
|
|
$
|
3,298,624,000.00
|
|
The expenses of the offering, not including the underwriting
discounts and commissions, to MetLife, Inc. are estimated at
$1 million.
No Sales
of Similar Securities
MetLife, Inc., its executive officers and directors, the Selling
Securityholder and AIG have each agreed not to sell or transfer
any Common Equity Units or Common Stock or securities
convertible into, exchangeable for or exercisable for Common
Equity Units or Common Stock, for 60 days after the date of
this prospectus supplement without first obtaining the written
consent of Goldman, Sachs & Co. Specifically, MetLife,
Inc., its executive officers and directors, the Selling
Securityholder and AIG have agreed, with certain limited
exceptions (including securities issued by MetLife, Inc. under
its benefit plans and securities held by affiliates of AIG and
the Selling Securityholder in connection with ordinary course
(i) proprietary and third party fund and asset management
activities, (ii) brokerage and securities trading activities and
(iii) financial services and insurance activities), not to
directly or indirectly:
|
|
|
|
|
offer, sell, issue, contract to sell, pledge or otherwise
dispose of any Common Equity Units or Common Stock or securities
convertible into or exchangeable or exercisable for any Common
Equity Units or Common Stock;
|
|
|
|
enter into a transaction that would have the same effect as
described above;
|
|
|
|
enter into any swap, hedge or other arrangement that transfers,
in whole or in part, any of the economic consequences of
ownership of the Common Equity Units or Common Stock;
|
|
|
|
in the case of MetLife, Inc., the Selling Securityholder and AIG
establish or increase a put equivalent position or liquidate or
decrease a call equivalent position in the Common Equity Units
or Common Stock;
|
|
|
|
in the case of our executive officers and directors, demand that
we file a registration statement related to the Common Equity
Units or Common Stock;
|
|
|
|
in the case of MetLife, Inc., file a registration statement
related to the Common Equity Units or Common Stock; or
|
|
|
|
in the case of MetLife, Inc., publicly disclose the intention to
take any of the foregoing actions;
|
in each case, without the prior written consent of Goldman,
Sachs & Co.
New York
Stock Exchange Listing
The Normal Common Equity Units have been approved for listing on
the New York Stock Exchange under the symbol MLU.
Price
Stabilization, Short Positions
Until the distribution of the Common Equity Units is completed,
SEC rules may limit underwriters and selling group members from
bidding for and purchasing the Common Equity Units. However, the
representatives may engage in transactions that stabilize the
price of the Common Equity Units, such as bids or purchases to
peg, fix or maintain that price.
S-127
In connection with the offering, the underwriters may purchase
and sell the Common Equity Units in the open market. These
transactions may include short sales, stabilizing transactions
and purchases on the open market to cover positions created by
short sales and stabilizing transactions. Short sales involve
the sale by the underwriters of a greater number of shares than
they are required to purchase in the offering. The underwriters
will need to close out any short sale by purchasing shares in
the open market. The underwriters are likely to create a short
position if they are concerned that there may be downward
pressure on the price of the common stock in the open market
after pricing that could adversely affect investors who purchase
in the offering. The underwriters may also impose a penalty bid.
This occurs when a particular underwriter repays to the
underwriters a portion of the underwriting discount received by
it because the representatives have repurchased Common Equity
Units sold by or for the account of such underwriter in
stabilizing or short covering transactions.
Similar to other purchase transactions, the underwriters
purchases to cover the syndicate short sales may have the effect
of raising or maintaining the market price of the Common Equity
Units or preventing or retarding a decline in the market price
of the Common Equity Units. As a result, the price of the Common
Equity Units may be higher than the price that might otherwise
exist in the open market. The underwriters may conduct these
transactions on the New York Stock Exchange, in the
over-the-counter
market or otherwise.
Neither MetLife, Inc. nor any of the underwriters makes any
representation or prediction as to the direction or magnitude of
any effect that the transactions described above may have on the
price of the Common Equity Units. In addition, neither MetLife,
Inc. nor any of the underwriters makes any representation that
the representatives will engage in these transactions or that
these transactions, once commenced, will not be discontinued
without notice.
Electronic
Offer, Sale and Distribution of Common Equity Units
In connection with the offering, certain of the underwriters or
securities dealers may distribute prospectuses by electronic
means, such as
e-mail. In
addition, one or more of the underwriters may facilitate
Internet distribution for this offering to certain of its
Internet subscription customers. One or more of the underwriters
may allocate a limited number of Common Equity Units for sale to
its online brokerage customers. An electronic prospectus is
available on the Internet web site maintained by one or more of
the underwriters. Other than the prospectus in electronic
format, the information on such underwriters web site is
neither part of this prospectus supplement nor of the
accompanying prospectus.
Other
Relationships
In the ordinary course of their respective businesses, the
underwriters and their affiliates have engaged, and may in the
future engage, in commercial, investment or retail banking
transactions with us and our affiliates for which they have in
the past received, and may in the future receive, customary fees.
In the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial
instruments (including bank loans) for their own account and for
the accounts of their customers and such investment and
securities activities may involve securities
and/or
instruments of MetLife, Inc. The underwriters and their
respective affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
Each underwriter has represented and agreed with MetLife, Inc.
as set forth below with respect to the following jurisdictions:
Notice to
Prospective Investors in the EEA
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a Relevant
Member State), with effect from and including the date on which
the Prospectus Directive is implemented in that Relevant Member
State, it has not made and will not make an offer of Common
Equity Units which is the subject of the offering contemplated
by this prospectus supplement to the public in that Relevant
Member State other than:
(a) to any legal entity which is a qualified investor as
defined in the Prospectus Directive;
S-128
(b) to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified
investors as defined in the Prospectus Directive), as permitted
under the Prospectus Directive, subject to obtaining the prior
consent of the representatives for any such offer; or
(c) in any other circumstances falling within
Article 3(2) of the Prospectus Directive,
provided, that no such offer of Common Equity Units shall
require MetLife, Inc. or any representative to publish a
prospectus pursuant to Article 3 of the Prospectus
Directive or supplement a prospectus pursuant to Article 16
of the Prospectus Directive.
For the purposes of this provision, the expression an
offer to the public in relation to any Common Equity
Units in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms
of the offer and any Common Equity Units to be offered so as to
enable an investor to decide to purchase or subscribe the Common
Equity Units, as the same may be varied in that Member State by
any measure implementing the Prospectus Directive in that Member
State, the expression Prospectus Directive
means Directive 2003/71/EC (and amendments thereto, including
the 2010 PD Amending Directive, to the extent implemented in the
Relevant Member State) and includes any relevant implementing
measure in each Relevant Member State and the expression
2010 PD Amending Directive means Directive
2010/73/EU.
Notice to
Prospective Investors in the United Kingdom
(a) It has only communicated or caused to be communicated
and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the Financial Services
and Market Act 2000, or FSMA) received by it in connection with
the issue or sale of the Common Equity Units in circumstances in
which Section 21(1) of the FSMA does not apply to MetLife,
Inc. or any representative; and
(b) It has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the Common Equity Units in, from or otherwise
involving the United Kingdom.
Notice to
Prospective Investors in Switzerland
This prospectus supplement (and the accompanying prospectus), as
well as any other material relating to the Common Equity Units
which is the subject of the offering contemplated by this
prospectus supplement (and the accompanying prospectus), do not
constitute an issue prospectus pursuant to Article 652a or
Article 1156 of the Swiss Code of Obligations. The Common
Equity Units will not be listed on the SIX Swiss Exchange and,
therefore, the documents relating to the Common Equity Units,
including, but not limited to, this prospectus supplement (and
the accompanying prospectus) may not comply with the disclosure
standards of the listing rules (including any additional listing
rules or prospectus schemes) of the SIX Swiss Exchange. The
Common Equity Units are being offered in Switzerland by way of a
private placement, i.e., to a small number of selected investors
only, without any public offer and only to investors who do not
purchase the Common Equity Units with the intention to
distribute it to the public. The investors will be individually
approached by the issuer from time to time. This prospectus
supplement (and the accompanying prospectus) as well as any
other material relating to the Common Equity Units, is personal
and confidential and does not constitute an offer to any other
person. This prospectus supplement (and the accompanying
prospectus) may only be used by those investors to whom it has
been handed out in connection with the offering described herein
and may neither directly nor indirectly be distributed or made
available to other persons without express consent of the
issuer. It may not be used in connection with any other offer
and shall in particular not be copied
and/or
distributed to the public in (or from) Switzerland.
Notice to
Prospective Investors in the Dubai International Financial
Centre
This prospectus supplement (and the accompanying prospectus)
relates to an exempt offer in accordance with the Offered
Securities Rules of the Dubai Financial Services Authority. This
prospectus supplement (and the accompanying prospectus) is
intended for distribution only to persons of a type specified in
those rules. It must not be delivered to, or relied on by, any
other person. The Dubai Financial Services Authority has no
responsibility for
S-129
reviewing or verifying any documents in connection with exempt
offers. The Dubai Financial Services Authority has not approved
this prospectus supplement (and the accompanying prospectus) nor
taken steps to verify the information set out in it, and has no
responsibility for it. The Common Equity Units which are the
subject of the offering contemplated by this prospectus
supplement may be illiquid
and/or
subject to restrictions on their resale. Prospective purchasers
of the Common Equity Units offered should conduct their own due
diligence on the Common Equity Units. If you do not understand
the contents of this prospectus supplement (and the accompanying
prospectus) you should consult an authorized financial adviser.
Notice to
Prospective Investors in Australia
This prospectus supplement (and the accompanying prospectus) is
not a formal disclosure document and has not been, nor will be,
lodged with the Australian Securities and Investments
Commission. This prospectus supplement (and the accompanying
prospectus) does not purport to contain all information that
investors or their professional advisers would expect to find in
a prospectus or other disclosure document (as defined in the
Corporations Act 2001 (Australia)) for the purposes of
Part 6D.2 of the Corporations Act 2001 (Australia) or in a
product disclosure statement for the purposes of Part 7.9
of the Corporations Act 2001 (Australia), in either case, in
relation to the Common Equity Units.
The Common Equity Units are not being offered in Australia to
retail clients as defined in sections 761G and
761GA of the Corporations Act 2001 (Australia). This offering is
being made in Australia solely to wholesale clients
for the purposes of section 761G of the Corporations Act
2001 (Australia) and, as such, no prospectus, product disclosure
statement or other disclosure document in relation to the Common
Equity Units has been, or will be, prepared.
This prospectus supplement (and the accompanying prospectus)
does not constitute an offer in Australia other than to
wholesale clients. By submitting an application for the Common
Equity Units, you represent and warrant to us that you are a
wholesale client for the purposes of section 761G of the
Corporations Act 2001 (Australia). If any recipient of this
prospectus supplement (and the accompanying prospectus) is not a
wholesale client, no offer of, or invitation to apply for, the
Common Equity Units shall be deemed to be made to such recipient
and no applications for the Common Equity Units will be accepted
from such recipient. Any offer to a recipient in Australia, and
any agreement arising from acceptance of such offer, is personal
and may only be accepted by the recipient. In addition, by
applying the Common Equity Units you undertake to us that, for a
period of 12 months from the date of issue of the Common
Equity Units, you will not transfer any interest in the Common
Equity Units to any person in Australia other than to a
wholesale client.
Notice to
Prospective Investors in Hong Kong
The Common Equity Units may not be offered or sold by means of
any document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the
Companies Ordinance (Cap. 32, Laws of Hong Kong), or
(ii) to professional investors within the
meaning of the Securities and Futures Ordinance (Cap. 571, Laws
of Hong Kong) and any rules made thereunder, or (iii) in
other circumstances which do not result in this prospectus
supplement (and the accompanying prospectus) being a
prospectus within the meaning of the Companies
Ordinance (Cap. 32, Laws of Hong Kong), and no advertisement,
invitation or document relating to the Common Equity Units may
be issued or may be in the possession of any person for the
purpose of issue (in each case, whether in Hong Kong or
elsewhere), which is directed at, or the contents of which are
likely to be accessed or read by, the public in Hong Kong
(except if permitted to do so under the laws of Hong Kong) other
than with respect to the Common Equity Units which are or are
intended to be disposed of only to persons outside Hong Kong or
only to professional investors within the meaning of
the Securities and Futures Ordinance (Cap. 571, Laws of Hong
Kong) and any rules made thereunder.
Notice to
Prospective Investors in Japan
The Common Equity Units have not been and will not be registered
under the Financial Instruments and Exchange Law of Japan (the
Financial Instruments and Exchange Law) and
each underwriter has agreed that it will not offer or sell any
Common Equity Units, directly or indirectly, in Japan or to, or
for the benefit of, any
S-130
resident of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of
Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws,
regulations and ministerial guidelines of Japan.
Notice to
Prospective Investors in Singapore
Neither this prospectus supplement nor the accompanying
prospectus has been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, this prospectus supplement,
the accompanying prospectus or any other document or material in
connection with the offer or sale, or invitation for
subscription or purchase, of the Common Equity Units may not be
circulated or distributed, nor may the Common Equity Units be
offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to
persons in Singapore other than (i) to an institutional
investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore (the SFA),
(ii) to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA.
Where the Common Equity Units are subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
common stock, debentures and units of common stock and
debentures of that corporation or the beneficiaries rights
and interest in that trust shall not be transferable for
6 months after that corporation or that trust has acquired
the Common Equity Units under Section 275 except:
(1) to an institutional investor under Section 274 of
the SFA or to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA; (2) where no
consideration is given for the transfer; or (3) by
operation of law.
S-131
LEGAL
OPINIONS
Certain legal matters will be passed upon for MetLife, Inc. by
Matthew Ricciardi, Chief Counsel Public Company and
Corporate Law, of MetLife Group, Inc., an affiliate of MetLife,
Inc. The validity of the Common Equity Units offered hereby will
be passed upon by Dewey & LeBoeuf LLP, New York, New
York, which has also acted as special tax counsel for MetLife,
Inc. Certain legal matters will be passed upon for the Selling
Securityholder by Sullivan & Cromwell LLP, New York,
New York. Mr. Ricciardi is paid a salary by an affiliate of
MetLife, Inc., is a participant in various employee benefit
plans offered by MetLife, Inc. and its affiliates to employees
generally, is paid equity-based compensation in accordance with
MetLifes compensation programs and owns MetLife, Inc.
Common Stock. Dewey & LeBoeuf LLP has, from time to
time, represented, currently represents, and may continue to
represent, some or all of the underwriters in connection with
various legal matters. Dewey & LeBoeuf LLP maintains
various group and other insurance policies with MLIC.
Debevoise & Plimpton LLP, New York, New York and
Cleary Gottlieb Steen & Hamilton LLP, New York, New
York are acting as counsel to the underwriters.
Debevoise & Plimpton LLP has in the past provided, and
continues to provide, legal services to MetLife, Inc. and
certain of its affiliates, and to AIG and certain of its
affiliates. Debevoise & Plimpton LLP maintains various
group insurance policies with MLIC.
EXPERTS
The consolidated financial statements and financial statement
schedules, incorporated by reference in this prospectus
supplement from the 2010
Form 10-K,
and the effectiveness of MetLifes internal control over
financial reporting for the year ended December 31, 2010,
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their reports (which (1) express an unqualified opinion on
the consolidated financial statements and financial statement
schedules and includes an explanatory paragraph regarding
changes in MetLifes method of accounting for the
recognition and presentation of
other-than-temporary
impairment losses for certain investments as required by
accounting guidance adopted on April 1, 2009, and its
method of accounting for certain assets and liabilities to a
fair value measurement approach as required by accounting
guidance adopted on January 1, 2008, and (2) express
an unqualified opinion on MetLifes effectiveness of
internal control over financial reporting), which are
incorporated herein by reference. Such consolidated financial
statements and financial statement schedules have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
The audited historical combined financial statements of American
Life, ALICO Services, Inc. and DelAm and subsidiaries
(collectively, the Company) included as
Exhibit 99.1 to MetLife, Inc.s Current Report on Form 8-K
dated August 2, 2010 and incorporated by reference in this
prospectus supplement have been so incorporated in reliance on
the report (which contains an explanatory paragraph related to
the Companys change in method of accounting for
other-than-temporary impairments of fixed maturity securities as
of March 1, 2009) of PricewaterhouseCoopers LLP, an independent
registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting.
S-132
PROSPECTUS
METLIFE,
INC.
DEBT SECURITIES, PREFERRED STOCK,
DEPOSITARY SHARES,
COMMON STOCK, WARRANTS, PURCHASE CONTRACTS AND UNITS
METLIFE
CAPITAL TRUST V
METLIFE CAPITAL TRUST VI
METLIFE CAPITAL TRUST VII
METLIFE CAPITAL TRUST VIII
METLIFE CAPITAL TRUST IX
TRUST PREFERRED
SECURITIES
Fully and Unconditionally Guaranteed by MetLife, Inc.,
As Described in this Prospectus and the Accompanying Prospectus
Supplement
MetLife, Inc., or any of the trusts named above, may offer these
securities, or any combination thereof, from time to time in
amounts, at prices and on other terms to be determined at the
time of the offering. MetLife, Inc., or any of the trusts named
above, will provide the specific terms of these securities in
supplements to this prospectus. You should read this prospectus
and the accompanying prospectus supplement carefully before you
make your investment decision.
THIS PROSPECTUS MAY NOT BE USED TO SELL SECURITIES UNLESS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
MetLife, Inc., or any of the trusts named above, may offer
securities through underwriting syndicates managed or co-managed
by one or more underwriters, through agents, or directly to
purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for
that offering. For general information about the distribution of
securities offered, please see Plan of Distribution
in this prospectus.
MetLife, Inc.s common stock is listed on the New York
Stock Exchange under the trading symbol MET. Unless
otherwise stated in this prospectus or an accompanying
prospectus supplement, none of these securities will be listed
on a securities exchange, other than MetLife, Inc.s common
stock.
MetLife, Inc., or any of the trusts named above, or any of their
respective affiliates may use this prospectus and the applicable
prospectus supplement in a remarketing or other resale
transaction involving the securities after their initial sale.
These transactions may be executed at negotiated prices that are
related to market prices at the time of purchase or sale, or at
other prices, as determined from time to time.
Investing in our securities or the securities of the trusts
involves risk. See Risk Factors on page 1 of
this prospectus.
None of the Securities and Exchange Commission, any state
securities commission, the New York Superintendent of Insurance
or any other regulatory body has approved or disapproved of
these securities or determined if this prospectus or the
accompanying prospectus supplement is truthful or complete. They
have not made, nor will they make, any determination as to
whether anyone should buy these securities. Any representation
to the contrary is a criminal offense.
The date of this prospectus is November 30, 2010
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
25
|
|
|
|
|
28
|
|
|
|
|
30
|
|
|
|
|
32
|
|
|
|
|
32
|
|
i
ABOUT
THIS PROSPECTUS
Unless otherwise stated or the context otherwise requires,
references in this prospectus to MetLife,
we, our, or us refer to
MetLife, Inc., and its direct and indirect subsidiaries, while
references to MetLife, Inc. refer only to MetLife,
Inc. on an unconsolidated basis. References in this prospectus
to the trusts refer to MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX.
This prospectus is part of a registration statement that
MetLife, Inc. and the trusts filed with the U.S. Securities
and Exchange Commission (the SEC) using a
shelf registration process. Under this shelf
process, MetLife, Inc. may, from time to time, sell any
combination of debt securities, preferred stock, depositary
shares, common stock, warrants, purchase contracts and units and
the trusts may, from time to time, sell trust preferred
securities guaranteed by MetLife, Inc., as described in this
prospectus, in one or more offerings in one or more foreign
currencies, foreign currency units or composite currencies. This
prospectus provides you with a general description of the
securities MetLife, Inc. and the trusts may offer. Each time
that securities are sold, a prospectus supplement that will
contain specific information about the terms of that offering
will be provided. The prospectus supplement may also add, update
or change information contained in this prospectus. You should
read both this prospectus and any prospectus supplement together
with additional information described under the heading
Where You Can Find More Information.
You should rely on the information contained or incorporated by
reference in this prospectus. Neither MetLife, Inc. nor the
trusts have authorized anyone to provide you with different
information. If anyone provides you with different or
inconsistent information, you should not rely on it. Neither
MetLife, Inc. nor the trusts are making an offer to sell these
securities in any jurisdiction where the offer or sale is not
permitted.
You should assume that the information in this prospectus is
accurate as of the date of the prospectus. Our business,
financial condition, results of operations and prospects may
have changed since that date.
RISK
FACTORS
Investing in MetLife, Inc. securities or the securities of the
trusts involve risks. We urge you to carefully consider the risk
factors described in our filings with the SEC that are
incorporated by reference in this prospectus and, if applicable,
in any prospectus supplement, pricing supplement or free writing
prospectus used in connection with an offering of our
securities, as well as the information relating to us identified
herein in Note Regarding Forward-Looking Statements,
before making an investment decision.
NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus and the accompanying prospectus supplement may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. These statements can be identified by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance. Actual results could
differ materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the U.S. Securities and Exchange
1
Commission (the SEC). These factors include:
(1) the imposition of onerous conditions following the
acquisition of American Life Insurance Company
(ALICO), a subsidiary of ALICO Holdings LLC
(ALICO Holdings) and Delaware American Life
Insurance Company (DelAm) (collectively, the
Acquisition); (2) difficulties in integrating
the business acquired in the Acquisition (the Alico
Business); (3) uncertainty with respect to the
outcome of the closing agreement entered into between ALICO and
the United States Internal Revenue Service in connection with
the Acquisition; (4) uncertainty with respect to the making
of elections under Section 338 of the U.S. Internal
Revenue Code of 1986, as amended, and any benefits therefrom;
(5) an inability to manage the growth of the Alico
Business; (6) a writedown of the goodwill established in
connection with the Acquisition; (7) exchange rate
fluctuations; (8) an inability to predict the financial
impact of the Acquisition on MetLifes business and
financial results; (9) events relating to American
International Group, Inc. (AIG) that could adversely
affect the Alico Business or MetLife; (10) the dilutive
impact on MetLife, Inc.s stockholders resulting from the
issuance of equity securities to ALICO Holdings in connection
with the Acquisition; (11) a decrease in MetLife,
Inc.s stock price as a result of ALICO Holdings
ability to sell its equity securities; (12) the conditional
payment obligation of approximately $300 million to ALICO
Holdings if the conversion of the Series B Contingent
Convertible Junior Participating Non-Cumulative Perpetual
Preferred Stock (Series B Preferred Stock)
issued to ALICO Holdings in connection with the Acquisition into
MetLife, Inc.s common stock is not approved;
(13) change of control provisions in the Alico
Business agreements; (14) effects of guarantees
within certain of the Alico Business variable life and
annuity products; (15) regulatory action in the financial
services industry affecting the combined business;
(16) financial instability in Europe and possible
writedowns of sovereign debt of European nations;
(17) difficult conditions in the global capital markets;
(18) increased volatility and disruption of the capital and
credit markets, which may affect MetLifes ability to seek
financing or access its credit facilities; (19) uncertainty
about the effectiveness of the U.S. governments
programs to stabilize the financial system, the imposition of
fees relating thereto, or the promulgation of additional
regulations; (20) impact of comprehensive financial
services regulation reform on MetLife; (21) exposure to
financial and capital market risk; (22) changes in general
economic conditions, including the performance of financial
markets and interest rates, which may affect MetLifes
ability to raise capital, generate fee income and market-related
revenue and finance statutory reserve requirements and may
require MetLife to pledge collateral or make payments related to
declines in value of specified assets; (23) potential
liquidity and other risks resulting from MetLifes
participation in a securities lending program and other trans
actions; (24) investment losses and defaults, and changes
to investment valuations; (25) impairments of goodwill and
realized losses or market value impairments to illiquid assets;
(26) defaults on MetLifes mortgage loans;
(27) the impairment of other financial institutions;
(28) MetLifes ability to address unforeseen
liabilities, asset impairments, or rating actions arising from
any future acquisitions or dispositions, and to successfully
integrate acquired businesses with minimal disruption;
(29) economic, political, currency and other risks relating
to MetLifes international operations; (30) MetLife,
Inc.s primary reliance, as a holding company, on dividends
from its subsidiaries to meet debt payment obligations and the
applicable regulatory restrictions on the ability of the
subsidiaries to pay such dividends; (31) downgrades in
MetLife, Inc.s and its affiliates claims paying
ability, financial strength or credit ratings;
(32) ineffectiveness of risk management policies and
procedures; (33) availability and effectiveness of
reinsurance or indemnification arrangements, as well as default
or failure of counterparties to perform; (34) discrepancies
between actual claims experience and assumptions used in setting
prices for MetLifes products and establishing the
liabilities for MetLifes obligations for future policy
benefits and claims; (35) catastrophe losses;
(36) heightened competition, including with respect to
pricing, entry of new competitors, consolidation of
distributors, the development of new products by new and
existing competitors, distribution of amounts available under
U.S. government programs, and for personnel;
(37) unanticipated changes in industry trends;
(38) changes in accounting standards, practices
and/or
policies; (39) changes in assumptions related to deferred
policy acquisition costs (DAC), deferred sales
inducements (DSI), value of business acquired
(VOBA) or goodwill; (40) increased expenses
relating to pension and postretirement benefit plans, as well as
health care and other employee benefits; (41) exposure to
losses related to variable annuity guarantee benefits, including
from significant and sustained downturns or extreme volatility
in equity markets, reduced interest rates, unanticipated
policyholder behavior, mortality or longevity, and the
adjustment for nonperformance risk; (42) deterioration in
the experience of the closed block established in
connection with the reorganization of Metropolitan Life
Insurance Company; (43) adverse results or other
consequences from litigation, arbitration or regulatory
investigations; (44) discrepancies between actual
experience and assumptions used in establishing liabilities
related to other contingencies or obligations;
(45) regulatory, legislative or tax changes relating to
MetLifes insurance,
2
banking, international, or other operations that may affect the
cost of, or demand for, MetLifes products or services,
impair its ability to attract and retain talented and
experienced management and other employees, or increase the cost
or administrative burdens of providing benefits to employees;
(46) the effects of business disruption or economic
contraction due to terrorism, other hostilities, or natural
catastrophes; (47) the effectiveness of MetLifes
programs and practices in avoiding giving its associates
incentives to take excessive risks; (48) other risks and
uncertainties described from time to time in MetLife,
Inc.s filings with the SEC; and (49) any of the
foregoing factors as they relate to the Alico Business and its
operations.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus and the
accompanying prospectus supplements, please remember that they
are included to provide you with information regarding their
terms and are not intended to provide any other factual or
disclosure information about MetLife, Inc., its subsidiaries or
the other parties to the agreements. The agreements contain
representations and warranties by each of the parties to the
applicable agreement. These representations and warranties have
been made solely for the benefit of the other parties to the
applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties if those statements prove to be inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time. Additional information about MetLife,
Inc. and its subsidiaries may be found elsewhere in this
prospectus and the accompanying prospectus supplement, as well
as MetLife, Inc.s other public filings, which are
available without charge through the SEC website at www.sec.gov.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the SEC. These reports, proxy statements and
other information, including the registration statement of which
this prospectus is a part, can be read and copied at the
SECs public reference room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and traded on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York
10005.
The SEC allows incorporation by reference into this
prospectus of information that MetLife, Inc. files with the SEC.
This permits MetLife, Inc. to disclose important information to
you by referencing these filed documents. Any information
referenced this way is considered part of this prospectus, and
any information filed with the SEC subsequent to the date of
this prospectus will automatically be deemed to update and
supersede this information. Information furnished under
Item 2.02 and Item 7.01 of MetLife, Inc.s
Current Reports on
Form 8-K
is not
3
incorporated by reference in this registration statement and
prospectus. MetLife, Inc. incorporates by reference the
following documents which have been filed with the SEC:
|
|
|
|
|
Annual Report on
Form 10-K
and
Form 10-K/A
for the year ended December 31, 2009;
|
|
|
|
Quarterly Reports on
Form 10-Q
and
Form 10-Q/A
for the quarter ended March 31, 2010 and Quarterly Reports
on
Form 10-Q
for the quarters ended June 30, 2010 and September 30,
2010;
|
|
|
|
Registration Statement on
Form 8-A,
dated March 31, 2000, relating to registration of shares of
MetLife, Inc.s common stock;
|
|
|
|
Definitive Proxy Statement filed on March 23, 2010
(Proxy Statement); and
|
|
|
|
Current Reports on
Form 8-K
filed January 29, 2010, February 22, 2010,
March 5, 2010, March 11, 2010, April 13, 2010,
May 3, 2010, May 7, 2010, May 17, 2010,
August 2, 2010, August 5, 2010, August 6, 2010,
August 16, 2010, October 18, 2010, October 28,
2010, October 29, 2010, November 2, 2010,
November 15, 2010 and November 30, 2010.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934 until MetLife, Inc. and the trusts file a
post-effective amendment which indicates the termination of the
offering of the securities made by this prospectus. Any reports
filed by us with the SEC after the date of this prospectus and
before the date that the offering of the securities by means of
this prospectus is terminated will automatically update and,
where applicable, supersede any information contained in this
prospectus or incorporated by reference in this prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents which are
incorporated by reference into this prospectus, other than
exhibits to those documents, unless those exhibits are
specifically incorporated by reference into those documents.
Requests should be directed to Investor Relations, MetLife,
Inc., 1095 Avenue of the Americas, New York, New York 10036, by
electronic mail (metir@metlife.com) or by telephone
(212-578-2211).
You may also obtain some of the documents incorporated by
reference into this document at MetLifes website,
www.metlife.com. You should be aware that all other information
contained on MetLifes website is not a part of this
document.
METLIFE,
INC.
We are a leading provider of insurance, employee benefits and
financial services with operations throughout the United States
and the Latin America, Asia Pacific and Europe, Middle East and
India regions. Through our subsidiaries and affiliates, we offer
life insurance, annuities, auto and homeowners insurance, retail
banking and other financial services to individuals, as well as
group insurance and retirement & savings products and
services to corporations and other institutions.
As a holding company, the primary source of MetLife, Inc.s
liquidity is dividends it receives from its insurance
subsidiaries. MetLife, Inc.s insurance subsidiaries are
subject to regulatory restrictions on the payment of dividends
imposed by the regulators of their respective domiciles. The
dividend limitation for U.S. insurance subsidiaries is
based on the surplus to policyholders as of the immediately
preceding calendar year and statutory net gain from operations
of the immediately preceding calendar year. Statutory accounting
practices, as prescribed by insurance regulators of various
states in which we conduct business, differ in certain respects
from accounting principles used in financial statements prepared
in conformity with GAAP. The significant differences relate to
the treatment of DAC, certain deferred income tax, required
investment reserves, reserve calculation assumptions, goodwill
and surplus notes.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188,
and its telephone number is
212-578-2211.
4
THE
TRUSTS
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX are statutory trusts formed on
October 31, 2007 under Delaware law pursuant to
declarations of trust between the trustees named therein and
MetLife, Inc. and the filing of certificates of trust with the
Secretary of State of the State of Delaware. MetLife, Inc., as
sponsor of the trusts, and the trustees named in the
declarations of trust will amend and restate the declarations of
trust in their entirety substantially in the forms which are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, as of or prior
to the date the trusts issue any trust preferred securities. The
declarations of trust will be qualified as indentures under the
Trust Indenture Act of 1939, as amended (the
Trust Indenture Act).
The trusts exist for the exclusive purposes of:
|
|
|
|
|
issuing preferred securities offered by this prospectus and
common securities to MetLife, Inc.;
|
|
|
|
investing the gross proceeds of the preferred securities and
common securities in related series of debt securities, which
may be senior or subordinated, issued by MetLife, Inc.; and
|
|
|
|
engaging in only those other activities which are necessary,
appropriate, convenient or incidental to the purposes set forth
above.
|
The payment of periodic cash distributions on the trust
preferred securities and payments on liquidation and redemption
with respect to the trust preferred securities, in each case to
the extent the trusts have funds legally and immediately
available, will be guaranteed by MetLife, Inc. to the extent set
forth under Description of Guarantees.
MetLife, Inc. will own, directly or indirectly, all of the
common securities of the trusts. The common securities will
represent an aggregate liquidation amount equal to at least 3%
of each trusts total capitalization. The preferred
securities of each trust will represent the remaining 97% of
each trusts total capitalization. The common securities
will have terms substantially identical to, and will rank equal
in priority of payment with, the preferred securities. However,
if MetLife, Inc. defaults on the related series of debt
securities, then cash distributions and liquidation, redemption
and other amounts payable on the common securities will be
subordinate to the trust preferred securities in priority of
payment.
The trusts each have a term of approximately 55 years, but
may dissolve earlier as provided in their respective
declarations of trust. The trusts activities will be
conducted by the trustees appointed by MetLife, Inc., as the
direct or indirect holder of all of the common securities. The
holder of the common securities of each trust will be entitled
to appoint, remove or replace any of, or increase or reduce the
number of, the trustees of the trust. However, the number of
trustees shall be at least three, at least one of which shall be
an administrative trustee. The duties and obligations of the
trustees will be governed by the declaration of trust for each
trust. A majority of the trustees of each trust will be persons
who are employees or officers of or affiliated with MetLife,
Inc. One trustee of each trust will be a financial institution
which will be unaffiliated with MetLife, Inc. and which will act
as property trustee and as indenture trustee for purposes of the
Trust Indenture Act, pursuant to the terms set forth in a
prospectus supplement. In addition, unless the property trustee
maintains a principal place of business in the State of
Delaware, and otherwise meets the requirements of applicable
law, one trustee of each trust will have its principal place of
business or reside in the State of Delaware.
The property trustee will hold title to the debt securities for
the benefit of the holders of the trust securities and the
property trustee will have the power to exercise all rights,
powers and privileges under the indenture as the holder of the
debt securities. In addition, the property trustee will maintain
exclusive control of a segregated non-interest bearing bank
account to hold all payments made in respect of the debt
securities for the benefit of the holders of the trust
securities. The property trustee will make payments of
distributions and payments on liquidation, redemption and
otherwise to the holders of the trust securities out of funds
from this property account.
The rights of the holders of the trust preferred securities,
including economic rights, rights to information and voting
rights, are provided in the declarations of trust of MetLife
Capital Trust V, MetLife Capital Trust VI, MetLife
Capital Trust VII, MetLife Capital Trust VIII and
MetLife Capital Trust IX, including any amendments thereto,
the trust preferred securities, the Delaware Statutory
Trust Act and the Trust Indenture Act.
5
MetLife, Inc. will pay all fees and expenses related to the
trusts and the offering of trust preferred securities. The
principal offices of each trust is: The Bank of New York
(Delaware), 100 White Clay Center, Route 273, Newark, Delaware
19711, Attention: Corporate Trust Administration. The
telephone number of each trust is:
302-283-8905.
Please read the prospectus supplement relating to the trust
preferred securities for further information concerning the
trusts and the trust preferred securities.
USE OF
PROCEEDS
We may use the proceeds of securities sold or re-sold under this
registration statement for, among other things, general
corporate purposes. The prospectus supplement for each offering
of securities will specify the intended use of the proceeds of
that offering. Unless otherwise indicated in an accompanying
prospectus supplement, the trusts will use all of the proceeds
they receive from the sale of trust preferred securities to
purchase debt securities issued by MetLife, Inc.
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth MetLifes historical ratio
of earnings to fixed charges for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine
|
|
|
|
|
|
|
|
|
|
|
|
|
Months Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
For the Years Ended December 31,
|
|
|
2010
|
|
2009
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
|
(In millions)
|
|
Ratio of Earnings to Fixed Charges(1),(2)
|
|
|
1.75
|
|
|
|
|
|
|
|
|
|
|
|
1.92
|
|
|
|
1.74
|
|
|
|
1.60
|
|
|
|
1.87
|
|
|
|
|
(1) |
|
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, non-controlling interest and fixed charges,
excluding capitalized interest. Fixed charges are the sum of
interest and debt issue costs, interest credited to bank
deposits, interest credited to policyholder account balances, an
estimated interest component of rent expense and preferred stock
dividends. Interest costs of $312 million related to
variable interest entities are included in this computation for
the nine months ended September 30, 2010. |
|
(2) |
|
Earnings were insufficient to cover fixed charges at a 1:1 ratio
by $3,069 million and $2,860 million for the nine
months ended September 30, 2009 and the year ended
December 31, 2009, respectively, primarily due to increased
net derivatives losses on freestanding derivatives. |
DESCRIPTION
OF SECURITIES
This prospectus contains summary descriptions of the debt
securities, preferred stock, depositary shares, common stock,
warrants, purchase contracts and units that MetLife, Inc. may
sell from time to time, and the trust preferred securities
guaranteed by MetLife, Inc. that the trusts may sell from time
to time. These summary descriptions are not meant to be complete
descriptions of each security. However, this prospectus and the
accompanying prospectus supplement contain the material terms of
the securities being offered.
DESCRIPTION
OF DEBT SECURITIES
As used in this prospectus, debt securities means the
debentures, notes, bonds and other evidences of indebtedness
that MetLife, Inc. may issue from time to time. The debt
securities will either be senior debt securities or subordinated
debt securities. Unless the applicable prospectus supplement
states otherwise, senior debt securities will be issued under
the Senior Indenture dated as of November 9, 2001 between
MetLife, Inc, and Bank One Trust Company, N.A. (predecessor
to The Bank of New York Mellon Trust Company, N.A.) (the
Senior Indenture) and subordinated debt securities
will be issued under the Subordinated Indenture dated as of
June 21, 2005 between MetLife, Inc. and J.P. Morgan
Trust Company, National Association (predecessor to The
Bank of
6
New York Mellon Trust Company, N.A.) (the
Subordinated Indenture). This prospectus sometimes
refers to the Senior Indenture and the Subordinated Indenture
collectively as the Indentures.
The Senior Indenture and the Subordinated Indenture are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part. The statements
and descriptions in this prospectus or in any prospectus
supplement regarding provisions of the Indentures and debt
securities are summaries thereof, do not purport to be complete
and are subject to, and are qualified in their entirety by
reference to, all of the provisions of the Indentures and the
debt securities, including the definitions therein of certain
terms.
General
The debt securities will be direct unsecured obligations of
MetLife, Inc. The senior debt securities will rank equally with
all of MetLife, Inc.s other senior and unsubordinated
debt. The subordinated debt securities will be subordinate and
junior in right of payment to all of MetLife, Inc.s
present and future senior indebtedness.
Because MetLife, Inc. is principally a holding company, its
right to participate in any distribution of assets of any
subsidiary, including Metropolitan Life Insurance Company, upon
the subsidiarys liquidation or reorganization or
otherwise, is subject to the prior claims of creditors of the
subsidiary, except to the extent MetLife, Inc. may be recognized
as a creditor of that subsidiary. Accordingly, MetLife,
Inc.s obligations under the debt securities will be
effectively subordinated to all existing and future indebtedness
and liabilities of its subsidiaries, including liabilities under
contracts of insurance and annuities written by MetLife,
Inc.s insurance subsidiaries, and holders of debt
securities should look only to MetLife, Inc.s assets for
payment thereunder.
The Indentures do not limit the aggregate principal amount of
debt securities that MetLife, Inc. may issue and provide that
MetLife, Inc. may issue debt securities from time to time in one
or more series, in each case with the same or various
maturities, at par or at a discount. MetLife, Inc. may issue
additional debt securities of a particular series without the
consent of the holders of the debt securities of such series
outstanding at the time of the issuance. Any such additional
debt securities, together with all other outstanding debt
securities of that series, will constitute a single series of
debt securities under the applicable Indenture. The Indentures
also do not limit our ability to incur other debt.
Each prospectus supplement will describe the terms relating to
the specific series of debt securities being offered. These
terms will include some or all of the following:
|
|
|
|
|
the title of debt securities and whether they are subordinated
debt securities or senior debt securities;
|
|
|
|
any limit on the aggregate principal amount of the debt
securities;
|
|
|
|
the price or prices at which MetLife, Inc. will sell the debt
securities;
|
|
|
|
the maturity date or dates of the debt securities;
|
|
|
|
the rate or rates of interest, if any, which may be fixed or
variable, per annum at which the debt securities will bear
interest, or the method of determining such rate or rates, if
any;
|
|
|
|
the date or dates from which any interest will accrue, the dates
on which interest will be payable, or the method by which such
date or dates will be determined;
|
|
|
|
the right, if any, to extend the interest payment periods and
the duration of any such deferral period, including the maximum
consecutive period during which interest payment periods may be
extended;
|
|
|
|
whether the amount of payments of principal of (and premium, if
any) or interest on the debt securities may be determined with
reference to any index, formula or other method, such as one or
more currencies, commodities, equity indices or other indices,
and the manner of determining the amount of such payments;
|
|
|
|
the dates on which MetLife, Inc. will pay interest on the debt
securities and the regular record date for determining who is
entitled to the interest payable on any interest payment date;
|
|
|
|
the place or places where the principal of (and premium, if any)
and interest on the debt securities will be payable;
|
7
|
|
|
|
|
if MetLife, Inc. possesses the option to do so, the periods
within which and the prices at which MetLife, Inc. may redeem
the debt securities, in whole or in part, pursuant to optional
redemption provisions, and the other terms and conditions of any
such provisions;
|
|
|
|
MetLife, Inc.s obligation, if any, to redeem, repay or
purchase debt securities by making periodic payments to a
sinking fund or through an analogous provision or at the option
of holders of the debt securities, and the period or periods
within which and the price or prices at which MetLife, Inc. will
redeem, repay or purchase the debt securities, in whole or in
part, pursuant to such obligation, and the other terms and
conditions of such obligation;
|
|
|
|
the denominations in which the debt securities will be issued,
if other than denominations of $1,000 and integral multiples of
$1,000;
|
|
|
|
the portion, or methods of determining the portion, of the
principal amount of the debt securities which MetLife, Inc. must
pay upon the acceleration of the maturity of the debt securities
in connection with an Event of Default (as described below), if
other than the full principal amount;
|
|
|
|
the currency, currencies or currency unit in which MetLife, Inc.
will pay the principal of (and premium, if any) or interest, if
any, on the debt securities, if not United States dollars and
the manner of determining the equivalent thereof in United
States dollars;
|
|
|
|
provisions, if any, granting special rights to holders of the
debt securities upon the occurrence of specified events;
|
|
|
|
any deletions from, modifications of or additions to the Events
of Default or MetLife, Inc.s covenants with respect to the
applicable series of debt securities, and whether or not such
Events of Default or covenants are consistent with those
contained in the applicable Indenture;
|
|
|
|
the application, if any, of the terms of the Indenture relating
to defeasance and covenant defeasance (which terms are described
below) to the debt securities;
|
|
|
|
whether the subordination provisions summarized below or
different subordination provisions will apply to the debt
securities;
|
|
|
|
the terms, if any, upon which the holders may or are required to
convert or exchange such debt securities into or for MetLife,
Inc.s common stock or other securities or property or into
securities of a third party, including conversion price (which
may be adjusted), the method of calculating the conversion
price, or the conversion period;
|
|
|
|
whether any of the debt securities will be issued in global or
certificated form and, if so, the terms and conditions upon
which global debt securities may be exchanged for certificated
debt securities;
|
|
|
|
any change in the right of the trustee or the requisite holders
of debt securities to declare the principal amount thereof due
and payable because of an Event of Default;
|
|
|
|
the depositary for global or certificated debt securities;
|
|
|
|
if applicable, a discussion of the U.S. federal income tax
considerations applicable to specific debt securities;
|
|
|
|
any trustees, authenticating or paying agents, transfer agents
or registrars or other agents with respect to the debt
securities; and
|
|
|
|
any other terms of the debt securities not inconsistent with the
provisions of the Indentures, as amended or supplemented.
|
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will not be listed on any
securities exchange.
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will be issued in fully
registered form without coupons.
8
Debt securities may be sold at a substantial discount below
their stated principal amount, bearing no interest or interest
at a rate which at the time of issuance is below market rates.
The applicable prospectus supplement will describe the federal
income tax consequences and special considerations applicable to
any such debt securities. The debt securities may also be issued
as indexed securities or securities denominated in foreign
currencies or currency units, as described in more detail in the
prospectus supplement relating to any of the particular debt
securities. The prospectus supplement relating to specific debt
securities will also describe any special considerations and
certain additional tax considerations applicable to such debt
securities.
Subordination
The prospectus supplement relating to any offering of
subordinated debt securities will describe the specific
subordination provisions. However, unless otherwise noted in the
prospectus supplement, subordinated debt securities will be
subordinate and junior in right of payment to all of MetLife,
Inc.s Senior Indebtedness (as described below).
Under the Subordinated Indenture, Senior
Indebtedness means all amounts due on obligations in
connection with any of the following, whether outstanding at the
date of execution of the Subordinated Indenture or thereafter
incurred or created:
|
|
|
|
|
the principal of (and premium, if any) and interest in respect
of indebtedness of MetLife, Inc. for borrowed money and
indebtedness evidenced by securities, debentures, bonds or other
similar instruments issued by MetLife, Inc.;
|
|
|
|
all capital lease obligations of MetLife, Inc.;
|
|
|
|
all obligations of MetLife, Inc. issued or assumed as the
deferred purchase price of property, all conditional sale
obligations of MetLife, Inc. and all obligations of MetLife,
Inc. under any title retention agreement (but excluding trade
accounts payable in the ordinary course of business);
|
|
|
|
all obligations of MetLife, Inc. for the reimbursement on any
letter of credit, bankers acceptance, security purchase
facility or similar credit transaction;
|
|
|
|
all obligations of MetLife, Inc. in respect of interest rate
swap, cap or other agreements, interest rate future or options
contracts, currency swap agreements, currency future or option
contracts and other similar agreements;
|
|
|
|
all obligations of the types referred to above of other persons
for the payment of which MetLife, Inc. is responsible or liable
as obligor, guarantor or otherwise; and
|
|
|
|
all obligations of the types referred to above of other persons
secured by any lien on any property or asset of MetLife, Inc.
whether or not such obligation is assumed by MetLife, Inc.
|
Senior Indebtedness does not include:
|
|
|
|
|
indebtedness or monetary obligations to trade creditors created
or assumed by MetLife, Inc. in the ordinary course of business
in connection with the obtaining of materials or services;
|
|
|
|
indebtedness that is, by its terms, subordinated to, or ranks
equal with, the subordinated debt securities; and
|
|
|
|
any indebtedness of MetLife, Inc. to its affiliates (including
all debt securities and guarantees in respect of those debt
securities issued to any trust, partnership or other entity
affiliated with MetLife, Inc. that is a financing vehicle of
MetLife, Inc. in connection with the issuance by such financing
entity of preferred securities or other securities guaranteed by
MetLife, Inc.) unless otherwise expressly provided in the terms
of any such indebtedness.
|
At September 30, 2010 and December 31, 2009, Senior
Indebtedness aggregated approximately $13,419 billion and
$10,458 billion, respectively. The amount of Senior
Indebtedness which MetLife, Inc. may issue is subject to
limitations imposed by its board of directors.
9
Senior Indebtedness shall continue to be Senior Indebtedness and
be entitled to the benefits of the subordination provisions
irrespective of any amendment, modification or waiver of any
term of such Senior Indebtedness.
Unless otherwise noted in the accompanying prospectus
supplement, if MetLife, Inc. defaults in the payment of any
principal of (or premium, if any) or interest on any Senior
Indebtedness when it becomes due and payable, whether at
maturity or at a date fixed for prepayment or by declaration or
otherwise, then, unless and until such default is cured or
waived or ceases to exist, MetLife, Inc. will make no direct or
indirect payment (in cash, property, securities, by set-off or
otherwise) in respect of the principal of or interest on the
subordinated debt securities or in respect of any redemption,
retirement, purchase or other requisition of any of the
subordinated debt securities.
In the event of the acceleration of the maturity of any
subordinated debt securities, the holders of all senior debt
securities outstanding at the time of such acceleration will
first be entitled to receive payment in full of all amounts due
on the senior debt securities before the holders of the
subordinated debt securities will be entitled to receive any
payment of principal (and premium, if any) or interest on the
subordinated debt securities.
If any of the following events occurs, MetLife, Inc. will pay in
full all Senior Indebtedness before it makes any payment or
distribution under the subordinated debt securities, whether in
cash, securities or other property, to any holder of
subordinated debt securities:
|
|
|
|
|
any dissolution or
winding-up
or liquidation or reorganization of MetLife, Inc., whether
voluntary or involuntary or in bankruptcy, insolvency or
receivership;
|
|
|
|
any general assignment by MetLife, Inc. for the benefit of
creditors; or
|
|
|
|
any other marshaling of MetLife, Inc.s assets or
liabilities.
|
In such event, any payment or distribution under the
subordinated debt securities, whether in cash, securities or
other property, which would otherwise (but for the subordination
provisions) be payable or deliverable in respect of the
subordinated debt securities, will be paid or delivered directly
to the holders of Senior Indebtedness in accordance with the
priorities then existing among such holders until all Senior
Indebtedness has been paid in full. If any payment or
distribution under the subordinated debt securities is received
by the trustee of any subordinated debt securities in
contravention of any of the terms of the Subordinated Indenture
and before all the Senior Indebtedness has been paid in full,
such payment or distribution or security will be received in
trust for the benefit of, and paid over or delivered and
transferred to, the holders of the Senior Indebtedness at the
time outstanding in accordance with the priorities then existing
among such holders for application to the payment of all Senior
Indebtedness remaining unpaid to the extent necessary to pay all
such Senior Indebtedness in full.
The Subordinated Indenture does not limit the issuance of
additional Senior Indebtedness.
If debt securities are issued to a trust in connection with the
issuance of trust preferred securities, such debt securities may
thereafter be distributed pro rata to the holders of such trust
securities in connection with the dissolution of such trust upon
the occurrence of certain events described in the applicable
prospectus supplement.
Restrictive
Covenants
Unless an accompanying prospectus supplement states otherwise,
the following restrictive covenants shall apply to each series
of senior debt securities:
Limitation on Liens. So long as any senior
debt securities are outstanding, neither MetLife, Inc. nor any
of its subsidiaries will create, assume, incur or guarantee any
debt which is secured by any mortgage, pledge, lien, security
interest or other encumbrance on any capital stock of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor.
|
10
However, this restriction will not apply if the debt securities
then outstanding are secured at least equally and ratably with
the otherwise prohibited secured debt so long as it is
outstanding.
Limitations on Dispositions of Stock of Certain
Subsidiaries. So long as any senior debt
securities are outstanding and subject to the provisions of the
Senior Indenture regarding mergers, consolidations and sales of
assets, neither MetLife, Inc. nor any of its subsidiaries will
sell or otherwise dispose of any shares of capital stock (other
than preferred stock having no voting rights of any kind) of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor;
|
except for, in each case:
|
|
|
|
|
a sale or other disposition of any of such stock to a
wholly-owned subsidiary of MetLife, Inc. or of such
subsidiary; or
|
|
|
|
a sale or other disposition of all of such stock for at least
fair value (as determined by MetLife, Inc.s board of
directors acting in good faith); or a sale or other disposition
required to comply with an order of a court or regulatory
authority of competent jurisdiction, other than an order issued
at MetLife, Inc.s request or the request of any of
MetLife, Inc.s subsidiaries.
|
Consolidation,
Merger, Sale of Assets and Other Transactions
(i) MetLife, Inc. may not merge with or into or consolidate
with another corporation or sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to,
any other corporation other than a direct or indirect
wholly-owned subsidiary of MetLife, Inc., and (ii) no
corporation may merge with or into or consolidate with MetLife,
Inc. or, except for any direct or indirect wholly-owned
subsidiary of MetLife, Inc., sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to
MetLife, Inc., unless:
|
|
|
|
|
MetLife, Inc. is the surviving corporation or the corporation
formed by or surviving such merger or consolidation or to which
such sale, assignment, transfer, lease or conveyance has been
made, if other than MetLife, Inc., has expressly assumed by
supplemental indenture all the obligations of MetLife, Inc.
under the debt securities, the Indentures, and any guarantees of
preferred securities or common securities issued by the trusts;
|
|
|
|
immediately after giving effect to such transaction, no default
or Event of Default has occurred and is continuing;
|
|
|
|
if at the time any preferred securities of the trusts are
outstanding, such transaction is not prohibited under the
applicable declaration of trust and the applicable preferred
securities guarantee of each trust; and
|
|
|
|
MetLife, Inc. delivers to the trustee an officers
certificate and an opinion of counsel, each stating that the
supplemental indenture complies with the applicable Indenture.
|
Events of
Default, Notice and Waiver
Unless an accompanying prospectus supplement states otherwise,
the following shall constitute Events of Default
under the Indentures with respect to each series of debt
securities:
|
|
|
|
|
MetLife, Inc.s failure to pay any interest on any debt
security of such series when due and payable, continued for
30 days;
|
|
|
|
MetLife, Inc.s failure to pay principal (or premium, if
any) on any debt security of such series when due, regardless of
whether such payment became due because of maturity, redemption,
acceleration or otherwise, or is required by any sinking fund
established with respect to such series;
|
11
|
|
|
|
|
MetLife, Inc.s failure to observe or perform any other of
its covenants or agreements with respect to such series for
90 days after MetLife, Inc. receives notice of such failure;
|
|
|
|
certain defaults with respect to MetLife, Inc.s debt which
result in a principal amount in excess of $100,000,000 becoming
or being declared due and payable prior to the date on which it
would otherwise have become due and payable (other than the debt
securities or non-recourse debt);
|
|
|
|
certain events of bankruptcy, insolvency or reorganization of
MetLife, Inc.; and
|
|
|
|
certain events of dissolution or
winding-up
of the trusts in the event that debt securities are issued to
the trusts or a trustee of the trusts in connection with the
issuance of securities by the trusts.
|
If an Event of Default with respect to any debt securities of
any series outstanding under either of the Indentures shall
occur and be continuing, the trustee under such Indenture or the
holders of at least 25% in aggregate principal amount of the
debt securities of that series outstanding may declare, by
notice as provided in the applicable Indenture, the principal
amount (or such lesser amount as may be provided for in the debt
securities of that series) of all the debt securities of that
series outstanding to be due and payable immediately; provided
that, in the case of an Event of Default involving certain
events in bankruptcy, insolvency or reorganization, acceleration
is automatic; and, provided further, that after such
acceleration, but before a judgment or decree based on
acceleration, the holders of a majority in aggregate principal
amount of the outstanding debt securities of that series may,
under certain circumstances, rescind and annul such acceleration
if all Events of Default, other than the nonpayment of
accelerated principal, have been cured or waived. Upon the
acceleration of the maturity of original issue discount
securities, an amount less than the principal amount thereof
will become due and payable. Reference is made to the prospectus
supplement relating to any original issue discount securities
for the particular provisions relating to acceleration of
maturity thereof.
Any past default under either Indenture with respect to debt
securities of any series, and any Event of Default arising
therefrom, may be waived by the holders of a majority in
principal amount of all debt securities of such series
outstanding under such Indenture, except in the case of
(i) default in the payment of the principal of (or premium,
if any) or interest on any debt securities of such series, or
(ii) default in respect of a covenant or provision which
may not be amended or modified without the consent of the holder
of each outstanding debt security of such series affected.
The trustee is required, within 90 days after the
occurrence of a default (which is known to the trustee and is
continuing), with respect to the debt securities of any series
(without regard to any grace period or notice requirements), to
give to the holders of the debt securities of such series notice
of such default; provided, however, that, except in the case of
a default in the payment of the principal of (and premium, if
any) or interest, or in the payment of any sinking fund
installment, on any debt securities of such series, the trustee
shall be protected in withholding such notice if it in good
faith determines that the withholding of such notice is in the
interests of the holders of the debt securities of such series.
The trustee, subject to its duties during default to act with
the required standard of care, may require indemnification by
the holders of the debt securities of any series with respect to
which a default has occurred before proceeding to exercise any
right or power under the Indentures at the request of the
holders of the debt securities of such series. Subject to such
right of indemnification and to certain other limitations, the
holders of a majority in aggregate principal amount of the
outstanding debt securities of any series under either Indenture
may direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or
exercising any trust or power conferred on the trustee with
respect to the debt securities of such series.
No holder of a debt security of any series may institute any
action against MetLife, Inc. under either of the Indentures
(except actions for payment of overdue principal of (and
premium, if any) or interest on such debt security or for the
conversion or exchange of such debt security in accordance with
its terms) unless (i) the holder has given to the trustee
written notice of an Event of Default and of the continuance
thereof with respect to the debt securities of such series
specifying an Event of Default, as required under the applicable
Indenture, (ii) the holders of at least 25% in aggregate
principal amount of the debt securities of that series then
outstanding under such Indenture shall have requested the
trustee to institute such action and offered to the trustee
reasonable indemnity
12
against the costs, expenses and liabilities to be incurred in
compliance with such request, and (iii) the trustee shall
not have instituted such action within 60 days of such
request.
MetLife, Inc. is required to furnish annually to the trustee
statements as to MetLife, Inc.s compliance with all
conditions and covenants under each Indenture.
Discharge,
Defeasance and Covenant Defeasance
If indicated in the applicable prospectus supplement, MetLife,
Inc. may discharge or defease its obligations under each
Indenture as set forth below.
MetLife, Inc. may discharge certain obligations to holders of
any series of debt securities issued under either the Senior
Indenture or the Subordinated Indenture which have not already
been delivered to the trustee for cancellation and which have
either become due and payable or are by their terms due and
payable within one year (or scheduled for redemption within one
year) by irrevocably depositing with the trustee cash or, in the
case of debt securities payable only in U.S. dollars,
U.S. government obligations (as defined in either
Indenture), as trust funds in an amount certified to be
sufficient to pay when due, whether at maturity, upon redemption
or otherwise, the principal of (and premium, if any) and
interest on such debt securities.
If indicated in the applicable prospectus supplement, MetLife,
Inc. may elect either (i) to defease and be discharged from
any and all obligations with respect to the debt securities of
or within any series (except as otherwise provided in the
relevant Indenture) (defeasance) or (ii) to be
released from its obligations with respect to certain covenants
applicable to the debt securities of or within any series
(covenant defeasance), upon the deposit with the
relevant Indenture trustee, in trust for such purpose, of money
and/or
government obligations which, through the payment of principal
and interest in accordance with their terms, will provide money
in an amount sufficient, without reinvestment, to pay the
principal of (and premium, if any) or interest on such debt
securities to maturity or redemption, as the case may be, and
any mandatory sinking fund or analogous payments thereon. As a
condition to defeasance or covenant defeasance, MetLife, Inc.
must deliver to the trustee an opinion of counsel to the effect
that the holders of such debt securities will not recognize
income, gain or loss for federal income tax purposes as a result
of such defeasance or covenant defeasance and will be subject to
federal income tax on the same amounts and in the same manner
and at the same times as would have been the case if such
defeasance or covenant defeasance had not occurred. Such opinion
of counsel, in the case of defeasance under clause (i)
above, must refer to and be based upon a ruling of the Internal
Revenue Service or a change in applicable federal income tax law
occurring after the date of the relevant Indenture. In addition,
in the case of either defeasance or covenant defeasance,
MetLife, Inc. shall have delivered to the trustee (i) an
officers certificate to the effect that the relevant debt
securities exchange(s) have informed it that neither such debt
securities nor any other debt securities of the same series, if
then listed on any securities exchange, will be delisted as a
result of such deposit, and (ii) an officers
certificate and an opinion of counsel, each stating that all
conditions precedent with respect to such defeasance or covenant
defeasance have been complied with.
MetLife, Inc. may exercise its defeasance option with respect to
such debt securities notwithstanding its prior exercise of its
covenant defeasance option.
Modification
and Waiver
Under the Indentures, MetLife, Inc. and the applicable trustee
may supplement the Indentures for certain purposes which would
not materially adversely affect the interests or rights of the
holders of debt securities of a series without the consent of
those holders. MetLife, Inc. and the applicable trustee may also
modify the Indentures or any supplemental indenture in a manner
that affects the interests or rights of the holders of debt
securities with the consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each affected series issued under the Indenture.
However, the Indentures require the consent of each holder of
debt securities that would be affected by any modification which
would:
|
|
|
|
|
extend the fixed maturity of any debt securities of any series,
or reduce the principal amount thereof, or reduce the rate or
extend the time of payment of interest thereon, or reduce any
premium payable upon the redemption thereof;
|
13
|
|
|
|
|
reduce the amount of principal of an original issue discount
debt security or any other debt security payable upon
acceleration of the maturity thereof;
|
|
|
|
change the currency in which any debt security or any premium or
interest is payable;
|
|
|
|
impair the right to enforce any payment on or with respect to
any debt security;
|
|
|
|
adversely change the right to convert or exchange, including
decreasing the conversion rate or increasing the conversion
price of, any debt security (if applicable);
|
|
|
|
reduce the percentage in principal amount of outstanding debt
securities of any series, the consent of whose holders is
required for modification or amendment of the Indentures or for
waiver of compliance with certain provisions of the Indentures
or for waiver of certain defaults;
|
|
|
|
reduce the requirements contained in the Indentures for quorum
or voting; or
|
|
|
|
modify any of the above provisions.
|
If debt securities are held by a trust or a trustee of a trust,
a supplemental indenture that affects the interests or rights of
the holders of debt securities will not be effective until the
holders of not less than a majority in liquidation preference of
the preferred securities and common securities of the applicable
trust, collectively, have consented to the supplemental
indenture; provided, further, that if the consent of the holder
of each outstanding debt security is required, the supplemental
indenture will not be effective until each holder of the
preferred securities and the common securities of the applicable
trust has consented to the supplemental indenture.
The Indentures permit the holders of at least a majority in
aggregate principal amount of the outstanding debt securities of
any series issued under the Indenture which is affected by the
modification or amendment to waive MetLife, Inc.s
compliance with certain covenants contained in the Indentures.
Payment
and Paying Agents
Unless otherwise indicated in the applicable prospectus
supplement, payment of interest on a debt security on any
interest payment date will be made to the person in whose name a
debt security is registered at the close of business on the
record date for the interest.
Unless otherwise indicated in the applicable prospectus
supplement, principal, interest and premium on the debt
securities of a particular series will be payable at the office
of such paying agent or paying agents as MetLife, Inc. may
designate for such purpose from time to time. Notwithstanding
the foregoing, at MetLife, Inc.s option, payment of any
interest may be made by check mailed to the address of the
person entitled thereto as such address appears in the security
register.
Unless otherwise indicated in the applicable prospectus
supplement, a paying agent designated by MetLife, Inc. and
located in the Borough of Manhattan, The City of New York, will
act as paying agent for payments with respect to debt securities
of each series. All paying agents initially designated by
MetLife, Inc. for the debt securities of a particular series
will be named in the applicable prospectus supplement. MetLife,
Inc. may at any time designate additional paying agents or
rescind the designation of any paying agent or approve a change
in the office through which any paying agent acts, except that
MetLife, Inc. will be required to maintain a paying agent in
each place of payment for the debt securities of a particular
series.
All moneys paid by MetLife, Inc. to a paying agent for the
payment of the principal, interest or premium on any debt
security which remain unclaimed at the end of two years after
such principal, interest or premium has become due and payable
will be repaid to MetLife, Inc. upon request, and the holder of
such debt security thereafter may look only to MetLife, Inc. for
payment thereof.
Denominations,
Registrations and Transfer
Unless an accompanying prospectus supplement states otherwise,
debt securities will be represented by one or more global
certificates registered in the name of a nominee for The
Depository Trust Company (DTC). In such
14
case, each holders beneficial interest in the global
securities will be shown on the records of DTC and transfers of
beneficial interests will only be effected through DTCs
records.
A holder of debt securities may only exchange a beneficial
interest in a global security for certificated securities
registered in the holders name if:
|
|
|
|
|
DTC notifies MetLife, Inc. that it is unwilling or unable to
continue serving as the depositary for the relevant global
securities or DTC ceases to maintain certain qualifications
under the Securities Exchange Act of 1934 and no successor
depositary has been appointed for 90 days; or
|
|
|
|
MetLife, Inc. determines, in its sole discretion and subject to
the procedures of DTC, that the global security shall be
exchangeable.
|
If debt securities are issued in certificated form, they will
only be issued in the minimum denomination specified in the
accompanying prospectus supplement and integral multiples of
such denomination. Transfers and exchanges of such debt
securities will only be permitted in such minimum denomination.
Transfers of debt securities in certificated form may be
registered at the trustees corporate office or at the
offices of any paying agent or trustee appointed by MetLife,
Inc. under the Indentures. Exchanges of debt securities for an
equal aggregate principal amount of debt securities in different
denominations may also be made at such locations.
Governing
Law
The Indentures and debt securities will be governed by, and
construed in accordance with, the internal laws of the State of
New York, without regard to its principles of conflicts of laws.
Relationship
with the Trustees
The trustee under the Indentures is The Bank of New York Mellon
Trust Company, N.A. (in the case of the Senior Indenture,
as successor to Bank One Trust Company, N.A., and in the
case of the Subordinated Indenture, as successor to
J.P. Morgan Trust Company, National Association).
MetLife, Inc. and its subsidiaries maintain ordinary banking and
trust relationships with a number of banks and trust companies,
including the trustee under the Indentures.
Conversion
or Exchange Rights
The prospectus supplement will describe the terms, if any, on
which a series of debt securities may be convertible into or
exchangeable for securities described in this prospectus. These
terms will include provisions as to whether conversion or
exchange is mandatory, at the option of the holder or at
MetLife, Inc.s option. These provisions may allow or
require the number of shares of MetLife, Inc.s common
stock or other securities to be received by the holders of such
series of debt securities to be adjusted.
DESCRIPTION
OF CAPITAL STOCK
MetLife, Inc.s authorized capital stock consists of:
|
|
|
|
|
200,000,000 shares of preferred stock, par value $0.01 per
share, of which 90,857,000 shares were issued and
outstanding as of November 23, 2010:
|
|
|
|
|
|
27,600,000 shares of Floating Rate Non-Cumulative Preferred
Stock, Series A (the Series A Preferred
Stock), of which 24,000,000 shares were issued and
outstanding as of November 23, 2010;
|
|
|
|
69,000,000 shares of 6.500% Non-Cumulative Preferred Stock,
Series B (the Series B Preferred Stock) of
which 60,000,000 shares were issued and outstanding as of
November 23, 2010;
|
|
|
|
6,857,000 shares of Series B Contingent Convertible Junior
Participating
Non-Cumulative
Perpetual Preferred Stock (the Series B Contingent
Convertible Preferred Stock), of which 6,857,000 shares
were issued and outstanding as of November 23, 2010; and
|
|
|
|
10,000,000 shares of Series A Junior Participating
Preferred Stock, par value $0.01 per share, of which no shares
were issued or outstanding as of the date of this
prospectus; and
|
15
|
|
|
|
|
3,000,000,000 shares of common stock, par value $0.01 per
share, of which 985,254,724 shares were outstanding as of
November 1, 2010. The 6,857,000 shares of Series B
Contingent Convertible Preferred Stock will be convertible into
68,570,000 shares of MetLife, Inc.s common stock upon a
favorable vote of MetLife, Inc.s stockholders. The
remaining shares of authorized and unissued common stock will be
available for future issuance without additional stockholder
approval.
|
Common
Stock
Dividends. The holders of common stock, after
any preferences of holders of any preferred stock, are entitled
to receive dividends as determined by the board of directors.
The issuance of dividends will depend upon, among other factors
deemed relevant by MetLife, Inc.s board of directors,
MetLifes financial condition, results of operations, cash
requirements, future prospects and regulatory restrictions on
the payment of dividends by Metropolitan Life Insurance Company
and MetLife, Inc.s other subsidiaries. There is no
requirement or assurance that MetLife, Inc. will declare and pay
any dividends. In addition, (i) the certificates of
designation for the Series A Preferred Stock, the
Series B Preferred Stock and Series B Contingent
Convertible Preferred Stock, (ii) MetLife, Inc.s
6.40%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066,
(iii) MetLife, Inc.s 10.75%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2069, (iv) MetLife,
Inc.s 6.817% Senior Debt Securities, Series A,
due 2018, (v) MetLife, Inc.s 7.717% Senior Debt
Securities, Series B, due 2019 (vi) upon an exchange
of the 7.875%
Fixed-to-Floating
Rate Exchangeable Surplus Trust Securities of MetLife
Capital Trust IV, the related 7.875%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2067 of MetLife, Inc.
and (vii) upon exchange of the 9.250%
Fixed-to-Floating
Rate Exchangeable Surplus Trust Securities of MetLife
Capital Trust X, the related 9.250%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2068 of MetLife, Inc.,
all prohibit the declaration or payment of dividends or
distributions on common stock under certain circumstances. Under
the certificates of designation for the Series A Preferred
Stock, the Series B Preferred Stock and Series B Contingent
Convertible Preferred Stock, if dividends on such securities are
not paid, no dividends may be paid on the common stock.
Similarly, under the 6.40%
Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066, under certain
circumstances, if interest is not paid in full on such
securities, whether because of an optional deferral or a trigger
event, subject to certain exceptions, then no dividends may be
paid on the common stock.
Voting Rights. The holders of common stock are
entitled to one vote per share on all matters on which the
holders of common stock are entitled to vote and do not have any
cumulative voting rights.
Liquidation and Dissolution. In the event of
MetLife, Inc.s liquidation, dissolution or
winding-up,
the holders of common stock are entitled to share equally and
ratably in MetLife, Inc.s assets, if any, remaining after
the payment of all of MetLife, Inc.s liabilities and the
liquidation preference of any outstanding class or series of
preferred stock.
Other Rights. The holders of common stock have
no preemptive, conversion, redemption or sinking fund rights.
The holders of shares of MetLife, Inc.s common stock are
not required to make additional capital contributions.
Transfer Agent and Registrar. The transfer
agent and registrar for MetLife, Inc.s common stock is
Mellon Investor Services LLC, successor to ChaseMellon
Shareholder Services, L.L.C.
Preferred
Stock
General. MetLife, Inc.s board of
directors has the authority to issue preferred stock in one or
more series and to fix the title and number of shares
constituting any such series and the designations, powers,
preferences, limitations and relative rights including offering
price, any dividend rights (including whether dividends will be
cumulative or non-cumulative), dividend rate, voting rights,
terms of any redemption, any redemption price or prices,
conversion or exchange rights and any liquidation preferences of
the shares constituting any series, without any further vote or
action by stockholders. The specific terms of the preferred
stock will be described in the prospectus supplement.
16
MetLife, Inc. has authorized 10,000,000 shares of
Series A Junior Participating Preferred Stock for issuance
in connection with a stockholder rights plan. The stockholder
rights plan expired at the close of business on April 4,
2010 and was not renewed.
Voting Rights. The Delaware General
Corporation Law provides that the holders of preferred stock
will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders
of such preferred stock. The prospectus supplement will describe
the voting rights, if any, of the preferred stock.
Conversion or Exchange. The prospectus
supplement will describe the terms, if any, on which the
preferred stock may be convertible into or exchangeable for
securities described in this prospectus. These terms will
include provisions as to whether conversion or exchange is
mandatory, at the option of the holder or at MetLife,
Inc.s option. These provisions may set forth the
conversion price, the method of determining the conversion price
and the conversion period and may allow or require the number of
shares of MetLife, Inc.s common stock or other securities
to be received by the holders of preferred stock to be adjusted.
Redemption. The prospectus supplement will
describe the obligation, if any, to redeem the preferred stock
in whole or in part at the times and at the redemption prices
set forth in the applicable prospectus supplement.
Unless otherwise indicated in the applicable prospectus
supplement, MetLife, Inc. may not purchase or redeem any of the
outstanding shares or any series of preferred stock unless full
cumulative dividends, if any, have been paid or declared and set
apart for payment upon all outstanding shares of any series of
preferred stock for all past dividend periods, and unless all of
MetLife, Inc.s matured obligations with respect to all
sinking funds, retirement funds or purchase funds for all series
of preferred stock then outstanding have been met.
Certain
Provisions in MetLife, Inc.s Certificate of Incorporation
and By-Laws and in Delaware and New York Law
A number of provisions of MetLife, Inc.s certificate of
incorporation and by-laws deal with matters of corporate
governance and rights of stockholders. The following discussion
is a general summary of selected provisions of MetLife,
Inc.s certificate of incorporation and by-laws and
regulatory provisions that might be deemed to have a potential
anti-takeover effect. These provisions may have the
effect of discouraging a future takeover attempt which is not
approved by MetLife, Inc.s board of directors but which
individual stockholders may deem to be in their best interests
or in which stockholders may receive a substantial premium for
their shares over then current market prices. As a result,
stockholders who might desire to participate in such a
transaction may not have an opportunity to do so. Such
provisions will also render the removal of the incumbent board
of directors or management more difficult. Some provisions of
the Delaware General Corporation Law and the New York Insurance
Law may also have an anti-takeover effect. The following
description of selected provisions of MetLife, Inc.s
certificate of incorporation and by-laws and selected provisions
of the Delaware General Corporation Law and the New York
Insurance Law is necessarily general and reference should be
made in each case to MetLife, Inc.s certificate of
incorporation and by-laws, which are incorporated by reference
as exhibits to the registration statement of which this
prospectus forms a part, and to the provisions of those laws.
Classified
Board of Directors and Removal of Directors
Pursuant to MetLife, Inc.s certificate of incorporation,
the directors are divided into three classes, as nearly equal in
number as possible, with each class having a term of three
years. The classes serve staggered terms, such that the term of
one class of directors expires each year. Any effort to obtain
control of MetLife, Inc.s board of directors by causing
the election of a majority of the board may require more time
than would be required without a staggered election structure.
MetLife, Inc.s certificate of incorporation also provides
that, subject to the rights of the holders of any class of
preferred stock, directors may be removed only for cause at a
meeting of stockholders by a vote of a majority of the shares
then entitled to vote. This provision may have the effect of
slowing or impeding a change in membership of MetLife,
Inc.s board of directors that would effect a change of
control. As disclosed in our Proxy Statement, we expect to seek
shareholder approval at our 2011 Annual Meeting to amend
MetLife, Inc.s certificate of incorporation in order to
declassify MetLife, Inc.s board of directors and provide
for the annual election of all directors. Declassifying MetLife,
Inc.s board of directors would be phased in over a
three-year period such that directors may serve the full terms
to which they have been elected before the change to annual
elections. If
17
classification of MetLife, Inc.s board of directors is
approved at the 2011 Annual Meeting, then beginning with
MetLife, Inc.s 2014 Annual Meeting, all directors will be
elected for terms that would end at the following years
Annual Meeting.
Exercise
of Duties by Board of Directors
MetLife, Inc.s certificate of incorporation provides that
while the MetLife Policyholder Trust (as described below) is in
existence, each MetLife, Inc. director is required, in
exercising his or her duties as a director, to take the
interests of the trust beneficiaries into account as if they
were holders of the shares of common stock held in the trust,
except to the extent that any such director determines, based on
advice of counsel, that to do so would violate his or her duties
as a director under Delaware law.
Restriction
on Maximum Number of Directors and Filling of Vacancies on
MetLife, Inc.s Board of Directors
Pursuant to MetLife, Inc.s by-laws and subject to the
rights of the holders of any class of preferred stock, the
number of directors may be fixed and increased or decreased from
time to time by resolution of the board of directors, but the
board of directors will at no time consist of fewer than three
directors. Subject to the rights of the holders of any class of
preferred stock, stockholders can only remove a director for
cause by a vote of a majority of the shares entitled to vote, in
which case the vacancy caused by such removal may be filled at
such meeting by the stockholders entitled to vote for the
election of the director so removed. Any vacancy on the board of
directors, including a vacancy resulting from an increase in the
number of directors or resulting from a removal for cause where
the stockholders have not filled the vacancy, subject to the
rights of the holders of any class of preferred stock, may be
filled by a majority of the directors then in office, although
less than a quorum. If the vacancy is not so filled it will be
filled by the stockholders at the next annual meeting of
stockholders. The stockholders are not permitted to fill
vacancies between annual meetings, except where the vacancy
resulted from a removal for cause. These provisions give
incumbent directors significant authority that may have the
effect of limiting the ability of stockholders to effect a
change in management.
Advance
Notice Requirements for Nomination of Directors and Presentation
of New Business at Meetings of Stockholders; Action by Written
Consent
MetLife, Inc.s by-laws provide for advance notice
requirements for stockholder proposals and nominations for
director. In addition, pursuant to the provisions of both the
certificate of incorporation and the by-laws, action may not be
taken by written consent of stockholder. Rather, any action
taken by the stockholders must be effected at a duly called
meeting. Moreover, the stockholders do not have the power to
call a special meeting. Only the chief executive officer or the
secretary pursuant to a board resolution or, under some
circumstances, the president or a director who also is an
officer, may call a special meeting. These provisions make it
more difficult for a stockholder to place a proposal or
nomination on the meeting agenda and prohibit a stockholder from
taking action without a meeting, and therefore may reduce the
likelihood that a stockholder will seek to take independent
action to replace directors or with respect to other matters
that are not supported by management for stockholder vote.
Limitations
on Director Liability
MetLife, Inc.s certificate of incorporation contains a
provision that is designed to limit the directors
liability to the extent permitted by the Delaware General
Corporation Law and any amendments to that law. Specifically,
directors will not be held liable to MetLife, Inc. or its
stockholders for an act or omission in their capacity as a
director, except for liability as a result of:
|
|
|
|
|
a breach of the duty of loyalty to MetLife, Inc. or its
stockholders;
|
|
|
|
acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
|
|
|
|
payment of an improper dividend or improper repurchase of
MetLife, Inc.s stock under Section 174 of the
Delaware General Corporation Law; or
|
|
|
|
actions or omissions pursuant to which the director received an
improper personal benefit.
|
18
The principal effect of the limitation on liability provision is
that a stockholder is unable to prosecute an action for monetary
damages against a director of MetLife, Inc. unless the
stockholder can demonstrate one of the specified bases for
liability. This provision, however, does not eliminate or limit
director liability arising in connection with causes of action
brought under the federal securities laws. MetLife, Inc.s
certificate of incorporation also does not eliminate the
directors duty of care. The inclusion of the limitation on
liability provision in the certificate may, however, discourage
or deter stockholders or management from bringing a lawsuit
against directors for a breach of their fiduciary duties, even
though such an action, if successful, might otherwise have
benefited MetLife, Inc. and its stockholders. This provision
should not affect the availability of equitable remedies such as
injunction or rescission based upon a directors breach of
the duty of care.
MetLife, Inc.s by-laws also provide that MetLife, Inc.
shall indemnify its directors and officers to the fullest extent
permitted by Delaware law. MetLife, Inc. is required to
indemnify its directors and officers for all judgments, fines,
settlements, legal fees and other expenses reasonably incurred
in connection with pending or threatened legal proceedings
because of the directors or officers position with
MetLife, Inc. or another entity, including Metropolitan Life
Insurance Company, that the director or officer serves at
MetLife, Inc.s request, subject to certain conditions, and
to advance funds to MetLife, Inc.s directors and officers
to enable them to defend against such proceedings. To receive
indemnification, the director or officer must succeed in the
legal proceeding or act in good faith and in a manner reasonably
believed to be in or not opposed to the best interests of
MetLife, Inc. and with respect to any criminal action or
proceeding, in a manner he or she reasonably believed to be
lawful.
Supermajority
Voting Requirement for Amendment of Certain Provisions of the
Certificate of Incorporation and By-Laws
Some of the provisions of MetLife, Inc.s certificate of
incorporation, including those that authorize the board of
directors to create stockholder rights plans, that set forth the
duties, election and exculpation from liability of directors and
that prohibit stockholders from taking actions by written
consent, may not be amended, altered, changed or repealed unless
the amendment is approved by the vote of holders of 75% of the
then outstanding shares entitled to vote at an election of
directors. This requirement exceeds the majority vote of the
outstanding stock that would otherwise be required by the
Delaware General Corporation Law for the repeal or amendment of
such provisions of the certificate of incorporation. MetLife,
Inc.s by-laws may be amended, altered or repealed by the
board of directors or by the vote of holders of 75% of the then
outstanding shares entitled to vote in the election of
directors. These provisions make it more difficult for any
person to remove or amend any provisions that have an
anti-takeover effect.
Business
Combination Statute
In addition, as a Delaware corporation, MetLife, Inc. is subject
to Section 203 of the Delaware General Corporation Law,
unless it elects in its certificate of incorporation not to be
governed by the provisions of Section 203. MetLife, Inc.
has not made that election. Section 203 can affect the
ability of an interested stockholder of MetLife,
Inc. to engage in certain business combinations, including
mergers, consolidations or acquisitions of additional shares of
MetLife, Inc. for a period of three years following the time
that the stockholder becomes an interested
stockholder. An interested stockholder is
defined to include any person owning, directly or indirectly,
15% or more of the outstanding voting stock of a corporation.
The provisions of Section 203 are not applicable in some
circumstances, including those in which (1) the business
combination or transaction which results in the stockholder
becoming an interested stockholder is approved by
the corporations board of directors prior to the time the
stockholder becomes an interested stockholder or
(2) the interested stockholder, upon
consummation of such transaction, owns at least 85% of the
voting stock of the corporation outstanding prior to such
transaction.
Restrictions
on Acquisitions of Securities
The insurance laws and regulations of New York, the jurisdiction
in which MetLife, Inc.s principal insurance subsidiary,
Metropolitan Life Insurance Company, is organized, may delay or
impede a business combination involving MetLife, Inc. In
addition to the limitations described in the immediately
preceding paragraph, the New York Insurance Law prohibits any
person from acquiring control of Metropolitan Life Insurance
Company, either
19
directly or indirectly through any acquisition of control of
MetLife, Inc., without the prior approval of the New York
Superintendent of Insurance. That law presumes that control
exists where any person, directly or indirectly, owns, controls,
holds the power to vote or holds proxies representing 10% or
more of MetLife, Inc.s outstanding voting stock, unless
the New York Superintendent, upon application, determines
otherwise. Even persons who do not acquire beneficial ownership
of more than 10% of the outstanding shares of MetLife,
Inc.s common stock may be deemed to have acquired such
control, if the New York Superintendent determines that such
persons, directly or indirectly, exercise a controlling
influence over MetLife, Inc.s management or policies.
Therefore, any person seeking to acquire a controlling interest
in MetLife, Inc. would face regulatory obstacles which may
delay, deter or prevent an acquisition.
The insurance holding company law and other insurance laws of
many other states also regulate changes of control (generally
presumed upon acquisitions of 10% or more of voting securities)
of domestic insurers (including insurers owned by MetLife, Inc.)
and insurance holding companies such as MetLife, Inc.
Stockholder
Rights Plan
In September 1999, MetLife, Inc.s board of directors
adopted a stockholder rights plan. The stockholder rights plan
expired at the close of business on April 4, 2010 and was
not renewed.
MetLife
Policyholder Trust
Under a plan of reorganization adopted in September 1999,
Metropolitan Life Insurance Company converted from a mutual life
insurance company to a stock life insurance company subsidiary
of MetLife, Inc. MetLife established the MetLife Policyholder
Trust to hold the shares of common stock allocated to eligible
policyholders. A total of 494,466,664 shares of common
stock were distributed to the MetLife Policyholder Trust on the
effective date of the plan of reorganization. As of
September 30, 2010, the trust held 225,909,098 shares
of MetLife, Inc.s common stock. Because of the number of
shares held by the trust and the voting provisions of the trust,
the trust may affect the outcome of matters brought to a
stockholder vote.
The trustee will generally vote all of the shares of common
stock held in the trust in accordance with the recommendations
given by MetLife, Inc.s board of directors to its
stockholders or, if the board gives no such recommendation, as
directed by the board, except on votes regarding certain
fundamental corporate actions. As a result of the voting
provisions of the trust, MetLife, Inc.s board of directors
will effectively be able to control votes on all matters
submitted to a vote of stockholders, excluding those fundamental
corporate actions described below, so long as the trust holds a
substantial number of shares of MetLife, Inc.s common
stock.
If the vote relates to fundamental corporate actions specified
in the trust, the trustee will solicit instructions from the
beneficiaries and vote all shares held in the trust in
proportion to the instructions it receives, which would give
disproportionate weight to the instructions actually given by
trust beneficiaries. These actions include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s board of directors
or a vote on a stockholders proposal to oppose a board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution of MetLife, Inc., in each case requiring a vote of
MetLife, Inc.s stockholders under applicable Delaware law;
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s board of directors
to amend or redeem the rights under the stockholder rights plan,
other than a proposal with respect to which MetLife, Inc. has
received advice of nationally-recognized legal counsel to the
effect that the proposal is not a proper subject for stockholder
action under Delaware law.
|
20
DESCRIPTION
OF DEPOSITARY SHARES
The following outlines some of the general terms and provisions
of the depositary shares. Further terms of the depositary shares
and the applicable deposit agreement will be stated in the
applicable prospectus supplement. The following description and
any description of the depositary shares in a prospectus
supplement may not be complete and is subject to and qualified
in its entirety by reference to the terms and provisions of the
deposit agreement, a form of which has been or will be filed as
an exhibit to the registration statement of which this
prospectus forms a part.
The particular terms of the depositary shares offered by any
prospectus supplement and the extent to which the general
provisions described below may apply to such depositary shares
will be outlined in the applicable prospectus supplement.
General
MetLife, Inc. may choose to offer fractional interests in debt
securities or fractional shares of common stock or preferred
stock. MetLife, Inc. may issue fractional interests in debt
securities, common stock or preferred stock, as the case may be,
in the form of depositary shares. Each depositary share would
represent a fractional interest in a security of a particular
series of debt securities or a fraction of a share of common
stock or of a particular series of preferred stock, as the case
may be, and would be evidenced by a depositary receipt.
MetLife, Inc. will deposit the debt securities or shares of
common stock or preferred stock represented by depositary shares
under a deposit agreement between MetLife, Inc. and a depositary
which will be named in the applicable prospectus supplement.
Subject to the terms of the deposit agreement, as an owner of a
depositary share, you will be entitled, in proportion to the
applicable fraction of a debt security or share of common stock
or preferred stock represented by the depositary share, to all
the rights and preferences of the debt security, common stock or
preferred stock, as the case may be, represented by the
depositary share, including, as the case may be, interest,
dividend, voting, conversion, redemption, sinking fund,
repayment at maturity, subscription and liquidation rights.
Interest,
Dividends and Other Distributions
The depositary will distribute all payments of interest, cash
dividends or other cash distributions received on the debt
securities, common stock or preferred stock, as the case may be,
to you in proportion to the number of depositary shares that you
own. In the event of a distribution other than in cash, the
depositary will distribute property received by it to you in an
equitable manner, unless the depositary determines that it is
not feasible to make a distribution. In that case, the
depositary may sell the property and distribute the net proceeds
from the sale to you.
Redemption
of Depositary Shares
If a debt security, common stock or series of preferred stock
represented by depositary shares is redeemed, the depositary
will redeem your depositary shares from the proceeds received by
the depositary resulting from the redemption. The redemption
price per depositary share will be equal to the applicable
fraction of the redemption price per debt security or share of
common stock or preferred stock, as the case may be, payable in
relation to the redeemed series of debt securities, common stock
or preferred stock. Whenever MetLife, Inc. redeems debt
securities or shares of common stock or preferred stock held by
the depositary, the depositary will redeem, as of the same
redemption date, the number of depositary shares representing,
as the case may be, fractional interests in the debt securities
or shares of common stock or preferred stock redeemed. If fewer
than all the depositary shares are to be redeemed, the
depositary shares to be redeemed will be selected by lot,
proportionately or by any other equitable method as the
depositary may determine.
Exercise
of Rights under the Indentures or Voting the Common Stock or
Preferred
Upon receipt of notice of any meeting at which you are entitled
to vote, or of any request for instructions or directions from
you as holder of fractional interests in debt securities, common
stock or preferred stock, the depositary will mail to you the
information contained in that notice. Each record holder of the
depositary shares on the record date will be entitled to
instruct the depositary how to give instructions or directions
with respect to the
21
debt securities represented by that holders depositary
shares or how to vote the amount of the common stock or
preferred stock represented by that holders depositary
shares. The record date for the depositary shares will be the
same date as the record date for the debt securities, common
stock or preferred stock, as the case may be. The depositary
will endeavor, to the extent practicable, to give instructions
or directions with respect to the debt securities or to vote the
amount of the common stock or preferred stock, as the case may
be, represented by the depositary shares in accordance with
those instructions. MetLife, Inc. will agree to take all
reasonable action which the depositary may deem necessary to
enable the depositary to do so. The depositary will abstain from
giving instructions or directions with respect to your
fractional interests in the debt securities or voting shares of
the common stock or preferred stock, as the case may be, if it
does not receive specific instructions from you.
Amendment
and Termination of the Deposit Agreement
MetLife, Inc. and the depositary may amend the form of
depositary receipt evidencing the depositary shares and any
provision of the deposit agreement at any time. However, any
amendment which materially and adversely affects the rights of
the holders of the depositary shares will not be effective
unless the amendment has been approved by the holders of at
least a majority of the depositary shares then outstanding.
The deposit agreement will terminate if:
|
|
|
|
|
all outstanding depositary shares have been redeemed;
|
|
|
|
if applicable, the debt securities and the preferred stock
represented by depositary shares have been converted into or
exchanged for common stock or, in the case of debt securities,
repaid in full; or
|
|
|
|
there has been a final distribution in respect of the common
stock or preferred stock, including in connection with the
liquidation, dissolution or
winding-up
of MetLife, Inc., and the distribution proceeds have been
distributed to you.
|
Resignation
and Removal of Depositary
The depositary may resign at any time by delivering to MetLife,
Inc. notice of its election to do so. MetLife, Inc. also may, at
any time, remove the depositary. Any resignation or removal will
take effect upon the appointment of a successor depositary and
its acceptance of such appointment. MetLife, Inc. must appoint
the successor depositary within 60 days after delivery of
the notice of resignation or removal. The successor depositary
must be a bank or trust company having its principal office in
the United States and having total assets of not less than
$1,000,000,000.
Charges
of Depositary
MetLife, Inc. will pay all transfer and other taxes and
governmental charges arising solely from the existence of the
depositary arrangements. MetLife, Inc. will pay charges of the
depositary in connection with the initial deposit of the debt
securities or common stock or preferred stock, as the case may
be, and issuance of depositary receipts, all withdrawals of
depositary shares of debt securities or common stock or
preferred stock, as the case may be, by you and any repayment or
redemption of the debt securities or preferred stock, as the
case may be. You will pay other transfer and other taxes and
governmental charges, as well as the other charges that are
expressly provided in the deposit agreement to be for your
account.
Miscellaneous
The depositary will forward all reports and communications from
MetLife, Inc. which are delivered to the depositary and which
MetLife, Inc. is required or otherwise determines to furnish to
holders of debt securities, common stock or preferred stock, as
the case may be. Neither MetLife, Inc. nor the depositary will
be liable under the deposit agreement to you other than for its
gross negligence, willful misconduct or bad faith. Neither
MetLife, Inc. nor the depositary will be obligated to prosecute
or defend any legal proceedings relating to any depositary
shares, debt securities, common stock or preferred stock unless
satisfactory indemnity is furnished. MetLife, Inc. and the
depositary may rely upon written advice of counsel or
accountants, or upon information provided by persons presenting
debt securities or shares of common stock or preferred stock for
deposit, you or other persons believed to be competent and on
documents which MetLife, Inc. and the depositary believe to be
genuine.
22
DESCRIPTION
OF WARRANTS
MetLife, Inc. may issue warrants to purchase debt securities,
preferred stock, common stock or other securities described in
this prospectus, or any combination of these securities, and
these warrants may be issued independently or together with any
underlying securities and may be attached or separate from the
underlying securities. MetLife, Inc. will issue each series of
warrants under a separate warrant agreement to be entered into
between MetLife, Inc. and a warrant agent. The warrant agent
will act solely as MetLife, Inc.s agent in connection with
the warrants of such series and will not assume any obligation
or relationship of agency for or with holders or beneficial
owners of warrants.
The following outlines some of the general terms and provisions
of the warrants. Further terms of the warrants and the
applicable warrant agreement will be stated in the applicable
prospectus supplement. The following description and any
description of the warrants in a prospectus supplement may not
be complete and is subject to and qualified in its entirety by
reference to the terms and provisions of the warrant agreement,
a form of which has been or will be filed as an exhibit to the
registration statement of which this prospectus forms a part.
The applicable prospectus supplement will describe the terms of
any warrants that MetLife, Inc. may offer, including the
following:
|
|
|
|
|
the title of the warrants;
|
|
|
|
the total number of warrants;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the currency or currencies investors may use to pay for the
warrants;
|
|
|
|
the designation and terms of the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the price at which and the currency, currencies, or currency
units in which investors may purchase the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the date on which the right to exercise the warrants will
commence and the date on which the right will expire;
|
|
|
|
whether the warrants will be issued in registered form or bearer
form;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
if applicable, the minimum or maximum amount of warrants which
may be exercised at any one time;
|
|
|
|
if applicable, the designation and terms of the underlying
securities with which the warrants are issued and the number of
warrants issued with each underlying security;
|
|
|
|
if applicable, the date on and after which the warrants and the
related underlying securities will be separately transferable;
|
|
|
|
if applicable, a discussion of material United States federal
income tax considerations;
|
|
|
|
the identity of the warrant agent;
|
|
|
|
the procedures and conditions relating to the exercise of the
warrants; and
|
|
|
|
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants.
|
Warrant certificates may be exchanged for new warrant
certificates of different denominations, and warrants may be
exercised at the warrant agents corporate trust office or
any other office indicated in the applicable prospectus
supplement. Prior to the exercise of their warrants, holders of
warrants exercisable for debt securities will not have any of
the rights of holders of the debt securities purchasable upon
such exercise and will not be entitled to payments of principal
(or premium, if any) or interest, if any, on the debt securities
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for shares of
preferred stock or common stock will not have any rights of
holders of the preferred stock or common stock purchasable upon
such
23
exercise and will not be entitled to dividend payments, if any,
or voting rights of the preferred stock or common stock
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for other securities
described in this prospectus will not have any rights of holders
of such securities purchasable upon such exercise.
Exercise
of Warrants
A warrant will entitle the holder to purchase for cash an amount
of securities at an exercise price that will be stated in, or
that will be determinable as described in, the applicable
prospectus supplement. Warrants may be exercised at any time up
to the close of business on the expiration date set forth in the
applicable prospectus supplement. After the close of business on
the expiration date, unexercised warrants will become void.
Warrants may be exercised as set forth in the applicable
prospectus supplement. Upon receipt of payment and the warrant
certificate properly completed and duly executed at the
corporate trust office of the warrant agent or any other office
indicated in the prospectus supplement, MetLife, Inc. will, as
soon as practicable, forward the securities purchasable upon
such exercise. If less than all of the warrants represented by
such warrant certificate is exercised, a new warrant certificate
will be issued for the remaining warrants.
Enforceability
of Rights; Governing Law
The holders of warrants, without the consent of the warrant
agent, may, on their own behalf and for their own benefit,
enforce, and may institute and maintain any suit, action or
proceeding against MetLife, Inc. to enforce their rights to
exercise and receive the securities purchasable upon exercise of
their warrants. Unless otherwise stated in the prospectus
supplement, each issue of warrants and the applicable warrant
agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without regard to
its principles of conflicts of laws.
DESCRIPTION
OF PURCHASE CONTRACTS
As may be specified in a prospectus supplement, MetLife, Inc.
may issue purchase contracts obligating holders to purchase from
MetLife, Inc., and MetLife, Inc. to sell to the holders, a
number of debt securities, shares of common stock or preferred
stock, or other securities described in this prospectus or the
applicable prospectus supplement at a future date or dates. The
purchase contracts may require MetLife, Inc. to make periodic
payments to the holders of the purchase contracts. These
payments may be unsecured or prefunded on some basis to be
specified in the applicable prospectus supplement.
The prospectus supplement relating to any purchase contracts
will specify the material terms of the purchase contracts and
any applicable pledge or depositary arrangements, including one
or more of the following:
|
|
|
|
|
The stated amount that a holder will be obligated to pay under
the purchase contract in order to purchase debt securities,
common stock, preferred stock, or other securities described in
this prospectus or the formula by which such amount shall be
determined.
|
|
|
|
The settlement date or dates on which the holder will be
obligated to purchase such securities. The prospectus supplement
will specify whether the occurrence of any events may cause the
settlement date to occur on an earlier date and the terms on
which an early settlement would occur.
|
|
|
|
The events, if any, that will cause MetLife, Inc.s
obligations and the obligations of the holder under the purchase
contract to terminate.
|
|
|
|
The settlement rate, which is a number that, when multiplied by
the stated amount of a purchase contract, determines the number
of securities that MetLife, Inc. or a trust will be obligated to
sell and a holder will be obligated to purchase under that
purchase contract upon payment of the stated amount of that
purchase contract. The settlement rate may be determined by the
application of a formula specified in the prospectus supplement.
If a formula is specified, it may be based on the market price
of such securities over a specified period or it may be based on
some other reference statistic.
|
24
|
|
|
|
|
Whether the purchase contracts will be issued separately or as
part of units consisting of a purchase contract and an
underlying security with an aggregate principal amount equal to
the stated amount. Any underlying securities will be pledged by
the holder to secure its obligations under a purchase contract.
|
|
|
|
The type of underlying security, if any, that is pledged by the
holder to secure its obligations under a purchase contract.
Underlying securities may be debt securities, common stock,
preferred stock, or other securities described in this
prospectus or the applicable prospectus supplement.
|
|
|
|
The terms of the pledge arrangement relating to any underlying
securities, including the terms on which distributions or
payments of interest and principal on any underlying securities
will be retained by a collateral agent, delivered to MetLife,
Inc. or be distributed to the holder.
|
|
|
|
The amount of the contract fee, if any, that may be payable by
MetLife, Inc. to the holder or by the holder to MetLife, Inc.,
the date or dates on which the contract fee will be payable and
the extent to which MetLife, Inc. or the holder, as applicable,
may defer payment of the contract fee on those payment dates.
The contract fee may be calculated as a percentage of the stated
amount of the purchase contract or otherwise.
|
The descriptions of the purchase contracts and any applicable
underlying security or pledge or depository arrangements in this
prospectus and in any prospectus supplement are summaries of the
material provisions of the applicable agreements and are subject
to and qualified in their entirety by reference to the terms and
provisions of the purchase contract agreement, pledge agreement
and deposit agreement, forms of which have been or will be filed
as exhibits to the registration statement of which this
prospectus forms a part.
DESCRIPTION
OF UNITS
As specified in the applicable prospectus supplement, MetLife,
Inc. may issue units comprised of one or more of the other
securities described in this prospectus in any combination. Each
unit may also include debt obligations of third parties, such as
U.S. Treasury securities. Each unit will be issued so that
the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security.
The prospectus supplement will describe:
|
|
|
|
|
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances the securities comprising the units may be held or
transferred separately;
|
|
|
|
a description of the terms of any unit agreement governing the
units;
|
|
|
|
a description of the provisions for the payment, settlement,
transfer or exchange of the units; and
|
|
|
|
whether the units will be issued in fully registered or global
form.
|
The descriptions of the units and any applicable underlying
security or pledge or depositary arrangements in this prospectus
and in any prospectus supplement are summaries of the material
provisions of the applicable agreements and are subject to, and
qualified in their entirety by reference to, the terms and
provisions of the applicable agreements, forms of which have
been or will be filed as exhibits to the registration statement
of which this prospectus forms a part.
DESCRIPTION
OF TRUST PREFERRED SECURITIES
The following outlines some of the general terms and provisions
of the trust preferred securities. Further terms of the trust
preferred securities and the amended and restated declarations
of trust will be stated in the applicable prospectus supplement.
The prospectus supplement will also indicate whether the general
terms described in this section apply to that particular series
of trust preferred securities. The following description and any
description of the trust preferred securities and amended and
restated declarations of trust in a prospectus supplement may
not be complete and are subject to and qualified in their
entirety by reference to the terms and provisions of the amended
and restated declarations of trust, forms of which have been or
will be filed as exhibits to the registration statement of which
this prospectus forms a part.
25
General
Each trust may issue only one series of trust preferred
securities having terms described in the prospectus supplement.
The declaration of trust of each trust will authorize the
administrative trustees, on behalf of the trust, to issue the
trust preferred securities of the trust. The trusts will use all
of the proceeds they receive from the sale of trust preferred
securities and common securities to purchase debt securities
issued by MetLife, Inc. The debt securities will be held in
trust by the trusts property trustee for the benefit of
the holders of the trust preferred securities and common
securities.
The trust preferred securities of each trust will have such
terms as are set forth in the trusts declaration of trust,
including as relates to distributions, redemption, voting,
liquidation rights and the other preferred, deferral and special
rights and restrictions. A prospectus supplement relating to the
trust preferred securities being offered will include specific
terms relating to the offering. These terms will include some or
all of the following:
|
|
|
|
|
the distinctive designation of the trust preferred securities;
|
|
|
|
the number of trust preferred securities issued by the trust;
|
|
|
|
the total and per-security liquidation amount of the trust
preferred securities;
|
|
|
|
the annual distribution rate, or method of determining such
rate, for trust preferred securities of the trust;
|
|
|
|
the date or dates on which distributions will be payable and any
corresponding record dates;
|
|
|
|
whether distributions on the trust preferred securities will be
cumulative;
|
|
|
|
if the trust preferred securities have cumulative distribution
rights, the date or dates, or method of determining the date or
dates, from which distributions on the trust preferred
securities will be cumulative;
|
|
|
|
the amount or amounts that will be paid out of the assets of the
trust to the holders of the trust preferred securities of the
trust upon voluntary or involuntary dissolution,
winding-up
or termination of the trust;
|
|
|
|
the obligation, if any, of the trust to purchase or redeem the
trust preferred securities;
|
|
|
|
if the trust is to purchase or redeem the trust preferred
securities:
|
|
|
|
the price or prices at which the trust preferred securities will
be purchased or redeemed in whole or in part;
|
|
|
|
the period or periods within which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the terms and conditions upon which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the voting rights, if any, of the trust preferred securities in
addition to those required by law, including:
|
|
|
|
|
|
the number of votes per trust preferred security; and
|
|
|
|
any requirement for the approval by the holders of trust
preferred securities as a condition to specified action or
amendments to the trusts declaration of trust;
|
|
|
|
|
|
the rights, if any, to defer distributions on the trust
preferred securities by extending the interest payment period on
the related debt securities;
|
|
|
|
if the trust preferred securities may be converted into or
exercised or exchanged for MetLifes common stock or
preferred stock or any other securities, the terms on which
conversion, exercise or exchange is mandatory, at the option of
the holder or at the option of each trust, the date on or the
period during which conversion, exercise or exchange may occur,
the initial conversion, exercise or exchange price or rate and
the circumstances or manner in which the amount of common stock
or preferred stock or other securities issuable upon conversion,
exercise or exchange may be adjusted;
|
|
|
|
the terms upon which the debt securities may be distributed to
holders of trust preferred securities;
|
26
|
|
|
|
|
whether the preferred securities are to be issued in book-entry
form and represented by one or more global certificates;
|
|
|
|
certain U.S. federal income tax considerations;
|
|
|
|
if applicable, any securities exchange upon which the trust
preferred securities shall be listed;
|
|
|
|
provisions relating to events of default and the rights of
holders of trust preferred securities in the event of default;
|
|
|
|
other agreements or other rights including upon the
consolidation or merger of the trust; and
|
|
|
|
any other relative rights, preferences, privileges, limitations
or restrictions of the trust preferred securities not
inconsistent with the trusts declaration of trust or
applicable law.
|
All trust preferred securities offered will be guaranteed by
MetLife, Inc. to the extent set forth under Description of
Guarantees. Any material United States federal income tax
considerations applicable to an offering of trust preferred
securities will be described in the applicable prospectus
supplement.
In connection with the issuance of preferred securities, each
trust will issue one series of common securities. The
declaration of each trust authorizes the administrative trustees
to issue on behalf of such trust one series of common securities
having such terms including distributions, redemption, voting,
liquidation rights or such restrictions as shall be set forth
therein. The terms of the common securities issued by the trust
will be substantially identical to the terms of the preferred
securities issued by such trust and the common securities will
rank equally, and payments will be made thereon pro rata, with
the preferred securities. However, upon an event of default
under the declaration of trust, the rights of the holders of the
common securities to payment in respect of distributions and
payments upon liquidation, redemption and otherwise will be
subordinated to the rights of the holders of the preferred
securities. Except in certain limited circumstances, the common
securities will also carry the right to vote, and appoint,
remove or replace any of the trustees of a trust. MetLife, Inc.
will own, directly or indirectly, all of the common securities
of each trust.
Enforcement
of Certain Rights by Holders of Trust Preferred
Securities
If an event of default occurs, and is continuing, under the
declaration of trust of any of the trusts, the holders of the
preferred securities of that trust would typically rely on the
property trustee to enforce its rights as a holder of the
related debt securities against MetLife, Inc. Additionally,
those who together hold a majority of the liquidation amount of
the trusts preferred securities will have the right to:
|
|
|
|
|
direct the time, method and place of conducting any proceeding
for any remedy available to the property trustee; or
|
|
|
|
direct the exercise of any trust or power that the property
trustee holds under the declaration of trust, including the
right to direct the property trustee to exercise the remedies
available to it as a holder of MetLife, Inc.s debt
securities.
|
If the property trustee fails to enforce its rights under the
applicable series of debt securities, to the fullest extent
permitted by law, a holder of trust preferred securities of such
trust may institute a legal proceeding directly against MetLife,
Inc. to enforce the property trustees rights under the
applicable series of debt securities without first instituting
any legal proceeding against the property trustee or any other
person or entity.
Notwithstanding the foregoing, if an event of default occurs and
the event is attributable to MetLife, Inc.s failure to pay
interest or principal on the debt securities when due, including
any payment on redemption, and this debt payment failure is
continuing, a preferred securities holder of the trust may
directly institute a proceeding for the enforcement of this
payment. Such a proceeding will be limited, however, to
enforcing the payment of this principal or interest only up to
the value of the aggregate liquidation amount of the
holders preferred securities as determined after the due
date specified in the applicable series of debt securities.
27
DESCRIPTION
OF GUARANTEES
The following outlines some of the general terms and provisions
of the guarantees. Further terms of the guarantees will be
stated in the applicable prospectus supplement. The prospectus
supplement will also indicate whether the general terms
described in this section apply to those guarantees. The
following description and any description of the guarantees in a
prospectus supplement may not be complete and is subject to and
qualified in its entirety by reference to the terms and
provisions of the guarantee agreements, forms of which have been
or will be filed as exhibits to the registration statement of
which this prospectus forms a part, and the Trust Indenture
Act.
MetLife, Inc. will execute and deliver the guarantees for the
benefit of the holders of the trust preferred securities. Each
guarantee will be held by the guarantee trustee for the benefit
of holders of the trust preferred securities to which it relates.
Each guarantee will be qualified as an indenture under the
Trust Indenture Act. The Bank of New York Mellon
Trust Company, N.A. will act as indenture trustee under
each guarantee for purposes of the Trust Indenture Act.
General
Pursuant to each guarantee, MetLife, Inc. will irrevocably and
unconditionally agree, to the extent set forth in the guarantee,
to pay in full, to the holders of the related trust preferred
securities, the following guarantee payments, to the extent
these guarantee payments are not paid by, or on behalf of, the
related trust, regardless of any defense, right of set-off or
counterclaim that MetLife, Inc. may have or assert against any
person:
|
|
|
|
|
any accrued and unpaid distributions required to be paid on the
trust preferred securities of the trust, but if and only if and
to the extent that the trust has funds legally and immediately
available to make those payments;
|
|
|
|
any distributions of MetLifes common stock or preferred
stock or any of its other securities, in the event that the
trust preferred securities may be converted into or exercised
for common stock or preferred stock, to the extent the
conditions of such conversion or exercise have occurred or have
been satisfied and the trust does not distribute such shares or
other securities but has received such shares or other
securities;
|
|
|
|
the redemption price, including all accrued and unpaid
distributions to the date of redemption, with respect to any
trust preferred securities called for redemption by the trust,
but if and only to the extent the trust has funds legally and
immediately available to make that payment; and
|
|
|
|
upon a dissolution,
winding-up
or termination of the trust, other than in connection with the
distribution of debt securities to the holders of trust
preferred securities of the trust, the lesser of:
|
|
|
|
|
|
the total of the liquidation amount and all accrued and unpaid
distributions on the trust preferred securities of the trust to
the date of payment, to the extent the trust has funds legally
and immediately available to make that payment; and
|
|
|
|
the amount of assets of the trust remaining available for
distribution to holders of trust preferred securities of the
trust in liquidation of the trust.
|
MetLife, Inc. may satisfy its obligation to make a guarantee
payment by directly paying the required amounts to the holders
of the related trust preferred securities or by causing the
related trust to pay such amounts to such holders.
Each guarantee will constitute a guarantee of payments with
respect to the related trust preferred securities from the time
of issuance of the trust preferred securities. The guarantees
will not apply to the payment of distributions and other
payments on the trust preferred securities when the related
trust does not have sufficient funds legally and immediately
available to make the distributions or other payments. If
MetLife, Inc. does not make interest payments on the debt
securities purchased by a trust, such trust will not pay
distributions on the preferred securities issued by such trust
and will not have funds available therefor. The guarantee, when
taken together with MetLife, Inc.s obligations under the
debt securities, the Indentures and the declarations of trust,
will provide a full and unconditional guarantee by MetLife, Inc.
of payments due on the trust preferred securities.
28
MetLife, Inc. will also agree separately, through guarantees of
the common securities, to irrevocably and unconditionally
guarantee the obligations of the trusts with respect to the
common securities to the same extent as the guarantees of the
preferred securities. However, upon an event of default under
the Indentures, holders of preferred securities shall have
priority over holders of common securities with respect to
distributions and payments on liquidation, redemption or
otherwise.
Subordination
MetLife, Inc.s obligation under each guarantee to make the
guarantee payments will be an unsecured obligation of MetLife,
Inc. and, if subordinated debt securities are issued to the
applicable trust and unless otherwise noted in the prospectus
supplement, will rank:
|
|
|
|
|
subordinate and junior in right of payment to all of MetLife,
Inc.s other liabilities, including the subordinated debt
securities, except those obligations or liabilities ranking
equal or subordinate to the guarantees by their terms;
|
|
|
|
equally with any other securities, liabilities or obligations
that may have equal ranking by their terms; and
|
|
|
|
senior to all of MetLife, Inc.s common stock.
|
If subordinated debt securities are issued to the applicable
trust, the terms of the trust preferred securities will provide
that each holder of trust preferred securities, by accepting the
trust preferred securities, agrees to the subordination
provisions and other terms of the guarantee related to
subordination.
Each guarantee will constitute a guarantee of payment and not of
collection. This means that the holder of trust preferred
securities may institute a legal proceeding directly against
MetLife, Inc. to enforce its rights under the guarantee without
first instituting a legal proceeding against any other person or
entity.
Each guarantee will be unsecured and, because MetLife, Inc. is
principally a holding company, will be effectively subordinated
to all existing and future liabilities of MetLife, Inc.s
subsidiaries, including liabilities under contracts of insurance
and annuities written by MetLife, Inc.s insurance
subsidiaries. The guarantee does not limit the incurrence or
issuance of other secured or unsecured debt by MetLife, Inc.
Amendments
and Assignment
For any changes that materially and adversely affect the rights
of holders of the related trust preferred securities, each
guarantee may be amended only if there is prior approval of the
holders of more than 50% in liquidation amount of the
outstanding trust preferred securities issued by the applicable
trust. All guarantees and agreements contained in each guarantee
will bind the successors, assigns, receivers, trustees and
representatives of MetLife, Inc. and will inure to the benefit
of the holders of the related trust preferred securities of the
applicable trust then outstanding.
Termination
Each guarantee will terminate and will have no further force and
effect as to the related trust preferred securities upon:
|
|
|
|
|
distribution of debt securities to the holders of all trust
preferred securities of the applicable trust; or
|
|
|
|
full payment of the amounts payable upon liquidation of the
applicable trust.
|
Each guarantee will continue to be effective or will be
reinstated, as the case may be, if at any time any holder of the
related trust preferred securities must restore payment of any
sums paid with respect to the trust preferred securities or
under the guarantee.
Events of
Default
Each guarantee provides that an event of default under a
guarantee occurs upon MetLife, Inc.s failure to perform
any of its obligations under the applicable guarantee.
29
The holders of a majority or more in liquidation amount of the
trust preferred securities to which any guarantee relates may
direct the time, method and place of conducting any proceeding
for any remedy available to the guarantee trustee with respect
to the guarantee or may direct the exercise of any trust or
power conferred upon the guarantee trustee in respect of the
guarantee.
If the guarantee trustee fails to enforce the guarantee, any
holder of the related trust preferred securities may institute a
legal proceeding directly against MetLife, Inc. to enforce the
holders rights under such guarantee without first
instituting a legal proceeding against the trust, the guarantee
trustee or any other person or entity.
Furthermore, if MetLife, Inc. fails to make a guarantee payment,
a holder of trust preferred securities may directly institute a
proceeding against MetLife, Inc. for enforcement of the trust
preferred securities guarantee for such payment.
The holders of a majority or more in liquidation amount of trust
preferred securities of any series may, by vote, on behalf of
the holders of all the trust preferred securities of the series,
waive any past event of default and its consequences.
Information
Concerning the Guarantee Trustee
Prior to an event of default with respect to any guarantee and
after the curing or waiving of all events of default with
respect to the guarantee, the guarantee trustee may perform only
the duties that are specifically set forth in the guarantee.
Once a guarantee event of default has occurred and is
continuing, the guarantee trustee is to exercise, with respect
to the holder of the trust preferred securities of the series,
the same degree of care as a prudent individual would exercise
in the conduct of his or her own affairs. Unless the guarantee
trustee is offered reasonable indemnity against the costs,
expenses and liabilities which may be incurred by the guarantee
trustee by a holder of the related trust preferred securities,
the guarantee trustee is not required to exercise any of its
powers under any guarantee at the request of the holder.
Additionally, the guarantee trustee is not required to expend or
risk its own funds or otherwise incur any financial liability in
the performance of its duties if the guarantee trustee
reasonably believes that it is not assured repayment or adequate
indemnity.
The guarantee trustee is The Bank of New York Mellon
Trust Company, N.A., which is one of a number of banks and
trust companies with which MetLife, Inc. and its subsidiaries
maintain ordinary banking and trust relationships.
Governing
Law
Each guarantee will be governed by, and construed in accordance
with, the internal laws of the State of New York, without
regard to its principles of conflicts of laws.
PLAN OF
DISTRIBUTION
MetLife, Inc. may sell the securities being offered hereby in
one or more of the following ways from time to time:
|
|
|
|
|
to underwriters or dealers for resale to the public or to
institutional investors;
|
|
|
|
directly to institutional investors; or
|
|
|
|
through agents to the public or to institutional investors.
|
The prospectus supplement with respect to each series of
securities will state the terms of the offering of the
securities, including:
|
|
|
|
|
the name or names of any underwriters or agents;
|
|
|
|
the purchase price of the securities and the proceeds to be
received by MetLife, Inc. or the applicable trust from the sale;
|
30
|
|
|
|
|
any underwriting discounts or agency fees and other items
constituting underwriters or agents compensation;
|
|
|
|
any initial public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchange on which the securities may be listed.
|
If MetLife, Inc. or the trusts use underwriters in the sale, the
securities will be acquired by the underwriters for their own
account and may be resold from time to time in one or more
transactions, including:
|
|
|
|
|
negotiated transactions;
|
|
|
|
at a fixed public offering price or prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to prevailing market prices; or
|
|
|
|
at negotiated prices.
|
The securities may also be offered and sold, if so indicated in
the prospectus supplement, in connection with a remarketing upon
their purchase, in accordance with a redemption or repayment
pursuant to their terms, or otherwise, by one or more
remarketing firms, acting as principals for their own accounts
or as agents for MetLife, Inc. or the trusts. The prospectus
supplement will identify any remarketing firm and will describe
the terms of its agreement, if any, with MetLife, Inc. or the
trusts and its compensation.
Unless otherwise stated in a prospectus supplement, the
obligations of the underwriters to purchase any securities will
be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of
securities, if any are purchased.
If MetLife, Inc. sells the securities directly or through agents
designated by it, MetLife, Inc. will identify any agent involved
in the offering and sale of the securities and will list any
commissions payable by MetLife, Inc. to the agent in the
accompanying prospectus supplement. Unless indicated otherwise
in the prospectus supplement, any such agent will be acting on a
best efforts basis to solicit purchases for the period of its
appointment.
MetLife, Inc. may authorize agents, underwriters or dealers to
solicit offers by certain institutional investors to purchase
securities and provide for payment and delivery on a future date
specified in an accompanying prospectus supplement. MetLife,
Inc. will describe any such arrangement in the prospectus
supplement. Any such institutional investor may be subject to
limitations on the minimum amount of securities that it may
purchase or on the portion of the aggregate principal amount of
such securities that it may sell under such arrangements.
Institutional investors from which such authorized offers may be
solicited include:
|
|
|
|
|
commercial and savings banks;
|
|
|
|
insurance companies;
|
|
|
|
pension funds;
|
|
|
|
investment companies;
|
|
|
|
educational and charitable institutions; and
|
|
|
|
such other institutions as MetLife, Inc. may approve.
|
Underwriters, dealers, agents and remarketing firms may be
entitled under agreements entered into with MetLife, Inc.
and/or the
applicable trust, or both, to indemnification by MetLife, Inc.
against certain civil liabilities, including liabilities under
the Securities Act, or to contribution with respect to payments
which the underwriters, dealers, agents and remarketing firms
may be required to make. Underwriters, dealers, agents and
remarketing agents may be customers of, engage in transactions
with, or perform services for MetLife, Inc., any trust,
and/or
MetLife, Inc.s affiliates in the ordinary course of
business.
31
Each series of securities will be a new issue of securities and
will have no established trading market other than the common
stock which is listed on the New York Stock Exchange. Any common
stock sold will be listed on the New York Stock Exchange, upon
official notice of issuance. The securities, other than the
common stock, may or may not be listed on a national securities
exchange. Any underwriters to whom securities are sold by
MetLife, Inc. or any trust for public offering and sale may make
a market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any
time without notice.
Any offering of trust preferred securities will be made in
compliance with Rule 2810 of the Conduct Rules of the
National Association of Securities Dealers, Inc.
LEGAL
OPINIONS
Unless otherwise indicated in the applicable prospectus
supplement, the validity of the securities offered hereby will
be passed upon for MetLife, Inc. by Matthew Ricciardi, Chief
Counsel Public Company and Corporate Law, of
MetLife Group, Inc., an affiliate of MetLife, Inc.
Mr. Ricciardi is paid a salary by an affiliate of MetLife,
Inc., is a participant in various employee benefit plans offered
by MetLife, Inc. and its affiliates to employees generally, is
paid equity-based compensation in accordance with MetLifes
compensation programs and owns MetLife, Inc. common stock.
Certain matters of Delaware law relating to the validity of the
trust preferred securities of MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX will be passed upon for the trust by Richards,
Layton & Finger, P.A., Wilmington, Delaware, special
Delaware counsel for the trusts.
EXPERTS
The consolidated financial statements and the related financial
statement schedules incorporated in this prospectus by reference
from MetLifes Annual Report on
Form 10-K,
and the effectiveness of MetLifes internal control over
financial reporting for the year ended December 31, 2009,
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their reports (which (1) express an unqualified opinion on
the consolidated financial statements and financial statement
schedules and includes an explanatory paragraph regarding
changes in MetLifes method of accounting for the
recognition and presentation of
other-than-temporary
impairment losses for certain investments as required by
accounting guidance adopted on April 1, 2009, its method of
accounting for certain assets and liabilities to a fair value
measurement approach as required by accounting guidance adopted
on January 1, 2008, and its method of accounting for
deferred acquisition costs and for income taxes as required by
accounting guidance adopted on January 1, 2007, and
(2) express an unqualified opinion on MetLifes
effectiveness of internal control over financial reporting),
which are incorporated herein by reference. Such consolidated
financial statements and financial statement schedules have been
so incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
The audited historical combined financial statements of American
Life Insurance Company, ALICO Services, Inc. and Delaware
American Life Insurance Company and subsidiaries included as
Exhibit 99.1 to MetLife, Inc.s Current Report on
Form 8-K
dated August 2, 2010 and incorporated by reference in this
prospectus have been so incorporated in reliance on the report
of PricewaterhouseCoopers LLP, an independent registered public
accounting firm, given on the authority of said firm as experts
in auditing and accounting.
32